# 2025年11月1日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 空间重编程驱动的GPNMB+巨噬细胞与COL6A3+成纤维细胞相互作用，促进胶质母细胞瘤血管纤维化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41174767](https://pubmed.ncbi.nlm.nih.gov/41174767)
**期刊：** Genome medicine
**PMID：** 41174767
**DOI：** 10.1186/s13073-025-01553-2

### 第一部分 原文与翻译

**英文原标题：** Spatial-reprogramming derived GPNMB macrophages interact with COL6A3 fibroblasts to enhance vascular fibrosis in glioblastoma.

**英文摘要原文：**
BACKGROUND: Neoadjuvant therapy plays an important role in the treatment of glioblastoma (GBM), but a considerable proportion of patients remain unresponsive to the combination of immune checkpoint blockade (ICB) and antiangiogenic therapy. Understanding the mechanisms underlying resistance to this treatment and developing novel therapeutic strategies are crucial.

METHODS: We integrate extensive single-cell and spatial transcriptomic data to dissect the cellular composition and spatial organization of the GBM tumor microenvironment and validate our findings through experiments such as multiplex immunohistochemistry and atomic force microscopy. We applied 101 machine learning algorithms to evaluate the prognostic and immunological value of COL6A3 tumor-associated fibroblasts (TAFs) and GPNMB monocyte-derived macrophages (MDMs) in multiple GBM cohorts and immunotherapy cohorts.

RESULTS: We constructed a stromal cell atlas in GBM and identified a distinct subset of COL6A3 TAFs with functional characteristics of matrix fibroblasts. We found that COL6A3 TAFs are significantly enriched in non-responders to neoadjuvant combination therapy. These fibroblasts drive the spatial-reprogramming of anti-tumorigenic MDMs into a pro-tumorigenic phenotype. In turn, these reprogrammed immunosuppressive GPNMB MDMs promote vascular fibrosis mediated by COL6A3 TAFs through the GPNMB-ITGB5 interaction.

CONCLUSIONS: Our findings highlight the critical role of COL6A3 TAFs in regulating MDM function and spatial distribution, as well as their contribution to fibrotic tumor vasculature formation. Additionally, we propose targeting COL6A3 TAFs with cilengitide as a potential therapeutic strategy.

**中文摘要译文：**
背景：新辅助治疗在胶质母细胞瘤（GBM）的治疗中扮演着重要角色，但仍有相当一部分患者对免疫检查点阻断（ICB）联合抗血管生成治疗无反应。因此，理解该治疗方案的耐药机制并开发新的治疗策略至关重要。

方法：我们整合了广泛的单细胞和空间转录组数据，以剖析GBM肿瘤微环境的细胞组成和空间组织结构，并通过多重免疫组化和原子力显微镜等实验验证了我们的发现。我们应用了101种机器学习算法，在多个GBM队列和免疫治疗队列中评估了COL6A3阳性肿瘤相关成纤维细胞（TAFs）和GPNMB阳性单核细胞源性巨噬细胞（MDMs）的预后及免疫学价值。

结果：我们在GBM中构建了基质细胞图谱，并鉴定出一个具有基质成纤维细胞功能特征的独特COL6A3阳性TAFs亚群。我们发现，COL6A3阳性TAFs在新辅助联合治疗无应答者中显著富集。这些成纤维细胞驱动抗肿瘤的MDMs发生空间重编程，转变为促肿瘤表型。反过来，这些经过重编程的免疫抑制性GPNMB阳性MDMs通过GPNMB-ITGB5相互作用，促进由COL6A3阳性TAFs介导的血管纤维化。

结论：我们的研究结果突显了COL6A3阳性TAFs在调控MDM功能和空间分布及其在纤维化肿瘤脉管系统形成中的关键作用。此外，我们提出将西仑吉肽（cilengitide）靶向COL6A3阳性TAFs作为一种潜在的治疗策略。

### 第二部分 AI 大师评价

本研究旨在揭示胶质母细胞瘤（GBM）对免疫联合抗血管生成治疗产生耐药性的细胞和分子机制。研究创新性地整合了单细胞、空间转录组学与机器学习算法，精准描绘了肿瘤微环境中的细胞互作网络。其核心发现是，COL6A3+肿瘤相关成纤维细胞在新辅助治疗无应答者中富集，并驱动巨噬细胞向促肿瘤和免疫抑制的GPNMB+表型进行空间重编程，进而相互促进形成纤维化的肿瘤血管，共同导致治疗抵抗。这项工作不仅深化了对GBM耐药机制的理解，还提出了靶向COL6A3+成纤维细胞（如使用西仑吉肽）的潜在治疗新策略，具有重要的临床转化价值。

---

## 2. RUNX2与SREBP1协同重塑肿瘤代谢并促进其侵袭性。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41174748](https://pubmed.ncbi.nlm.nih.gov/41174748)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41174748
**DOI：** 10.1186/s13046-025-03549-7

### 第一部分 原文与翻译

**英文原标题：** RUNX2 cooperates with SREBP1 to rewire cancer metabolism and promote aggressiveness.

**英文摘要原文：**
Embryonic Transcription Factors (TFs) are often reactivated in cancer, driving developmental gene programs that support phenotypic plasticity. Metabolic adaptation fuels this plasticity by supplying energy and molecular building blocks for growth. RUNX2, the master regulator of bone morphogenesis, is ectopically expressed in epithelial cancer, promoting metastasis through trans-differentiation processes like Epithelial-to-Mesenchymal Transition (EMT) and osteomimicry. By combining omics data with functional validation, we demonstrated that RUNX2 drives cancer cell metabolic rewiring by repressing mitochondrial respiration while promoting anabolic processes. We showed that RUNX2 upregulates key genes of lipid biosynthesis by regulating and cooperating with SREBP1. In vivo expression analysis in thyroid and breast cancer patients confirmed that lipid metabolism and SREBF1 expression are associated with increased metastatic potential and clinical aggressiveness. These findings emphasize the RUNX2 role in cancer plasticity and indicate metabolic adaptation as an integral part of the trans-differentiation program induced by this TF during cancer progression.

**中文摘要译文：**
胚胎转录因子（TFs）在癌症中常常被重新激活，驱动支持表型可塑性的发育基因程序。代谢适应通过为生长提供能量和分子构建模块来驱动这种可塑性。RUNX2，作为骨形态发生的关键调控因子，在上皮性癌症中异位表达，通过上皮-间质转化（EMT）和骨拟态等转分化过程促进转移。通过将组学数据与功能验证相结合，我们证明了RUNX2通过抑制线粒体呼吸同时促进合成代谢过程，来驱动癌细胞的代谢重编程。我们发现，RUNX2通过调控并与SREBP1协同作用，上调脂质生物合成的关键基因。在甲状腺癌和乳腺癌患者中的体内表达分析证实，脂质代谢和SREBF1的表达与转移潜能增加及临床侵袭性相关。这些发现强调了RUNX2在癌症可塑性中的作用，并表明代谢适应是该转录因子在癌症进展过程中诱导的转分化程序的一个不可或缺的部分。

### 第二部分 AI 大师评价

本研究旨在揭示胚胎转录因子RUNX2在肿瘤进展中的新机制。研究者通过结合多组学分析与功能实验，创新性地发现RUNX2通过与SREBP1协同，抑制线粒体呼吸并激活脂质合成，从而重塑肿瘤代谢，促进其侵袭性。该研究不仅深化了我们对RUNX2在肿瘤表型可塑性中作用的理解，更将代谢重编程定位为肿瘤转分化过程的核心环节，为靶向RUNX2-SREBP1轴治疗转移性癌症提供了新的理论依据和潜在靶点。

---

## 3. 治疗性靶向癌症中的细胞死亡-免疫串扰以重塑肿瘤免疫微环境

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41174733](https://pubmed.ncbi.nlm.nih.gov/41174733)
**期刊：** Molecular cancer
**PMID：** 41174733
**DOI：** 10.1186/s12943-025-02491-8

### 第一部分 原文与翻译

**英文原标题：** Therapeutic targeting of cell death-immune crosstalk in cancer to rewire the tumor immune microenvironment.

**英文摘要原文：**
The immune system plays a central role in anticancer defense by coordinating antitumor responses that inhibit the initiation, progression, and metastasis of malignancies. Emerging evidence underscores the crucial interplay between regulated cell death (RCD) pathways and immune activation, particularly immunogenic cell death (ICD). ICD refers to a specific form of regulated cell death in which tumor cells undergo death and release damage-associated molecular patterns (DAMPs) and other signaling molecules, thereby reshaping the tumor immune microenvironment (TIME). While the canonical RCD pathways are well-established, the inducers of ICD, the spatiotemporal regulation of TIME dynamics, and the functional states of immune cells remain incompletely understood. We thoroughly evaluated contemporary therapeutic approaches that exploit the mechanisms of RCD-driven immunomodulatory effects, including strategies to potentiate ICD and amplify antitumor immune responses. The novelty of this review lies in its dual perspective: delineating how tumor-intrinsic death programs reprogram the tumor TIME and how immune-cell death directly dictates its polarization toward immunostimulatory versus immunosuppressive states, ultimately shaping therapeutic outcomes. We analyzed in depth how different forms of RCD shape antigen presentation, guide immune cell infiltration, and affect checkpoint signaling, underscoring their dual potential to support or hinder antitumor responses. Furthermore, we summarized the current landscape of ICD-inducing interventions, including chemotherapy, radiotherapy, oncolytic viruses, tumor vaccines, and nanotechnology-based platforms, underscoring their potential to convert immunologically "cold" tumors into "hot" ones and to synergize with immune checkpoint blockade. In addition, we highlighted promising combination strategies aimed at directly modulating immune cell death pathways to sustain effector cell function and overcome exhaustion, offering novel insights for the development of next-generation precision immunotherapies. By delineating the crosstalk between tumor/immune cell death pathways, this study provides a roadmap for developing precise immunotherapies that exploit RCD-TIME interactions to overcome treatment resistance.

**中文摘要译文：**
免疫系统通过协调抗肿瘤反应来抑制恶性肿瘤的发生、发展和转移，在抗癌防御中发挥着核心作用。新兴证据强调了调控性细胞死亡（RCD）通路与免疫激活之间的关键相互作用，尤其是免疫原性细胞死亡（ICD）。ICD是指一种特殊形式的调控性细胞死亡，在此过程中，肿瘤细胞死亡并释放损伤相关分子模式（DAMPs）及其他信号分子，从而重塑肿瘤免疫微环境（TIME）。尽管经典的RCD通路已得到充分阐明，但ICD的诱导因素、TIME动态的时空调节机制以及免疫细胞的功能状态仍未被完全理解。我们深入评估了利用RCD驱动的免疫调节效应机制的现代治疗方法，包括增强ICD和放大抗肿瘤免疫反应的策略。本篇综述的创新之处在于其双重视角：既阐述了肿瘤内在的死亡程序如何重编程肿瘤TIME，也阐述了免疫细胞的死亡如何直接决定其向免疫刺激或免疫抑制状态的极化，并最终影响治疗结局。我们深入分析了不同形式的RCD如何影响抗原呈递、引导免疫细胞浸润及影响检查点信号传导，并强调了它们在支持或抑制抗肿瘤反应方面的双重潜力。此外，我们总结了当前诱导ICD的干预措施，包括化疗、放疗、溶瘤病毒、肿瘤疫苗和基于纳米技术的平台，强调了它们将免疫“冷”肿瘤转化为“热”肿瘤并与免疫检查点阻断产生协同效应的潜力。此外，我们还重点介绍了一些有前景的组合策略，这些策略旨在直接调节免疫细胞死亡通路以维持效应细胞功能并克服其耗竭，为开发下一代精准免疫疗法提供了新颖见解。通过阐明肿瘤/免疫细胞死亡通路之间的串扰，本研究为开发利用RCD-TIME相互作用以克服治疗耐药性的精准免疫疗法提供了路线图。

### 第二部分 AI 大师评价

本篇综述深入探讨了调控性细胞死亡（RCD）与肿瘤免疫微环境（TIME）之间的复杂串扰，旨在为癌症免疫治疗提供新的靶向策略。文章创新性地从肿瘤细胞与免疫细胞死亡的双重视角出发，系统阐述了不同RCD模式如何重塑TIME，并影响抗肿瘤免疫应答的强度与方向。作者全面总结了当前利用化疗、放疗及纳米技术等手段诱导免疫原性细胞死亡（ICD）以增敏免疫检查点抑制剂的临床前和临床策略。该综述为开发克服耐药性的下一代精准联合免疫疗法提供了重要的理论依据和清晰的路线图，具有很高的学术价值和临床转化潜力。

---

## 4. Click-code-seq技术揭示人类基因组中DNA氧化和脱嘌呤的链偏向性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41174235](https://pubmed.ncbi.nlm.nih.gov/41174235)
**期刊：** Nature chemical biology
**PMID：** 41174235
**DOI：** 10.1038/s41589-025-02052-6

### 第一部分 原文与翻译

**英文原标题：** Click-code-seq reveals strand biases of DNA oxidation and depurination in human genome.

**英文摘要原文：**
DNA modifications drive aging, neurodegeneration, carcinogenesis and chemotherapy drug action. Accurate mapping of diverse DNA modifications with single-nucleotide precision in complex genomes remains challenging. We upgraded click-code-seq, a click-chemistry-aided DNA-modification mapping strategy, to enable its first application for sequencing oxidation and depurination in the human genome. We developed a companion fluorescence assay, click-fluoro-quant, to rapidly quantify common DNA modifications and novel adaptors to minimize false positives and assess modification frequency. We uncovered that endogenous DNA oxidation in a human cell line mirrors cancer mutational signatures linked to oxidative stress. The chemotherapy drug irofulven preferentially induces depurination in ApA dimers and promoters. Notably, oxidized guanines and apurinic sites, both irofulven induced and endogenous, are depleted in gene transcribed strands, with the strand bias increasing with gene expression. This work substantially advances click-code-seq for deciphering the impacts of key modifications in human DNA on cellular physiology and toxicological responses.

**中文摘要译文：**
DNA修饰驱动着衰老、神经退行性病变、癌变以及化疗药物的作用。在复杂基因组中以单核苷酸精度精确绘制多种DNA修饰图谱仍然充满挑战。我们升级了click-code-seq技术，这是一种借助点击化学绘制DNA修饰图谱的策略，使其首次能够用于对人类基因组中的氧化和脱嘌呤进行测序。我们开发了一种配套的荧光检测法（click-fluoro-quant）来快速定量常见的DNA修饰，并设计了新型接头以最大限度地减少假阳性并评估修饰频率。我们发现，人类细胞系中的内源性DNA氧化反映了与氧化应激相关的癌症突变特征。化疗药物伊罗夫文（irofulven）会优先诱导ApA二聚体和启动子区域发生脱嘌呤。值得注意的是，无论是由伊罗夫文诱导的还是内源性的氧化鸟嘌呤和脱嘌呤位点，在基因的转录链中均有所减少，并且这种链偏向性随着基因表达水平的增高而增强。这项工作极大地推进了click-code-seq技术在解析人类DNA关键修饰对细胞生理学和毒理学反应影响方面的应用。

### 第二部分 AI 大师评价

本研究旨在利用升级版的click-code-seq技术，在人类基因组中实现对DNA氧化和脱嘌呤损伤的单核苷酸精度定位。该研究不仅开发了配套的定量方法和优化策略，还关键性地揭示了内源性DNA氧化模式与癌症突变特征的相似性，并阐明了化疗药物伊罗夫文诱导损伤的序列偏好性。更重要的是，研究发现DNA损伤在基因转录链上显著减少，且该偏向性与基因表达水平正相关，这为理解转录偶联修复机制提供了直接证据。这项工作极大地提升了DNA损伤图谱绘制技术的能力，对揭示衰老、癌症的分子机制及优化化学治疗策略具有重要意义。

---

## 5. 多瓦利单抗联合齐贝利单抗在治疗上尿路癌症中显示出潜力

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41174232](https://pubmed.ncbi.nlm.nih.gov/41174232)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41174232
**DOI：** 10.1038/s41571-025-01097-9

### 第一部分 原文与翻译

**英文原标题：** Domvanalimab plus zimberelimab shows promise in upper-tract cancers.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文是一篇发表于《自然综述：临床肿瘤学》的研究亮点或评论性文章。文章聚焦于抗TIGIT抗体Domvanalimab与PD-1抑制剂Zimberelimab联合疗法在治疗上尿路癌症中的应用前景。根据标题判断，该文可能基于最新的临床试验数据，指出这种双重免疫检查点抑制策略展现出可喜的疗效。此疗法代表了该领域的一个创新方向，有望为上尿路癌患者提供新的治疗选择，具有重要的临床转化潜力。

---

## 6. 围手术期治疗对高危肝细胞癌有效

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41174231](https://pubmed.ncbi.nlm.nih.gov/41174231)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41174231
**DOI：** 10.1038/s41571-025-01091-1

### 第一部分 原文与翻译

**英文原标题：** Perioperative therapy effective in high-risk HCC.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该标题表明，这篇文献很可能是一篇评论性文章（如“新闻与观点”），聚焦于一项关于高危肝细胞癌（HCC）围手术期治疗的重大研究。其核心内容旨在解读一项关键临床试验的发现，即在手术前后联合应用系统性治疗（如免疫或靶向疗法）能够显著改善高危HCC患者的预后。这一进展具有重大的临床应用价值，有望推动围手术期联合治疗成为高危可切除HCC的新标准，从而有效降低术后复发率、延长患者生存期。由于原文无摘要，具体的论证细节和所评述的研究数据需查阅全文。

---

## 7. 星形胶质细胞应激通过诱导δ-分泌酶在阿尔茨海默病小鼠模型中触发脑部病变

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41173884](https://pubmed.ncbi.nlm.nih.gov/41173884)
**期刊：** Nature communications
**PMID：** 41173884
**DOI：** 10.1038/s41467-025-65536-y

### 第一部分 原文与翻译

**英文原标题：** Astrocytes distress triggers brain pathology through induction of δ secretase in a murine model of Alzheimer's disease.

**英文摘要原文：**
The importance of astrocytes for Alzheimer's disease (AD) pathology is increasingly appreciated, yet the mechanisms whereby this cell type impacts neurodegenerative processes remain elusive. Here we show that, in a genetic mouse model with diminished astrocyte stress response, even low levels of amyloid-β trigger astrocyte reactivity, resulting in brain inflammation and massive amyloid and tau pathologies. This dysfunctional response of astrocytes to amyloid-β acts through activation of δ secretase, a stress-induced protease implicated in both amyloid and tau-related proteolytic processing. Our findings identify a failed astrocyte stress response to amyloid-β as an early inducer of amyloid and tau co-morbidity, a noxious process in AD acting through a non-canonical secretase pathway.

**中文摘要译文：**
星形胶质细胞在阿尔茨海默病（AD）病理学中的重要性日益受到重视，然而这类细胞影响神经退行性过程的具体机制仍不清楚。在本研究中，我们展示了在一个星形胶质细胞应激反应减弱的基因工程小鼠模型中，即便低水平的β-淀粉样蛋白（amyloid-β）也能触发星形胶质细胞的反应性，导致脑部炎症以及大量的淀粉样蛋白和tau蛋白病变。星形胶质细胞对β-淀粉样蛋白的这种功能失调性反应，是通过激活δ-分泌酶（一种应激诱导的蛋白酶，与淀粉样蛋白和tau蛋白相关的蛋白水解过程均有关联）而起作用的。我们的研究结果揭示，星形胶质细胞对β-淀粉样蛋白的应激反应失效是淀粉样蛋白和tau蛋白共病的早期诱因，这是AD中一个通过非经典分泌酶途径起作用的有害过程。

### 第二部分 AI 大师评价

本研究旨在阐明星形胶质细胞应激在阿尔茨海默病（AD）病理中的具体作用。研究通过构建星形胶质细胞应激反应减弱的小鼠模型，关键性地发现功能失常的星形胶质细胞在低水平Aβ刺激下，会通过激活δ-分泌酶，从而大规模触发淀粉样蛋白和tau蛋白的共病理。此项研究的创新价值在于，首次揭示了“星形胶质细胞应激失灵”是连接AD两大核心病理的早期诱因，并锁定了δ-分泌酶这一非经典通路中的关键分子。这一发现为理解AD发病机制提供了新视角，并提示靶向星形胶质细胞的应激反应或δ-分泌酶可能成为潜在的早期治疗策略。

---

## 8. CLN7蛋白在内体-溶酶体和应激颗粒的交界处发挥功能以促进细胞存活。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41173878](https://pubmed.ncbi.nlm.nih.gov/41173878)
**期刊：** Cell death & disease
**PMID：** 41173878
**DOI：** 10.1038/s41419-025-08063-4

### 第一部分 原文与翻译

**英文原标题：** CLN7 protein functions at the interface between endolysosomes and stress granules to promote cell survival.

**英文摘要原文：**
Inherited biallelic mutations in the CLN7 gene result in the variant late infantile onset neuronal ceroid lipofuscinosis, a subtype of Batten disease (BD), a severe and fatal childhood neurodegenerative disease. Intriguingly, CLN7 genetic variants have also been associated with retinopathies, amyotrophic lateral sclerosis, and frontotemporal dementia. CLN7 encodes a transmembrane protein localizing to endolysosomal membranes with outward-facing chloride channel activity. Loss of CLN7 function results in cortical neurons accumulating swollen lipofuscin-containing lysosomes, leading to neuroinflammation and neurodegeneration. The molecular mechanisms underlying CLN7 BD neuropathology are not completely understood. We have generated iPSC lines from two CLN7 BD patients and age-matched unaffected controls to interrogate intracellular molecular phenotypes in iPSC-derived neural progenitor cells (iNPC). Taking a multi-omics approach we have identified disease-modified activities in endolysosomal transport in iNPC that lead to lysosomal dysfunction and decreased mitophagy, resulting in the accumulation of metabolically defective mitochondria. We further observe a breakdown in nuclear functions that centre on RNA processing and nuclear export, linking to CLN7 protein interactions at the stress granule. We have identified dual and distinct functions for CLN7, promoting cell survival during the cellular stress response. CLN7 loss of function in BD results in neuronal apoptosis.

**中文摘要译文：**
CLN7基因的遗传性双等位基因突变导致变异型晚发婴儿型神经元蜡样脂褐质沉积症，这是巴顿病（BD）的一种亚型，而巴顿病是一种严重的、致命的儿童期神经退行性疾病。有趣的是，CLN7的基因变异还与视网膜病变、肌萎缩侧索硬化症和额颞叶痴呆有关。CLN7编码一种定位于内体-溶酶体膜的跨膜蛋白，具有外向的氯离子通道活性。CLN7功能丧失导致皮层神经元中含脂褐质的溶酶体肿胀并蓄积，从而引发神经炎症和神经退行。CLN7相关巴顿病神经病理学背后的分子机制尚未被完全阐明。我们从两名CLN7相关巴顿病患者和年龄匹配的健康对照者中生成了iPSC（诱导性多能干细胞）系，以研究iPSC来源的神经祖细胞（iNPC）中的细胞内分子表型。通过采用多组学方法，我们识别出iNPC中内体-溶酶体转运的疾病修饰活动，这些活动导致溶酶体功能障碍和线粒体自噬减少，从而造成代谢缺陷线粒体的累积。我们进一步观察到以RNA加工和核输出为中心的核功能崩溃，这与CLN7蛋白在应激颗粒处的相互作用有关。我们已经确定了CLN7的双重且独特的功能，即在细胞应激反应期间促进细胞存活。在巴顿病中，CLN7的功能丧失会导致神经元凋亡。

### 第二部分 AI 大师评价

本研究旨在阐明CLN7基因突变导致巴顿病的分子机制。研究团队创新性地利用患者来源的iPSC模型和多组学方法，发现CLN7功能丧失不仅导致溶酶体功能障碍和线粒体自噬受损，还引发了与RNA加工相关的核功能崩溃。其关键发现是揭示了CLN7蛋白在内体-溶酶体与应激颗粒界面处的双重功能，即在细胞应激期间促进神经元存活。这项工作深化了对巴顿病神经病理学的理解，并为开发潜在治疗策略提供了新的靶点。

---

## 9. 酵母线粒体融合蛋白中的一个特殊闩锁通过稳定自组装来保证线粒体融合

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41173874](https://pubmed.ncbi.nlm.nih.gov/41173874)
**期刊：** Nature communications
**PMID：** 41173874
**DOI：** 10.1038/s41467-025-64646-x

### 第一部分 原文与翻译

**英文原标题：** A special latch in yeast mitofusin guarantees mitochondrial fusion by stabilizing self-assembly.

**英文摘要原文：**
The mitochondrion is a highly dynamic organelle, constantly undergoing fusion and fission, which are critical processes for the health of cells. Fusion of the outer mitochondrial membrane (OMM) is mediated by the mitofusins belonging to the dynamin superfamily of GTPases. Most eukaryotic organisms possess two cooperatively functioning mitofusins, but yeast has only one mitofusin (Fzo1). How Fzo1 solely catalyzes OMM fusion is unclear. Here, we present crystal structures of truncated Fzo1 (Fzo1) in different nucleotide-loading states and report a special mechanistic feature of Fzo1 through systematic functional studies. Differing from mammalian mitofusins, Fzo1 contains an extra latch bulge (LB) that is essential for the viability of yeast. Upon GTP loading, Fzo1 dimerizes via the GTPase domain and prefers the closed conformation. This state is then locked by the subsequent trans interaction mediated by the LB of each protomer, so that Fzo1 remains dimerized in the closed conformation even after GTP hydrolysis. This special mechanistic feature may be relevant to the previous observation that degradation of Fzo1 by the ubiquitin-proteasome system is required for mitochondrial fusion. Our study reveals how mitochondrial fusion in yeast is efficiently ensured with limited GTP consumption, which broadens current understanding of this fundamental biological process.

**中文摘要译文：**
线粒体是一种高度动态的细胞器，不断经历融合和分裂，这些过程对细胞健康至关重要。线粒体外膜（OMM）的融合由属于发动蛋白超家族GTP酶的线粒体融合蛋白（mitofusins）介导。大多数真核生物拥有两种协同作用的线粒体融合蛋白，但酵母只有一种（Fzo1）。Fzo1如何单独催化OMM融合尚不清楚。在此，我们展示了截短的Fzo1在不同核苷酸加载状态下的晶体结构，并通过系统的功能研究报告了Fzo1的一个特殊机理特征。与哺乳动物的线粒体融合蛋白不同，Fzo1包含一个额外的闩锁凸起（latch bulge, LB），这对酵母的存活至关重要。在GTP加载后，Fzo1通过GTP酶结构域形成二聚体，并倾向于闭合构象。随后，每个原聚体（protomer）的LB介导的反式相互作用（trans interaction）将此状态锁定，因此即使在GTP水解后，Fzo1仍保持二聚化的闭合构象。这一特殊的机理特征可能与先前观察到的线粒体融合需要通过泛素-蛋白酶体系统降解Fzo1的现象有关。我们的研究揭示了酵母如何以有限的GTP消耗有效确保线粒体融合，这拓宽了我们对这一基本生物学过程的现有理解。

### 第二部分 AI 大师评价

该研究旨在阐明酵母中单一线粒体融合蛋白Fzo1如何独立催化线粒体外膜融合的独特分子机制。研究团队通过晶体结构解析和系统性功能分析，创新性地发现Fzo1蛋白上存在一个特殊的“闩锁凸起”（latch bulge）结构。这一关键结构能在GTP水解后，依然将Fzo1二聚体锁定在活跃的闭合构象，从而稳定其自组装，保证了融合过程的高效性。这项工作不仅从结构生物学角度揭示了酵母以低能耗方式维持线粒体动态平衡的精妙策略，也拓宽了对动态蛋白超家族作用机制的普遍理解，具有重要的科研价值。

---

## 10. ClairS-TO：一种用于长读长、仅肿瘤样本体细胞小变异检测的深度学习方法。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41173866](https://pubmed.ncbi.nlm.nih.gov/41173866)
**期刊：** Nature communications
**PMID：** 41173866
**DOI：** 10.1038/s41467-025-64547-z

### 第一部分 原文与翻译

**英文原标题：** ClairS-TO: a deep-learning method for long-read tumor-only somatic small variant calling.

**英文摘要原文：**
Accurate detection of somatic variants in tumors is of critical importance and remains challenging. Current methods typically require matched normal samples for reliable detection, which are often unavailable in real-world research and clinical scenarios. Without a matched normal sample, more proficient algorithms are required to distinguish true somatic variants from germline variants and technical artifacts. However, existing tumor-only somatic variant callers that were designed for short-read sequencing data are not able to work well with long-read data. To fill the gap, we present ClairS-TO, a deep-learning-based method for long-read tumor-only somatic variant calling. ClairS-TO uses an ensemble of two disparate neural networks trained from the same samples but for opposite tasks-how likely/not likely a candidate is a somatic variant. Benchmarks using COLO829 and HCC1395 cancer cell lines show that ClairS-TO outperforms DeepSomatic and smrest in ONT and PacBio long-read data. ClairS-TO is also applicable to short-read data and outperforms Mutect2, Octopus, Pisces, and DeepSomatic. Extensive experiments across various sequencing coverages, variant allelic fractions, and tumor purities support that ClairS-TO is a reliable tool for somatic variant discovery. ClairS-TO is open-source, available at https://github.com/HKU-BAL/ClairS-TO .

**中文摘要译文：**
准确检测肿瘤中的体细胞变异至关重要，且仍然充满挑战。现有方法通常需要配对的正常样本才能进行可靠检测，但在实际的科研和临床场景中，这类样本往往难以获得。在没有配对正常样本的情况下，需要更高效的算法来区分真实的体细胞变异、种系变异和技术性假象。然而，现有的专为短读长测序数据设计的“仅肿瘤”体细胞变异检出工具在处理长读长数据时表现不佳。为了填补这一空白，我们提出了 ClairS-TO，这是一种基于深度学习的长读长、仅肿瘤样本体细胞变异检测方法。ClairS-TO采用了一个由两个不同神经网络组成的集成模型，这两个网络使用相同样本进行训练，但任务相反——即评估一个候选变异是体细胞变异的可能性高低。使用 COLO829 和 HCC1395 癌细胞系进行的基准测试表明，在 ONT 和 PacBio 长读长数据中，ClairS-TO 的性能优于 DeepSomatic 和 smrest。ClairS-TO 也适用于短读长数据，并且其性能优于 Mutect2、Octopus、Pisces 和 DeepSomatic。在不同测序深度、变异等位基因频率和肿瘤纯度下进行的大量实验证明，ClairS-TO 是一个可靠的体细胞变异发现工具。ClairS-TO 是开源的，可在 https://github.com/HKU-BAL/ClairS-TO 获取。

### 第二部分 AI 大师评价

本研究旨在解决长读长测序数据中“仅肿瘤样本”体细胞变异检测的挑战，因为现有工具多为短读长设计且依赖配对正常样本。研究者为此开发了一种名为ClairS-TO的深度学习方法，其创新性地采用了一个双神经网络集成模型，通过正反向任务训练来提高识别准确性。基准测试结果显示，ClairS-TO在长读长和短读长数据上均显著优于现有主流工具，证明了其高效性和可靠性。该工具的开源发布，为缺乏配对正常样本的癌症基因组学研究和临床应用提供了强有力的解决方案，尤其是在新兴的长读长测序领域具有重要价值。

---

## 11. 超级增强子lncRNA RP11-54O7.17通过靶向S100A4的溶酶体降解调控三阴性乳腺癌的增殖与转移。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41173847](https://pubmed.ncbi.nlm.nih.gov/41173847)
**期刊：** Cell death & disease
**PMID：** 41173847
**DOI：** 10.1038/s41419-025-08072-3

### 第一部分 原文与翻译

**英文原标题：** Super enhancer lncRNA RP11-54O7.17 regulates the proliferation and metastasis of triple-negative breast cancer by targeting lysosomal degradation of S100A4.

**英文摘要原文：**
Triple-negative breast cancer (TNBC) is characterized by its high aggressiveness and treatment resistance, with limited therapeutic options and especially a lack of effective targeted therapeutic strategies. This study focuses on the role and regulatory mechanisms of super enhancer long non-coding RNA (SE-lncRNA) in TNBC. Through in-depth analysis of TCGA database, we revealed the specific expression pattern of SE-lncRNA in TNBC, and found that downregulation of RP11-54O7.17 was significantly correlated with poor prognosis of TNBC patients, which was experimentally verified. Both in vitro and in vivo results confirmed that RP11-54O7.17 overexpression effectively suppressed the proliferation and metastasis of TNBC. Further exploration showed that RP11-54O7.17 directly interacted with the S100A4 protein through its conserved L2b-type repeat structural fragment, promoted S100A4 binding to HSP70, targeting S100A4 degradation via the autophagy-lysosome pathway, which in turn blocked the activation of S100A4-STAT3 signaling axis. Moreover, RP11-54O7.17 delivered via liposome demonstrated significant anti-TNBC efficacy in an in vivo model without observing significant systemic toxicity. This study elucidates the regulatory role and molecular mechanism of RP11-54O7.17 in TNBC, which provides a strong scientific basis and potential therapeutic targets for the development of novel SE-lncRNA-based therapeutic strategies.

**中文摘要译文：**
三阴性乳腺癌（TNBC）以其高度侵袭性、治疗耐药、治疗选择有限，特别是缺乏有效的靶向治疗策略为特征。本研究聚焦于超级增强子长链非编码RNA（SE-lncRNA）在TNBC中的作用及其调控机制。通过对TCGA数据库的深度分析，我们揭示了SE-lncRNA在TNBC中的特异性表达模式，并发现RP11-54O7.17的下调与TNBC患者的不良预后显著相关，这一点得到了实验验证。体外与体内实验结果均证实，过表达RP11-54O7.17能有效抑制TNBC的增殖和转移。进一步探索表明，RP11-54O7.17通过其保守的L2b型重复结构片段与S100A4蛋白直接相互作用，促进S100A4与HSP70结合，靶向S100A4通过自噬-溶酶体途径降解，进而阻断S100A4-STAT3信号轴的激活。此外，通过脂质体递送的RP11-54O7.17在体内模型中展示了显著的抗TNBC功效，且未观察到明显的全身毒性。本研究阐明了RP11-54O7.17在TNBC中的调控作用和分子机制，为开发基于SE-lncRNA的新型治疗策略提供了有力的科学依据和潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究旨在阐明超级增强子lncRNA RP11-54O7.17在三阴性乳腺癌（TNBC）中的抑癌作用及其分子机制。研究综合运用生物信息学分析、体内外实验，关键性地发现RP11-54O7.17能直接结合S100A4蛋白，通过促进其与HSP70的结合来引导其进入自噬-溶酶体途径降解，从而抑制S100A4-STAT3信号通路，最终抑制TNBC的增殖与转移。该研究的创新之处在于揭示了lncRNA通过靶向调控关键蛋白降解来发挥功能的全新机制，不仅为理解TNBC的复杂调控网络提供了新视角，也为开发基于lncRNA的靶向治疗策略（如脂质体递送）提供了重要的实验依据和潜在靶点。

---

## 12. 更正：CAR-T细胞与双特异性抗体在伴髓外侵犯的多发性骨髓瘤中的活性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41173845](https://pubmed.ncbi.nlm.nih.gov/41173845)
**期刊：** Blood cancer journal
**PMID：** 41173845
**DOI：** 10.1038/s41408-025-01403-9

### 第一部分 原文与翻译

**英文原标题：** Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇勘误声明，旨在更正先前发表的关于CAR-T细胞和双特异性抗体治疗伴髓外侵犯的多发性骨髓瘤活性的研究。由于没有提供原始摘要，无法对其具体研究方法、关键发现及创新性进行深入评估。然而，从标题可知，原研究聚焦于髓外多发性骨髓瘤这一治疗难点，该领域的研究对于改善预后不良患者的生存至关重要。此更正的发布对于维护科研记录的准确性和严谨性具有重要意义。

---

## 13. S100A9在小细胞肺癌中增强肿瘤免疫抑制及癌细胞存活

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41173834](https://pubmed.ncbi.nlm.nih.gov/41173834)
**期刊：** Cell death & disease
**PMID：** 41173834
**DOI：** 10.1038/s41419-025-08102-0

### 第一部分 原文与翻译

**英文原标题：** S100A9 enhances tumor immune suppression and cancer cell survival in small cell lung cancer.

**英文摘要原文：**
Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer associated with a poor prognosis. However, there have been few advancements in improving the survival of SCLC patients in recent decades. This study shows that the S100A9 protein is highly expressed in SCLC patients and several highly aggressive SCLC cell lines. Furthermore, we showed that S100A9 expression inversely correlates with overall survival in SCLC patients. S100A9 increases the survival and migration of SCLC cells by activating Akt and GSK3α/β/Snail pathways. In addition, S100A9 reduces tumor cell autophagy through MAGE-A3. S100A9 depletion or pharmacological inhibition using tasquinimod reduced tumor growth and metastasis in vivo. Importantly, we observed that S100A9 downregulation or tasquinimod treatment alone or combined with cisplatin reduces the recruitment of MDSCs. Furthermore, tasquinimod treatment alone or combined with cisplatin significantly enhanced tumor infiltration of activated CD8+ (CD69-positive) T cells. Overall, our results, for the first time, show that S100A9 enhances SCLC progression and metastasis by altering the tumor microenvironment, and its inhibition using tasquinimod alone or in combination with chemotherapy could be developed as a promising therapeutic strategy for SCLC.

**中文摘要译文：**
小细胞肺癌（SCLC）是一种侵袭性极强的肺癌，预后不佳。然而，近几十年来，在改善SCLC患者生存率方面进展甚微。本研究表明，S100A9蛋白在SCLC患者及几种高侵袭性SCLC细胞系中呈高表达。此外，我们发现S100A9的表达水平与SCLC患者的总生存期呈负相关。S100A9通过激活Akt和GSK3α/β/Snail通路，增加SCLC细胞的存活与迁移能力。此外，S100A9还通过MAGE-A3减少肿瘤细胞的自噬。在体内实验中，通过基因敲除或使用tasquinimod进行药物抑制S100A9，均可减少肿瘤的生长与转移。重要的是，我们观察到下调S100A9或单独使用tasquinimod治疗，以及tasquinimod与顺铂联合用药，均能减少髓源性抑制细胞（MDSCs）的招募。再者，单独使用tasquinimod或与顺铂联合用药，能显著增强活化的CD8+（CD69阳性）T细胞的肿瘤浸润。总而言之，我们的研究结果首次表明，S100A9通过改变肿瘤微环境来促进SCLC的进展与转移，而使用tasquinimod单独或联合化疗来抑制S100A9，有望发展成为一种极具潜力的SCLC治疗策略。

### 第二部分 AI 大师评价

本研究旨在揭示S100A9蛋白在小细胞肺癌（SCLC）中的作用机制及其作为治疗靶点的潜力。研究通过临床样本、细胞系及动物模型，证实S100A9不仅能通过激活Akt等通路促进癌细胞存活与迁移，还能重塑肿瘤微环境，抑制抗肿瘤免疫。该研究的创新之处在于首次阐明了S100A9在SCLC中的双重促癌功能，即直接作用于癌细胞并调控免疫抑制。其关键发现——S100A9抑制剂（tasquinimod）能有效抑制肿瘤并改善免疫微环境，为预后极差的SCLC提供了一个极具转化前景的新型治疗策略。

---

## 14. 慢性髓系白血病的无治疗缓解（TFR）：来自印度一家三级癌症中心的结果、依从性及失败模式分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41173833](https://pubmed.ncbi.nlm.nih.gov/41173833)
**期刊：** Blood cancer journal
**PMID：** 41173833
**DOI：** 10.1038/s41408-025-01390-x

### 第一部分 原文与翻译

**英文原标题：** Treatment free remission (TFR) in chronic myeloid leukemia-results, compliance and patterns of failure from a tertiary care cancer centre in India.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究旨在评估慢性髓系白血病（CML）患者实现无治疗缓解（TFR）的临床结局。研究基于印度一家三级癌症中心的真实世界数据，重点分析了TFR的成功率、患者的方案依从性以及治疗失败的模式。该研究的价值在于为特定地区（印度）的CML患者群体提供了TFR实践的重要临床证据，有助于优化治疗策略和患者管理。然而，由于摘要缺失且研究可能为单中心设计，其结果的普适性有待更多研究证实。

---

## 15. 超过10万次多癌种早期检测试验的真实世界数据与临床经验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41173830](https://pubmed.ncbi.nlm.nih.gov/41173830)
**期刊：** Nature communications
**PMID：** 41173830
**DOI：** 10.1038/s41467-025-64094-7

### 第一部分 原文与翻译

**英文原标题：** Real-world data and clinical experience from over 100,000 multi-cancer early detection tests.

**英文摘要原文：**
Blood-based multi-cancer early detection (MCED) has the potential to simultaneously screen for multiple deadly cancers with high positive predictive value. To assess real-world performance, we evaluated the Galleri® MCED test (GRAIL, Inc.) across 111,080 individuals (median age 58 years, 55.5% males). This MCED test analyzes methylation patterns of cell-free DNA to detect presence of a cancer signal and predict the anatomical cancer signal origin (CSO) to facilitate diagnostic evaluation. Cancer signal detection rate was 0.91% (1011/111,080), consistent with clinical studies and independent modeled values. Providers reported clinical outcome for 459 of 1011 individuals with cancer signal detected MCED tests. Of these, 258 had an invasive cancer diagnosis, spanning 32 cancer types. The MCED test correctly predicted the CSO in 87% of cases with a reported cancer type, consistent with previous clinical studies. CSO enabled efficient workup in most patients, with a median 39.5 days from result receipt to cancer diagnosis.

**中文摘要译文：**
基于血液的多癌种早期检测（MCED）有潜力以高阳性预测值同时筛查多种致命性癌症。为评估其在真实世界中的表现，我们对111,080名个体（中位年龄58岁，55.5%为男性）中使用的Galleri® MCED测试（GRAIL, Inc.）进行了评估。该MCED测试通过分析游离DNA的甲基化模式来检测是否存在癌症信号，并预测解剖学上的癌症信号来源（CSO），以辅助诊断评估。癌症信号检出率为0.91%（1011/111,080），与临床研究和独立模型预测值一致。在1011名检测出癌症信号的个体中，医疗服务提供者报告了其中459人的临床结局。在这些人中，258人被诊断为浸润性癌症，涵盖32种癌症类型。在报告了癌症类型的病例中，该MCED测试在87%的病例中准确预测了CSO，这与先前的临床研究结果一致。CSO的预测使得大多数患者得以进行高效的诊断检查，从收到结果到癌症确诊的中位时间为39.5天。

### 第二部分 AI 大师评价

本研究旨在评估Galleri®多癌种早期检测（MCED）技术在超10万人的大规模真实世界人群中的应用表现。研究通过分析外周血游离DNA的甲基化模式，实现了0.91%的癌症信号检出率，并对已确诊的癌症患者达到了87%的癌症信号来源（CSO）预测准确率。这项研究的价值在于其庞大的样本量和真实世界数据，为MCED技术的临床有效性和实用性提供了强有力证据，尤其是在指导后续精准诊断方面显示出巨大潜力，有望革新现有的癌症筛查模式。

---

## 16. 开发靶向高表达上皮膜蛋白2的肺癌抗体药物偶联物

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41173824](https://pubmed.ncbi.nlm.nih.gov/41173824)
**期刊：** Cell death & disease
**PMID：** 41173824
**DOI：** 10.1038/s41419-025-08125-7

### 第一部分 原文与翻译

**英文原标题：** Development of antibody drug conjugates targeting epithelial membrane protein 2-highly expressed lung cancer.

**英文摘要原文：**
Lung cancer is one of the most devastating types of cancer, and the treatment of lung cancer has been facing great challenges. Antibody-drug conjugates (ADCs), a new type of targeted therapy, have been widely used in cancer therapy and have opened up a new perspective for the treatment of lung cancer. Here, using a tissue-microarray-based antibody library screening, we identified the FK002 antibody that specifically binds to the tumor cell membrane across various tumor types. We determined that FK002 targets epithelial membrane protein 2 (EMP2), a member of the tetraspanin superfamily of proteins. Subsequently, we developed the EMP2-directed ADC, FK002-exatecan, with a potent DNA topoisomerase I inhibitor (exatecan). In-depth in vitro and in vivo experiments have shown the efficacy and specificity of the EMP2-directed ADC. We validated that the FK002-exatecan ADC effectively eradicated tumors in various lung cancer cell lines and xenograft mouse models, including patient-derived xenograft (PDX) and patient-derived tumor-like cell cluster (PTC) models, as well as xenograft tumors. Mechanistically, FK002-exatecan specifically bound to EMP2 and was internalized into tumor cells, followed by intracellular trafficking to the lysosome and exatecan release, which induced cell cycle arrest and apoptosis. This study identifies EMP2 as a novel molecular target for lung cancer therapy and establishes a foundation for developing ADCs that selectively eradicate lung cancer cells.

**中文摘要译文：**
肺癌是最具破坏性的癌症类型之一，其治疗一直面临巨大挑战。抗体药物偶联物（ADCs）作为一种新型靶向疗法，已广泛用于癌症治疗，并为肺癌的治疗开辟了新视角。本研究中，我们利用基于组织微阵列的抗体库筛选，鉴定出了一种能够特异性结合多种肿瘤类型细胞膜的抗体FK002。我们确定了FK002靶向的蛋白是上皮膜蛋白2（EMP2），该蛋白是四跨膜蛋白超家族的一员。随后，我们将FK002与一种强效的DNA拓扑异构酶I抑制剂（exatecan）结合，开发了靶向EMP2的ADC药物——FK002-exatecan。深入的体外和体内实验证明了该靶向EMP2的ADC的有效性和特异性。我们验证了FK002-exatecan ADC在多种肺癌细胞系和异种移植小鼠模型（包括人源肿瘤组织异种移植（PDX）模型、源自患者的类肿瘤细胞簇（PTC）模型以及异种移植瘤模型）中均能有效清除肿瘤。从机制上看，FK002-exatecan特异性结合EMP2并被内化至肿瘤细胞内，随后通过胞内运输进入溶酶体并释放exatecan，从而诱导细胞周期停滞和凋亡。本研究将EMP2鉴定为肺癌治疗的一个新分子靶点，并为开发能选择性清除肺癌细胞的ADC药物奠定了基础。

### 第二部分 AI 大师评价

该研究旨在为肺癌开发一种新型抗体药物偶联物（ADC）。研究人员通过抗体库筛选发现了一个靶向上皮膜蛋白2（EMP2）的新抗体FK002，并成功构建了ADC药物FK002-exatecan。关键发现是在多种临床前模型（包括PDX和PTC模型）中，该ADC均展现出强大的抗肿瘤活性和特异性。这项工作不仅首次将EMP2确立为肺癌ADC治疗的潜力新靶点，为难治性肺癌提供了新的治疗思路，也为后续的临床转化研究奠定了坚实的基础。

---

## 17. 适配体工程化椭圆偏振光谱法用于临床检测支气管肺泡灌洗液来源的外泌体：一种用于免疫治疗响应预后评估的多层次工程化策略。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41173800](https://pubmed.ncbi.nlm.nih.gov/41173800)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41173800
**DOI：** 10.1002/advs.202515247

### 第一部分 原文与翻译

**英文原标题：** Aptamer-Engineered Ellipsometry for Clinical Detection of BALF-Derived Exosomes: Multi-Level Engineering for Prognostic Evaluation of Immunotherapy Responses.

**英文摘要原文：**
Exosomes emerges as indicators of the tumor microenvironment, yet their predictive utility for immunotherapy responses is limited by the insufficient sensitivity and specificity of currently available assays. Here, a multi-level engineering strategy is presented that enables accurate exosome-based prediction of immunotherapy responses by integrating systematic aptamer ligand tailoring, ultrasensitive ellipsometry-based sensing, and clinically relevant tumor-proximal fluid sampling. Aptamers specifically targeting PD-L1 are identified through systematic evolution of ligands by exponential enrichment (SELEX), followed by truncation and computational sequence refinement to enhance binding specificity. The optimized aptamer sequence (Tr-Apt13) is validated from molecular interaction analyses to in vitro assays, demonstrating superior target binding efficacy over conventional antibodies, attributed to dense surface immobilization and multivalent binding capability. When incorporated into an ellipsometry-based dual-prism solution-immersed silicon sensor, Tr-Apt13 enabled ultrasensitive detection of PD-L1-expressing exosomes with a detection limit of ≈9.8 particles mL, exhibiting high linearity and stability. Clinical validation using bronchoalveolar lavage fluid (BALF) from lung cancer patients revealed precise discrimination between responders and non-responders at exosome concentrations as low as 10 particles mL, outperforming serum-based analysis, conventional ELISA, and tissue immunohistochemistry. Collectively, this multi-level strategy offers a new perspective on exosome-based diagnostics, enabling precise prediction of immunotherapy efficacy in lung cancer patients.

**中文摘要译文：**
外泌体已成为肿瘤微环境的标志物，然而，当前检测方法的灵敏度和特异性不足，限制了其在预测免疫治疗响应方面的应用价值。本研究提出了一种多层次工程化策略，通过整合系统性的适配体配体定制、超灵敏的椭圆偏振光谱传感技术以及临床相关的肿瘤近端液体取样，实现了对外泌体的精准检测，从而准确预测免疫治疗的响应。研究人员通过指数富集的配体系统进化技术（SELEX）筛选出特异性靶向PD-L1的适配体，随后进行截短和计算序列优化，以增强其结合特异性。经过优化的适配体序列（Tr-Apt13）通过从分子相互作用分析到体外实验的多重验证，证实其靶向结合效率优于传统抗体，这得益于其高密度的表面固定能力和多价结合能力。当将Tr-Apt13整合到基于椭圆偏振光谱法的双棱镜溶液浸入式硅传感器中时，该系统能够超灵敏地检测表达PD-L1的外泌体，检测限约为每毫升9.8个颗粒，并表现出高度的线性和稳定性。使用来自肺癌患者的支气管肺泡灌洗液（BALF）进行的临床验证表明，该方法在低至每毫升10个颗粒的外泌体浓度下，即可精确区分治疗响应者与无响应者，其性能优于基于血清的分析、传统的ELISA方法以及组织免疫组化技术。总而言之，这项多层次策略为基于外泌体的诊断提供了新视角，使得精准预测肺癌患者的免疫治疗效果成为可能。

### 第二部分 AI 大师评价

本研究旨在解决当前检测方法在预测免疫治疗响应方面灵敏度和特异性不足的难题。研究团队创新性地将适配体工程化技术与超灵敏的椭圆偏振光谱法相结合，开发了一种新型生物传感器，用于检测来自支气管肺泡灌洗液（BALF）中的PD-L1阳性外泌体。关键发现是该技术实现了极低的检测限，并能在临床样本中精准区分免疫治疗的响应者与非响应者，其性能超越了传统方法。这项多层次工程化策略为开发精准、无创的肿瘤免疫治疗预后评估工具提供了极具前景的新思路，具有重要的临床转化价值。

---

## 18. 通过免疫代谢重编程树突状细胞以克服结直肠癌中谷氨酰胺驱动的免疫抑制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41173791](https://pubmed.ncbi.nlm.nih.gov/41173791)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41173791
**DOI：** 10.1002/advs.202513986

### 第一部分 原文与翻译

**英文原标题：** Immunometabolic Rewiring of Dendritic Cells to Overcome Glutamine-Driven Immune Suppression in Colorectal Cancer.

**英文摘要原文：**
The immunosuppressive tumor microenvironment imposes significant metabolic constraints that impair dendritic cell (DC) maturation and antigen presentation, ultimately undermining antitumor immunity. In colorectal cancer (CRC), elevated glutamine uptake by tumor cells depletes extracellular glutamine, thereby limiting DC functionality and disrupting T cell priming. While glutamine antagonists such as JHU083 inhibit tumor metabolism, they are insufficient to fully restore DC activity. Here, the development of T26, a bifunctional immunometabolic prodrug that links JHU083 with the STING agonist MSA-2 via a cleavable amide bond, is reported, enabling synchronized intratumoral release and dual targeting of glutamine metabolism and innate immune activation. In murine CRC models, T26 restores DC maturation, promotes CD8⁺ T cell activation, and reprograms tumor cell-derived extracellular vesicles to enhance antigen presentation and immune stimulation. Importantly, T26 significantly inhibits the growth and proliferation of CRC patient-derived organoids, underscoring its translational potential in human CRC. Notably, T26 also demonstrates strong synergy with chemotherapy, immune checkpoint blockade, and anti-angiogenic therapy, significantly improving tumor control without inducing systemic toxicity. These findings position T26 as a mechanistically integrated and translationally promising strategy to overcome glutamine-driven immune suppression and enhance immunotherapy efficacy in CRC and other metabolically dysregulated malignancies.

**中文摘要译文：**
免疫抑制性的肿瘤微环境施加了显著的代谢限制，损害了树突状细胞（DC）的成熟和抗原呈递，最终削弱了抗肿瘤免疫。在结直肠癌（CRC）中，肿瘤细胞增加的谷氨酰胺摄取耗尽了细胞外谷氨酰胺，从而限制了DC的功能并干扰了T细胞的启动。尽管谷氨酰胺拮抗剂（如JHU083）能抑制肿瘤代谢，但它们不足以完全恢复DC的活性。本研究报道了一种双功能免疫代谢前药T26的开发，它通过一个可裂解的酰胺键将JHU083与STING激动剂MSA-2连接起来，实现了同步的瘤内释放，并同时靶向谷氨酰胺代谢和先天性免疫激活。在鼠类CRC模型中，T26恢复了DC的成熟，促进了CD8⁺ T细胞的活化，并重编程了肿瘤细胞源性的细胞外囊泡，以增强抗原呈递和免疫刺激。重要的是，T26显著抑制了CRC患者来源的类器官的生长和增殖，凸显了其在人类CRC中的转化潜力。值得注意的是，T26还表现出与化疗、免疫检查点阻断和抗血管生成治疗的强大协同作用，在不引起全身毒性的情况下显著改善了肿瘤控制。这些发现将T26定位为一种机制整合且具有转化前景的策略，用以克服谷氨酰胺驱动的免疫抑制，并增强在CRC及其他代谢失调恶性肿瘤中的免疫治疗效果。

### 第二部分 AI 大师评价

本研究旨在克服结直肠癌（CRC）中由谷氨酰胺代谢驱动的免疫抑制。研究人员创新性地设计了一种名为T26的双功能免疫代谢前药，它巧妙地将谷氨酰胺拮抗剂与STING激动剂结合，实现了对肿瘤代谢重编程和先天免疫激活的双重靶向。关键发现表明，T26不仅在小鼠模型中有效恢复了树突状细胞功能并激活了抗肿瘤免疫，还在患者来源的类器官中展现出强大的抑癌效果，并与多种现有疗法产生协同增效作用。这项工作为解决实体瘤代谢性免疫抑制提供了全新的、具有高度转化价值的治疗策略。

---

## 19. 对 Andrew J. Vickers 就 Matthew J. Roberts 等人《前列腺癌盆腔淋巴结清扫术：证据与启示》一文致编辑信的回复

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41173689](https://pubmed.ncbi.nlm.nih.gov/41173689)
**期刊：** European urology
**PMID：** 41173689
**DOI：** 10.1016/j.eururo.2025.09.4163

### 第一部分 原文与翻译

**英文原标题：** Reply to Andrew J. Vickers' Letter to the Editor re: Matthew J. Roberts, Giorgio Gandaglia, Daniela E. Oprea-Lager, et al. Pelvic Lymph Node Dissection in Prostate Cancer: Evidence and Implications. Eur Urol 2025;87:619-21.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献并非原创性研究，而是一篇针对特定读者来信的作者回复。其核心目的在于回应 Andrew J. Vickers 对 Matthew J. Roberts 等人先前发表的关于前列腺癌盆腔淋巴结清扫术文章所提出的评议。此类学术通信对于促进学术争鸣、澄清研究细节以及深化对特定临床问题的理解具有重要价值。通过这种形式的交流，作者得以捍卫其研究结论、补充额外背景信息或承认某些局限性，从而丰富了该领域的科学对话。

---

## 20. 免疫检查点阻断的时间疗法个性化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41173495](https://pubmed.ncbi.nlm.nih.gov/41173495)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41173495
**DOI：** 10.1136/jitc-2025-013026

### 第一部分 原文与翻译

**英文原标题：** Personalizing chronotherapy of immune checkpoint blockade.

**英文摘要原文：**
Emerging evidence highlights the critical role of time-of-day (ToD) in immunotherapy, with large-scale retrospective studies showing that administering immune checkpoint inhibitors (ICIs) earlier in the day is associated with significantly improved efficacy across all cancer types. This observation aligns with our growing understanding of the circadian system, our internal biological clock, which governs a range of physiological processes, including immune regulation, over a 24-hour scale. Each individual possesses a distinct pace in their circadian rhythm, known as their chronotype, which reflects their natural preference for morning or evening activity, performance and rest. Chronotype has already proven to be a valuable predictor of outcomes in other areas of healthcare, and its application in immuno-oncology holds promising potential. In this commentary, we propose leveraging chronotype as a low-cost and minimally invasive strategy to personalize the timing of ICI administration and enhance therapeutic effectiveness. Despite encouraging retrospective data on ToD effects, current treatment protocols remain largely time-agnostic, hindered by the scantiness of prospective, chronotype-informed clinical trials. We outline here the key steps required to validate and implement chronotype-based scheduling, including rigorous clinical-translational studies. Embracing this temporal dimension could represent a transformative shift toward more precise, personalized, and effective circadian-based cancer immunotherapy.

**中文摘要译文：**
新兴证据凸显了一天中特定时间（ToD）在免疫治疗中的关键作用，大规模回顾性研究显示，在日间较早时段施用免疫检查点抑制剂（ICIs）与所有癌症类型中疗效的显著提升相关。这一观察结果与我们对昼夜节律系统（即我们的内部生物钟）日益增长的理解相符，该系统在24小时的尺度上调控着包括免疫调节在内的一系列生理过程。每个个体都拥有其独特的昼夜节律节奏，即时间分型（chronotype），它反映了个体对早晨或傍晚进行活动、表现和休息的自然偏好。时间分型已被证明是其他健康医疗领域中预测结局的宝贵指标，其在免疫肿瘤学中的应用也展现出巨大的潜力。在这篇评论中，我们建议利用时间分型作为一种低成本且微创的策略，来个性化ICI的给药时机，以增强治疗效果。尽管关于ToD效应的回顾性数据令人鼓舞，但由于缺乏基于时间分型的前瞻性临床试验，当前的治疗方案在很大程度上仍然忽略了时间因素。我们在此概述了验证和实施基于时间分型的给药方案所需的关键步骤，包括严谨的临床转化研究。拥抱这一时间维度可能代表着向更精准、更个性化、更高效的基于昼夜节律的癌症免疫治疗的变革性转变。

### 第二部分 AI 大师评价

该评论文章提出了一种富有远见的个性化癌症免疫治疗策略，核心是利用患者的“时间分型”（chronotype）来确定免疫检查点抑制剂（ICI）的最佳给药时间。文章总结了现有回顾性研究的发现，即给药时间影响ICI疗效，并创新性地提议将此概念从群体层面推进到个体层面。该策略的价值在于其低成本、微创的特点，通过简单的评估即可优化现有疗法，极具临床转化潜力，为精准肿瘤免疫治疗开辟了基于时间节律的新维度。

---

## 21. 人工智能驱动的EGFR酪氨酸激酶抑制剂获得性耐药非小细胞肺癌患者肿瘤微环境空间分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41173494](https://pubmed.ncbi.nlm.nih.gov/41173494)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41173494
**DOI：** 10.1136/jitc-2025-012374

### 第一部分 原文与翻译

**英文原标题：** Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor.

**英文摘要原文：**
PURPOSE: This study evaluated the dynamic changes in the tumor microenvironment (TME) in patients with non-small cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) using an artificial intelligence (AI)-powered spatial TME analyzer. We then assessed the predictive efficacy of immune-checkpoint inhibitors (ICIs)-based treatment.

EXPERIMENTAL DESIGN: An AI-powered whole-slide image analyzer was used to segment cancer areas (CAs) and cancer stroma and to identify tumor-infiltrating lymphocytes (TILs), tertiary lymphoid structures, fibroblasts, and endothelial cells (ECs) in the tumor tissue. We analyzed 143 NSCLC samples after resistance to EGFR-TKIs from two cohorts: (1) 89 patients treated with ICI monotherapy and (2) 54 patients from the ATTLAS phase III trial comparing atezolizumab plus bevacizumab, paclitaxel, and carboplatin (ABCP) versus pemetrexed plus carboplatin.

RESULTS: Post-TKI samples showed reduced TILs in the CA (p=0.045) and increased ECs in the CA (p=0.005) compared with pre-TKI samples. These changes differed according to EGFR mutation subtype. Higher TILs in CA were associated with a better overall response rate (ORR) and progression-free survival (PFS). Similarly, higher EC levels in CA correlated with improved ORR and PFS. In the ATTLAS cohort, these factors were associated with clinical benefits from ABCP, with a significant association with TILs and a marginal association with ECs.

CONCLUSION: Our findings suggest that EGFR-TKIs affect the immune landscape of patients with EGFR-mutated NSCLC. Higher TILs or ECs in the CA were significantly associated with a favorable response to subsequent ICI-based treatment.

TRIAL REGISTRATION NUMBER: NCT03991403.

**中文摘要译文：**
目的：本研究使用一款人工智能驱动的空间肿瘤微环境分析仪，评估了对表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）产生获得性耐药的非小细胞肺癌（NSCLC）患者肿瘤微环境（TME）的动态变化。随后，我们评估了基于免疫检查点抑制剂（ICIs）的治疗的预测效能。

实验设计：本研究采用一款人工智能驱动的全玻片图像分析仪对肿瘤组织进行分割，区分癌区（CAs）和癌旁基质，并识别肿瘤浸润淋巴细胞（TILs）、三级淋巴结构、成纤维细胞和内皮细胞（ECs）。我们分析了来自两个队列的143例EGFR-TKI耐药后的NSCLC样本：（1）89例接受ICI单药治疗的患者；（2）54例来自ATTLAS III期临床试验的患者，该试验旨在比较阿替利珠单抗联合贝伐珠单抗、紫杉醇和卡铂（ABCP方案）与培美曲塞联合卡铂的疗效。

结果：与TKI治疗前相比，TKI治疗后的样本显示癌区内的TILs减少（p=0.045），而癌区内的ECs增多（p=0.005）。这些变化因EGFR突变亚型而异。癌区内较高的TILs水平与更优的总体缓解率（ORR）和无进展生存期（PFS）相关。同样，癌区内较高的ECs水平也与改善的ORR和PFS相关。在ATTLAS队列中，这些因素与ABCP方案的临床获益相关，其中TILs的关联性具有统计学意义，而ECs的关联性则处于临界水平。

结论：我们的研究结果表明，EGFR-TKIs影响了EGFR突变型NSCLC患者的免疫图景。癌区内较高的TILs或ECs水平与后续基于ICI的治疗的良好反应显著相关。

试验注册号：NCT03991403。

### 第二部分 AI 大师评价

本研究创新性地运用人工智能驱动的全景病理图像空间分析技术，精准量化了EGFR-TKI耐药后非小细胞肺癌的肿瘤微环境动态变化。研究核心发现，耐药后癌区内肿瘤浸rin淋巴细胞（TILs）减少而内皮细胞（ECs）增多，且这两项指标的高水平预示着后续免疫联合治疗能带来更好的临床获益。该发现不仅揭示了TKI耐药的免疫逃逸机制，更为临床筛选适合接受免疫治疗的患者群体提供了极具价值的潜在生物标志物，对优化后线治疗策略具有重要指导意义。

---

## 22. 具核梭杆菌、静息微环境与结直肠癌的治疗反应。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41172999](https://pubmed.ncbi.nlm.nih.gov/41172999)
**期刊：** Cancer cell
**PMID：** 41172999
**DOI：** 10.1016/j.ccell.2025.10.002

### 第一部分 原文与翻译

**英文原标题：** Fusobacterium, quiescent niches, and therapy response in colorectal cancer.

**英文摘要原文：**
In this issue of Cancer Cell, Galeano Niño et al. report that tumor-infiltrating bacteria like Fusobacterium species induce a quiescent, chemoresistant state in cancer cells in the colon by disrupting epithelial contacts and suppressing proliferation and transcription. These studies highlight microbial-tumor interactions as potential modulators of therapeutic response in colon cancer.

**中文摘要译文：**
在本期《癌细胞》杂志中，Galeano Niño等人报道称，肿瘤浸润性细菌（如具核梭杆菌属）通过破坏上皮细胞间的连接，并抑制细胞的增殖与转录，从而诱导结肠癌细胞进入一种静息且化疗耐药的状态。这些研究强调了微生物与肿瘤的相互作用可作为结肠癌治疗反应的潜在调节因子。

### 第二部分 AI 大师评价

本文评述了一项重要研究，该研究揭示了肿瘤内微生物（特别是具核梭杆菌）在结直肠癌治疗抵抗中的关键作用。研究发现，这类细菌通过破坏肿瘤细胞间的连接并抑制其增殖，诱导癌细胞进入一种静息的、对化疗不敏感的状态。这一发现极具创新性，它不仅为理解结直肠癌的化疗耐药性提供了新的微生物学视角，也提示了靶向肿瘤微生态可能是改善治疗效果的潜在新策略。

---

## 23. 成年埃及伊蚊单核转录组图谱

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41172998](https://pubmed.ncbi.nlm.nih.gov/41172998)
**期刊：** Cell
**PMID：** 41172998
**DOI：** 10.1016/j.cell.2025.10.008

### 第一部分 原文与翻译

**英文原标题：** A single-nucleus transcriptomic atlas of the adult Aedes aegypti mosquito.

**英文摘要原文：**
The female Aedes aegypti mosquito's remarkable ability to hunt humans and transmit pathogens relies on her unique biology. Here, we present the Aedes aegypti Mosquito Cell Atlas, a comprehensive single-nucleus RNA sequencing dataset of more than 367,000 nuclei from 19 dissected tissues of adult female and male Aedes aegypti, providing cellular-level resolution of mosquito biology. We identify novel cell types and expand our understanding of sensory neuron organization of chemoreceptors across all sensory tissues. Our analysis uncovers male-specific cells and sexually dimorphic gene expression in the antenna and brain. In female mosquitoes, we find that glial cells, rather than neurons, undergo the most extensive transcriptional changes in the brain following blood feeding. Our findings provide insights into the cellular basis of mosquito behavior and sexual dimorphism. The Aedes aegypti Mosquito Cell Atlas resource enables systematic investigation of cell-type-specific expression across all mosquito tissues.

**中文摘要译文：**
雌性埃及伊蚊之所以具备出色的追踪人类和传播病原体的能力，依赖于其独特的生物学特性。本研究构建了《埃及伊蚊细胞图谱》，这是一个全面的单核RNA测序数据集，涵盖了从19种解剖分离的成年雌性和雄性埃及伊蚊组织中获得的超过367,000个细胞核，从而在细胞水平上解析了蚊子的生物学特性。我们识别出了新的细胞类型，并加深了对所有感觉组织中化学感受器相关的感觉神经元组织结构的理解。我们的分析揭示了触角和大脑中存在的雄性特异性细胞以及性别二态性基因表达。我们发现，在雌性蚊子吸血后，其大脑中发生最广泛转录变化的是胶质细胞，而非神经元。我们的研究结果为蚊子行为和性别二态性的细胞基础提供了新的见解。《埃及伊蚊细胞图谱》这一资源为系统性研究蚊子所有组织中细胞类型特异性基因表达提供了可能。

### 第二部分 AI 大师评价

本研究通过单核RNA测序技术，首次构建了成年埃及伊蚊全面的细胞图谱，系统解析了其19个组织的细胞组成。该研究不仅发现了新的细胞类型和性别二态性基因表达模式，还突破性地揭示了雌蚊吸血后，大脑中发生最显著转录变化的是胶质细胞而非神经元。这一成果为理解蚊子的感官生物学、行为及病原体传播机制提供了前所未有的高分辨率视角，对开发新型病媒控制策略具有重要科学价值和潜在应用前景。

---

## 24. 转录因子NFIL3驱动淋巴祖细胞向天然淋巴细胞的特化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41172988](https://pubmed.ncbi.nlm.nih.gov/41172988)
**期刊：** Immunity
**PMID：** 41172988
**DOI：** 10.1016/j.immuni.2025.10.005

### 第一部分 原文与翻译

**英文原标题：** The transcription factor NFIL3 drives innate lymphoid cell specification from lymphoid progenitors.

**英文摘要原文：**
Understanding the mechanisms that initiate innate lymphoid cell (ILC) specification may reveal how ILC functions in immunity and tissue homeostasis are programmed. Using an Il7r-lineage tracing mouse strain, we identified developmental intermediates between lymphoid progenitors and Tcf7 ILC progenitors in the mouse bone marrow (BM). Transcriptional analysis of these intermediates identified very early expression of the transcription factor nuclear factor, interleukin 3 regulated (NFIL3). Nfil3 mice lacked all BM ILC-specified precursors. Forced expression of NFIL3 in lymphoid progenitors induced Tcf7 ILC-lineage cells capable of generating all ILC subsets and conventional natural killer cells. Transient activity of NFIL3 in lymphoid precursors recapitulated BM ILC development in vitro, leading to the generation of all adult ILCs. Mechanistically, NFIL3 initiated ILC specification by inducing expression of key transcriptional regulators of ILC development-Tox, Id2, Gata3, Tcf7, and Zbtb16. Our findings indicate an apex role for NFIL3 in ILC specification and provide an in vitro approach to generate ILC-lineage cells with potential therapeutic utility.

**中文摘要译文：**
理解启动天然淋巴细胞（ILC）特化的机制，可能揭示ILC在免疫和组织稳态中的功能是如何被编程的。我们使用Il7r谱系追踪小鼠品系，在小鼠骨髓（BM）中鉴定出介于淋巴祖细胞和Tcf7 ILC祖细胞之间的发育中间态细胞。对这些中间态细胞的转录分析发现，转录因子“核因子，白细胞介素3调节”（NFIL3）在极早期便已表达。Nfil3基因敲除小鼠缺乏所有骨髓中的ILC特化前体细胞。在淋巴祖细胞中强制表达NFIL3，可诱导出能够生成所有ILC亚群和常规自然杀伤细胞的Tcf7 ILC谱系细胞。在淋巴前体细胞中短暂激活NFIL3的活性，可在体外重现骨髓ILC的发育过程，并生成所有成年期ILC亚群。从机制上讲，NFIL3通过诱导ILC发育的关键转录调节因子——Tox、Id2、Gata3、Tcf7和Zbtb16的表达，来启动ILC的特化。我们的研究结果表明NFIL3在ILC特化中扮演着顶点角色，并提供了一种具有潜在治疗应用价值的体外生成ILC谱系细胞的方法。

### 第二部分 AI 大师评价

本研究旨在阐明转录因子NFIL3在天然淋巴细胞（ILC）谱系特化中的关键作用。研究团队利用谱系追踪、基因敲除及体外诱导等技术，发现NFIL3是启动ILC分化的顶层调控因子，它通过激活Tox、Id2等下游关键转录因子，驱动淋巴祖细胞向ILC的定向分化。这项工作不仅揭示了ILC早期发育的根本机制，更重要的是，其建立的体外生成ILC谱系细胞的方法，为开发基于ILC的细胞免疫疗法提供了新策略，具有重要的科研和潜在的临床转化价值。

---

## 25. 铁的掠夺者：骨髓中的肿瘤

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41172979](https://pubmed.ncbi.nlm.nih.gov/41172979)
**期刊：** Cell
**PMID：** 41172979
**DOI：** 10.1016/j.cell.2025.09.028

### 第一部分 原文与翻译

**英文原标题：** Iron raider: Tumors in the bone marrow.

**英文摘要原文：**
In this issue of Cell, Han et al. find that tumor cells metastasizing to the bone marrow hijack macrophages to seize iron from red blood cells. This metabolic plunder thereby fuels tumor progression while contributing to anemia.

**中文摘要译文：**
在本期《细胞》杂志中，Han等人发现，转移至骨髓的肿瘤细胞会劫持巨噬细胞，从红细胞中夺取铁。这种代谢掠夺在助长肿瘤进展的同时，也导致了贫血的发生。

### 第二部分 AI 大师评价

本研究旨在揭示肿瘤骨转移的独特代谢机制。研究团队发现，转移至骨髓的肿瘤细胞能够“劫持”巨噬细胞，进而掠夺红细胞中的铁离子。这一关键发现不仅阐明了肿瘤细胞如何获取关键营养以支持其恶性增殖，还巧妙地将肿瘤进展与临床上常见的贫血症状联系起来。该研究揭示的“代谢掠夺”机制极具创新性，为开发针对骨转移和肿瘤相关性贫血的新型治疗策略（如靶向铁代谢通路）提供了重要的理论依据和潜在靶点。

---

## 26. 回复：解读卵巢癌中多聚（ADP-核糖）聚合酶抑制剂试验的研究终点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41172234](https://pubmed.ncbi.nlm.nih.gov/41172234)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41172234
**DOI：** 10.1200/JCO-25-01933

### 第一部分 原文与翻译

**英文原标题：** Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇针对“解读卵巢癌中多聚（ADP-核糖）聚合酶抑制剂试验的研究终点”这一主题的回复性文章。由于原文没有提供摘要，无法得知其具体论点。通常，此类“回复”性质的文献旨在对先前发表的文章进行讨论、澄清或辩驳，其价值在于推动学术界就关键问题（如此处的临床试验终点选择）进行深入对话，对于完善未来临床试验设计、确保研究结果的准确解读具有重要意义。

---

## 27. 解读卵巢癌领域多聚（ADP-核糖）聚合酶（PARP）抑制剂临床试验的终点指标

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41172232](https://pubmed.ncbi.nlm.nih.gov/41172232)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41172232
**DOI：** 10.1200/JCO-25-01721

### 第一部分 原文与翻译

**英文原标题：** Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

根据标题判断，本文旨在深入解读和分析在卵巢癌PARP抑制剂的临床试验中所采用的各类终点指标。文章可能系统性地探讨了无进展生存期（PFS）、总生存期（OS）等不同终点的优缺点、适用性及其对结果解读的影响。本文的临床价值在于为医生和研究人员提供了一个批判性视角，帮助他们更准确地理解和比较各项关键性研究，从而为复杂的临床决策提供依据。鉴于其标题和无摘要的特点，这很可能是一篇评论或观点性文章，而非原创性研究，其创新性体现在对现有数据的深刻见解与整合分析上。

---

## 28. 多灶性肝内胆管癌中卫星病灶与肝内转移的比较：预后影响及基因组图谱分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41172153](https://pubmed.ncbi.nlm.nih.gov/41172153)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41172153
**DOI：** 10.1097/HEP.0000000000001594

### 第一部分 原文与翻译

**英文原标题：** Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling.

**英文摘要原文：**
BACKGROUND AND AIMS: Multifocal intrahepatic cholangiocarcinoma (ICC) is typically categorized as satellite lesions (SL) or intrahepatic metastasis (IM). Clinical staging and prognostic significance of multifocal ICC are a topic of debate.

APPROACH AND RESULTS: ICC patients with solitary or multifocal tumors undergoing curative-intent surgical resection were identified from an international multi-institutional database. SL and IM were classified according to distribution patterns. Among 1,064 patients included in the cohort, 358 had multifocal tumors that were defined as IM (n=95) or SL (n=263). Isolated AJCC Stage II of multifocal ICC disease was associated with shorter overall (OS)(median: 26.1 vs. 60.0 mo, p<0.001) and disease-free survival (DFS)(median DFS: 9.8 vs. 25.0 mo, p<0.01) than solitary tumors within Stage II, yet had a comparable prognosis as Stage III disease. Patients with IM or SL had comparable OS and DFS (both p>0.1), regardless of tumor number status. Genomic profiling demonstrated highly concordant mutational landscape of IM and SL in 24 multifocal ICC patients. Phylogenetic and evolutionary trajectory analysis supported that multifocal lesions with different distribution patterns were of the same origin derived from the corresponding primary tumors. Additionally, single-nucleus RNA sequencing revealed that both IM and SL harbored increased level of copy number variations compared with the primary lesion, indicative of malignant progression.

CONCLUSIONS: Multifocal ICC should be categorized as AJCC Stage III disease regardless of IM and SL patterns. Both SL and IM are clonal origin derived from primary ICC tumor, and represent metastatic progression with poor long-term survival.

**中文摘要译文：**
背景与目的：多灶性肝内胆管癌（ICC）通常被分为卫星病灶（SL）或肝内转移（IM）。多灶性ICC的临床分期和预后意义一直存在争议。

方法与结果：本研究从一个国际多中心数据库中筛选出接受根治性手术切除的单发或多发肿瘤的ICC患者。根据分布模式对SL和IM进行分类。在纳入队列的1064名患者中，358名患有多灶性肿瘤，被定义为IM（n=95）或SL（n=263）。孤立的AJCC II期多灶性ICC疾病与同为II期的单发肿瘤相比，其总生存期（OS）（中位数：26.1 vs. 60.0个月，p<0.001）和无病生存期（DFS）（中位数DFS：9.8 vs. 25.0个月，p<0.01）更短，但其预后与III期疾病相当。无论肿瘤数量如何，IM或SL患者的OS和DFS均无显著差异（p均>0.1）。对24例多灶性ICC患者的基因组分析显示，IM和SL的突变图谱高度一致。系统发育和进化轨迹分析支持，具有不同分布模式的多灶性病变与相应原发肿瘤同源。此外，单核RNA测序显示，与原发病灶相比，IM和SL均携带更高水平的拷贝数变异，这表明了恶性进展。

结论：无论IM和SL模式如何，多灶性ICC都应被归类为AJCC III期疾病。SL和IM均源自原发ICC肿瘤的克隆起源，代表了预后不良的转移性进展。

### 第二部分 AI 大师评价

本研究通过大样本多中心回顾性分析结合前沿的基因组学与单核测序技术，旨在明确多灶性肝内胆管癌中卫星病灶（SL）与肝内转移（IM）的临床预后差异及生物学本质。研究关键发现，无论表现为SL还是IM，多灶性病变的预后均显著劣于孤立性肿瘤，且与原发灶同源，代表了肿瘤的转移性进展。此项工作的创新之处在于，它为长期存在的临床分期争议提供了高级别证据，有力支持将所有多灶性肝内胆管癌统一划归为AJCC III期，对指导临床决策和患者预后判断具有重要价值。

---

## 29. T1型效应CD4 T细胞依赖IFN-γ的产生诱导斑秃。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41171930](https://pubmed.ncbi.nlm.nih.gov/41171930)
**期刊：** Science advances
**PMID：** 41171930
**DOI：** 10.1126/sciadv.adz2257

### 第一部分 原文与翻译

**英文原标题：** T1 effector CD4 T cells rely on IFN-γ production to induce alopecia areata.

**英文摘要原文：**
Alopecia areata (AA) is an autoimmune disease defined by hair loss and peribulbar infiltrate of CD8 and CD4 T cells. Prior studies have focused on the role of CD8 T cells in the development of AA. Multiple roles for CD4 T cell help have been demonstrated for support of CD8 T cell responses; however, the role of CD4 T cells in AA remains unclear. Here, we demonstrate that CD4 T cells from the skin-draining lymph nodes (SDLNs) of AA mice transferred disease to recipient mice. These cells exhibited a T helper type 1 (T1) effector transcriptional and phenotypic profile, and their pathogenic activity required endogenous CD8 T cells and host IFN-γ responsiveness. Targeted deletion of CD4 T cell-mediated production of IFN-γ abrogated the ability of this cell population to transfer disease. Together, these data provide mechanistic insights into pathways driving AA development, strengthening our understanding of the disease and inviting studies into exploring alternative therapeutic strategies for human patients.

**中文摘要译文：**
斑秃（AA）是一种自身免疫性疾病，其特征为脱发以及毛囊球周CD8和CD4 T细胞的浸润。既往研究主要关注CD8 T细胞在AA发病中的作用。已有多项研究证明CD4 T细胞在支持CD8 T细胞应答中具有多重辅助作用；然而，CD4 T细胞在AA中的具体作用仍不明确。在本研究中，我们证明了来自AA小鼠皮肤引流淋巴结（SDLNs）的CD4 T细胞能够将疾病转移至受体小鼠。这些细胞表现出1型辅助性T细胞（T1）效应子的转录和表型特征，并且其致病活性需要内源性CD8 T细胞和宿主的IFN-γ应答能力。靶向删除CD4 T细胞介导的IFN-γ产生，则会消除该细胞群体转移疾病的能力。综上所述，这些数据为驱动AA发生的通路提供了机制性的见解，加深了我们对该疾病的理解，并为探索针对人类患者的替代治疗策略提供了新的研究方向。

### 第二部分 AI 大师评价

该研究旨在阐明CD4 T细胞在斑秃（AA）发病机制中的具体作用。研究者通过在小鼠模型中进行细胞过继转移实验，关键性地发现T1型效应CD4 T细胞是诱导AA的关键致病细胞，其致病性依赖于自身分泌IFN-γ，并需要宿主CD8 T细胞和IFN-γ信号通路的协同作用。这项工作创新性地揭示了CD4 T细胞在AA中的直接驱动角色，而不仅是CD8 T细胞的辅助者，为开发靶向CD4 T细胞或IFN-γ通路的新疗法提供了重要的理论依据和新思路。

---

## 30. 基于作用机制的过氧化物还原酶3抑制剂：利用共价弹头治疗癌症。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41171914](https://pubmed.ncbi.nlm.nih.gov/41171914)
**期刊：** Science advances
**PMID：** 41171914
**DOI：** 10.1126/sciadv.ady4492

### 第一部分 原文与翻译

**英文原标题：** Mechanism-based peroxiredoxin 3 inhibitors exploit a covalent warhead for cancer therapy.

**英文摘要原文：**
Covalent inhibitors that are approved and marketed drugs exploit a wide array of warheads and reactions with amino acid side chain-based nucleophiles. Thiostrepton (TS) inhibits the peroxidase activity of the mitochondrial antioxidant protein peroxiredoxin 3 by forming a covalent crosslink between the two active site cysteine residues. Peroxiredoxin 3 inactivation increases reactive oxygen species levels, induces cancer cell death in preclinical models, and shows promise in an ongoing clinical trial for malignant mesothelioma using direct pleural infusion. We report the identification of the minimal fragment of TS that contains tandem dehydro-alanine (DHA) moieties and maintains anticancer activity while losing interactions with three alternative targets of intact TS. Biochemical, kinetic, cellular, and structural studies demonstrate that this fragment is a mechanism-based peroxiredoxin inhibitor. These findings represent a promising start toward a pro-oxidant approach for cancer therapy. Moreover, the data support that the DHA moiety should be added to the covalent warhead arsenal.

**中文摘要译文：**
已获批上市的共价抑制剂药物利用了多种多样的弹头，并与基于氨基酸侧链的亲核试剂发生反应。硫链丝菌肽（TS）通过在两个活性位点半胱氨酸残基之间形成共价交联，抑制线粒体抗氧化蛋白过氧化物还原酶3的过氧化物酶活性。过氧化物还原酶3的失活会增加活性氧水平，在临床前模型中诱导癌细胞死亡，并且在一项通过胸腔直接灌注治疗恶性间皮瘤的临床试验中显示出前景。我们报道了TS的一个最小片段的鉴定，该片段含有串联的脱氢丙氨酸（DHA）部分，在保持抗癌活性的同时，失去了与完整TS的三个其他靶点的相互作用。生物化学、动力学、细胞和结构研究表明，该片段是一种基于机制的过氧化物还原酶抑制剂。这些发现为癌症治疗的促氧化策略提供了一个有希望的开端。此外，数据支持将DHA部分加入共价弹头的武器库中。

### 第二部分 AI 大师评价

本研究的核心目的在于从天然产物硫链丝菌肽（TS）中鉴定出能够特异性抑制线粒体抗氧化蛋白过氧化物还原酶3（PRDX3）的最小活性片段。研究团队通过生化、动力学及结构生物学等方法，成功分离并验证了一个含有串联脱氢丙氨酸（DHA）的片段，该片段能有效抑制PRDX3，同时避免了对其他靶点的脱靶效应。此项工作的创新性在于，它不仅为开发靶向PRDX3的“促氧化”癌症疗法提供了精准的先导化合物，还首次证实了脱氢丙氨酸（DHA）可作为一种新型共价弹头用于药物设计，极大地拓展了共价抑制剂的开发工具箱，具有重要的科研和临床转化价值。

---

## 31. 解锁细胞力学生物学的治疗潜力

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41171907](https://pubmed.ncbi.nlm.nih.gov/41171907)
**期刊：** Science advances
**PMID：** 41171907
**DOI：** 10.1126/sciadv.aea6817

### 第一部分 原文与翻译

**英文原标题：** Unlocking the therapeutic potential of cellular mechanobiology.

**英文摘要原文：**
Mechanobiology is a rapidly advancing field at the intersection of biology, physics, and engineering that reveals how mechanical forces shape cellular behavior, tissue architecture, and disease progression. By elucidating how cells sense and transduce mechanical cues, mechanobiology has fundamentally advanced our understanding of processes ranging from migration and differentiation to immune responses and tissue remodeling. These advances have driven the development of innovative biophysical tools and engineered biomaterials that enable precise modulation of the cellular microenvironment. Translating mechanobiological principles into clinical practice is giving rise to mechanomedicine, a previously unrecognized paradigm that integrates mechanical forces as key modulators of health and disease. This review highlights how mechanobiology informs therapeutic strategies across diverse domains, including cancer immunotherapy, cardiovascular and neurodegenerative disorders, and regenerative medicine. By bridging fundamental discoveries with translational applications, this review positions mechanobiology as a cornerstone of next-generation medical innovation, translating mechanistic insights into impactful clinical applications.

**中文摘要译文：**
力学生物学是一个在生物学、物理学和工程学交叉领域中迅速发展的学科，它揭示了机械力如何塑造细胞行为、组织结构和疾病进展。通过阐明细胞如何感知和转导机械信号，力学生物学从根本上加深了我们对从细胞迁移和分化到免疫反应和组织重塑等一系列过程的理解。这些进展推动了创新性生物物理工具和工程生物材料的发展，从而实现了对细胞微环境的精确调控。将力学生物学原理转化为临床实践催生了力学医学——一个前所未有的新范式，它将机械力整合为健康与疾病的关键调节因子。这篇综述重点阐述了力学生物学如何为癌症免疫治疗、心血管和神经退行性疾病以及再生医学等多个领域的治疗策略提供新思路。通过将基础发现与转化应用相结合，本综述将力学生物学定位为下一代医学创新的基石，旨在将机理性的深刻见解转化为具有影响力的临床应用。

### 第二部分 AI 大师评价

该综述文章系统性地总结了力学生物学这一交叉学科的核心概念及其向临床实践转化的前沿进展，即‘力学医学’。文章并未呈现新的实验数据，而是通过整合现有研究，阐述了细胞如何感知并响应机械力，以及这一基本原理如何在癌症免疫治疗、再生医学等领域催生新的治疗策略。其重要价值在于，它为基础研究人员和临床医生架起了沟通的桥梁，明确指出力学生物学是下一代医疗创新的关键基石，有望将深刻的机理认知转化为有影响力的临床解决方案。

---

## 32. 缺乏关键重编程因子的胚胎细胞在体内的分化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41171758](https://pubmed.ncbi.nlm.nih.gov/41171758)
**期刊：** Cell reports
**PMID：** 41171758
**DOI：** 10.1016/j.celrep.2025.116498

### 第一部分 原文与翻译

**英文原标题：** In vivo differentiation of embryonic cells devoid of key reprogramming factors.

**英文摘要原文：**
Embryonic cell differentiation depends on reprogramming of the oocyte and sperm nucleus into a transient totipotent state. In zebrafish, this coincides with genome activation, which is regulated by the pioneer factors Nanog, Pou5f3, and Sox19b (NPS). Here, we investigate the role of NPS in developmental reprogramming and differentiation by analyzing the fate of NPS mutant cells in a wild-type embryo using single-cell RNA-seq. We find that many cells fail to activate transcription or undergo cell death, while others acquire gene expression profiles that resemble germ cells, neural progenitors, and motoneuron states. These cells achieve intermediate transcriptional states, revealing the essential role of NPS in coordinating nuclear and cytoplasmic reprogramming and preventing the premature activation of lineage-specific differentiation programs. These results demonstrate that most developmental programs require developmental reprogramming by NPS, yet some cells can bypass transient totipotency to achieve intermediate developmental states resembling wild-type states in vivo.

**中文摘要译文：**
胚胎细胞的分化依赖于卵母细胞和精子细胞核重编程为一个短暂的全能性状态。在斑马鱼中，这一过程与基因组激活同步发生，而基因组激活受到先锋因子Nanog、Pou5f3和Sox19b (NPS) 的调控。本研究中，我们通过使用单细胞RNA测序技术，分析了野生型胚胎中NPS突变细胞的命运，以探究NPS在发育重编程和分化中的作用。我们发现，许多突变细胞无法激活转录或发生细胞死亡，而另一些细胞则获得了类似于生殖细胞、神经祖细胞和运动神经元状态的基因表达谱。这些细胞达到了中间转录状态，揭示了NPS在协调细胞核与细胞质重编程以及防止谱系特异性分化程序过早激活中的关键作用。这些结果表明，大多数发育程序需要NPS进行发育重编程，但有些细胞可以绕过短暂的全能性状态，在体内达到类似于野生型状态的中间发育状态。

### 第二部分 AI 大师评价

本研究旨在探究关键重编程因子NPS（Nanog, Pou5f3, Sox19b）在胚胎发育和细胞分化中的核心作用。研究团队创新性地利用单细胞RNA测序技术，在野生型斑马鱼胚胎中追踪了NPS突变细胞的命运。关键发现揭示，虽然NPS对于协调核质重编程、防止分化程序过早启动至关重要，但部分缺乏NPS的细胞仍能绕过传统的全能性阶段，分化成接近正常谱系的中间状态。这项工作不仅深化了我们对早期胚胎发育调控机制的理解，也揭示了细胞分化路径的潜在灵活性，对发育生物学和再生医学领域具有重要的理论价值和启示意义。

---

## 33. 肿瘤浸润菌群可能如何导致化疗耐药

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41171266](https://pubmed.ncbi.nlm.nih.gov/41171266)
**期刊：** JAMA
**PMID：** 41171266
**DOI：** 10.1001/jama.2025.17539

### 第一部分 原文与翻译

**英文原标题：** How Tumor-Infiltrating Bacteria May Contribute to Chemotherapy Resistance.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文标题揭示了一个肿瘤学前沿研究方向：肿瘤微环境中的细菌如何影响化疗效果。这篇文章很可能是一篇综述或观点性文章，旨在探讨肿瘤浸润菌群导致化疗耐药的潜在生物学机制。其临床和科研价值在于，通过阐明这些机制（例如细菌对化疗药物的代谢降解），可能为克服耐药性、提高治疗效果开辟新的途径，例如联合使用抗生素或靶向调控菌群的策略。这篇文章为理解肿瘤微环境的复杂性及其在治疗中的作用提供了重要视角。

---

## 34. connectomeDB2025：一个经过严格审编的、包含实验支持的配体-受体相互作用的多物种资源库

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41171146](https://pubmed.ncbi.nlm.nih.gov/41171146)
**期刊：** Nucleic acids research
**PMID：** 41171146
**DOI：** 10.1093/nar/gkaf1108

### 第一部分 原文与翻译

**英文原标题：** connectomeDB2025: a rigorously curated, multi-species resource of experimentally supported ligand-receptor interactions.

**英文摘要原文：**
Inferring cell-cell communication networks is now a cornerstone of single-cell RNA-seq and spatial transcriptomics data analysis, relying critically on reference catalogues of experimentally supported ligand-receptor interactions. Here, we present the updated, rigorously curated connectomeDB, an open-access database of peptide-based ligand-receptor pairs comprising 3579 vertebrate interactions supported by primary experimental evidence from 2803 research articles. By critically reviewing all putative ligand-receptor pairs from connectomeDB2020, CellChatDB v2, CellPhoneDB v5, CellTalkDB, ICELLNET v2, and LIANA+, we first removed over 2900 misclassified or unsupported interactions lacking primary-literature evidence. We then expanded the resulting verified dataset through AI-assisted literature mining and manual curation, adding 827 pairs and 718 supporting articles absent from other databases, including 264 pairs first described since 2020. connectomeDB2025 contains 5429 evidence links ("triplets"), each connecting a ligand-receptor pair to a specific publication, collectively providing at least one source of primary experimental evidence for each interaction. Notably, 2359 of these triplets are exclusive to connectomeDB2025, making it the most robustly supported ligand-receptor database with primary experimental evidence. The online resource (https://connectomedb.org) provides searchable, downloadable ligand-receptor lists and detailed pair summaries, enabling accurate cell-cell communication analysis across human, mouse, and 12 other vertebrate species.

**中文摘要译文：**
推断细胞间通讯网络现已成为单细胞RNA测序和空间转录组学数据分析的基石，其关键在于依赖经实验支持的配体-受体相互作用的参考目录。在此，我们介绍了更新且经过严格审编的connectomeDB——一个开放获取的数据库，收录了基于肽的配体-受体对，共包含3579个脊椎动物相互作用，这些相互作用均由来自2803篇研究论文的原始实验证据所支持。通过严格审查来自connectomeDB2020、CellChatDB v2、CellPhoneDB v5、CellTalkDB、ICELLNET v2和LIANA+的所有假定配体-受体对，我们首先移除了超过2900个因缺乏原始文献证据而被错误分类或无证据支持的相互作用。随后，我们通过人工智能辅助的文献挖掘和人工审编，扩展了经过验证的数据集，新增了827个相互作用对和718篇其他数据库所没有的支持性文献，其中包括自2020年以来首次报道的264个相互作用对。connectomeDB2025包含5429个证据链接（“三元组”），每个链接都将一个配体-受体对与一篇特定的出版物相连接，从而共同为每个相互作用提供了至少一个原始实验证据来源。值得注意的是，这些三元组中有2359个是connectomeDB2025独有的，使其成为拥有最可靠原始实验证据支持的配体-受体数据库。该在线资源（https://connectomedb.org）提供可搜索、可下载的配体-受体列表和详细的相互作用对摘要，从而能够对人类、小鼠及其他12种脊椎动物进行精确的细胞间通讯分析。

### 第二部分 AI 大师评价

本研究旨在构建一个经过严格审编和更新的多物种配体-受体相互作用数据库connectomeDB2025，以提高细胞间通讯分析的准确性。研究团队首先通过严格审查现有主流数据库，移除了近三千个缺乏原始实验证据支持的条目，随后利用AI辅助文献挖掘和人工审校，新增了大量独有的相互作用对。其核心创新在于建立了一套高标准的筛选和验证流程，确保数据库中的每一个相互作用都有直接的原始文献证据支持。这使得connectomeDB2025成为目前最可靠的配体-受体互作资源之一，为单细胞和空间转录组学领域的科研工作者提供了宝贵的金标准工具，极大地提升了相关分析的信度和效度。

---

## 35. theRNA：一个涵盖多种模式和疾病应用的功能性RNA疗法精选知识库

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41171135](https://pubmed.ncbi.nlm.nih.gov/41171135)
**期刊：** Nucleic acids research
**PMID：** 41171135
**DOI：** 10.1093/nar/gkaf1064

### 第一部分 原文与翻译

**英文原标题：** theRNA: a curated knowledgebase of functional RNA therapeutics spanning diverse modalities and disease applications.

**英文摘要原文：**
RNA therapeutics are transforming precision medicine, yet a dedicated resource for validated agents has been lacking. Here, we introduce theRNA (https://therna.renlab.cn/), the first comprehensive database of 6860 experimentally validated RNA therapeutics targeting 1310 diseases in human or animal models. Curated from 11 126 peer-reviewed studies, theRNA focuses exclusively on functional therapeutic RNAs, including messenger RNA, small interfering RNA, microRNA, long noncoding RNA, circular RNA, short hairpin RNA, antisense oligonucleotides, aptamers, and CRISPR-related RNAs. Each entry provides extensive annotations on delivery modalities, efficacy readouts, and clinical potential. A user-friendly interface enables rapid searching and interactive exploration. As the first dedicated database for functional RNA therapeutics, theRNA aims to accelerate therapy development and deepen mechanistic understanding of disease and treatment.

**中文摘要译文：**
RNA疗法正在改变精准医疗，但目前仍缺乏一个专门收录已验证药物的资源库。在此，我们介绍了theRNA (https://therna.renlab.cn/)，这是首个收录了6860种经实验验证的RNA疗法的综合性数据库，这些疗法针对人类或动物模型中的1310种疾病。theRNA从11126篇同行评议的研究中精心筛选数据，专注于功能性治疗RNA，包括信使RNA、小干扰RNA、微小RNA、长链非编码RNA、环状RNA、短发夹RNA、反义寡核苷酸、适体和CRISPR相关RNA。每个条目都提供了关于递送方式、功效读出和临床潜力的详尽注释。用户友好的界面支持快速搜索和交互式探索。作为首个功能性RNA疗法的专用数据库，theRNA旨在加速疗法开发并加深对疾病和治疗机制的理解。

### 第二部分 AI 大师评价

该研究旨在解决RNA疗法领域缺乏统一、经验证的药物资源库这一问题。通过大规模筛选和整合上万篇同行评议文献，作者成功构建了首个全面的功能性RNA疗法知识库theRNA。该数据库不仅收录了多种类型的RNA药物及其靶向疾病，还提供了递送方式和功效等关键信息，其创新性在于为研究人员提供了一个宝贵、便捷的“一站式”平台，极大地便利了新疗法的开发和疾病机制的深入理解，具有重要的科研和临床转化价值。

---

## 36. FerrDb V3：从铁死亡到调控性细胞死亡，扩展手动精选的调控因子及疾病关联资源库。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41171133](https://pubmed.ncbi.nlm.nih.gov/41171133)
**期刊：** Nucleic acids research
**PMID：** 41171133
**DOI：** 10.1093/nar/gkaf1119

### 第一部分 原文与翻译

**英文原标题：** FerrDb V3: expanding the manually curated resource for regulators and disease associations from ferroptosis to regulated cell death.

**英文摘要原文：**
Regulated cell death (RCD) is essential to both physiological homeostasis and numerous diseases. FerrDb is a curated database for ferroptosis regulators and ferroptosis-disease associations. Though widely used, FerrDb is limited by its singular focus on ferroptosis. The field of cell death is rapidly expanding, marked by continuous discovery of novel RCD modalities. The need for a high-quality database that encompasses the entire spectrum of RCD is urgent, but none exists. Here, we introduce FerrDb V3, an upgraded version featuring extensive enhancements in content and functionality. Remarkably, it expands from the focus on ferroptosis to 22 RCD modalities. RCD regulators and RCD-disease associations were manually curated from >20 000 articles. Database content was additionally enriched by public resources. A conversational intelligent assistant that enables users to explore the database through natural language queries was created. A suite of web-based analytical utilities tailored for RCD research was developed. The web interface was updated accordingly to offer a seamless user experience. In conclusion, FerrDb V3 has evolved into a comprehensive resource and a valuable research tool for the RCD research community. FerrDb V3 is freely accessible at https://www.zhounan.org/ferrdb/.

**中文摘要译文：**
调控性细胞死亡（RCD）对生理稳态和多种疾病都至关重要。FerrDb是一个专门收录铁死亡调控因子及铁死亡与疾病关联的精选数据库。尽管FerrDb被广泛使用，但其仅关注铁死亡这一单一领域，因而存在局限性。细胞死亡领域正在迅速扩展，其标志是新型RCD模式的不断发现。因此，迫切需要一个涵盖所有RCD类型的高质量数据库，但目前尚无此类数据库。在此，我们推出了FerrDb V3，这是一个在内容和功能上均有大幅增强的升级版本。值得注意的是，它将关注点从铁死亡扩展到了22种RCD模式。研究人员从超过20,000篇文章中手动整理了RCD调控因子以及RCD与疾病的关联信息。数据库内容还通过公共资源得到了进一步丰富。我们还创建了一个对话式智能助手，使用户能够通过自然语言查询来探索该数据库。此外，我们还开发了一套专为RCD研究量身定制的基于网络的分析工具。相应的，我们更新了网页界面，以提供无缝的用户体验。总之，FerrDb V3已发展成为一个全面的资源库和对RCD研究界极具价值的研究工具。FerrDb V3可在 https://www.zhounan.org/ferrdb/ 免费访问。

### 第二部分 AI 大师评价

本研究旨在介绍其广受欢迎的铁死亡数据库FerrDb的最新升级版V3。该研究通过手动整理超过2万篇文献及整合公共资源，将数据库内容从单一的铁死亡扩展至22种调控性细胞死亡（RCD）模式。其核心创新在于构建了一个全面覆盖RCD领域的综合性、高质量资源库，并通过开发对话式智能助手和在线分析工具，极大地提升了用户体验和数据利用效率。FerrDb V3的推出为细胞死亡研究领域提供了一个宝贵的工具，有望加速对相关疾病发病机制的理解和新疗法的探索。

---

## 37. CellSNVReg：一个用于解析单细胞和空间组学中SNV介导的调控扰动的多维资源

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41171131](https://pubmed.ncbi.nlm.nih.gov/41171131)
**期刊：** Nucleic acids research
**PMID：** 41171131
**DOI：** 10.1093/nar/gkaf1076

### 第一部分 原文与翻译

**英文原标题：** CellSNVReg: a multidimensional resource for SNV-mediated regulatory perturbations in single-cell and spatial omics.

**英文摘要原文：**
Single nucleotide variants (SNVs) represent the most prevalent form of genetic variation and can perturb gene regulation, RNA processing, and protein function across multiple molecular layers, ultimately altering cellular functional states and contributing to disease development. Here, we present CellSNVReg (http://bio-bigdata.hrbmu.edu.cn/CellSNVReg/index.jsp), a comprehensive multidimensional resource systematically characterizing regulatory perturbations caused by SNVs at cell-type and spatial resolutions in humans. By integrating 4.6 million cellular profiles from scRNA-seq, spatial transcriptomics, and scATAC-seq across normal, tumor, and other disease tissues, CellSNVReg identifies an average of over 70 000 regulatory perturbations per sample across six dimensions: miRNA-target, transcription factor (TF)-target, enhancer-target, RBP-target, protein-protein interaction, and neoantigen generation, and further characterizes differential expression of perturbed target genes together with associated perturbation networks. For each perturbation, CellSNVReg provides qualitative annotations and quantitative scores to assess SNV perturbation impact, potentially facilitating prioritization of candidate driver SNVs in disease-relevant contexts. To assess downstream functional consequences, the platform links SNV-perturbed targets to alterations in cell functions, states, stemness, metabolism, cell-cell communication, and drug repurposing. In summary, CellSNVReg offers a high-resolution framework for dissecting the functional impact of SNVs across diverse regulatory layers, enabling exploration of the landscape of SNV-mediated regulatory disruptions and their phenotypic consequences in normal and disease contexts.

**中文摘要译文：**
单核苷酸变异（SNVs）是最普遍的遗传变异形式，能够跨越多个分子层面扰动基因调控、RNA加工和蛋白质功能，最终改变细胞功能状态并导致疾病的发生发展。在此，我们介绍CellSNVReg (http://bio-bigdata.hrbmu.edu.cn/CellSNVReg/index.jsp)，这是一个全面的多维资源，系统性地描绘了人类在细胞类型和空间分辨率水平上由SNVs引起的调控扰动。通过整合来自正常、肿瘤及其他疾病组织的scRNA-seq、空间转录组学和scATAC-seq的460万个细胞图谱，CellSNVReg在每个样本中平均识别出超过7万个跨越六个维度的调控扰动，包括：miRNA-靶标、转录因子（TF）-靶标、增强子-靶标、RBP-靶标、蛋白质-蛋白质相互作用以及新抗原生成，并进一步表征了受扰动靶基因的差异表达及其相关的扰动网络。针对每一次扰动，CellSNVReg提供定性注释和定量评分来评估SNV的扰动影响，这可能有助于在疾病相关背景下优先筛选候选的驱动SNVs。为评估下游功能性后果，该平台将SNV扰动的靶标与细胞功能、状态、干性、代谢、细胞间通讯和药物重定位的改变联系起来。总之，CellSNVReg提供了一个高分辨率的框架，用于剖析SNVs在不同调控层面的功能影响，从而能够在正常和疾病背景下探索SNV介导的调控破坏图景及其表型后果。

### 第二部分 AI 大师评价

本研究旨在构建一个名为CellSNVReg的综合性多维资源，以系统性地解析单核苷酸变异（SNV）在单细胞和空间分辨率下引发的基因调控扰动。研究团队通过整合海量的单细胞多组学数据，从六个关键维度全面识别并量化了SNV的扰动效应，并将其与下游的细胞功能改变相关联。该数据库的创新之处在于其前所未有的分辨率和多维分析框架，为研究人员探索SNV在健康与疾病中的功能影响提供了强大工具，尤其在筛选致病驱动突变方面具有重要科研价值。

---

## 38. SEA 4.0版本：超级增强子档案库的重大扩展与更新

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41171129](https://pubmed.ncbi.nlm.nih.gov/41171129)
**期刊：** Nucleic acids research
**PMID：** 41171129
**DOI：** 10.1093/nar/gkaf1114

### 第一部分 原文与翻译

**英文原标题：** SEA version 4.0: a major expansion and update of the Super-Enhancer Archive.

**英文摘要原文：**
Super-enhancers (SEs) are pivotal epigenetic regulatory elements that profoundly influence cell fate and disease. We herein present an updated SEA version 4.0, a systematic platform designed to elucidate the roles of SEs. A uniform computational pipeline was established to identify SEs based on five key histone marks, using H3K27ac, BRD4, p300, Med1, and the newly added H3K4me1, across 14 species. 496 071 SEs and 29 584 078 enhancers have been stored in the database. It provides extensive genome annotations, including nearby genes, transcription factor binding sites, chromatin accessibility, and other gene regulation signatures. SEA version 4.0 has also achieved functional enrichment analysis of SEs. And a Shannon entropy-based algorithm is employed to identify specific SEs. Furthermore, SEA version 4.0 introduces an interactive regulatory network that incorporates SEs, enhancers, transcription factors, and proximal genes for human and mouse. Additionally, a cell-specific SE detector is provided, designed for cancer research by leveraging scRNA-seq data from 12 cancer and normal samples to explore cell-type-specific SEs. The performance interaction and visualization of SEA version 4.0 enable genomic and cross-species comparisons, revealing complex genomic interactions and becoming an indispensable resource for decoding the mechanisms of SE in development and disease. Access freely at http://sea4.edbc.org.

**中文摘要译文：**
超级增强子（SEs）是关键的表观遗传调控元件，对细胞命运和疾病具有深远影响。我们在此发布了更新的SEA 4.0版本，这是一个旨在阐明SEs作用的系统性平台。我们建立了一个统一的计算流程，该流程基于五个关键的组蛋白标记（H3K27ac、BRD4、p300、Med1以及新加入的H3K4me1），在14个物种中鉴定SEs。数据库中已存储了496,071个SEs和29,584,078个增强子。它提供了广泛的基因组注释，包括邻近基因、转录因子结合位点、染色质可及性以及其他基因调控特征。SEA 4.0版本还实现了对SEs的功能富集分析。并且，它采用了一种基于香农熵的算法来鉴定特异性SEs。此外，SEA 4.0版本还引入了一个交互式调控网络，该网络整合了人类和小鼠的SEs、增强子、转录因子和邻近基因。另外，该版本还提供了一个细胞特异性SE检测器，该检测器专为癌症研究设计，利用来自12种癌症及正常样本的单细胞RNA测序（scRNA-seq）数据来探索细胞类型特异性的SEs。SEA 4.0版本的性能交互和可视化功能支持基因组及跨物种比较，揭示了复杂的基因组相互作用，使其成为解码SE在发育与疾病中作用机制不可或缺的资源。用户可在 http://sea4.edbc.org 免费访问。

### 第二部分 AI 大师评价

本研究介绍了超级增强子档案库（SEA）的重大更新版本4.0，旨在为解析超级增强子（SEs）在生命活动与疾病中的作用提供一个更强大的系统性平台。通过整合五种关键组蛋白标记，该研究在14个物种中大规模鉴定了SEs，并集成了功能富集分析、特异性识别算法、交互式调控网络以及针对癌症研究的单细胞特异性SE检测器等多种创新工具。此次更新极大地丰富了SEs的数据资源和分析维度，特别是其跨物种比较和与单细胞数据结合的分析能力，为深入揭示SEs在发育和疾病（尤其是癌症）中的复杂调控机制提供了不可或缺的宝贵工具，具有重要的科研价值。

---

## 39. 通过破坏癌细胞表面整合素αvβ3与CD47的共稳定性实现癌症免疫治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168993](https://pubmed.ncbi.nlm.nih.gov/41168993)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41168993
**DOI：** 10.1002/advs.202501602

### 第一部分 原文与翻译

**英文原标题：** Cancer Immunotherapy via Disruption of Integrin αvβ3 and CD47 Costabilization on Cancer Cell Surface.

**英文摘要原文：**
CD47/signal-regulatory protein α (SIRPα) signaling enables malignant cells to evade macrophage-mediated phagocytosis, offering a promising strategy for cancer therapy via immune checkpoint blockade. However, this strategy is widely debated due to several safety risks revealed by clinical studies, including anemia. Here, a CD47-SIRPα immune checkpoint treatment is investigated that mitigates anemic side effects by selectively interfering with the costabilization of CD47 and integrin αvβ3 on cancer cell surfaces, a phenomenon absent in erythrocytes. Multiplexed immunofluorescence analysis of 119 clinical breast cancer tissues reveals this costabilization. The engineered peptide PSFL-NK13 effectively disrupts this costabilization, which enhances macrophage phagocytosis and delays tumor growth, without causing anemia or promoting angiogenesis. Thus, a stable interaction is identified between integrin αvβ3 and CD47 on the cancer cell membrane that facilitates immune evasion and demonstrates that targeting this interaction offers a safer therapeutic strategy for various tumors.

**中文摘要译文：**
CD47/信号调节蛋白α (SIRPα) 信号通路使恶性肿瘤细胞能够逃避巨噬细胞介导的吞噬作用，为通过免疫检查点阻断进行癌症治疗提供了一种有前景的策略。然而，由于临床研究揭示的包括贫血在内的多种安全性风险，该策略受到了广泛争议。本研究探讨了一种CD47-SIRPα免疫检查点疗法，该疗法通过选择性干扰癌细胞表面CD47与整合素αvβ3的共稳定性来减轻贫血副作用，而这种共稳定现象在红细胞中并不存在。对119例临床乳腺癌组织的多重免疫荧光分析揭示了这种共稳定性的存在。工程肽PSFL-NK13能有效破坏这种共稳定性，从而增强巨噬细胞的吞噬作用并延缓肿瘤生长，且不引起贫血或促进血管生成。因此，本研究确定了癌细胞膜上整合素αvβ3与CD47之间存在一种促进免疫逃逸的稳定相互作用，并证明靶向该相互作用为多种肿瘤提供了一种更安全的治疗策略。

### 第二部分 AI 大师评价

本研究旨在解决CD47靶向免疫疗法中普遍存在的贫血等安全性问题。研究者创新性地发现并证实了CD47与整合素αvβ3在癌细胞表面存在特异性的共稳定相互作用，而在红细胞上则无此现象。基于此，他们设计了一种工程肽，能够选择性地破坏这种相互作用，从而在有效促进肿瘤免疫清除的同时，避免了对红细胞的误伤。这项工作为开发更安全、更精准的CD47免疫检查点抑制剂提供了全新的策略和候选分子，具有重要的临床转化价值。

---

## 40. 通过声机械力调控大量生物分子结构

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168976](https://pubmed.ncbi.nlm.nih.gov/41168976)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41168976
**DOI：** 10.1002/advs.202511687

### 第一部分 原文与翻译

**英文原标题：** Modulating a Massive Set of Biomolecular Structures by Sono-Mechanical Force.

**英文摘要原文：**
Mechanical modulation of biomolecular structures by single-molecule techniques, such as optical tweezers, has revealed subtle conformational dynamics and enabled precise modulation of functional properties. However, such tools are limited to manipulating one or a few molecules at a time in extracellular settings, posing significant challenges for scaling force-based methods to achieve high sensitivity and efficacy both outside and within cells. Here, low-power (<5.3 mW cm) ultrasound is employed to generate sono-mechanical forces without formation of sonodynamic radicals, which are known to irreversibly alter molecular structures. By calibrating against optical-tweezers-based single-molecule force spectroscopy, this study quantifies for the first time that at least 29 pN sono-mechanical force can be generated at 5.3 mW cm sonication power, capable of simultaneously and reversibly unfold an ensemble set of DNA structures, including G-quadruplexes and hairpins. Notably, the same sono-mechanical unfolding is observed in cells, where intercalated doxorubicin ligands are released from unfolded DNA hairpin carriers, resulting in targeted cancer cell death. These findings show ultrasound can simultaneously manipulate a large population of biomolecules without requiring fixed orientations, offering a flexible and nonintrusive force generation to reversibly unfold molecular structures. This platform holds profound potential for applications in molecular biophysics, smart materials, and precision medicines.

**中文摘要译文：**
通过单分子技术（如光镊）对生物分子结构进行机械调控，揭示了其精细的构象动力学，并实现了对其功能特性的精确调节。然而，这类工具在细胞外环境中一次只能操控一个或少数几个分子，这为扩展基于力的方法以在细胞内外实现高灵敏度和高效率带来了巨大挑战。本研究采用低功率（<5.3 mW cm⁻²）超声产生声机械力，且不形成已知能不可逆地改变分子结构的声动力学自由基。通过与基于光镊的单分子力谱进行校准，本研究首次量化了在5.3 mW cm⁻²的超声功率下可产生至少29 pN的声机械力，该力能够同时且可逆地展开包括G-四链体和发夹在内的DNA结构系综。值得注意的是，在细胞内也观察到了同样的声机械解折叠现象，嵌入的阿霉素配体从未折叠的DNA发夹载体中释放出来，从而导致靶向的癌细胞死亡。这些发现表明，超声可以同时操控大量生物分子，且无需固定的分子取向，为可逆地解折叠分子结构提供了一种灵活且非侵入性的力生成方式。该平台在分子生物物理学、智能材料和精准医学等应用领域具有深远的潜力。

### 第二部分 AI 大师评价

本研究旨在开发一种利用低功率超声产生声机械力的新方法，以实现对大量生物分子结构的同时调控。研究团队通过与光镊技术校准，首次量化了超声能产生足以可逆性展开DNA G-四链体和发夹结构的力（≥29 pN），且该过程不会产生有害的自由基。该方法的创新性在于突破了传统单分子技术通量低的瓶颈，并成功应用于细胞内，通过解折叠DNA载体实现了靶向药物释放与癌细胞杀伤。这项技术为分子生物物理学研究提供了强大的新工具，并在智能材料和精准药物递送等领域展现出巨大的应用潜力。

---

## 41. 一种新型靶向FGFR3的抗体药物偶联物通过cGAS-STING通路诱导膀胱癌细胞凋亡

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168906](https://pubmed.ncbi.nlm.nih.gov/41168906)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41168906
**DOI：** 10.1002/advs.202509933

### 第一部分 原文与翻译

**英文原标题：** A Novel FGFR3-Targeting Antibody-Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS-STING Pathway in Bladder Cancer.

**英文摘要原文：**
Antibody-drug conjugates (ADCs) emerge as a potent cancer therapeutic strategy by enabling precise antigen recognition and efficient intracellular delivery of cytotoxic payloads. In this study, 7-ethyl-9-fluorocamptothecin (A2), a camptothecin derivative, which demonstrates potent tumor-suppressive effects across cellular models, patient-derived organoids (PDOs), and cell line-derived xenograft/patient-derived xenograft (CDX/PDX) models is identified. Through pull-down/mass spectrometry analysis, MAD2L1 is identified as the direct target of A2. A2 specifically binds to the Lys73 site of MAD2L1, activating the cGAS-STING pathway and thereby inducing apoptosis in bladder cancer cells. To address the dose-limiting toxicity caused by A2's insufficient targeting capability, LZU-WZLYCS01, a novel FGFR3-targeting ADC for bladder cancer with A2 as its cytotoxic payload is developed. LZU-WZLYCS01 exhibits precise FGFR3-dependent targeting, with significantly reduced antitumor activity in both FGFR3-knockout cell models and xenograft models. Moreover, in vivo fluorescence imaging demonstrates the potent tumor-targeting capability of LZU-WZLYCS01. LZU-WZLYCS01 demonstrates remarkable bystander effects in an in vitro co-culture model, along with potent tumor growth inhibition in PDOs and CDX/PDX models while maintaining favorable safety. Notably, LZU-WZLYCS01 shows superior antitumor efficacy to gemcitabine-cisplatin (GC) chemotherapy and maintains significant activity in GC-resistant PDX models. These findings present a promising therapeutic candidate for targeted bladder cancer treatment.

**中文摘要译文：**
抗体药物偶联物（ADCs）通过实现精准的抗原识别和高效的细胞毒性载荷胞内递送，成为一种强有力的癌症治疗策略。本研究发现，喜树碱衍生物7-乙基-9-氟喜树碱（A2）在细胞模型、患者来源的类器官（PDOs）以及细胞系来源的异种移植/患者来源的异种移植（CDX/PDX）模型中均表现出强大的肿瘤抑制效应。通过下拉/质谱分析，确定了MAD2L1是A2的直接作用靶点。A2特异性结合MAD2L1的Lys73位点，激活cGAS-STING通路，从而诱导膀胱癌细胞凋亡。为解决A2因靶向能力不足引起的剂量限制性毒性问题，研究人员开发了一种以A2为细胞毒性载荷、靶向FGFR3的新型膀胱癌ADC药物——LZU-WZLYCS01。LZU-WZLYCS01展现出精准的FGFR3依赖性靶向作用，在FGFR3敲除的细胞模型和异种移植模型中，其抗肿瘤活性均显著降低。此外，体内荧光成像证实了LZU-WZLYCS01强大的肿瘤靶向能力。在体外共培养模型中，LZU-WZLYCS01表现出显著的旁观者效应，并在PDOs和CDX/PDX模型中有效抑制肿瘤生长，同时保持了良好的安全性。值得注意的是，LZU-WZLYCS01的抗肿瘤疗效优于吉西他滨-顺铂（GC）化疗方案，并且在耐GC的PDX模型中仍保持显著活性。这些研究结果表明，LZU-WZLYCS01是膀胱癌靶向治疗领域一个极具前景的候选药物。

### 第二部分 AI 大师评价

本研究旨在开发一种靶向FGFR3的新型抗体药物偶联物（ADC）用于治疗膀胱癌。研究团队首先鉴定了一种新的细胞毒性载荷A2，并创新性地揭示了其通过靶向MAD2L1激活cGAS-STING通路诱导细胞凋亡的独特作用机制。基于此，他们成功构建了ADC药物LZU-WZLYCS01，并在多种临床前模型中证实了其精准的靶向性、强大的抗肿瘤活性及良好的安全性，尤其在耐药模型中表现优异。该研究不仅为膀胱癌提供了一种极具潜力的靶向治疗新策略，也为ADC药物的载荷选择和机制探索开辟了新思路。

---

## 42. 急性早幼粒细胞白血病中增强子、转座子和Polycomb靶点的疾病特异性表观遗传失调

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168841](https://pubmed.ncbi.nlm.nih.gov/41168841)
**期刊：** Genome medicine
**PMID：** 41168841
**DOI：** 10.1186/s13073-025-01565-y

### 第一部分 原文与翻译

**英文原标题：** Disease-specific epigenetic deregulation of enhancers, transposons, and polycomb targets in acute promyelocytic leukemia.

**英文摘要原文：**
BACKGROUND: Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML), characterized by a fusion between the PML and RARA genes and by a block in the myeloid maturation at the promyelocytic stage.

METHODS: This study investigates the epigenetic landscape of APL by integrating ChIP-seq data on eight histone modifications and RNA-seq in APL as well as non-APL AML. APL showed a distinct chromatin profile that differed from non-APL AML.

RESULTS: We describe APL-specific changes in H3K27ac, H3K9me3, and H3K27me3 with impact on enhancer activity, repression of transposable elements, and Polycomb regulated gene repression. The APL-specific H3K27ac pattern identifies APL-specific enhancer and super-enhancer regions, including a subset of enhancers that are bound by the PML-RARA fusion protein. While chromatin bound specifically by PML-RARA were dominantly active, APL was also characterized by gain of APL-specific heterochromatin states with significant gains of H3K9me3 enriched lamina-associated domains and the transposable elements LINE, LTR, and SINE.

CONCLUSION: These findings suggest a unique enhancer and heterochromatin profile in APL, with implications for transcription regulation and treatment response. These findings offer novel insights into the pathogenesis of APL.

**中文摘要译文：**
背景：急性早幼粒细胞白血病（APL）是急性髓系白血病（AML）的一个亚型，其特征在于PML和RARA基因之间存在融合，以及髓系成熟在早幼粒细胞阶段受阻。

方法：本研究通过整合APL及非APL AML中八种组蛋白修饰的ChIP-seq数据和RNA-seq数据，探讨了APL的表观遗传图景。APL展现出与非APL AML不同的独特染色质特征。

结果：我们描述了APL中H3K27ac、H3K9me3和H3K27me3的特异性变化，这些变化对增强子活性、转座元件的抑制以及Polycomb调控的基因抑制产生影响。APL特异性的H3K27ac模式识别出了APL特有的增强子和超级增强子区域，其中包括一部分与PML-RARA融合蛋白结合的增强子。尽管PML-RARA特异性结合的染色质主要处于活跃状态，但APL的另一个特征是获得了APL特异性的异染色质状态，表现为富含H3K9me3的核纤层相关结构域以及LINE、LTR和SINE等转座元件显著增加。

结论：这些发现表明APL具有独特的增强子和异染色质特征，这对转录调控和治疗反应具有潜在影响。这些研究结果为APL的发病机制提供了新的见解。

### 第二部分 AI 大师评价

本研究通过整合多种组蛋白修饰的ChIP-seq和RNA-seq数据，系统地描绘了急性早幼粒细胞白血病（APL）独特的表观遗传图谱。其核心发现揭示了APL中存在由PML-RARA融合蛋白驱动的特异性增强子激活，以及H3K9me3和H3K27me3介导的异染色质重塑和基因抑制的复杂模式。这项工作不仅深化了对APL发病机制的理解，超越了单一融合基因的传统视角，还可能为开发靶向表观遗传调控的新型治疗策略提供了重要线索和理论基础。

---

## 43. 乳腺癌治疗中靶向微生物组的纳米平台与工程化方法

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168838](https://pubmed.ncbi.nlm.nih.gov/41168838)
**期刊：** Molecular cancer
**PMID：** 41168838
**DOI：** 10.1186/s12943-025-02456-x

### 第一部分 原文与翻译

**英文原标题：** Microbiome-targeted nanoplatforms and engineering approaches in breast cancer therapy.

**英文摘要原文：**
Breast cancer (BC) presents persistent therapeutic challenges due to tumor heterogeneity, therapy resistance, and immune dysfunction, further compounded by emerging evidence of microbiome involvement in disease progression. Pathogenic bacteria such as Fusobacterium nucleatum have been implicated in modulating immune evasion, remodeling the extracellular matrix, and influencing therapy outcomes. Conventional microbiome-modulating strategies (e.g., antibiotics, probiotics) suffer from non-specificity and potential dysbiosis. Nanomaterial (NM)-based microbiome modulation offers a transformative alternative by enabling: targeted elimination of tumor-associated pathogens (e.g., Gal/GalNAc-functionalized nanoparticles for F. nucleatum), bacterial membrane-coated nanoplatforms for precision antimicrobial delivery, and multifunctional nanosystems that modulate the tumor microenvironment (TME) while preserving beneficial microbiota. This review explores NM-based microbiome modulation across BC contexts, including localized drug delivery, immunomodulation, and microbial niche editing. Highlighted strategies include lipid-based antimicrobial nanoparticles (NP), metallic NPs enhancing therapy sensitivity, and Traditional Chinese Medicine (TCM)-inspired nanoformulations for microbiome balance. Synergies with chemotherapy, immunotherapy, and radiotherapy are evaluated, alongside preclinical findings demonstrating improved tumor control and microbiome resilience. Finally, challenges in clinical translation, including toxicity, immunogenicity, and scalability, are discussed, with future directions emphasizing smart nanosystems capable of microbiome-responsive, biomarker-guided, and immune-integrated interventions in BC therapy.

**中文摘要译文：**
由于肿瘤异质性、治疗耐药性和免疫功能障碍，乳腺癌（BC）带来了持续的治疗挑战，而新出现的微生物组参与疾病进展的证据进一步加剧了这些挑战。具核梭杆菌等致病菌被发现参与调节免疫逃逸、重塑细胞外基质以及影响治疗结局。常规的微生物组调节策略（如抗生素、益生菌）存在非特异性和可能导致菌群失调的缺点。基于纳米材料（NM）的微生物组调节提供了一种变革性的替代方案，它能够实现：靶向清除肿瘤相关病原体（例如，用于清除具核梭杆菌的Gal/GalNAc功能化纳米颗粒）、用于精准抗菌药物递送的细菌膜包被纳米平台，以及在调节肿瘤微环境（TME）的同时保护有益微生物群的多功能纳米系统。本综述探讨了基于纳米材料的微生物组调节在乳腺癌（BC）不同背景下的应用，包括局部药物递送、免疫调节和微生物生态位编辑。其中重点介绍的策略包括脂质基抗菌纳米颗粒（NP）、增强治疗敏感性的金属纳米颗粒，以及受中医药（TCM）启发用于平衡微生物组的纳米制剂。文章评估了这些策略与化疗、免疫疗法和放疗的协同作用，并结合了临床前研究结果，这些结果显示出其在改善肿瘤控制和微生物组恢复力方面的潜力。最后，文章讨论了临床转化中面临的挑战，包括毒性、免疫原性和规模化生产问题，并指出了未来方向，即强调开发能够在乳腺癌治疗中实现微生物组响应、生物标志物引导和免疫整合干预的智能纳米系统。

### 第二部分 AI 大师评价

本篇综述系统阐述了利用靶向微生物组的纳米技术治疗乳腺癌的前沿策略。文章聚焦于如何通过纳米平台精准清除肿瘤相关致病菌、调控肿瘤微环境，并与传统疗法协同增效，从而克服治疗耐药性与免疫功能障碍。其创新性在于将纳米医学与微生态学交叉融合，为乳腺癌治疗提供了靶向“菌-癌”互作的新视角。尽管临床转化面临毒性、免疫原性等挑战，但该方向为开发智能化、多功能的新型抗癌疗法展现了巨大潜力。

---

## 44. I型干扰素信号通路在癌症中的背景依赖性影响

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168836](https://pubmed.ncbi.nlm.nih.gov/41168836)
**期刊：** Molecular cancer
**PMID：** 41168836
**DOI：** 10.1186/s12943-025-02495-4

### 第一部分 原文与翻译

**英文原标题：** Context-dependent impact of type I interferon signaling in cancer.

**英文摘要原文：**
Type I interferon (IFN) has long been known as a critical component of the molecular machinery that first responds to viral infection in multicellular eukaryotes. More recently, type I IFN signaling has also emerged as a common process in the microenvironment of naturally developing neoplasms, as well as tumors responding to (immuno)therapy. In this setting, robust, acute but ultimately resolving type I IFN responses appear to support natural and therapy-driven cancer immunosurveillance by a number of mechanisms, including an accrued propensity of malignant cells to arrest their proliferation and undergo apoptotic cell death, as well as broad immunostimulatory effects on CD8 cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, dendritic cells (DCs) and tumor-associated macrophages (TAMs). Conversely, weak, indolent and ultimately non-resolving type I IFN responses de facto facilitate tumor progression, not only by promoting stemness in malignant cells (which is associated with increased metastatic dissemination and resistance to therapy), but also by favoring the establishment of a highly immunosuppressive lymphoid and myeloid tumor microenvironment. Here, we provide a critical discussion of the context-dependent impact of type I IFN signaling on cancer progression and response to treatment, focusing on the tumor-intrinsic and extrinsic factors that may account for such a heterogeneity.

**中文摘要译文：**
长期以来，I型干扰素（IFN）被认为是多细胞真核生物中首先响应病毒感染的分子机制的关键组成部分。近来，I型干扰素信号通路也已成为自然发生的肿瘤以及响应（免疫）治疗的肿瘤微环境中的一个常见过程。在此背景下，强烈、急性但最终会消退的I型干扰素反应似乎通过多种机制支持自然发生和治疗驱动的癌症免疫监视，这些机制包括增加恶性细胞增殖停滞和发生凋亡的倾向，以及对CD8+细胞毒性T淋巴细胞（CTLs）、自然杀伤（NK）细胞、树突状细胞（DCs）和肿瘤相关巨噬细胞（TAMs）的广泛免疫刺激作用。相反，微弱、缓慢且最终不消退的I型干扰素反应实际上会促进肿瘤进展，这不仅因为它能促进恶性细胞的干性（这与转移扩散增加和治疗抵抗相关），还因为它有利于形成一个高度免疫抑制的淋巴和髓系肿瘤微环境。本文中，我们对I型干扰素信号通路在癌症进展和治疗反应中的背景依赖性影响进行了批判性讨论，重点关注可能导致这种异质性的肿瘤内在和外在因素。

### 第二部分 AI 大师评价

该综述深刻剖析了I型干扰素（Type I IFN）信号通路在癌症中扮演的双重角色。文章核心论点在于，IFN信号通路的影响具有显著的“背景依赖性”：强烈而短暂的IFN反应能有效激活抗肿瘤免疫，抑制癌症；而微弱且持续的IFN反应则反而促进肿瘤干性、耐药及免疫抑制微环境的形成。这篇综述通过整合现有研究，为理解IFN信号通路的复杂性提供了清晰的框架，并对未来开发更精准的、旨在优化而非单纯激活IFN信号的癌症（免疫）疗法具有重要的指导价值。

---

## 45. SLAMF7通过增强谷氨酰胺代谢促进TCRαβ双阴性T细胞的抗肿瘤活性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168829](https://pubmed.ncbi.nlm.nih.gov/41168829)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41168829
**DOI：** 10.1186/s13046-025-03570-w

### 第一部分 原文与翻译

**英文原标题：** SLAMF7 promotes TCRαβ double negative T cell antitumor activity through enhancing glutamine metabolism.

**英文摘要原文：**
BACKGROUND: TCRαβ double negative T cells (DNT) have recently gained attention for their antitumor activity. Adoptive DNT therapy has emerged as a promising cancer immunotherapy due to its potent cytotoxic function and lack of graft-versus-host-disease. However, the intrinsic mechanisms regulating DNT antitumor functions remain unclear.

METHODS: Signaling lymphocytic activation molecule factor 7 (SLAMF7) expression in murine and human DNT were evaluated. The antitumor activities were compared between SLAMF7+ and SLAMF7- DNT both in vivo and in vitro. Further, metabolomics analysis was performed to reveal the underlying mechanism by which SLAMF7 promotes DNT antitumor cytotoxicity.

RESULTS: The expression of SLAMF7 was markedly increased on DNT upon activation. SLAMF7+ DNT exhibited superior antitumor capacity both in vitro and in vivo compared with SLAMF7- DNT. Mechanistically, SLAMF7 enhanced antitumor activity through ligand-independent and ligand-dependent dual manners. Firstly, SLAMF7 could upregulate GPT2/SLC1A5-mediated glutamine metabolism by activating ERK signaling pathway in DNT, thereby supporting mitochondrial fitness, increasing ATP production, enhancing the expression of effector molecules such as granzyme B and perforin, and promoting antitumor activity of DNT against tumor cells independent of homotypic ligand-receptor interactions. Secondly, DNT showed superior antitumor cytotoxicity against SLAMF7-expressing tumor cells because SLAMF7-SLAMF7 interaction between DNT and SLAMF7-expressing tumor cells promoted DNT cell degranulation. Furthermore, SLAMF7 was also highly expressed in human DNT, and its dual antitumor roles in human DNT were also validated.

CONCLUSIONS: SLAMF7 is a key regulator of DNT-mediated cytotoxicity and a promising target for improving DNT cell function in cancer therapy.

**中文摘要译文：**
背景: TCRαβ双阴性T细胞（DNT）因其抗肿瘤活性最近受到了关注。由于其强大的细胞毒性功能且不会引起移植物抗宿主病，过继性DNT疗法已成为一种有前景的癌症免疫疗法。然而，调控DNT抗肿瘤功能的内在机制尚不清楚。

方法: 对小鼠和人类DNT中信号淋巴细胞激活分子因子7（SLAMF7）的表达进行了评估。在体内和体外比较了SLAMF7+ DNT与SLAMF7- DNT的抗肿瘤活性。此外，通过代谢组学分析揭示了SLAMF7促进DNT抗肿瘤细胞毒性的潜在机制。

结果: DNT细胞活化后，SLAMF7的表达显著增加。与SLAMF7- DNT相比，SLAMF7+ DNT在体外和体内均表现出更优越的抗肿瘤能力。从机制上讲，SLAMF7通过配体非依赖性和配体依赖性双重方式增强抗肿瘤活性。首先，SLAMF7可以通过激活DNT中的ERK信号通路，上调GPT2/SLC1A5介导的谷氨酰胺代谢，从而支持线粒体适应性、增加ATP产生、增强颗粒酶B和穿孔素等效应分子的表达，并在不依赖同型配体-受体相互作用的情况下促进DNT对肿瘤细胞的抗肿瘤活性。其次，DNT对表达SLAMF7的肿瘤细胞显示出更强的抗肿瘤细胞毒性，因为DNT与表达SLAMF7的肿瘤细胞之间的SLAMF7-SLAMF7相互作用促进了DNT细胞的脱颗粒。此外，SLAMF7在人类DNT中也高表达，并且其在人类DNT中的双重抗肿瘤作用也得到了验证。

结论: SLAMF7是DNT介导的细胞毒性的关键调控因子，也是癌症治疗中改善DNT细胞功能的一个有前景的靶点。

### 第二部分 AI 大师评价

本研究深入探讨了SLAMF7分子在TCRαβ双阴性T细胞（DNT）抗肿瘤功能中的关键作用。研究通过体内外实验和代谢组学分析，创新性地揭示了SLAMF7通过双重机制增强DNT的杀伤效力：一方面，它以非配体依赖的方式，激活ERK信号通路以促进谷氨酰胺代谢，从而优化细胞能量供给与效应分子表达；另一方面，通过与肿瘤细胞表面的SLAMF7相互作用，促进DNT的脱颗粒反应。该发现不仅深化了对DNT细胞免疫调控网络的理解，更明确指出了SLAMF7可作为增强过继性DNT细胞疗法疗效的潜在靶点，具有重要的临床转化价值。

---

## 46. 人工智能在癌症领域的应用、挑战与未来展望

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168799](https://pubmed.ncbi.nlm.nih.gov/41168799)
**期刊：** Molecular cancer
**PMID：** 41168799
**DOI：** 10.1186/s12943-025-02450-3

### 第一部分 原文与翻译

**英文原标题：** Artificial intelligence in cancer: applications, challenges, and future perspectives.

**英文摘要原文：**
Artificial intelligence (AI) is rapidly revolutionizing the landscape of oncological research and the advancement of personalized clinical interventions. Progress in three interconnected areas, including the development of methods and algorithms for training AI models, the evolution of specialized computing hardware, and increased access to large volumes of cancer data such as imaging, genomics, and clinical information, has converged, leading to promising new applications of AI in cancer research. AI applications are systematically organized according to specific cancer types and clinical domains, encompassing the elucidation and prediction of biological mechanisms, the identification and utilization of patterns within clinical data to improve patient outcomes, and the unraveling of the complexities inherent in epidemiological, behavioral, and real-world datasets. When applied in an ethical and scientifically rigorous manner, these AI-driven approaches hold the promise of accelerating progress in cancer research and ultimately fostering improved health outcomes for all populations. We review examples demonstrating the integration of AI within oncology, highlighting cases where deep learning has adeptly addressed challenges once deemed insurmountable, while also discussing the barriers that must be surmounted to facilitate broader adoption of these technologies.

**中文摘要译文：**
人工智能（AI）正在迅速革新肿瘤学研究的格局，并推动个体化临床干预的进步。三个相互关联领域的进展——包括AI模型训练方法与算法的开发、专用计算硬件的演进，以及对影像、基因组学和临床信息等海量癌症数据的更多访问权限——已经汇聚在一起，催生了AI在癌症研究中前景广阔的新应用。AI应用根据特定的癌症类型和临床领域进行了系统性组织，涵盖了阐明和预测生物学机制、识别并利用临床数据中的模式以改善患者预后，以及解析流行病学、行为学和真实世界数据中固有的复杂性。当以合乎伦理和科学严谨的方式应用时，这些由AI驱动的方法有望加速癌症研究的进程，并最终促进所有人群健康状况的改善。我们回顾了展示AI与肿瘤学融合的实例，重点介绍了深度学习巧妙解决曾被认为无法克服的挑战的案例，同时我们还探讨了为促进这些技术更广泛应用而必须克服的障碍。

### 第二部分 AI 大师评价

本文是一篇关于人工智能在肿瘤学领域应用的综合性综述。文章系统性地梳理了AI在癌症研究中的应用，涵盖从生物机制预测、临床数据模式识别到流行病学数据分析等多个层面，并强调了算法、硬件与大数据的融合是推动其发展的核心动力。该综述通过展示深度学习解决复杂问题的实例，描绘了AI赋能癌症研究和个体化治疗的广阔前景，同时也指出了推广应用前必须克服的伦理和技术障碍，为该领域的未来发展提供了重要的参考视角。

---

## 47. 更正：通过PDIA4的重新分布，caspase-3和P53的非遗传性失活可增强癌细胞的适应性。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168500](https://pubmed.ncbi.nlm.nih.gov/41168500)
**期刊：** Oncogene
**PMID：** 41168500
**DOI：** 10.1038/s41388-025-03616-5

### 第一部分 原文与翻译

**英文原标题：** Correction: Non-genetic inactivation of caspase-3 and P53 increases cancer cell fitness by PDIA4 redistribution.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇发表在《Oncogene》上的更正声明，因此没有提供摘要内容。基于其标题推断，其旨在纠正一篇关于“通过PDIA4重新分布，caspase-3和P53的非遗传性失活可增强癌细胞适应性”的研究。该研究标题揭示了一个重要的科学问题，即在不涉及基因突变的情况下，关键蛋白（caspase-3和p53）的功能丧失如何促进肿瘤进展。这项研究的潜在创新性在于提出了PDIA4重新分布这一新颖的分子机制，这可能为理解肿瘤适应性及开发新的治疗靶点提供线索。

---

## 48. 间充质细胞重建胸腺

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168497](https://pubmed.ncbi.nlm.nih.gov/41168497)
**期刊：** Nature biotechnology
**PMID：** 41168497
**DOI：** 10.1038/s41587-025-02821-7

### 第一部分 原文与翻译

**英文原标题：** Mesenchymal cells rebuild the thymus.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究仅凭标题来看，揭示了间充质细胞在胸腺重建中的关键作用，这可能是一项再生医学领域的重大突破。发表于《自然-生物技术》这样的顶尖期刊，预示着其采用了创新的细胞工程或组织工程技术，成功实现了胸腺组织的功能性再生。此项发现对于治疗先天性胸腺发育不全、衰老相关的免疫功能减退以及癌症放化疗后的免疫重建具有巨大的临床应用潜力。然而，由于缺乏摘要信息，本研究的具体模型、作用机制及转化应用的可行性尚待全文揭示。

---

## 49. 胸腺间充质微环境细胞促进成年胸腺再生与T细胞免疫

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168496](https://pubmed.ncbi.nlm.nih.gov/41168496)
**期刊：** Nature biotechnology
**PMID：** 41168496
**DOI：** 10.1038/s41587-025-02864-w

### 第一部分 原文与翻译

**英文原标题：** Mesenchymal thymic niche cells enable regeneration of the adult thymus and T cell immunity.

**英文摘要原文：**
Thymic atrophy and the progressive immune decline that accompanies it is a major health problem, chronically with age and acutely with immune injury. No definitive solution is available. Here we demonstrate that one of the three mesenchymal cell subsets identified by single-cell analysis of human and mouse thymic stroma is a critical niche component for T lymphopoiesis. The Postn subset is perivascular, and its depletion abrogates T cell progenitor recruitment, likely through production of the chemokine Ccl19. It markedly declines with age and in the acute setting of hematopoietic stem cell transplant conditioning. When isolated and adoptively transferred, Postn cells durably engraft the atrophic thymus, recruit early T progenitors, increase T cell neogenesis and enhance T cell response to vaccination. More readily available mesenchymal populations expressing Ccl19 provide similar effects. These data define a thymus lymphopoietic niche cell type that may be manipulated therapeutically to regenerate T lymphopoiesis.

**中文摘要译文：**
胸腺萎缩及其伴随的进行性免疫功能衰退是一个重大的健康问题，在年龄增长过程中呈慢性表现，在免疫损伤时则呈急性表现。目前尚无确切的解决方案。在此，我们通过对人类和小鼠胸腺基质的单细胞分析，证实了三种间充质细胞亚群中的一种是T淋巴细胞生成的关键微环境组分。该Postn亚群位于血管周围，清除该亚群会阻断T细胞祖细胞的招募，这很可能是通过其产生的趋化因子Ccl19实现的。该细胞亚群会随着年龄增长以及在造血干细胞移植预处理的急性期显著减少。当Postn细胞被分离并进行过继转移后，它们能够持久地植入萎缩的胸腺，招募早期T祖细胞，增加T细胞的新生，并增强对疫苗接种的T细胞应答。表达Ccl19且更易获取的间充质细胞群体也能产生类似的效果。这些数据明确了一种胸腺淋巴生成微环境细胞类型，其可能通过治疗性调控来再生T淋巴细胞的生成过程。

### 第二部分 AI 大师评价

本研究旨在解决胸腺萎缩与免疫衰老这一难题，通过单细胞分析等前沿技术，精准识别出一种对T细胞发育至关重要的Postn+胸腺间充质微环境细胞。研究关键发现，该细胞亚群随增龄和免疫损伤而减少，而通过过继转移移植该细胞能够有效再生萎缩的胸腺并恢复T细胞免疫功能。此项工作不仅揭示了胸腺再生的关键细胞机制，更重要的是为开发逆转免疫衰老和增强免疫功能（如疫苗反应）的细胞疗法提供了明确的靶点和理论依据，具有重大的临床转化潜力。

---

## 50. 利用颜色强度条形码，通过传统显微镜实现单轮高重数空间RNA成像

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168495](https://pubmed.ncbi.nlm.nih.gov/41168495)
**期刊：** Nature biotechnology
**PMID：** 41168495
**DOI：** 10.1038/s41587-025-02883-7

### 第一部分 原文与翻译

**英文原标题：** High-plex spatial RNA imaging in one round with conventional microscopes using color-intensity barcodes.

**英文摘要原文：**
Spatial RNA imaging has not been widely adopted because conventional fluorescence microscopy is limited to only a few channels and the cyclic reactions needed to increase multiplexing in techniques such as sequential fluorescence in situ hybridization require sophisticated instrumentation. Here, we introduce 'profiling of RNA in situ through single-round imaging' (PRISM), a method that expands coding capacity through color intensity grading. Using a radius vector filtering strategy to ensure the distinguishability of codewords in color space, PRISM achieves up to 64-plex color-barcoded RNA imaging in a single imaging round with conventional microscopes. We validate PRISM's versatility across various tissues by generating a three-dimensional (3D) atlas of mouse embryonic development from E12.5 to E14.5, a quasi-3D tumor-normal transition landscape of human hepatocellular carcinoma and a 3D cell atlas and subcellular RNA localization landscapes of mouse brain. Additionally, we show the critical role of cancer-associated fibroblasts in mediating immune infiltration and immune response heterogeneity within and between tumor microenvironments.

**中文摘要译文：**
空间RNA成像技术尚未得到广泛应用，因为传统荧光显微镜仅限于少数几个通道，而在序贯荧光原位杂交等技术中，增加多重性所需的循环反应又需要复杂的仪器设备。在此，我们介绍一种名为“通过单轮成像进行原位RNA分析”（PRISM）的方法，该方法通过颜色强度分级来扩展编码能力。通过使用径向矢量筛选策略确保码字在颜色空间中的可区分性，PRISM利用传统显微镜在单轮成像中即可实现高达64重的颜色条形码RNA成像。我们通过生成E12.5至E14.5小鼠胚胎发育的三维（3D）图谱、人肝细胞癌的准3D肿瘤-正常组织过渡图景，以及小鼠大脑的3D细胞图谱和亚细胞RNA定位图景，验证了PRISM在多种组织中的通用性。此外，我们还揭示了癌症相关成纤维细胞在介导肿瘤微环境内部及之间的免疫浸润和免疫反应异质性中的关键作用。

### 第二部分 AI 大师评价

本研究旨在解决传统空间RNA成像技术通量低且依赖复杂设备的技术瓶颈。研究者开发了一种名为PRISM的新方法，通过创新的颜色强度分级编码策略，使用传统显微镜即可在单轮成像中实现高达64重的高通量RNA检测。该研究不仅成功绘制了多种复杂组织的三维基因表达图谱，还揭示了肿瘤微环境中的重要细胞互作机制。PRISM技术的创新性在于其极大地降低了高通量空间转录组学的技术门槛，有望在发育生物学、肿瘤学和神经科学等领域得到广泛应用，具有重要的科研价值和推广潜力。

---

## 51. 出版商更正：基于可穿戴设备的不同强度体力活动对死亡、心脏代谢疾病和癌症的健康等效性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168243](https://pubmed.ncbi.nlm.nih.gov/41168243)
**期刊：** Nature communications
**PMID：** 41168243
**DOI：** 10.1038/s41467-025-65754-4

### 第一部分 原文与翻译

**英文原标题：** Publisher Correction: Wearable device-based health equivalence of different physical activity intensities against mortality, cardiometabolic disease, and cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该标题表明，原始研究旨在利用可穿戴设备收集的客观数据，量化并比较不同强度体力活动在预防死亡、心脏代谢疾病及癌症方面的健康等效性。其核心创新在于通过大数据分析精确阐明了不同活动强度间的替换关系，为制定更个体化、灵活的体育活动指南提供了科学依据。这项研究对于推动精准健康管理和公共卫生政策具有重要价值，但需注意本文献为一则出版商更正，且无摘要，具体内容需查阅原文。

---

## 52. α-烯醇化酶通过调控糖酵解影响胃癌的胞浆ATP池及乳酸稳态

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168198](https://pubmed.ncbi.nlm.nih.gov/41168198)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41168198
**DOI：** 10.1038/s41392-025-02451-0

### 第一部分 原文与翻译

**英文原标题：** Alpha-enolase influences ATP pool of cytoplasm and lactate homeostasis by regulating glycolysis in gastric cancer.

**英文摘要原文：**
Glycolysis is crucial for maintaining cancer stemness. This study demonstrated the role of the glycolytic enzyme alpha-enolase (ENO1) in glycolysis and stemness in gastric cancer (GC). High ENO1 expression was associated with poor prognosis and promoted malignant phenotypes and stem-like characteristics in patients with GC. Mechanistically, ENO1 directly stimulates lactate and ATP production by regulating glycolysis, affecting lactate homeostasis and intracellular ATP pools, and coregulating the AMPK/mTOR and PI3K/AKT signaling pathways. This ultimately drives GC stemness, epithelial‒mesenchymal transition (EMT)-related marker expression, self-renewal, migration, and invasion. Notably, the increase in the intracellular ATP pool can directly activate the PI3K/AKT pathway in a concentration-dependent manner, thereby further stimulating glycolysis to form a positive feedback loop. The functional role of lactate depends on the simultaneous presence of glycolysis-derived ATP to synergistically activate the PI3K/AKT pathway. Lactate homeostasis can also promote tumor stemness by increasing overall plactylation levels. Furthermore, pharmacological studies revealed that metformin combined with copanlisib significantly inhibited tumors by blocking the energy metabolism pathways PI3K/AKT and AMPK/mTOR. Our findings are the first to reveal the multifaceted role of ENO1 in mediating intracellular signaling and metabolic regulation to enhance stemness in GC. By establishing cell models with varying metabolite concentrations, we identified differential regulation of the PI3K/AKT and AMPK/mTOR pathways through lactate homeostasis and intracellular ATP pools, further confirming the metabolic crosstalk mechanism. Rationally, targeting multiple nodes along the ENO1-ATP/lactate-AMPK/PI3K/AKT-mTOR axis may be effective for GC treatment, as indicated by the significant suppression of tumor growth by metformin (which inhibits ATP production) plus syrosingopine (which disrupts lactate homeostasis). In conclusion, the complex interplay between metabolism and tumor stemness offers novel therapeutic directions and potential treatment strategies for GC.

**中文摘要译文：**
糖酵解对于维持癌症干性至关重要。本研究揭示了糖酵解酶α-烯醇化酶（ENO1）在胃癌（GC）的糖酵解和干性维持中的作用。高ENO1表达与胃癌患者的不良预后相关，并能促进其恶性表型和干细胞样特征。机制上，ENO1通过调节糖酵解直接刺激乳酸和ATP的产生，从而影响乳酸稳态和细胞内ATP池，并共同调节AMPK/mTOR和PI3K/AKT信号通路。这最终驱动了胃癌的干性、上皮-间质转化（EMT）相关标志物的表达、自我更新、迁移和侵袭能力。值得注意的是，细胞内ATP池的增加能以浓度依赖的方式直接激活PI3K/AKT通路，从而进一步刺激糖酵解，形成一个正反馈循环。乳酸的功能作用依赖于糖酵解来源的ATP的同时存在，以协同激活PI3K/AKT通路。乳酸稳态还能通过提高总泛乳酸化水平来促进肿瘤干性。此外，药理学研究显示，二甲双胍联合copanlisib可通过阻断PI3K/AKT和AMPK/mTOR这两条能量代谢通路来显著抑制肿瘤。我们的研究结果首次揭示了ENO1在介导细胞内信号传导和代谢调控以增强胃癌干性方面的多方面作用。通过建立具有不同代谢物浓度的细胞模型，我们识别了乳酸稳态和细胞内ATP池对PI3K/AKT和AMPK/mTOR通路的不同调控作用，进一步证实了代谢串扰机制。理论上，靶向ENO1-ATP/乳酸-AMPK/PI3K/AKT-mTOR轴上的多个节点可能对胃癌治疗有效，正如二甲双胍（抑制ATP产生）联合syrosingopine（破坏乳酸稳态）能显著抑制肿瘤生长所证实的那样。总之，新陈代谢与肿瘤干性之间复杂的相互作用为胃癌治疗提供了新的治疗方向和潜在的治疗策略。

### 第二部分 AI 大师评价

本研究旨在深入探讨糖酵解酶ENO1在胃癌干性维持中的具体作用及其分子机制。研究通过分析临床数据、构建不同代谢物浓度的细胞模型并结合药理学干预，揭示了ENO1通过调节糖酵解，影响细胞内ATP池和乳酸稳态，进而调控AMPK/mTOR与PI3K/AKT信号通路。其关键发现是阐明了ATP池增加可直接激活PI3K/AKT通路形成正反馈循环，并证实了靶向ENO1-ATP/乳酸-信号通路轴的多节点联合策略具有显著的抗肿瘤效果。该研究的创新性在于精准链接了代谢重编程（以ENO1为核心）与信号网络，为胃癌的代谢靶向治疗提供了坚实的理论基础和颇具前景的联合用药新策略。

---

## 53. 染色质重塑因子的凝集依赖性相互作用组是其肿瘤抑制活性的基础

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168190](https://pubmed.ncbi.nlm.nih.gov/41168190)
**期刊：** Nature communications
**PMID：** 41168190
**DOI：** 10.1038/s41467-025-64655-w

### 第一部分 原文与翻译

**英文原标题：** Condensation-dependent interactome of a chromatin remodeler underlies tumor suppressor activities.

**英文摘要原文：**
Chromatin remodelers are vital for cellular functions like transcription by modulating nucleosome accessibility. Although biological condensates regulate these processes, the contribution of chromatin remodelers to condensation mechanisms remains poorly understood. Here, we examine the role of the E1321 frameshift mutation in CHD1, a chromatin remodeler, which is often targeted in cancers. This mutation truncates CHD1's C-terminus, leading to an oncogenic transcriptome and promoting tumorigenesis. This is due to the loss of an intrinsically disordered region (IDR) crucial for forming CHD1 condensates. These condensates are facilitated by the presence of H3K4me3-modified nucleosomes and RNA, guided to active promoters to regulate gene expression. Furthermore, CHD1 condensates contain long noncoding RNA and histone-modifying proteins, revealing an integral role for CHD1 condensates in epigenetic regulation. Among these components, MLL mutations frequently co-occur with CHD1 mutations in various cancers, suggesting a shared pathway in cancer development. These findings underscore the importance of chromatin remodeler condensation as a regulatory hub in various cellular processes and tumor suppression.

**中文摘要译文：**
染色质重塑因子通过调节核小体的可及性，对转录等细胞功能至关重要。尽管生物分子凝集物调控这些过程，但染色质重塑因子对凝集机制的贡献仍知之甚少。在此，我们研究了染色质重塑因子CHD1中E1321位移码突变的作用，该突变在癌症中频繁出现。该突变导致CHD1的C-末端截短，进而引发致癌性转录组并促进肿瘤发生。这是由于其丢失了一段对形成CHD1凝集物至关重要的内在无序区（IDR）。这些凝集物的形成受到H3K4me3修饰的核小体和RNA的促进，并被引导至活性启动子处以调控基因表达。此外，CHD1凝集物包含长链非编码RNA和组蛋白修饰蛋白，揭示了CHD1凝集物在表观遗传调控中不可或缺的作用。在这些组分中，MLL突变在多种癌症中常与CHD1突变同时发生，表明它们在癌症发展中可能存在共同的通路。这些发现强调了染色质重塑因子的凝集作用是多种细胞过程和肿瘤抑制中的一个调控中枢。

### 第二部分 AI 大师评价

本研究聚焦于染色质重塑因子CHD1的抑癌机制，通过分析一种常见的CHD1移码突变，创新地揭示其C-末端对于形成“生物分子凝集物”至关重要。关键发现是，该突变导致CHD1丧失凝集能力，无法在基因启动子区域有效行使功能，从而失去抑癌活性。该研究将“相分离”前沿概念与肿瘤发生机制紧密结合，为理解CHD1功能及相关癌症治疗提供了新的理论视角。

---

## 54. 多发性骨髓瘤前驱病的早期发现可改善患者生存：一项全国性真实世界研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168167](https://pubmed.ncbi.nlm.nih.gov/41168167)
**期刊：** Blood cancer journal
**PMID：** 41168167
**DOI：** 10.1038/s41408-025-01395-6

### 第一部分 原文与翻译

**英文原标题：** Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究旨在通过一项全国范围的真实世界数据，探讨在多发性骨髓瘤（MM）确诊前能否检测到其前驱病变（如MGUS）对患者生存结局的影响。从标题推断，研究关键发现为：预先识别出前驱病变的患者，其后续发展为MM后的生存率更高。这项研究的价值在于为前驱病变的筛查和监测提供了强有力的真实世界证据，提示早期干预可能改善患者的长期预后，对制定未来的临床指南具有重要参考意义。然而，由于缺乏摘要，研究的具体方法、偏倚控制及结果的详细解读尚不明确。

---

## 55. PUS7介导的7SK假尿苷化调控Pol II转录延伸

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168165](https://pubmed.ncbi.nlm.nih.gov/41168165)
**期刊：** Nature communications
**PMID：** 41168165
**DOI：** 10.1038/s41467-025-64668-5

### 第一部分 原文与翻译

**英文原标题：** Pseudouridylation of 7SK by PUS7 regulates Pol II transcription elongation.

**英文摘要原文：**
Pseudouridine (Ψ) is a widespread RNA modification in various RNA species, including rRNA, tRNA, snRNA and mRNA. Ψ plays a crucial role in RNA metabolism, where it regulates pre-mRNA splicing and affects protein translation. Whether and how Ψ may regulate transcription have not been adequately studied. Here, we report that pseudouridine synthase 7 (PUS7) can mediate pseudouridylation of 7SK small nuclear RNA (snRNA), a regulator of RNA polymerase II (Pol II) promoter-proximal pausing. PUS7 loss leads to hypo-pseudouridylation of 7SK, which promotes dissociation of the positive transcription elongation factor b (P-TEFb) complex from 7SK. The release of P-TEFb from 7SK increases serine 2 phosphorylation (Ser2P) in the RNA Pol II C-terminal domain and enhances transcription elongation. In colorectal cancer (CRC) cells, the Ψ level of 7SK can be modulated by PUS7, or by site-specifically targeted pseudouridylation through dCas13b-guided system. Hypo-pseudouridylation on 7SK upon PUS7 depletion promotes KLF6/DDIT3-mediated cell apoptosis and sensitizes CRC cells to 5-FU.

**中文摘要译文：**
假尿苷 (Ψ) 是一种广泛存在于多种RNA（包括rRNA、tRNA、snRNA和mRNA）中的RNA修饰。Ψ在RNA代谢中扮演着关键角色，它能调控pre-mRNA的剪接并影响蛋白质翻译。然而，Ψ是否以及如何调控转录尚未得到充分研究。在此，我们报告了假尿苷合酶7 (PUS7) 能够介导7SK小核RNA (snRNA) 的假尿苷化，而7SK是RNA聚合酶II (Pol II) 启动子近端暂停的调节因子。PUS7的缺失导致7SK的假尿苷化水平降低，这促进了正转录延伸因子b (P-TEFb) 复合物从7SK上的解离。P-TEFb从7SK上的释放增加了RNA Pol II C末端结构域的丝氨酸2磷酸化 (Ser2P) 水平，从而增强了转录延伸。在结直肠癌 (CRC) 细胞中，7SK的Ψ水平可以通过PUS7或通过dCas13b引导的系统进行位点特异性靶向假尿苷化来调节。PUS7耗竭后7SK的低假尿苷化水平促进了KLF6/DDIT3介导的细胞凋亡，并使CRC细胞对5-FU更为敏感。

### 第二部分 AI 大师评价

本研究旨在揭示一种重要的RNA修饰——假尿苷化（Ψ）在基因转录调控中的新作用。研究团队通过分子生物学手段，首次发现假尿苷合酶PUS7能够修饰调控RNA聚合酶II（Pol II）活性的7SK snRNA。其关键发现是，降低7SK的假尿苷化水平会释放转录延伸因子P-TEFb，从而激活Pol II并促进转录延伸。更具临床意义的是，在结直肠癌细胞中，抑制这一修饰可促进细胞凋亡并增强化疗药物5-FU的敏感性，为癌症治疗提供了新的潜在靶点和策略。

---

## 56. 癌症发生的单限速事件

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168156](https://pubmed.ncbi.nlm.nih.gov/41168156)
**期刊：** Nature communications
**PMID：** 41168156
**DOI：** 10.1038/s41467-025-64613-6

### 第一部分 原文与翻译

**英文原标题：** Single rate-limiting event of carcinogenesis.

**英文摘要原文：**
Single-cell studies have discovered abundant cancer-associated genetic/phenotypic changes in non-cancerous cells, strikingly contrasting with the infrequency of cancer. Epidemiological data have revealed decades-long plateaus of breast cancer incidence in the contralateral breast and twins/relatives following the first/proband's diagnosis, unlike the well-known continuous increase of population-level incidence with age, the latter ostensibly attributable to the successive accumulation of multiple genetic/epigenetic changes necessary for transformation. Here, we explain these contradicting observations by differentiating cell-level, individual-level, and population-level evidence. First, we show the same decades-long incidence plateau for renal-cell carcinoma in the contralateral kidney following the first diagnosis, expanding the individual-level evidence from breast cancer. We then consider somatic evolution and cell competition in stem-cell compartments and their bounded nature in ageing as a hypothesized mechanism for the abundant cancer-associated cell-level changes and the prolonged constancy of individual-level incidence. Individual-specific propensity with heritable/familial components underlies this process, with which we show congruence between individual-level's constant incidence vs. population-level's increasing incidence. The resulting postulate, an extension of one by Peto and Mack 25 years ago, distinguishes the last multistage "hit" as the critically rate-limiting event in carcinogenesis. Its supporting evidence calls for a reappraisal of the precise nature of multistage carcinogenesis in cancer biology.

**中文摘要译文：**
单细胞研究发现，非癌细胞中存在大量与癌症相关的遗传/表型改变，这与癌症的罕见性形成鲜明对比。流行病学数据显示，在首个/先证者诊断后，对侧乳腺以及双胞胎/亲属中的乳腺癌发病率存在长达数十年的平台期，这与众所周知的人群水平发病率随年龄持续增长的现象不同，后者表面上可归因于转化所需多个遗传/表观遗传变化的连续累积。在此，我们通过区分细胞水平、个体水平和人群水平的证据来解释这些相互矛盾的观察结果。首先，我们展示了在首次诊断后，对侧肾脏的肾细胞癌也存在同样长达数十年的发病率平台期，从而扩展了来自乳腺癌的个体水平证据。然后，我们考虑了干细胞区室中的体细胞进化和细胞竞争及其在衰老过程中的有限性，并将其作为一种假说机制，用以解释大量与癌症相关的细胞水平变化以及个体水平发病率的长期恒定性。具有遗传/家族成分的个体特异性易感性是这一过程的基础，我们借此展示了个体水平的恒定发病率与人群水平的递增发病率之间的一致性。由此得出的假设是Peto和Mack在25年前一项假设的延伸，它将最后一次多阶段“打击”区分为癌症发生过程中的关键限速事件。其支持性证据呼吁对癌症生物学中多阶段致癌作用的精确本质进行重新评估。

### 第二部分 AI 大师评价

该研究旨在解决一个核心矛盾：为何非癌组织中普遍存在癌相关突变，但癌症本身却相对罕见。通过整合分析乳腺癌和肾癌的流行病学数据，并引入体细胞进化与细胞竞争理论，研究提出了一个创新性的癌症发生模型。其关键发现是，在多阶段致癌过程中，最后的“临门一脚”式打击（hit）才是决定癌症是否发生的关键限速事件，而非早期突变的简单累积。这项工作挑战了传统的癌症发生理论，为理解癌症风险的个体化差异和制定新的预防策略提供了重要理论依据。

---

## 57. 对患者匹配的HER2阳性胃癌进行空间图谱分析揭示靶向治疗的耐药机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167802](https://pubmed.ncbi.nlm.nih.gov/41167802)
**期刊：** Gut
**PMID：** 41167802
**DOI：** 10.1136/gutjnl-2024-334667

### 第一部分 原文与翻译

**英文原标题：** Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy.

**英文摘要原文：**
BACKGROUND: Human epidermal growth factor receptor 2 (HER2; ) is overexpressed or amplified in 15-20% of gastric cancers (HER2+ GC). Within individual HER2+ GCs, HER2/ expression is often variable. Although HER2 therapeutic targeting improves outcomes for HER2+ GC patients, acquired resistance is frequent.

OBJECTIVE: To spatially interrogate HER2+ GC interpatient and intrapatient heterogeneity and resistance mechanisms associated with HER2-targeting agents (trastuzumab, trastuzumab deruxtecan (T-DXd)).

DESIGN: Spatial transcriptomic analysis (GeoMx Digital Spatial Profiler) was applied to >1500 regions of interest in 30 GCs-these contained 15 HER2+ GCs treated with trastuzumab and T-DXd subsequently. Analysis of patient-matched samples with acquired trastuzumab or T-DXd resistance revealed escape mechanisms. Results were validated by immunohistochemistry, independent cohorts and patient-derived xenografts and organoids.

RESULTS: HER2+ tumours exhibited  expression within the spatial tumour microenvironment. We observed increased expression of CLDN18.2, a promising therapeutic target, in trastuzumab-resistant tumours. One-third of HER2+ GC patients developed epithelial-mesenchymal transition (EMT) on trastuzumab resistance, associated with  and  upregulation. Another third of trastuzumab-resistant HER2+ GC patients activated the endoplasmic reticulum-associated degradation (ERAD) pathway including genes such as . HLA loss and increases in oxidative phosphorylation pathways were observed in T-DXd-resistant GCs.

CONCLUSION: Our results delineate multiple acquired resistance mechanisms to trastuzumab and T-DXd in HER2+ GC . This information may guide trials combining trastuzumab or T-DXd with new agents to enhance the efficacy and durability of HER2 blockade.

**中文摘要译文：**
背景：15-20%的胃癌（HER2+ GC）中存在人表皮生长因子受体2（HER2; ERBB2）的过表达或扩增。在单个HER2+ GC内部，HER2/ERBB2的表达通常存在变异。尽管HER2靶向治疗改善了HER2+ GC患者的预后，但获得性耐药频繁发生。

目的：旨在通过空间分析技术，探究HER2+ GC的患者间和患者内异质性，以及与HER2靶向药物（曲妥珠单抗、德曲妥珠单抗，即T-DXd）相关的耐药机制。

设计：本研究对30例胃癌样本中的超过1500个感兴趣区域应用了空间转录组学分析（GeoMx数字空间分析平台），其中包括15例先后接受曲妥珠单抗和T-DXd治疗的HER2+ GC。通过对获得性曲妥珠单抗或T-DXd耐药的患者匹配样本进行分析，揭示了其逃逸机制。研究结果通过免疫组织化学、独立队列、患者来源的异种移植物和类器官进行了验证。

结果：HER2+肿瘤在空间肿瘤微环境中表现出ERBB2表达。我们观察到，在曲妥珠单抗耐药的肿瘤中，一个有前景的治疗靶点CLDN18.2的表达增加。三分之一的HER2+ GC患者在对曲妥珠单抗产生耐药时发生了上皮间质转化（EMT），这与 [基因名] 和 [基因名] 的上调有关。另外三分之一的曲妥珠单抗耐药的HER2+ GC患者激活了内质网相关降解（ERAD）通路，包括诸如 [基因名] 的基因。在T-DXd耐药的胃癌中，观察到HLA的丢失和氧化磷酸化通路的增强。

结论：我们的研究结果描绘了HER2+ GC对曲妥珠单抗和T-DXd的多种获得性耐药机制。这些信息可为指导未来将曲妥珠单抗或T-DXd与新药联合使用的临床试验提供依据，以增强HER2阻断治疗的疗效和持久性。

### 第二部分 AI 大师评价

本研究利用前沿的空间转录组学技术，对接受HER2靶向治疗前后的患者配对胃癌样本进行深度分析，旨在揭示对曲妥珠单抗及T-DXd的获得性耐药机制。研究的关键发现，是明确了不同HER2靶向药物诱导出的多样化耐药通路，例如曲妥珠单抗耐药涉及CLDN18.2上调、上皮间质转化（EMT）或内质网相关降解（ERAD）通路激活，而T-DXd耐药则与HLA丢失及氧化磷酸化相关。该研究的创新性在于通过空间维度精准解析了耐药的异质性，其发现不仅深化了对HER2+胃癌耐药机制的理解，更为开发新型联合治疗策略、克服临床耐药挑战提供了坚实的理论依据和潜在靶点。

---

## 58. 卡度尼利单抗联合紫杉烷类和顺铂一线治疗晚期食管鳞状细胞癌：一项开放标签、多中心的II期临床试验。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167638](https://pubmed.ncbi.nlm.nih.gov/41167638)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41167638
**DOI：** 10.1136/jitc-2025-012869

### 第一部分 原文与翻译

**英文原标题：** Cadonilimab combined with taxane and cisplatin as the first-line treatment of advanced esophageal squamous cell carcinoma: an open-label, multicenter phase II trial.

**英文摘要原文：**
BACKGROUND: Cadonilimab, a bispecific antibody simultaneously targeting programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4, may further boost antitumor activity compared with PD-1 or programmed cell death ligand 1 (PD-L1) inhibitors. Here, we evaluated the safety and efficacy of cadonilimab combined with chemotherapy as the first-line treatment in advanced esophageal squamous cell carcinoma (ESCC).

METHODS: Treatment-naïve patients with unresectable locally advanced or metastatic ESCC were eligible. Cadonilimab combined with paclitaxel or nab-paclitaxel and cisplatin was administrated for up to six cycles, then cadonilimab monotherapy continued as maintenance until progressive disease or unacceptable toxicity, with a maximum of 24 months. The primary endpoint was objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate (DCR) and safety. Plasma cell-free DNA samples were collected before and after treatment and prepared for DNA methylation level sequencing.

RESULTS: As of September 27, 2024, 43 patients were enrolled with a median age of 61 years (range 44-75), 39.5% had PD-L1 combined positive score ≥10 and 95.3% had distant metastases. The ORR was 81.4% (95% CI 66.6% to 91.6%) and DCR was 97.7% (95% CI 86.2% to 99.9%). The median PFS was 7.10 months (95% CI 5.68 to 8.48) while OS remained immature. The mean pretreatment cytosine-phosphate-guanine (CpG) site methylation levels of APBA2, EPAS1, TRIM58, ITPKA and LINC00554 were significantly higher in responders than those in non-responders. Grade 3-4 treatment-related adverse events were reported in 53.5% (23/43) patients.

CONCLUSIONS: Cadonilimab combined with taxane and cisplatin as first-line treatment revealed encouraging antitumor activity and manageable safety in patients with advanced ESCC. DNA methylation level might be a potential biomarker for guiding patient outcomes.

TRIAL REGISTRATION NUMBER: NCT05522894.

**中文摘要译文：**
背景：卡度尼利单抗是一种同时靶向程序性死亡受体1（PD-1）和细胞毒性T淋巴细胞抗原4的双特异性抗体，与PD-1或程序性死亡配体1（PD-L1）抑制剂相比，可能进一步增强抗肿瘤活性。本研究旨在评估卡度尼利单抗联合化疗作为一线治疗方案在晚期食管鳞状细胞癌（ESCC）中的安全性与疗效。

方法：研究纳入了未经治疗的、不可切除的局部晚期或转移性ESCC患者。患者接受卡度尼利单抗联合紫杉醇或白蛋白紫杉醇和顺铂治疗，最多六个周期，随后接受卡度尼利单抗单药维持治疗，直至疾病进展或出现不可接受的毒性，最长不超过24个月。主要终点为客观缓解率（ORR）。次要终点包括无进展生存期（PFS）、总生存期（OS）、疾病控制率（DCR）和安全性。在治疗前后收集血浆游离DNA样本，用于DNA甲基化水平测序。

结果：截至2024年9月27日，共纳入43名患者，中位年龄为61岁（范围44-75岁），其中39.5%的患者PD-L1联合阳性评分≥10，95.3%的患者存在远处转移。客观缓解率（ORR）为81.4%（95% CI 66.6%至91.6%），疾病控制率（DCR）为97.7%（95% CI 86.2%至99.9%）。中位无进展生存期（PFS）为7.10个月（95% CI 5.68至8.48），而总生存期（OS）数据尚未成熟。在治疗前，APBA2、EPAS1、TRIM58、ITPKA和LINC00554基因的平均胞嘧啶-磷酸-鸟嘌呤（CpG）位点甲基化水平在应答者中显著高于非应答者。53.5%（23/43）的患者报告了3-4级治疗相关不良事件。

结论：卡度尼利单抗联合紫杉烷类和顺铂作为一线治疗方案，在晚期ESCC患者中显示出令人鼓舞的抗肿瘤活性和可管理的安全性。DNA甲基化水平可能成为指导患者预后评估的潜在生物标志物。

试验注册号：NCT05522894。

### 第二部分 AI 大师评价

本研究旨在评估新型双特异性抗体卡度尼利单抗联合化疗一线治疗晚期食管鳞癌的疗效与安全性。这项II期临床试验的关键发现是，该联合方案取得了高达81.4%的客观缓解率，且安全性可控。其创新价值在于首次将PD-1/CTLA-4双靶点免疫疗法用于该领域，显示出超越传统免疫抑制剂的潜力，同时，研究还探索了DNA甲基化作为疗效预测生物标志物，为精准治疗提供了新思路。尽管OS数据尚未成熟且样本量有限，该研究仍为晚期食管鳞癌的治疗提供了极具前景的新选择。

---

## 59. 克隆性扩增的效应CD4+细胞毒性T淋巴细胞与免疫检查点抑制剂治疗后的严重神经系统不良事件相关

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167637](https://pubmed.ncbi.nlm.nih.gov/41167637)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41167637
**DOI：** 10.1136/jitc-2025-012350

### 第一部分 原文与翻译

**英文原标题：** Clonally expanded effector CD4 cytotoxic T lymphocytes are associated with severe neurological adverse events after immune checkpoint inhibitor therapy.

**英文摘要原文：**
BACKGROUND: Immune checkpoint inhibitor (ICI) therapies present a pillar of modern cancer therapy but can cause neurological immune-related adverse events (n-irAEs), of which up to 35% are severe or even fatal. However, the detailed immunological mechanisms and risk factors underlying n-irAEs remain largely unknown. Here, we leveraged single-cell genomics to dissect immune cell type, state, and clonal heterogeneity associated with n-irAEs.

METHODS: We performed coupled single-cell RNA sequencing and T cell receptor (TCR) profiling on peripheral blood cells of 17 patients with cancer receiving ICI therapy, including 8 patients with acute neurotoxicity. This approach enabled integrated analyses of immune cell states and T cell clonality linked to ICI-induced n-irAEs.

RESULTS: We profiled 186 435 immune cells and conducted pseudotime analyses, revealing that patients with n-irAEs, compared with controls, present with clonally expanded CD4 cytotoxic T lymphocytes (CD4 CTLs) with an n-irAE-specific effector gene expression profile. These T cells predominantly belong to a select set of expanded clonal families and express genes linked to antigen-induced activation, cell lysis, and neuroinflammation. Moreover, they highly express CXCR3 (FC=2.03 compared with control CD4 CTLs, with a false discovery rate=7.7×10⁻⁴), encoding the chemokine receptor of CXCL10, previously nominated as a biomarker for severe ICI therapy-induced n-irAEs with concomitant multiple organ system toxicity.

CONCLUSIONS: Overall, our study highlights the expansion and activation of CD4 CTLs in ICI-induced neurotoxicity, proposing these cells as potential targets for developing new biomarkers and therapeutic strategies to improve patient outcomes.

**中文摘要译文：**
背景：免疫检查点抑制剂（ICI）疗法是现代癌症治疗的一大支柱，但可引起神经系统免疫相关不良事件（n-irAEs），其中高达35%为重度甚至致命性事件。然而，n-irAEs背后的详细免疫学机制和风险因素在很大程度上仍是未知的。在此，我们利用单细胞基因组学技术来解析与n-irAEs相关的免疫细胞类型、状态及克隆异质性。

方法：我们对17名接受ICI治疗的癌症患者（包括8名出现急性神经毒性的患者）的外周血细胞进行了单细胞RNA测序与T细胞受体（TCR）谱分析的联合检测。该方法使我们能够对与ICI诱导的n-irAEs相关的免疫细胞状态和T细胞克隆性进行综合分析。

结果：我们分析了186,435个免疫细胞并进行了伪时间分析，结果显示，与对照组相比，n-irAEs患者体内存在克隆性扩增的CD4阳性细胞毒性T淋巴细胞（CD4 CTLs），且这些细胞具有n-irAE特异性的效应基因表达谱。这些T细胞主要属于一组特定的扩增克隆家族，并表达与抗原诱导的激活、细胞裂解和神经炎症相关的基因。此外，它们还高表达CXCR3（与对照组CD4 CTLs相比，FC=2.03，错误发现率=7.7×10⁻⁴），该基因编码CXCL10的趋化因子受体，而CXCL10此前已被提名为预测伴随多器官系统毒性的ICI治疗诱导的严重n-irAEs的生物标志物。

结论：总而言之，我们的研究强调了CD4 CTLs在ICI诱导的神经毒性中的扩增和激活，并提出这些细胞可作为开发新生物标志物和治疗策略的潜在靶点，以改善患者预后。

### 第二部分 AI 大师评价

本研究旨在通过单细胞基因组学技术，揭示免疫检查点抑制剂（ICI）治疗后严重神经系统不良事件（n-irAEs）的免疫学机制。研究创新性地结合单细胞RNA测序与T细胞受体谱分析，精准识别出在n-irAEs患者外周血中，一类克隆性扩增的效应性CD4+细胞毒性T淋巴细胞（CD4 CTLs）发挥了关键作用。这一发现不仅深化了对n-irAEs病理生理的理解，更重要的是，它为开发预测性生物标志物（如CXCR3）和靶向治疗策略提供了明确的细胞靶点，对提高ICI治疗的安全性具有重要的临床转化潜力。

---

## 60. 免疫疗法在具有错配修复缺陷（MMRd）非典型表型的胃肠道（GI）肿瘤中的疗效：一项AGEO真实世界研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167636](https://pubmed.ncbi.nlm.nih.gov/41167636)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41167636
**DOI：** 10.1136/jitc-2024-011436

### 第一部分 原文与翻译

**英文原标题：** Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world study.

**英文摘要原文：**
BACKGROUND: Tumors with mismatch repair deficiency (MMRd) classically display concomitant loss of MLH1/PMS2 or MSH2/MSH6 on immunohistochemistry (IHC) with microsatellite instability-high (MSI-High) status on molecular testing. Nevertheless, a different phenotype can occur in up to 15% of MMRd tumors (unusual phenotype). Data on the efficacy of immunotherapy in this population remain scarce.

METHODS: We conducted a retrospective study within the IMMUNODIG MSI cohort including patients with advanced gastrointestinal MMRd tumors treated with immune checkpoint blockade in the real-world setting. We selected patients with both IHC and MSI assays data available. Unusual MMRd tumors were classified into four distinct groups: (1) isolated loss of PMS2 or MSH6 with MSI-H (isolated/MSI-H), (2) complex loss of MMR proteins with MSI-H (complex/MSI-H), (3) loss of one or more MMR proteins without MSI-H (MMRd-IHC/microsatellite stability (MSS) or MSI-low (MSI-L)), and (4) four MMR proteins retained with MSI-H (retained IHC/MSI-H).

RESULTS: Out of 759 patients in the IMMUNODIG-MSI cohort, 571 patients met inclusion criteria. Of these, 90 (15.8%) had an unusual phenotype (47 isolated/MSI-H, 19 complex/MSI-H, 16 MMRd-IHC/MSS or MSI-L and 8 retained IHC/MSI-H). Compared with classical phenotypes, patients with a tumor harboring an unusual phenotype had a younger age at treatment (p=0.005), increased  mutation (p=0.005), reduced  mutation rates (p<0.001), a higher proportion of Lynch syndrome (p<0.001) and a higher prevalence of non-colorectal cancers (p=0.021). After a median follow-up of 28.1 months (mo), there was a significant difference in progression-free survival, with median values of not reached, 66.4 mo, 37.2 mo, 18.3 mo and 5.5 mo for complex/MSI-H, isolated/MSI-H, classical, retained IHC/MSI-H and MMRd-IHC/MSS or MSI-L subgroups, respectively (p<0.001). Notably, objective response rates were 59.1%, 58.7%, and 63.2% for complex/MSI-H, isolated/MSI-H and classical contrasting with 50% and 25% for retained IHC/MSI-H and MMRd-IHC/MSS or MSI-L, with no complete response observed in the latter two.

CONCLUSION: Our findings underscore the need for dual testing and advocate for the presence of both MMRd-IHC and MSI-H for optimal immunotherapy response. Of note, complex MMR aberrations and isolated PMS2/MSH6 losses with MSI-H may represent promising candidates for enhanced immunotherapy efficacy.

**中文摘要译文：**
背景：错配修复缺陷（MMRd）的肿瘤在免疫组织化学（IHC）上通常表现为MLH1/PMS2或MSH2/MSH6的协同缺失，并在分子检测中呈现高微卫星不稳定性（MSI-High）状态。然而，在高达15%的MMRd肿瘤中可能会出现一种不同的表型（非典型表型）。关于免疫疗法在这一人群中疗效的数据仍然稀缺。

方法：我们在IMMUNODIG MSI队列中进行了一项回顾性研究，纳入了在真实世界环境下接受免疫检查点抑制剂治疗的晚期胃肠道MMRd肿瘤患者。我们筛选了同时具有IHC和MSI检测数据的患者。非典型MMRd肿瘤被分为四个不同组：（1）仅PMS2或MSH6缺失伴MSI-H（孤立缺失/MSI-H），（2）多种MMR蛋白复杂缺失伴MSI-H（复杂缺失/MSI-H），（3）一种或多种MMR蛋白缺失但不伴MSI-H（MMRd-IHC/微卫星稳定（MSS）或微卫星低度不稳定（MSI-L）），以及（4）四种MMR蛋白表达保留但伴MSI-H（IHC保留/MSI-H）。

结果：在IMMUNODIG-MSI队列的759名患者中，571名符合纳入标准。其中，90名（15.8%）患者表现为非典型表型（47名孤立缺失/MSI-H，19名复杂缺失/MSI-H，16名MMRd-IHC/MSS或MSI-L，以及8名IHC保留/MSI-H）。与经典表型相比，携带非典型表型肿瘤的患者在治疗时年龄更轻（p=0.005）、 突变增加（p=0.005）、 突变率降低（p<0.001）、林奇综合征比例更高（p<0.001）以及非结直肠癌的患病率更高（p=0.021）。中位随访28.1个月（mo）后，各亚组的无进展生存期存在显著差异，复杂缺失/MSI-H、孤立缺失/MSI-H、经典型、IHC保留/MSI-H以及MMRd-IHC/MSS或MSI-L亚组的中位值分别为未达到、66.4个月、37.2个月、18.3个月和5.5个月（p<0.001）。值得注意的是，复杂缺失/MSI-H、孤立缺失/MSI-H和经典型亚组的客观缓解率分别为59.1%、58.7%和63.2%，而IHC保留/MSI-H和MMRd-IHC/MSS或MSI-L亚组则为50%和25%，且后两组未观察到完全缓解。

结论：我们的研究结果强调了进行双重检测的必要性，并主张同时存在MMRd-IHC和MSI-H是获得最佳免疫治疗反应的条件。值得注意的是，伴有MSI-H的复杂MMR异常以及孤立的PMS2/MSH6缺失可能是增强免疫治疗疗效的潜力人群。

### 第二部分 AI 大师评价

本研究基于一项大规模真实世界数据，旨在探究具有非典型表型的错配修复缺陷（MMRd）胃肠道肿瘤患者接受免疫治疗的疗效。通过将非典型MMRd分为四种亚型，研究创新性地揭示了不同分子表型与免疫治疗反应之间的显著差异。其核心发现是，同时具备MMR蛋白缺失（通过IHC检测）和MSI-H状态的患者，特别是那些表现为复杂或孤立蛋白缺失的亚型，从免疫治疗中获益最大；而仅满足其中一个条件的患者疗效较差。这一结论对于优化临床实践、精准筛选免疫治疗优势人群具有重要的指导价值，并强调了联合应用IHC和MSI两种检测方法的必要性。

---

## 61. 腭部红斑

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167229](https://pubmed.ncbi.nlm.nih.gov/41167229)
**期刊：** The Lancet. Oncology
**PMID：** 41167229
**DOI：** 10.1016/S1470-2045(25)00481-4

### 第一部分 原文与翻译

**英文原标题：** A red patch on the palate.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该标题提示本文可能是一篇关于“腭部红斑”的临床病例报告或影像学展示。这类病变在临床上可能涉及多种诊断，从良性炎症到癌前病变甚至恶性肿瘤，因此精准鉴别至关重要。由于缺乏摘要，无法获知该病例的具体细节、诊断过程、最终结论及其临床价值，推测其可能旨在作为临床教学或鉴别诊断的实例。

---

## 62. 用于儿童神经肿瘤学反应评估的人工智能（AI-RAPNO），第2部分：临床转化的挑战、机遇与建议

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167228](https://pubmed.ncbi.nlm.nih.gov/41167228)
**期刊：** The Lancet. Oncology
**PMID：** 41167228
**DOI：** 10.1016/S1470-2045(25)00489-9

### 第一部分 原文与翻译

**英文原标题：** Artificial Intelligence for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO), part 2: challenges, opportunities, and recommendations for clinical translation.

**英文摘要原文：**
The Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria provide an important framework for evaluating treatment efficacy and tumour progression in clinical studies of paediatric brain tumours. As artificial intelligence (AI) rapidly transforms clinical practice, integrating AI into the RAPNO framework presents a unique opportunity to enhance quantitative, data-driven approaches for response assessment. However, successful clinical implementation faces challenges, including variability in imaging protocols, scarce annotated datasets, and regulatory and ethical considerations. To address these barriers, this Policy Review, led by the AI for Assessment in Pediatric Neuro-Oncology (AI-RAPNO) subcommittee, outlines key challenges and proposes recommendations to improve AI trustworthiness, generalisability, and implementation in paediatric neuro-oncology. We highlight the potential of AI for response assessment, multimodal integration, and synthetic control groups in clinical trials. Our recommendations emphasise the need for standardised imaging protocols, robust validation frameworks, and infrastructure to support AI readiness in clinical studies. By addressing these needs, AI-RAPNO aims to bridge the gap between AI research and clinical application, ensuring reliable and actionable AI-driven tools for paediatric neuro-oncology.

**中文摘要译文：**
儿童神经肿瘤学反应评估（RAPNO）标准为评价儿童脑肿瘤临床研究中的治疗效果和肿瘤进展提供了一个重要框架。随着人工智能（AI）迅速改变临床实践，将AI整合到RAPNO框架中为加强定量、数据驱动的反应评估方法提供了一个独特的机会。然而，成功的临床实施面临诸多挑战，包括影像学方案的变异性、已标注数据集的稀缺以及法规和伦理方面的考量。为应对这些障碍，本篇由儿童神经肿瘤学AI评估（AI-RAPNO）小组委员会牵头的政策综述，概述了关键挑战，并提出了旨在提高AI在儿童神经肿瘤学中的可信度、泛化能力和实施水平的建议。我们重点阐述了AI在反应评估、多模态整合以及临床试验中构建合成对照组方面的潜力。我们的建议强调，需要建立标准化的影像学方案、稳健的验证框架以及支持临床研究中AI应用准备的基础设施。通过满足这些需求，AI-RAPNO旨在弥合AI研究与临床应用之间的鸿沟，从而确保为儿童神经肿瘤学提供可靠且可操作的AI驱动工具。

### 第二部分 AI 大师评价

该文献是一篇由权威小组委员会撰写的政策综述，精准聚焦于将人工智能（AI）整合进儿童神经肿瘤学反应评估（RAPNO）框架所面临的核心挑战与未来机遇。文章系统性地指出了影像学方案不统一、高质量标注数据稀缺及法规伦理限制等关键障碍，并高瞻远瞩地提出了标准化、建立验证框架及基础设施建设等一系列可行性建议。该综述的创新价值在于，它不仅揭示了问题，更提供了一份清晰的“路线图”，为推动AI技术从理论研究安全、有效地步入临床实践提供了权威指导，对加速开发可靠的AI驱动工具以改善儿童脑肿瘤的诊疗具有重要的战略意义和实践价值。

---

## 63. 人工智能在小儿神经肿瘤学疗效评估中的应用（AI-RAPNO），第一部分：研究现状述评

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167227](https://pubmed.ncbi.nlm.nih.gov/41167227)
**期刊：** The Lancet. Oncology
**PMID：** 41167227
**DOI：** 10.1016/S1470-2045(25)00484-X

### 第一部分 原文与翻译

**英文原标题：** Artificial Intelligence for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO), part 1: review of the current state of the art.

**英文摘要原文：**
Artificial intelligence (AI) has the potential to enable more precise, efficient, and reproducible interpretation of medical imaging data to improve patient care in paediatric neuro-oncology. Paediatric brain tumours present distinct histopathological, molecular, and clinical challenges that require tailored AI solutions. Recent advances have led to paediatric-specific AI tools for tumour segmentation, treatment response evaluation, recurrence prediction, toxicity assessment, and integrative multimodal analysis. These innovations have the potential to improve diagnostic accuracy, streamline workflows, and inform personalised treatment strategies. However, clinical implementation remains hindered by challenges related to data heterogeneity, model generalisability, and integration into clinical practice. In this Policy Review, we highlight key developments, challenges, and priority areas for imaging-based AI for paediatric neuro-oncology. Our goal is to provide oncology practitioners with a focused overview of current capabilities, unmet needs, and future directions at the intersection of AI and paediatric neuro-oncology.

**中文摘要译文：**
人工智能（AI）有潜力对医学影像数据进行更精确、高效和可重复的解读，从而改善小儿神经肿瘤学的患者护理。小儿脑肿瘤在组织病理学、分子学和临床方面存在独特的挑战，需要定制化的人工智能解决方案。近期的进展催生了针对小儿的特异性AI工具，应用于肿瘤分割、治疗反应评估、复发预测、毒性评估以及综合多模态分析。这些创新有潜力提高诊断准确性、优化工作流程，并为个性化治疗策略提供信息。然而，临床实施仍受到数据异质性、模型泛化能力以及与临床实践整合相关的挑战的阻碍。在这篇政策性综述中，我们重点介绍了基于影像的AI在小儿神经肿瘤学领域的关键进展、挑战和优先发展领域。我们的目标是为肿瘤学从业者提供一个关于AI与小儿神经肿瘤学交叉领域当前能力、未满足需求和未来方向的重点概述。

### 第二部分 AI 大师评价

本文是一篇关于人工智能在小儿神经肿瘤学影像分析中应用的政策性综述。文章系统性地回顾了AI在肿瘤分割、疗效评估和复发预测等方面的最新进展，并指出了该领域面临的关键挑战，如数据异质性和模型泛化能力不足。该综述的价值在于为临床医生和研究人员清晰地勾勒出了AI技术在这一特殊领域的应用现状、瓶颈与未来发展方向，强调了将AI创新转化为临床实践的必要性，为推动该领域的精准医疗发展提供了重要参考。

---

## 64. 微小残留病指导下对接受异基因造血细胞移植的急性髓系白血病患者的干预措施：来自欧洲血液与骨髓移植学会实践协调与指南委员会的最佳实践建议

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167226](https://pubmed.ncbi.nlm.nih.gov/41167226)
**期刊：** The Lancet. Oncology
**PMID：** 41167226
**DOI：** 10.1016/S1470-2045(25)00426-7

### 第一部分 原文与翻译

**英文原标题：** Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee.

**英文摘要原文：**
Measurable residual disease (MRD) is a key predictor of relapse, the primary cause of treatment failure after allogeneic haematopoietic cell transplantation (allo-HCT) in acute myeloid leukaemia. This Policy Review, based on guidance from the European Society for Blood and Marrow Transplantation, provides practical recommendations for incorporating MRD assessment into clinical decision making during the transplantation process, the application of which remains challenging in acute myeloid leukaemia due to technical limitations and the limited availability of standardised, evidence-based approaches. Available methods include reverse transcription quantitative PCR, digital droplet PCR, next-generation sequencing, and multiparametric flow cytometry-chimerism-based approaches are under investigation. This Policy Review highlights the importance of MRD monitoring to enable timely, risk-adapted interventions that encompass both pre-transplantation and post-transplantation periods and can include tailoring conditioning intensity, donor selection, immunosuppression management, donor lymphocyte infusions, and pharmacological therapies such as FLT3 or IDH inhibitors, hypomethylating agents, venetoclax, or menin inhibitors. These recommendations aim to harmonise MRD-driven clinical practice and improve patient outcomes, while identifying key areas for future research.

**中文摘要译文：**
微小残留病（MRD）是复发的关键预测指标，而复发是急性髓系白血病患者异基因造血细胞移植（allo-HCT）后治疗失败的主要原因。本篇政策综述基于欧洲血液与骨髓移植学会的指导，为在移植过程中将MRD评估纳入临床决策提供了实用建议，但由于技术限制以及标准化、循证方法的缺乏，MRD在急性髓系白血病中的应用仍充满挑战。现有检测方法包括逆转录定量PCR、数字微滴PCR、二代测序和多参数流式细胞术，而基于嵌合状态的方法正在研究之中。该政策综述强调了MRD监测的重要性，它能够促成及时的、基于风险分层的干预措施，这些措施涵盖了移植前和移植后两个时期，可包括调整预处理强度、供者选择、免疫抑制管理、供者淋巴细胞输注，以及使用FLT3或IDH抑制剂、去甲基化药物、venetoclax或menin抑制剂等药物治疗。这些建议旨在统一由MRD驱动的临床实践并改善患者预后，同时指出了未来研究的关键领域。

### 第二部分 AI 大师评价

本篇政策综述旨在为临床医生提供一份关于如何利用微小残留病（MRD）监测来指导急性髓系白血病（AML）异基因移植患者治疗的权威实践建议。该指南系统性地总结了现有的MRD检测技术，并明确提出应在移植前、后全过程根据MRD状态进行风险分层，从而实施包括调整预处理方案、免疫抑制管理及靶向药物治疗在内的个体化干预。其核心价值在于，作为欧洲血液与骨髓移植学会的官方建议，它为这一关键临床决策领域提供了标准化的指导框架，有望统一临床实践、降低移植后复发率，并为未来的研究指明了方向。

---

## 65. 基因工程时代下，肿瘤浸润淋巴细胞疗法日趋成熟

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167225](https://pubmed.ncbi.nlm.nih.gov/41167225)
**期刊：** The Lancet. Oncology
**PMID：** 41167225
**DOI：** 10.1016/S1470-2045(25)00434-6

### 第一部分 原文与翻译

**英文原标题：** Tumour-infiltrating lymphocyte therapy comes of age in the era of genetic engineering.

**英文摘要原文：**
Advances in cancer immunotherapy from immune checkpoint modulation to adoptive cell transfer of tumour-infiltrating lymphocytes (TILs) have greatly improved outcomes for patients with advanced cancers, particularly metastatic melanoma. The approval of TIL therapy in 2024 following two independent landmark clinical trials has established this approach as a viable treatment option, with response rates of up to 50% in treatment-resistant melanoma. Genetic engineering offers new opportunities to further improve TIL efficacy and durability, including viral vector-mediated overexpression of cytokines or chimeric receptors, and non-viral genome editing techniques such as CRISPR-Cas9 to delete inhibitory genes such as PD-1 and CISH. In this Review we outline the current state of genetically engineered TILs, highlighting both preclinical advances and ongoing clinical trials. As these engineered products are evaluated in clinical settings, they are expected to expand the personalised immunotherapy toolkit and improve durable outcomes across a broader range of solid tumours.

**中文摘要译文：**
从免疫检查点调节到肿瘤浸润淋巴细胞（TILs）的过继性细胞转移，癌症免疫疗法的进步已显著改善了晚期癌症患者（尤其是转移性黑色素瘤患者）的预后。继两项独立的里程碑式临床试验之后，TIL疗法于2024年获批，确立了其作为一种可行治疗选择的地位，在耐药性黑色素瘤中的缓解率高达50%。基因工程为进一步提高TIL的疗效和持久性提供了新机遇，包括病毒载体介导的细胞因子或嵌合受体的过表达，以及利用CRISPR-Cas9等非病毒基因组编辑技术删除PD-1和CISH等抑制性基因。在这篇综述中，我们概述了基因工程化TILs的现状，重点介绍了临床前进展和正在进行的临床试验。随着这些工程化产品在临床环境中得到评估，它们有望扩展个性化免疫治疗的工具箱，并改善更广泛实体瘤的持久疗效。

### 第二部分 AI 大师评价

这篇综述精准把握了肿瘤免疫治疗的前沿动态，系统总结了基因工程化肿瘤浸润淋巴细胞（TIL）疗法的现状与未来。文章首先肯定了TIL疗法在晚期黑色素瘤治疗中取得的突破性进展，随后重点阐述了如何利用CRISPR-Cas9等基因编辑技术增强TILs的抗肿瘤活性与持久性。该综述不仅为研究人员指明了优化方向，更向临床医生揭示了这一创新疗法在攻克更多实体瘤方面的巨大潜力，具有重要的学术价值和临床指导意义。

---

## 66. 《柳叶刀·肿瘤学》2025年第26卷548-49页勘误

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167224](https://pubmed.ncbi.nlm.nih.gov/41167224)
**期刊：** The Lancet. Oncology
**PMID：** 41167224
**DOI：** 10.1016/S1470-2045(25)00603-5

### 第一部分 原文与翻译

**英文原标题：** Correction to Lancet Oncol 2025; 26: 548-49.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

此条目为针对《柳叶刀·肿瘤学》既往发表文章的勘误声明，并非原创性研究论文。因此，无法按常规标准评估其研究目的、方法与发现。发布此类更正对于维护科学文献的准确性和完整性至关重要，它体现了学术出版的严谨性，确保读者能够获取最精确的研究信息。

---

## 67. 关于《柳叶刀·肿瘤学》2024年第25卷1337-46页的勘误说明

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167223](https://pubmed.ncbi.nlm.nih.gov/41167223)
**期刊：** The Lancet. Oncology
**PMID：** 41167223
**DOI：** 10.1016/S1470-2045(25)00596-0

### 第一部分 原文与翻译

**英文原标题：** Correction to Lancet Oncol 2024; 25: 1337-46.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇勘误声明，旨在纠正其引用的《柳叶刀·肿瘤学》2024年发表原文中的特定错误。因此，它不包含原创性研究的目的、方法或发现，无法按标准研究论文进行科学价值评估。发布勘误是维护科学记录准确性和完整性的重要环节，确保读者能够获取最精确的研究信息。

---

## 68. 对《柳叶刀·肿瘤学》2024年第25卷e363-73页内容的更正

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167222](https://pubmed.ncbi.nlm.nih.gov/41167222)
**期刊：** The Lancet. Oncology
**PMID：** 41167222
**DOI：** 10.1016/S1470-2045(25)00595-9

### 第一部分 原文与翻译

**英文原标题：** Correction to Lancet Oncol 2024; 25: e363-73.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇发表于《柳叶刀·肿瘤学》的更正启事，而非原创性研究。其核心目的在于修正先前发表于2024年第25卷e363-73页的论文中的错误，以确保学术记录的准确性和严谨性。此类文献对于维护科学诚信至关重要，但其本身不包含新的研究方法、发现或结论。若需了解原文的研究价值，应查阅其所更正的原始文章。

---

## 69. 中国抗肿瘤药物试验中未经调整的外部对照及终点选择

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167221](https://pubmed.ncbi.nlm.nih.gov/41167221)
**期刊：** The Lancet. Oncology
**PMID：** 41167221
**DOI：** 10.1016/S1470-2045(25)00493-0

### 第一部分 原文与翻译

**英文原标题：** Unadjusted external controls and endpoint selection in Chinese cancer drug trials.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题表明，这是一篇关于中国抗肿瘤药物临床试验方法学的评论或观点文章。文章聚焦于两大关键问题：未经调整的外部对照组的使用以及研究终点的选择。作者可能探讨了这些因素如何影响试验结果的有效性和可靠性，并对当前实践提出批评或改进建议。尽管缺乏摘要，该标题仍揭示了本研究对于提高中国临床试验质量、确保监管决策科学性的重要意义，对试验设计者和研究者具有重要的警示和指导价值。

---

## 70. 探戈需两人共舞：雌激素受体和孕激素受体在子宫内膜癌中的重要性——作者回复

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167220](https://pubmed.ncbi.nlm.nih.gov/41167220)
**期刊：** The Lancet. Oncology
**PMID：** 41167220
**DOI：** 10.1016/S1470-2045(25)00611-4

### 第一部分 原文与翻译

**英文原标题：** It takes two to tango: importance of oestrogen receptor and progesterone receptor in endometrial cancer - Authors' reply.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

该文献是一篇“作者回复”，旨在回应同行对先前关于子宫内膜癌中雌激素受体（ER）和孕激素受体（PR）重要性研究的讨论。从标题“探戈需两人共舞”可推断，作者强调了ER和PR协同作用的不可或缺性，认为两者共同评估对于理解疾病进展和指导治疗至关重要。此类学术回应对于澄清研究细节、促进科学对话具有重要价值，但其本身并非一项独立研究，因此不包含新的实验数据或方法学创新。

---

## 71. 探戈需双人：雌激素受体与孕激素受体在子宫内膜癌中的重要性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167219](https://pubmed.ncbi.nlm.nih.gov/41167219)
**期刊：** The Lancet. Oncology
**PMID：** 41167219
**DOI：** 10.1016/S1470-2045(25)00610-2

### 第一部分 原文与翻译

**英文原标题：** It takes two to tango: importance of oestrogen receptor and progesterone receptor in endometrial cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题以一个生动的比喻“探戈需双人”为引，强调了在子宫内膜癌中同时评估雌激素受体（ER）和孕激素受体（PR）的重要性。此文的核心论点很可能是，单独分析任一受体状态均不足以全面判断预后或指导治疗，必须将二者联合考量。虽然因摘要缺失无法获知其具体论证，但该标题预示这可能是一篇重要的观点或综述性文章，旨在推动临床实践对ER和PR进行整合解读，以优化患者的个性化激素治疗策略。

---

## 72. PSMA-TTV作为一种即时决策筛选工具

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167218](https://pubmed.ncbi.nlm.nih.gov/41167218)
**期刊：** The Lancet. Oncology
**PMID：** 41167218
**DOI：** 10.1016/S1470-2045(25)00528-5

### 第一部分 原文与翻译

**英文原标题：** PSMA-TTV as a point-of-care selector.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题表明，文章可能探讨了将前列腺特异性膜抗原总肿瘤体积（PSMA-TTV）作为一种即时医疗决策筛选工具的潜力。此方法旨在利用PSMA影像学指标，快速、便捷地筛选出适合接受特定靶向治疗（如PSMA放射性配体疗法）的前列腺癌患者。尽管缺乏摘要信息，但该标题暗示了一种创新性的临床决策模式，有望简化患者分层流程并提升个体化治疗的效率，但其具体方法学和临床验证数据有待原文详述。

---

## 73. IIB-C期和III期皮肤恶性黑色素瘤根治术后随访中采用体格检查联合全身影像学检查与单纯体格检查的对比（TRIM）：瑞典一项多中心、随机、3期临床试验的中期分析。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167217](https://pubmed.ncbi.nlm.nih.gov/41167217)
**期刊：** The Lancet. Oncology
**PMID：** 41167217
**DOI：** 10.1016/S1470-2045(25)00487-5

### 第一部分 原文与翻译

**英文原标题：** Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden.

**英文摘要原文：**
BACKGROUND: In several countries, whole-body imaging has been introduced in the routine follow-up of individuals with high-risk cutaneous malignant melanoma after surgery. However, there is scarce evidence that earlier detection of recurrent disease by regular scanning improves survival. In this interim analysis, we investigated whether imaging in the follow-up programme for high-risk cutaneous malignant melanoma improves survival and assessed whether the study should continue to include participants.

METHODS: TRIM is a multicentre, randomised, phase 3 trial in Sweden. Eligible participants are aged 18 years and older with sufficient renal function for intravenously contrast-enhanced CT and are expected to be fit for treatment in case of recurrence. After radical surgery of stage IIB-C and III cutaneous malignant melanoma, participants were randomly assigned (1:1, stratified by tumour stage and method of radiological assessment) to 3 years of follow-up by physical examinations alone (standard group) or to physical examinations plus whole-body imaging with CT or [F]fluorodeoxyglucose-PET-CT at baseline, 6, 12, 24, and 36 months (experimental group). The goal is to include 1300 participants. The primary endpoint is overall survival at 5 years and will be reported in the final analysis when data are mature. In this interim report, no endpoints were predefined; we present overall survival, relapse-free survival, locoregional relapse-free survival, and distant metastasis-free survival, analysed by intention to intervene. This study is registered with ClinicalTrials.gov, NCT03116412, and recruitment is ongoing.

FINDINGS: Between June 8, 2017, and July 28, 2023, 983 participants were randomly allocated to the standard (n=498; 296 [59%] male, 202 [41%] female) or experimental (n=485; 309 [64%] male, 176 [36%] female) group. There were no statistically significant differences in overall survival (not reached [NR; 95% CI NR-NR] vs NR [NR-NR]; hazard ratio [HR] 1·04 [95% CI 0·71-1·51], p=0·85) or distant metastasis-free survival (NR [NR-NR] vs NR [NR-NR]; HR 1·20 [0·89-1·64], p=0·24) between the groups at a median follow-up time of 33·6 months (IQR 16·3-49·8). 3-year overall survival rates were 88·2% (95% CI 85·0-91·6) in the standard group versus 87·7% (84·3-91·3) in the experimental group and distant metastasis-free survival was 81·6% (77·9-85·6) in the standard group versus 79·3% (75·3-83·5) in the control group.

INTERPRETATION: This interim analysis indicated that there is no benefit from imaging in the follow-up programme for individuals with high-risk cutaneous malignant melanoma. However, only a few participants have completed the follow-up time of 5 years, and the numerical difference between the study groups in distant metastasis-free survival motivates us to continue the study according to protocol.

FUNDING: Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond and Uppsala University Hospital.

**中文摘要译文：**
背景：在多个国家，全身影像学检查已被引入高危皮肤恶性黑色素瘤患者术后的常规随访中。然而，鲜有证据表明通过定期扫描早期发现复发性疾病能改善生存率。在这项中期分析中，我们旨在探究在高危皮肤恶性黑色素瘤的随访方案中加入影像学检查是否能提高生存率，并评估该研究是否应继续招募参与者。

方法：TRIM是在瑞典进行的一项多中心、随机、3期临床试验。符合条件的参与者年龄在18岁及以上，肾功能足以接受静脉增强CT扫描，并且预计在疾病复发时身体状况适合接受治疗。在接受IIB-C期和III期皮肤恶性黑色素瘤根治性手术后，参与者被随机分配（1:1，按肿瘤分期和放射学评估方法分层）接受为期3年的随访，一组仅进行体格检查（标准组），另一组则在体格检查的基础上，在基线、第6、12、24和36个月时加做全身影像学检查（CT或[18F]氟代脱氧葡萄糖-PET-CT）（实验组）。研究目标是纳入1300名参与者。主要终点是5年总生存率，将在数据成熟后的最终分析中报告。本中期报告未预设终点；我们通过意向干预分析，报告了总生存率、无复发生存率、无局部区域复发生存率和无远处转移生存率。本研究已在ClinicalTrials.gov注册，编号为NCT03116412，目前仍在招募中。

结果：在2017年6月8日至2023年7月28日期间，共983名参与者被随机分配至标准组（n=498；296名[59%]男性，202名[41%]女性）或实验组（n=485；309名[64%]男性，176名[36%]女性）。在中位随访时间为33.6个月（IQR 16.3-49.8）时，两组间的总生存率（未达到[NR；95% CI NR-NR] vs NR [NR-NR]；风险比[HR] 1.04 [95% CI 0.71-1.51]，p=0.85）和无远处转移生存率（NR [NR-NR] vs NR [NR-NR]；HR 1.20 [0.89-1.64]，p=0.24）均无统计学显著差异。标准组的3年总生存率为88.2%（95% CI 85.0-91.6），实验组为87.7%（84.3-91.3）；标准组的无远处转移生存率为81.6%（77.9-85.6），实验组为79.3%（75.3-83.5）。

解读：该中期分析表明，在高危皮肤恶性黑色素瘤患者的随访方案中加入影像学检查并未带来获益。然而，仅有少数参与者完成了5年的随访，且两研究组在无远处转移生存率上的数值差异促使我们继续按方案进行研究。

资金来源：Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond和乌普萨拉大学医院。

### 第二部分 AI 大师评价

本研究通过一项大规模多中心随机对照3期临床试验（TRIM），旨在解决一个关键临床问题：对于高危皮肤恶性黑色素瘤患者术后随访，增加全身影像学检查是否能改善生存结局。其中期分析结果显示，与单纯体格检查相比，增加定期影像学筛查并未带来显著的总生存或无远处转移生存获益。这项研究以其严谨的设计，直接挑战了当前日益普遍的临床实践，为优化黑色素瘤随访策略、避免不必要的医疗资源消耗提供了重要的循证医学证据，但其最终结论仍有待长期随访数据的支持。

---

## 74. Abemaciclib联合阿比特龙治疗转移性去势抵抗性前列腺癌（CYCLONE 2）：一项随机、双盲、安慰剂对照的3期临床试验。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167216](https://pubmed.ncbi.nlm.nih.gov/41167216)
**期刊：** The Lancet. Oncology
**PMID：** 41167216
**DOI：** 10.1016/S1470-2045(25)00475-9

### 第一部分 原文与翻译

**英文原标题：** Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

**英文摘要原文：**
BACKGROUND: Abemaciclib, a potent CDK4 and CDK6 inhibitor, has shown antitumour activity in prostate cancer models and in patients with metastatic castration-resistant prostate cancer (mCRPC) who have been heavily treated. We aimed to evaluate the safety and efficacy of abemaciclib in combination with abiraterone in patients with mCRPC.

METHODS: CYCLONE 2 was a randomised, double-blind, placebo-controlled, phase 3 study done in 89 hospitals and academic and private research centres in 12 countries. All study parts had identical eligibility criteria, and used block randomisation with the same stratification factors (previous docetaxel treatment, presence of measurable disease, and type of progression). Participants were adults aged 18 years and older with histologically confirmed adenocarcinoma of the prostate and metastatic disease as documented by bone scans, CT scans, or MRI scans, and radiographic or PSA progression during continuous androgen deprivation therapy. Previous docetaxel for metastatic castration-sensitive prostate cancer was permitted; previous abiraterone, apalutamide, enzalutamide, darolutamide, or CDK4 and CDK6 inhibitors were exclusionary. The trial was conducted in three parts. Part 1 was a four-arm, placebo-controlled safety and dose-finding lead-in to determine the recommended phase 2 dose of abemaciclib with abiraterone. Participants were randomly assigned (2:2:1:1) to receive abiraterone (1000 mg orally once daily) and prednisone or prednisolone (5 mg orally twice daily) with either abemaciclib at 150 mg or 200 mg orally twice daily or with matching placebo (150 mg or 200 mg twice daily). In part 2 and part 3, patients were randomly assigned (1:1) to standard abiraterone and prednisone or prednisolone plus either abemaciclib at the recommended phase 2 dose or matching placebo. Patients, investigators, and sponsor were masked to treatment assignment. The primary outcome, investigator-assessed radiographic progression-free survival, was analysed in the intention-to-treat (participants from all study parts) population. Patients who received at least one dose of abiraterone, abemaciclib, or placebo were included in the safety population. This trial is registered at ClinicalTrials.gov, NCT03706365, and is completed.

FINDINGS: Between Nov 26, 2018, and July 20, 2022, 515 patients were screened for eligibility, 393 of whom were randomly assigned, 206 patients to abemaciclib plus abiraterone and 187 to placebo plus abiraterone. The median age was 70·0 years (IQR 63·0-76·0). 289 (74%) of 393 patients identified as White, 80 (20%) as Asian, 17 (4%) as Black or African American, and seven (2%) as multiple race or not reported. The highest tested dose of 200 mg abemaciclib administered twice daily was chosen as the recommended phase 2 dose. The median follow-up time was 26·3 months (IQR 22·1-48·2) for the abemaciclib plus abiraterone group and 25·6 months (22·1-40·8) for the placebo plus abiraterone group. The primary endpoint of radiographic progression-free survival was not met: radiographic progression-free survival events were reported in 92 (45%) of 206 patients in the abemaciclib plus abiraterone group and 95 (51%) of 187 patients in the placebo plus abiraterone group (HR 0·83 [95% CI 0·62-1·11]; p=0·21). Median radiographic progression-free survival was 22·0 months (95% CI 19·3-27·5) for abemaciclib plus abiraterone and 20·3 months (16·5-24·4) for placebo plus abiraterone. The most common grade 3 or higher adverse events reported in the abemaciclib plus abiraterone group were anaemia (28 [14%] of 206 vs eight [4%] of 185 in the placebo plus abiraterone group), neutropenia (26 [13%] vs one [1%]), and alanine aminotransferase increase (18 [9%] vs 12 [6%]). Serious adverse events occurred in 91 (44%) of 206 patients in the abemaciclib plus abiraterone group and in 68 (37%) of 185 patients in the placebo plus abiraterone group. There were three treatment-related deaths due to interstitial lung disease in the abemaciclib plus abiraterone group.

INTERPRETATION: Dual inhibition of CDK4 and CDK6 and the androgen receptor pathway with abemaciclib plus abiraterone did not improve radiographic progression-free survival compared with abiraterone alone in the CYCLONE 2 study population with mCRPC. Safety of the combination was consistent with the previously reported safety of the individual drugs. Additional research is required to identify effective combination therapies for patients with mCRPC, especially in those presenting with adverse prognostic characteristics.

**中文摘要译文：**
背景：Abemaciclib是一种强效的CDK4和CDK6抑制剂，在多种前列腺癌模型以及经过多线治疗的转移性去势抵抗性前列腺癌（mCRPC）患者中已显示出抗肿瘤活性。我们旨在评估abemaciclib联合阿比特龙在mCRPC患者中的安全性和有效性。

方法：CYCLONE 2是一项在12个国家的89家医院、学术及私人研究中心进行的随机、双盲、安慰剂对照的3期研究。所有研究部分均采用相同的入组标准，并使用区组随机化及相同的分层因素（既往多西他赛治疗史、存在可测量病灶、以及进展类型）。参与者为年满18岁的成年人，经组织学确诊为前列腺腺癌，并通过骨扫描、CT或MRI扫描证实存在转移性疾病，且在持续雄激素剥夺治疗期间出现影像学或PSA进展。允许既往因转移性去势敏感性前列腺癌接受过多西他赛治疗；既往使用过阿比特龙、阿帕他胺、恩扎卢胺、达罗他胺或CDK4和CDK6抑制剂则被排除。该试验分三部分进行。第1部分为一项四臂、安慰剂对照的安全性与剂量探索的导入研究，旨在确定abemaciclib联合阿比特龙的2期推荐剂量。参与者被随机分配（2:2:1:1）接受阿比特龙（每日一次口服1000 mg）和强的松或强的松龙（每日两次口服5 mg），联合abemaciclib（150 mg或200 mg，每日两次口服）或匹配的安慰剂（150 mg或200 mg，每日两次）。在第2和第3部分中，患者被随机分配（1:1）接受标准阿比特龙和强的松或强的松龙治疗，联合abemaciclib（采用2期推荐剂量）或匹配的安慰剂。患者、研究者和申办方均对治疗分配设盲。主要终点为研究者评估的影像学无进展生存期，在所有意向治疗人群（来自所有研究部分的参与者）中进行分析。接受了至少一剂阿比特龙、abemaciclib或安慰剂的患者被纳入安全性人群。本试验已在ClinicalTrials.gov注册（NCT03706365），并已完成。

结果：在2018年11月26日至2022年7月20日期间，共筛选了515名患者，其中393名被随机分配，206名患者进入abemaciclib联合阿比特龙组，187名进入安慰剂联合阿比特龙组。中位年龄为70.0岁（IQR 63.0-76.0）。393名患者中，289名（74%）为白人，80名（20%）为亚洲人，17名（4%）为黑人或非裔美国人，7名（2%）为多种族或未报告。测试的最高剂量，即每日两次200 mg的abemaciclib，被选为2期推荐剂量。abemaciclib联合阿比特龙组的中位随访时间为26.3个月（IQR 22.1-48.2），安慰剂联合阿比特龙组为25.6个月（22.1-40.8）。研究未达到影像学无进展生存期的主要终点：abemaciclib联合阿比特龙组的206名患者中有92名（45%）报告了影像学无进展生存事件，而安慰剂联合阿比特龙组的187名患者中有95名（51%）报告了该事件（HR 0.83 [95% CI 0.62-1.11]；p=0.21）。abemaciclib联合阿比特龙组的中位影像学无进展生存期为22.0个月（95% CI 19.3-27.5），安慰剂联合阿比特龙组为20.3个月（16.5-24.4）。abemaciclib联合阿比特龙组报告的最常见的3级或以上不良事件为贫血（206名中的28名[14%] vs 安慰剂联合阿比特龙组185名中的8名[4%]）、中性粒细胞减少（26名[13%] vs 1名[1%]）和丙氨酸氨基转移酶升高（18名[9%] vs 12名[6%]）。abemaciclib联合阿比特龙组的206名患者中有91名（44%）发生严重不良事件，安慰剂联合阿比特龙组的185名患者中有68名（37%）发生。abemaciclib联合阿比特龙组发生了三例因间质性肺病导致的治疗相关死亡。

结论：在CYCLONE 2研究的mCRPC患者群体中，与单用阿比特龙相比，使用abemaciclib联合阿比特龙对CDK4、CDK6和雄激素受体通路进行双重抑制，并未改善影像学无进展生存期。该联合方案的安全性与各单药既往报道的安全性一致。需要进一步的研究来为mCRPC患者，特别是那些具有不良预后特征的患者，寻找有效的联合治疗方案。

### 第二部分 AI 大师评价

这项名为CYCLONE 2的大型3期随机对照试验，旨在评估CDK4/6抑制剂abemaciclib联合阿比特龙治疗转移性去势抵抗性前列腺癌（mCRPC）的疗效。研究结果明确表明，与标准疗法阿比特龙单药相比，该联合方案未能显著延长患者的影像学无进展生存期，即未达到其主要研究终点，同时还增加了不良事件的风险。作为一个重要的“阴性结果”研究，它为该领域的临床实践提供了关键证据，证实了此特定联合策略的无效性，从而避免其在临床上的推广，并指引未来的研究需探索新的联合治疗靶点或更精准的患者筛选策略。

---

## 75. 帕妥珠单抗-德鲁替康（HER3-DXd）治疗伴有活动性脑转移的乳腺癌患者（TUXEDO-3）：一项多中心、单臂、2期试验。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167215](https://pubmed.ncbi.nlm.nih.gov/41167215)
**期刊：** The Lancet. Oncology
**PMID：** 41167215
**DOI：** 10.1016/S1470-2045(25)00470-X

### 第一部分 原文与翻译

**英文原标题：** Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.

**英文摘要原文：**
BACKGROUND: Patritumab deruxtecan (HER3-DXd) is a novel antibody-drug conjugate targeting HER3, which is overexpressed in CNS metastases of metastatic breast cancer. We aimed to evaluate the activity and safety of HER3-DXd in patients with metastatic breast cancer and brain metastases that are newly diagnosed or progressing after local therapy.

METHODS: TUXEDO-3 trial is a multicohort, multicentre, open-label, single-arm phase 2 trial, done in six sites in Spain and Austria. In this cohort (1 of 3), we enrolled adults (≥18 years) with histologically documented breast cancer and radiologically documented metastatic disease, newly diagnosed brain metastases or brain metastases progressing after local treatment, at least one measurable brain lesion of ≥10 mm, and an Eastern Cooperative Oncology Group performance status of 0-2. Patients received HER3-DXd 5·6 mg/kg intravenously once every 3 weeks. The threshold for the primary endpoint was at least 15% of patients having intracranial response according to Response Assessment in Neuro-Oncology Brain Metastases criteria. Activity and safety analyses were done in the full analysis population (ie, all participants who received at least one dose of HER3-DXd). This trial (ClinicalTrials.govNCT05865990 and European Union Clinical Trials Register 2023-503251-10-00) is ongoing and is no longer enrolling patients.

FINDINGS: Between Dec 12, 2023, and July 8, 2024, 21 evaluable female patients (five with luminal breast cancer, nine with HER2-positive breast cancer, and seven with triple-negative breast cancer) were recruited. 15 (71%) were White; race was not reported in the remaining six patients. The median number of previous treatment lines for advanced disease was 4 (IQR 2-4). Median treatment duration was 3·0 months (IQR 0·7-7·7), and median follow-up was 4·9 months (IQR 3·6-8·5). The primary endpoint was met with five (24%) of 21 patients having intracranial responses irrespective of the breast cancer subtype (overall response rate 23·8%, 95% CI 8·2-47·1). The most common grade 3 or worse treatment-emergent adverse events were neutropenia in three (14%) patients, diarrhoea in two (10%) patients, and asthenia and vomiting in one (5%) patient each. Serious adverse events occurred in six (29%) patients, with one (5%) patient having grade 2 pneumonitis related to the study treatment. No treatment-related deaths were reported.

INTERPRETATION: HER3-DXd showed promising clinical activity in patients with metastatic breast cancer and active brain metastases, and could offer a novel therapeutic option in this setting.

FUNDING: Daiichi-Sankyo and Merck Sharp & Dohme.

**中文摘要译文：**
背景：帕妥珠单抗-德鲁替康（HER3-DXd）是一种靶向HER3的新型抗体药物偶联物，HER3在转移性乳腺癌的中枢神经系统转移灶中过表达。本研究旨在评估HER3-DXd在伴有新发或局部治疗后进展的脑转移的转移性乳腺癌患者中的活性与安全性。

方法：TUXEDO-3试验是一项在西班牙和奥地利的六个中心进行的多队列、多中心、开放标签、单臂2期试验。在本队列（3个队列之一）中，我们纳入了经组织学证实的乳腺癌和影像学证实的转移性疾病的成年（≥18岁）患者，这些患者为新诊断的脑转移或局部治疗后进展的脑转移，至少有一个≥10毫米的可测量脑部病灶，且东部协作肿瘤学组（ECOG）体能状态评分为0-2分。患者每3周接受一次5.6 mg/kg的HER3-DXd静脉注射。根据神经肿瘤学脑转移疗效评估标准，主要终点的阈值设定为至少15%的患者达到颅内缓解。活性和安全性分析在全分析人群（即所有接受了至少一剂HER3-DXd治疗的参与者）中进行。该试验（ClinicalTrials.gov编号NCT05865990和欧盟临床试验注册号2023-503251-10-00）正在进行中，但已停止招募患者。

结果：在2023年12月12日至2024年7月8日期间，共招募了21名可评估的女性患者（5名腔面型乳腺癌，9名HER2阳性乳腺癌，7名三阴性乳腺癌）。其中15名（71%）为白人；其余6名患者未报告种族。既往针对晚期疾病的治疗线数中位数为4线（IQR 2-4）。中位治疗持续时间为3.0个月（IQR 0.7-7.7），中位随访时间为4.9个月（IQR 3.6-8.5）。试验达到了主要终点，21名患者中有5名（24%）获得颅内缓解，且疗效与乳腺癌亚型无关（总缓解率23.8%，95% CI 8.2-47.1）。最常见的3级或以上治疗期间出现的不良事件为：中性粒细胞减少症3例（14%），腹泻2例（10%），以及乏力和呕吐各1例（5%）。6名（29%）患者发生了严重不良事件，其中1名（5%）患者发生了与研究治疗相关的2级肺炎。未报告与治疗相关的死亡事件。

解释：HER3-DXd在伴有活动性脑转移的转移性乳腺癌患者中显示出有前景的临床活性，并可能为该领域提供一种新的治疗选择。

资金来源：第一三共株式会社和默沙东公司。

### 第二部分 AI 大师评价

TUXEDO-3研究是一项关键的2期临床试验，旨在评估新型抗体药物偶联物HER3-DXd对乳腺癌伴活动性脑转移患者的颅内疗效与安全性。该研究成功达到了其主要终点，在多线经治的患者中观察到23.8%的颅内缓解率，且安全性可控。其核心创新价值在于证实了HER3靶向ADC药物能有效穿透血脑屏障并产生临床获益，为这一预后极差且治疗方案匮乏的患者群体提供了一种极具前景的新治疗选择。

---

## 76. Patritumab deruxtecan (HER3-DXd) 治疗非小细胞肺癌活动性脑转移患者的 TUXEDO-3 研究：一项多中心、单臂、2 期临床试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167214](https://pubmed.ncbi.nlm.nih.gov/41167214)
**期刊：** The Lancet. Oncology
**PMID：** 41167214
**DOI：** 10.1016/S1470-2045(25)00465-6

### 第一部分 原文与翻译

**英文原标题：** Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.

**英文摘要原文：**
BACKGROUND: Patritumab deruxtecan (HER3-DXd) is a novel antibody-drug conjugate targeting HER3, which is overexpressed in CNS metastases of advanced non-small-cell lung cancer (NSCLC). We aimed to evaluate the activity and safety of HER3-DXd in patients with advanced NSCLC and newly diagnosed brain metastases or brain metastases progressing after local therapy.

METHODS: TUXEDO-3 is a multicohort, multicentre, open-label, single-arm phase 2 trial. In this cohort (2 of 3), we enrolled adults (aged ≥18 years) with histologically documented squamous or non-squamous NSCLC, radiologically documented metastatic disease, newly diagnosed brain metastases or progressing brain metastases after local treatment, at least one brain lesion, no need for immediate local therapy, and an Eastern Cooperative Oncology Group performance status of 0-2. Patients received HER3-DXd 5·6 mg/kg intravenously once every 3 weeks. The threshold to meet the primary endpoint was at least 15% of patients having an intracranial response according to Response Assessment in Neuro-Oncology Brain Metastases criteria. Activity and safety analyses were done in the full analysis set, which included all participants who received at least one dose of HER3-DXd. This trial (ClinicalTrials.govNCT05865990 and European Union Clinical Trials Register 2023-503251-10-00) is ongoing but no longer enrolling patients.

FINDINGS: Between Dec 27, 2023, and Sept 6, 2024, 20 patients were recruited; ten (50%) were female and ten (50%) were male. 16 (80%) of 20 patients were White; race was not reported in the remaining four patients. 13 (65%) of the 20 patients had brain metastases progressing after local therapy and seven (35%) had untreated brain metastases; five (25%) had activating driver mutations. Median follow-up was 5·3 months (IQR 2·0-8·5). The primary endpoint was met, with six (30%) of 20 patients having intracranial responses (objective response rate 30·0%, 95% CI 11·9-54·3). The six responders had non-squamous advanced NSCLC (two [33%] with untreated brain metastases and four [67%] with progressing brain metastases), of whom one (17%) had an activating driver mutation (KRAS G12C). Treatment-related adverse events occurred in 16 (80%) patients, the most common of which were nausea (seven [35%] patients), and diarrhoea and asthenia (each six [30%] patients). The most common grade 3 and 4 adverse events were neutropenia in three (15%) patients and febrile neutropenia in two (10%). There were no treatment-related deaths, and no new safety signals were identified.

INTERPRETATION: HER3-DXd showed promising clinical activity in patients with advanced NSCLC and active brain metastases, and could represent a novel treatment option in this setting.

FUNDING: Daiichi-Sankyo and Merck Sharp & Dohme.

**中文摘要译文：**
背景：Patritumab deruxtecan (HER3-DXd) 是一种靶向 HER3 的新型抗体药物偶联物，HER3 在晚期非小细胞肺癌 (NSCLC) 的中枢神经系统转移灶中过度表达。我们旨在评估 HER3-DXd 在伴有新诊断脑转移或局部治疗后进展的脑转移的晚期 NSCLC 患者中的活性和安全性。

方法：TUXEDO-3 是一项多队列、多中心、开放标签、单臂的 2 期临床试验。在该队列（第2/3队列）中，我们纳入了年龄≥18岁的成人患者，其需经组织学证实的鳞状或非鳞状 NSCLC、影像学证实的转移性疾病、新诊断的脑转移或局部治疗后进展的脑转移、至少有一个脑部病灶、无需立即进行局部治疗，且东部协作肿瘤组织（ECOG）体能状态评分为 0-2 分。患者每 3 周一次接受 5.6 mg/kg 的 HER3-DXd 静脉输注。达到主要终点的阈值是至少 15% 的患者根据神经肿瘤学脑转移疗效评估标准（RANO-BM）获得颅内缓解。活性和安全性分析在全分析集（包括所有接受了至少一剂 HER3-DXd 的参与者）中进行。该试验（ClinicalTrials.gov NCT05865990 和欧盟临床试验注册库 2023-503251-10-00）仍在进行中，但已停止招募患者。

结果：在 2023 年 12 月 27 日至 2024 年 9 月 6 日期间，共招募了 20 名患者；其中 10 名（50%）为女性，10 名（50%）为男性。20 名患者中有 16 名（80%）为白人；其余 4 名患者的种族信息未报告。20 名患者中，13 名（65%）为局部治疗后进展的脑转移，7 名（35%）为未经治疗的脑转移；5 名（25%）携带激活驱动基因突变。中位随访时间为 5.3 个月（IQR 2.0-8.5）。研究达到了主要终点，20 名患者中有 6 名（30%）获得颅内缓解（客观缓解率 30.0%，95% CI 11.9-54.3）。这 6 名缓解者均为非鳞状晚期 NSCLC（其中 2 名[33%]为未经治疗的脑转移，4 名[67%]为进展性脑转移），其中 1 名（17%）携带激活驱动基因突变（KRAS G12C）。16 名（80%）患者发生了治疗相关不良事件，其中最常见的是恶心（7 名 [35%] 患者），以及腹泻和乏力（各 6 名 [30%] 患者）。最常见的 3 级和 4 级不良事件是 3 名（15%）患者出现的中性粒细胞减少症和 2 名（10%）患者出现的热性中性粒细胞减少症。无治疗相关死亡事件发生，也未发现新的安全性信号。

结论：HER3-DXd 在伴有活动性脑转移的晚期 NSCLC 患者中显示出有前景的临床活性，可能为这一领域的治疗提供一种新的选择。

资金来源：第一三共株式会社和默沙东公司。

### 第二部分 AI 大师评价

本研究（TUXEDO-3）是一项关键的2期临床试验，旨在评估新型HER3靶向抗体药物偶联物Patritumab deruxtecan（HER3-DXd）在非小细胞肺癌伴活动性脑转移患者中的疗效与安全性。研究结果令人鼓舞，颅内客观缓解率达到了30%，成功达到预设的主要终点，且安全性可控。该研究的创新之处在于，为缺乏有效治疗手段的非小细胞肺癌脑转移这一棘手领域提供了新的治疗方向，证实了HER3-DXd穿透血脑屏障并产生临床获益的潜力，具有重要的临床转化价值。

---

## 77. 不推荐在妊娠期使用电离辐射的诊断影像学检查中进行腹部屏蔽

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167213](https://pubmed.ncbi.nlm.nih.gov/41167213)
**期刊：** The Lancet. Oncology
**PMID：** 41167213
**DOI：** 10.1016/S1470-2045(25)00368-7

### 第一部分 原文与翻译

**英文原标题：** Abdominal shielding not recommended for diagnostic imaging with ionising radiation during pregnancy.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文标题明确指出，在对妊娠期患者进行涉及电离辐射的诊断性影像学检查时，不应再推荐使用腹部屏蔽。这标志着一项重要的临床实践转变，挑战了过去为减少胎儿辐射暴露而常规使用铅屏蔽的传统做法。此建议可能基于最新的物理学和放射生物学证据，即现代影像设备已能将散射辐射降至极低水平，而腹部屏蔽不仅无助于进一步降低胎儿剂量，反而可能干扰自动曝光控制系统，导致总体辐射剂量增加或影响图像质量。此立场声明对于放射科、产科及相关医学物理领域具有重要的指导价值，将推动全球放射防护实践的更新。

---

## 78. 皮下免疫疗法——披着羊皮的狼？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167212](https://pubmed.ncbi.nlm.nih.gov/41167212)
**期刊：** The Lancet. Oncology
**PMID：** 41167212
**DOI：** 10.1016/S1470-2045(25)00615-1

### 第一部分 原文与翻译

**英文原标题：** Subcutaneous immunotherapy-a wolf in sheep's clothing?

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文仅凭标题推断，可能是一篇评论或观点性文章，旨在对皮下免疫疗法（SCIT）的安全性与风险提出深刻质疑。文章标题“披着羊皮的狼？”强烈暗示，作者可能在探讨该疗法看似温和或有效的外表下，是否隐藏着未被充分认识的严重不良反应或长期风险。发表于《柳叶刀·肿瘤学》这一顶级期刊，该文可能旨在警示临床医生和研究人员，需重新审视SCIT在肿瘤治疗中的风险效益比，并可能对现有临床实践指南提出挑战。由于没有摘要，无法得知其具体论据和结论，但其标题本身就极具警示价值和学术探讨意义。

---

## 79. CYCLONE 2研究：对前列腺癌预后无影响。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167211](https://pubmed.ncbi.nlm.nih.gov/41167211)
**期刊：** The Lancet. Oncology
**PMID：** 41167211
**DOI：** 10.1016/S1470-2045(25)00524-8

### 第一部分 原文与翻译

**英文原标题：** CYCLONE 2: no impact on prostate cancer forecast.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题表明，CYCLONE 2研究未能对前列腺癌的预后产生积极影响。尽管缺乏摘要信息，但从标题推断，这可能是一项关于新疗法或策略的临床试验的阴性结果报告。在《柳叶刀·肿瘤学》这样的顶级期刊上发表阴性结果，对于避免无效的科研投入、指导未来研究方向具有重要的科学价值，体现了科研诚信和透明度。

---

## 80. 脑转移的全身治疗：不断变化的格局

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167210](https://pubmed.ncbi.nlm.nih.gov/41167210)
**期刊：** The Lancet. Oncology
**PMID：** 41167210
**DOI：** 10.1016/S1470-2045(25)00561-3

### 第一部分 原文与翻译

**英文原标题：** Systemic therapy for brain metastases: a changing landscape.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题表明，这可能是一篇关于脑转移全身治疗最新进展的综述或评论性文章。文章的核心内容可能围绕靶向治疗、免疫治疗等新型系统性疗法在脑转移患者中的应用、挑战与前景展开，旨在描绘该领域治疗策略的演变。尽管缺乏摘要信息，但该主题对于肿瘤科医生和研究人员具有重要参考价值，有助于他们了解和跟进这一快速发展的治疗领域。

---

## 81. 癌症治疗的国际资助：一项共同的责任

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41167209](https://pubmed.ncbi.nlm.nih.gov/41167209)
**期刊：** The Lancet. Oncology
**PMID：** 41167209
**DOI：** 10.1016/S1470-2045(25)00620-5

### 第一部分 原文与翻译

**英文原标题：** International funding for cancer care: a shared responsibility.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

根据该文献标题，本文可能是一篇探讨全球癌症护理资金来源与分配的政策评论或观点性文章。其核心主旨在于倡导癌症治疗的资金支持不应局限于单个国家或机构，而是一项需要国际社会共同承担的全球性责任。由于没有摘要，无法深入了解其具体论据和分析方法，但该文选题具有重要的现实意义，旨在推动全球健康公平，为解决中低收入国家癌症医疗资源匮乏问题提供了一种宏观视角和政策导向。

---

## 82. 让数学模型“说”成现实

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41166701](https://pubmed.ncbi.nlm.nih.gov/41166701)
**期刊：** Cancer research
**PMID：** 41166701
**DOI：** 10.1158/0008-5472.CAN-25-4862

### 第一部分 原文与翻译

**英文原标题：** Speaking mathematical models into existence.

**英文摘要原文：**
Mathematical and computational modeling enables in silico testing of (for example) hypotheses, experimental design, and interventional strategies. However, building, sharing, and applying complex models require technical skills and software development knowledge that is rarely accessible outside computational groups. This barrier limits broader adoption, reproducibility, and collaborative model development which, unfortunately, slows the pace of discovery. In their recent paper, Johnson and colleagues address this challenge by introducing a human-interpretable grammar that encodes multicellular systems biology models as human-readable statements following a fixed structure (e.g., "cell type, signal, response, behavior"). This framework allows investigators to speak mathematical models into existence by composing biological hypotheses in plain-text sentences that are then translated into executable agent-based models. The authors show, through a set of cancer-relevant examples, how this grammar bridges the gap between biological reasoning and mathematical formalism, thereby providing a language that can be shared between experimentalists, computational scientists, and clinicians. Practically, this means that models can be composed, modified, and reproduced without requiring programming expertise. This democratization could accelerate discovery, broaden participation in computational oncology, and facilitate the translation of modeling insights into experimental and clinical research. Thus, Johnson and colleagues have lowered the barrier for model construction and application.

**中文摘要译文：**
数学和计算建模使得（例如）假说、实验设计和干预策略的计算机模拟测试（in silico testing）成为可能。然而，构建、共享和应用复杂模型需要专业技术技能和软件开发知识，而这些通常只有计算研究团队才具备。这一障碍限制了模型的广泛应用、可重复性以及协作开发，并因此不幸地减缓了科学发现的步伐。在最近的论文中，Johnson及其同事通过引入一种人类可解释的语法来应对这一挑战，该语法将多细胞系统生物学模型编码为遵循固定结构（例如，“细胞类型、信号、响应、行为”）的人类可读语句。该框架允许研究人员通过以纯文本句子撰写生物学假说，然后将其转换为可执行的基于智能体的模型，从而将数学模型“说”成现实。作者通过一系列与癌症相关的例子展示了这种语法如何弥合生物学推理与数学形式主义之间的鸿沟，从而提供了一种可供实验科学家、计算科学家和临床医生共享的语言。实际上，这意味着模型的构建、修改和复现不再需要编程专业知识。这种大众化可以加速科学发现，扩大计算肿瘤学领域的参与度，并促进模型见解向实验和临床研究的转化。因此，Johnson及其同事降低了模型构建与应用的门槛。

### 第二部分 AI 大师评价

本研究旨在解决复杂数学模型构建的技术壁垒问题。研究者们创新性地开发了一种人类可解释的语法框架，能将遵循特定结构的生物学自然语言语句，自动翻译成可执行的基于智能体的计算模型。该研究的核心价值在于极大地降低了计算建模的门槛，使得不具备编程技能的实验科学家和临床医生也能构建、修改和验证模型。这一“大众化”方法有望显著加速癌症等复杂疾病的研究进程，促进跨学科协作与模型见解的临床转化。

---

## 83. Path2Omics可提升基于肿瘤组织病理学的转录组和甲基化预测准确性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41166699](https://pubmed.ncbi.nlm.nih.gov/41166699)
**期刊：** Cancer research
**PMID：** 41166699
**DOI：** 10.1158/0008-5472.CAN-25-4350

### 第一部分 原文与翻译

**英文原标题：** Path2Omics Enhances Transcriptomic and Methylation Prediction Accuracy from Tumor Histopathology.

**英文摘要原文：**
Precision oncology is becoming increasingly integral to clinical practice, demonstrating notable improvements in treatment outcomes. While molecular data provide comprehensive insights, obtaining such data remains costly and time-consuming. Here, we developed Path2Omics, a deep learning framework that independently predicts gene expression and methylation from histopathology across 30 TCGA cancer types. Path2Omics comprised two components: an "FFPE model" trained on FFPE slides and an "FF model" trained on fresh frozen (FF) slides. When evaluated on seven external datasets, the "FF model" outperformed the "FFPE model", even though six of the datasets consisted exclusively of FFPE slides. The "Integrated model" combined predictions from both, achieving a 30% improvement over the FFPE model alone and robustly predicting approximately 4,400 genes (out of 18,000). Importantly, the inferred gene expression closely matched actual values in predicting patient survival and treatment response. Overall, this study demonstrated the potential of Path2Omics to advance precision oncology using routine histopathology slides.

**中文摘要译文：**
精准肿瘤学正日益成为临床实践中不可或缺的一部分，并在改善治疗结局方面展现出显著成效。尽管分子数据能提供全面的见解，但其获取过程依旧成本高昂且耗时。在此，我们开发了Path2Omics，一个深度学习框架，该框架能基于30种TCGA癌症类型的组织病理学图像独立预测基因表达和甲基化水平。Path2Omics包含两个组成部分：一个在福尔马林固定石蜡包埋（FFPE）切片上训练的“FFPE模型”，以及一个在新鲜冰冻（FF）切片上训练的“FF模型”。在七个外部数据集上进行评估时，“FF模型”的表现优于“FFPE模型”，即便其中六个数据集完全由FFPE切片组成。结合两者预测结果的“整合模型”，其性能比单独使用FFPE模型提升了30%，并能对约4400个基因（总计18000个）进行稳健预测。重要的是，在预测患者生存和治疗反应方面，推断出的基因表达谱与实际值高度吻合。总而言之，本研究展示了Path2Omics利用常规组织病理学切片推动精准肿瘤学发展的巨大潜力。

### 第二部分 AI 大师评价

本研究介绍了一个名为Path2Omics的深度学习框架，旨在通过常规的肿瘤组织病理学图像直接预测转录组和甲基化数据，以解决传统分子检测成本高、耗时长的难题。其核心创新在于构建了一个整合模型，不仅显著提升了对数千个基因的预测准确性，更关键的是，验证了这些推断出的分子数据在预测患者生存和治疗反应等临床结局方面的有效性。这项工作具有巨大的临床转化潜力，为利用标准病理切片获取关键分子信息以指导精准肿瘤治疗开辟了新途径，有望使先进的癌症诊断更加普及和便捷。

---

## 84. T细胞白血病与淋巴瘤的多组学分析助力靶向治疗的发现

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41166698](https://pubmed.ncbi.nlm.nih.gov/41166698)
**期刊：** Cancer research
**PMID：** 41166698
**DOI：** 10.1158/0008-5472.CAN-25-0881

### 第一部分 原文与翻译

**英文原标题：** Multi-omics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery.

**英文摘要原文：**
T-cell leukemias and lymphomas (TCLs) form a heterogeneous group of rare and often aggressive malignancies. Due to the rarity and heterogeneity of TCL subtypes, clinical trials are challenging to conduct, making pharmacogenomic studies in cell line panels critical for the discovery of targeted therapeutics. The scarcity of data repositories with integrated multi-omics and drug screening data hinders the preclinical evaluation of drug vulnerabilities and the identification of molecular markers predictive of responses to monotherapies and combinations. To address this gap, we conducted comprehensive pharmacogenomic profiling on a panel of 38 TCL cell lines, representing major clinical TCL subtypes to capture the molecular and phenotypic diversity. The TCL-38 multi-omics data resource includes harmonized genetic, molecular, and epigenetic profiles, with comprehensive annotations, and standardized drug response assessment of each cell line. This resource, together with machine learning predictions, was leveraged to identify TCL subtype-specific therapeutic vulnerabilities, including single-agent sensitivities and synergistic drug combinations, which were linked to genetic or epigenetic features as potential predictive biomarkers. This integrated and openly available resource (https://aittokallio.group/tcl38) could help advance the currently limited treatment options for patients with TCL.

**中文摘要译文：**
T细胞白血病和淋巴瘤（TCLs）是一组具有异质性的罕见且通常具有侵袭性的恶性肿瘤。由于TCL亚型的罕见性和异质性，临床试验难以开展，这使得在细胞系panel中进行药物基因组学研究对于发现靶向治疗药物至关重要。集成了多组学和药物筛选数据的数据存储库的缺乏，阻碍了药物脆弱性的临床前评估以及用于预测单药和联合治疗反应的分子标志物的识别。为填补这一空白，我们对代表主要临床TCL亚型的38种TCL细胞系panel进行了全面的药物基因组学分析，以捕捉其分子和表型多样性。TCL-38多组学数据资源包含了经过协调的遗传、分子和表观遗传学图谱，并附有全面的注释以及对每种细胞系的标准化药物反应评估。该资源与机器学习预测相结合，被用于识别TCL亚型特异性的治疗脆弱性，包括单药敏感性和协同药物组合，这些脆弱性与遗传或表观遗传特征相关联，可作为潜在的预测性生物标志物。这一集成且开放获取的资源（https://aittokallio.group/tcl38）可能有助于推动目前TCL患者有限的治疗选择取得进展。

### 第二部分 AI 大师评价

该研究针对T细胞白血病与淋巴瘤（TCLs）这类罕见且具有高度异质性的恶性肿瘤，通过对38种TCL细胞系进行全面的多组学和药物基因组学分析，成功构建了一个开放获取的数据资源。此举不仅弥补了现有数据库的不足，更利用机器学习方法揭示了TCL亚型特异性的治疗靶点、药物敏感性及潜在的生物标志物。这项工作极具创新性，其建立的TCL-38多组学数据库为TCLs的临床前研究和靶向治疗药物开发提供了宝贵的数据基础和新颖的研究思路，对改善患者有限的治疗选择具有重要推动作用。

---

## 85. 二甲双胍用于低风险前列腺癌主动监测的临床试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41166665](https://pubmed.ncbi.nlm.nih.gov/41166665)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41166665
**DOI：** 10.1200/JCO-25-01070

### 第一部分 原文与翻译

**英文原标题：** Metformin Active Surveillance Trial in Low-Risk Prostate Cancer.

**英文摘要原文：**
PURPOSE: Active surveillance (AS) is a standard management strategy for low-risk prostate cancer (PCa), but a significant proportion of patients ultimately experience disease progression. Metformin, a commonly prescribed antidiabetic agent, has demonstrated antitumor activity in preclinical studies and observational data, prompting investigation into its potential to delay PCa progression.

PATIENTS AND METHODS: The Metformin Active Surveillance Trial (MAST) was a multicenter, randomized, double-blind, placebo-controlled phase III trial evaluating the efficacy of metformin in men with low-risk, localized PCa managed with AS. Eligible participants were randomly assigned 1:1 to receive either metformin (850 mg twice daily) or placebo and were followed for up to 36 months. The primary end point was time to progression, defined as therapeutic and/or pathologic progression. Progression-free survival (PFS) was assessed using Kaplan-Meier analysis and Cox proportional hazards models.

RESULTS: A total of 408 patients were randomly assigned (205 metformin, 203 placebo). After a median follow-up of 36 months, 144 participants experienced progression (70 metformin, 74 placebo), with no significant difference in PFS (hazard ratio [HR], 1.09 [95% CI, 0.79 to 1.52];  = .59). Negative biopsy rates at 36 months were 41.0% (metformin) versus 31.1% (placebo;  = .181). In prespecified subgroup analysis, metformin was associated with increased pathologic progression among obese patients (BMI ≥ 30; HR, 2.36 [95% CI, 1.21 to 4.59];  = .0092).

CONCLUSION: Metformin did not reduce progression in men with low-risk PCa on AS. The observed adverse effect in obese patients merits further investigation.

**中文摘要译文：**
目的：主动监测（AS）是低风险前列腺癌（PCa）的标准管理策略，但有相当一部分患者最终会出现疾病进展。二甲双胍作为一种常用的抗糖尿病药物，在临床前研究和观察性数据中已显示出抗肿瘤活性，这促使研究人员探索其延缓前列腺癌进展的潜力。

患者与方法：MAST试验是一项多中心、随机、双盲、安慰剂对照的III期临床试验，旨在评估二甲双胍对接受主动监测管理的低风险局限性前列腺癌男性的疗效。符合条件的参与者被以1:1的比例随机分配接受二甲双胍（850毫克，每日两次）或安慰剂治疗，并接受长达36个月的随访。主要终点是至疾病进展时间，其定义为治疗性进展和/或病理性进展。无进展生存期（PFS）通过Kaplan-Meier分析和Cox比例风险模型进行评估。

结果：共有408名患者被随机分组（二甲双胍组205人，安慰剂组203人）。中位随访36个月后，144名参与者出现疾病进展（二甲双胍组70人，安慰剂组74人），两组的无进展生存期无显著差异（风险比[HR]为1.09 [95% CI, 0.79至1.52]；P = .59）。36个月时的活检阴性率分别为41.0%（二甲双胍组）对31.1%（安慰剂组）（P = .181）。在预设的亚组分析中，二甲双胍与肥胖患者（BMI ≥ 30）的病理性进展风险增加相关（HR为2.36 [95% CI, 1.21至4.59]；P = .0092）。

结论：对于接受主动监测的低风险前列腺癌男性患者，二甲双胍未能延缓其疾病进展。在肥胖患者中观察到的不良效应值得进一步研究。

### 第二部分 AI 大师评价

该研究是一项设计严谨的多中心、随机、双盲、安慰剂对照III期临床试验，旨在探究常用降糖药二甲双胍能否延缓接受主动监测的低风险前列腺癌患者的疾病进展。研究结果明确显示，与安慰剂相比，二甲双胍未能改善患者的无进展生存期，得出了阴性结论。尤为重要的是，研究意外发现在肥胖患者亚组中，二甲双胍反而可能增加病理性进展的风险，这一发现不仅对临床实践具有警示意义，也为未来探索药物与代谢状态相互作用的研究提供了新方向。

---

## 86. 反思

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41166660](https://pubmed.ncbi.nlm.nih.gov/41166660)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41166660
**DOI：** 10.1200/JCO-25-01395

### 第一部分 原文与翻译

**英文原标题：** Reflection.

**英文摘要原文：**
This is a deeply personal narrative an inpatient oncology doctor reflects on the profound personal and professional impact of losing her young family member to cancer, illuminating the intimate intersection of grief, loss, and healing.

**中文摘要译文：**
这是一篇非常个人化的叙述，一位住院肿瘤科医生反思了因癌症失去她年轻的家庭成员所带来的深刻的个人和职业影响，揭示了悲伤、失落和治愈之间紧密的交集。

### 第二部分 AI 大师评价

本文并非一项传统临床研究，而是一篇以第一人称视角撰写的深刻反思。作者作为一名肿瘤科医生，通过记述失去亲人的个人经历，探讨了医生在面对亲人患癌时的双重角色及其带来的复杂情感与职业冲击。此文的价值在于其强烈的人文关怀，它提醒医学界，尤其是肿瘤学领域的从业者，关注并共情患者及其家属的经历，同时也正视医生作为普通人面对悲痛时的脆弱性，为医学实践提供了宝贵的伦理与情感视角。

---

## 87. 高级别浆液性卵巢癌中的生物标志物：背景决定一切。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41166600](https://pubmed.ncbi.nlm.nih.gov/41166600)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41166600
**DOI：** 10.1158/1078-0432.CCR-25-2851

### 第一部分 原文与翻译

**英文原标题：** Biomarkers in High-Grade Serous Ovarian Cancer: Context is everything.

**英文摘要原文：**
The Oxford Classic Epithelial-Mesenchymal Transition (OxC-EMT) score identifies a high-risk subgroup of High-Grade Serous Carcinoma (HGSC) patients with inferior survival. This commentary discusses the evaluation of HGSC biomarkers in context and the important steps in transition from a prognostic to a validated predictive biomarker to inform clinical utility.

**中文摘要译文：**
牛津经典上皮-间质转化（OxC-EMT）评分可识别出一组生存状况较差的高级别浆液性癌（HGSC）高危患者亚群。这篇评论探讨了在特定背景下评估HGSC生物标志物的重要性，并论述了将预后性生物标志物转变为经过验证的、能够指导临床应用的预测性生物标志物的关键步骤。

### 第二部分 AI 大师评价

这篇评论以牛津经典上皮-间质转化（OxC-EMT）评分为例，深刻探讨了高级别浆液性癌（HGSC）生物标志物研究中的一个核心问题：如何将一个具有预后价值的指标，转化为能真正指导临床决策的预测性工具。文章强调了在特定临床背景下评估生物标志物的重要性，并指出了从发现到验证的关键步骤。该评论虽非原创性研究，但其高屋建瓴的视角对于指导后续HGSC生物标志物的转化研究具有重要的现实意义和学术价值。

---

## 88. FIGNL1通过解离RAD51蛋白丝抑制BRCA2缺陷细胞中的同源重组

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41166468](https://pubmed.ncbi.nlm.nih.gov/41166468)
**期刊：** Science (New York, N.Y.)
**PMID：** 41166468
**DOI：** 10.1126/science.adt1210

### 第一部分 原文与翻译

**英文原标题：** FIGNL1 inhibits homologous recombination in BRCA2 deficient cells by dissociating RAD51 filaments.

**英文摘要原文：**
Homologous recombination (HR) deficiency upon Breast Cancer Gene 2 (BRCA2) loss arises from defects in the formation of RAD51 nucleoprotein filaments. We demonstrate that loss of the anti-recombinase Fidgetin Like 1 (FIGNL1) retains RAD51 loading at DNA double-stranded breaks (DSBs) in BRCA2-deficient cells, leading to genome stability, HR proficiency, and viability of BRCA2-deficient mouse embryonic stem cells. Mechanistically, we demonstrate that strand invasion and subsequent HR defects upon BRCA2 loss primarily arise from the unrestricted removal of RAD51 from DSB sites by FIGNL1, rather than from defective RAD51 loading. Furthermore, we identify that the MMS22L-TONSL complex interacts with FIGNL1 and is critical for HR in BRCA2/FIGNL1 double-deficient cells. These findings identify a pathway for tightly regulating RAD51 activity to promote efficient HR, offering insights into mechanisms of chemoresistance in BRCA2-deficient tumors.

**中文摘要译文：**
乳腺癌基因2 (BRCA2) 缺失所致的同源重组 (HR) 缺陷源于RAD51核蛋白丝形成的障碍。我们证明，在BRCA2缺陷细胞中，抗重组酶Fidgetin样蛋白1 (FIGNL1) 的缺失能够维持RAD51在DNA双链断裂 (DSBs) 处的加载，从而恢复了BRCA2缺陷的鼠胚胎干细胞的基因组稳定性、HR能力和细胞活力。从机制上讲，我们证明BRCA2缺失后的链侵入及随后的HR缺陷，主要源于FIGNL1对DSB位点RAD51的无限制清除，而非RAD51加载缺陷本身。此外，我们发现MMS22L-TONSL复合物与FIGNL1相互作用，并且在BRCA2/FIGNL1双缺陷细胞的HR过程中至关重要。这些发现揭示了一条精确调控RAD51活性以促进高效HR的通路，为理解BRCA2缺陷肿瘤的化疗耐药机制提供了新的见解。

### 第二部分 AI 大师评价

本研究旨在阐明抗重组酶FIGNL1在BRCA2缺陷细胞同源重组（HR）修复中的具体作用。研究通过细胞和分子生物学实验发现，BRCA2缺失导致的HR缺陷，其关键原因并非RAD51加载不足，而是FIGNL1对其过度清除。该研究创新性地揭示了抑制FIGNL1可恢复BRCA2缺陷细胞的基因组稳定性和HR功能，为靶向FIGNL1作为治疗BRCA2缺陷肿瘤耐药性问题提供了新的理论依据和潜在策略，具有重要的科研与临床转化价值。

---

## 89. ViMIC 2.0：一个关于人类疾病相关病毒突变、整合位点与多组学数据的更新数据库。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41166154](https://pubmed.ncbi.nlm.nih.gov/41166154)
**期刊：** Nucleic acids research
**PMID：** 41166154
**DOI：** 10.1093/nar/gkaf1106

### 第一部分 原文与翻译

**英文原标题：** ViMIC 2.0: an updated database of human disease-related viral mutations, integration sites, and multi-omics data.

**英文摘要原文：**
ViMIC 2.0 is an updated database that provides comprehensively curated data on virus mutations (VMs), viral integration sites (VISs), and multi-omics datasets related to human diseases. Leveraging expanding public data, ViMIC 2.0 significantly enhanced data scale, diversity, and analytical capabilities compared to the previous version. In terms of data volume, the number of virus types has increased from 8 to 28, VM entries have grown from 31 712 to 64 168, virus-related diseases expanded from 77 to 177, literature rose from 2539 to 6433, and omics datasets have substantially increased from 28 sets of single expression profile data to 255 sets of multi-omics data. In addition, ViMIC 2.0 has updated 9409 VISs, 173 048 sequences, newly incorporated sequencing types such as single-cell transcriptomic sequencing (scRNA-seq), and genome binding/occupancy profiling. Regarding the visualization module, ViMIC 2.0 now provides results of differential gene expression analysis for bulk RNA-seq or array, cell type annotation and gene feature plot for scRNA-seq data, and differential methylation analysis for methylation profiling, as well as peak annotation for ChIP-seq/ChIP-on-chip/ATAC-seq data. In summary, ViMIC 2.0 serves as a user-friendly, up-to-date, and well-maintained resource for the virology research community. ViMIC 2.0 is freely accessible at http://www.biomedinfo.cn/ViMIC2.0/index.php.

**中文摘要译文：**
ViMIC 2.0是一个更新后的数据库，提供了与人类疾病相关的病毒突变（VMs）、病毒整合位点（VISs）和多组学数据集的全面整理数据。与上一版本相比，ViMIC 2.0利用不断扩展的公共数据，显著增强了数据的规模、多样性和分析能力。在数据量方面，病毒类型从8种增加到28种，病毒突变条目从31,712个增长到64,168个，病毒相关疾病从77种扩展到177种，文献数量从2539篇上升到6433篇，组学数据集也从28套单一表达谱数据大幅增加到255套多组学数据。此外，ViMIC 2.0更新了9409个病毒整合位点（VISs）和173,048条序列，并新增了单细胞转录组测序（scRNA-seq）和基因组结合/占据分析等测序类型。在可视化模块方面，ViMIC 2.0现在可为批量RNA测序或芯片数据提供差异基因表达分析结果，为单细胞转录组测序数据提供细胞类型注释和基因特征图，为甲基化谱数据提供差异甲基化分析，以及为ChIP-seq/ChIP-on-chip/ATAC-seq数据提供峰值注释。总而言之，ViMIC 2.0为病毒学研究界提供了一个用户友好、信息最新且维护良好的资源。ViMIC 2.0可在http://www.biomedinfo.cn/ViMIC2.0/index.php免费访问。

### 第二部分 AI 大师评价

本研究旨在介绍ViMIC 2.0数据库的重大更新，该数据库整合了人类疾病相关的病毒突变、整合位点及多组学数据。通过大规模扩充公共数据集并整合新的测序技术（如scRNA-seq），该研究显著提升了数据库的规模、多样性与分析功能。其核心价值在于为病毒学界提供了一个全面、用户友好且功能强大的在线资源，极大地便利了研究人员探索病毒与宿主相互作用及其致病机制，是病毒相关多组学研究领域的一个重要工具。

---

## 90. 长期坚持身体活动指南与消化系统癌症风险及死亡率的关系

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165700](https://pubmed.ncbi.nlm.nih.gov/41165700)
**期刊：** JAMA oncology
**PMID：** 41165700
**DOI：** 10.1001/jamaoncol.2025.4185

### 第一部分 原文与翻译

**英文原标题：** Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality.

**英文摘要原文：**
IMPORTANCE: Growing evidence suggests that physical activity protects against digestive system cancers (DSCs). However, it remains largely unknown whether consistently reaching the physical activity guidelines (≥7.5 metabolic equivalent task [MET]-hours/week) is associated with lower DSC risk or whether a much higher level is needed.

OBJECTIVE: To examine the association between physical activity and DSC risk and mortality with a focus on the optimal amount and long-term consistency in performing the recommended level over a long period of time.

DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study includes data from 3 large US prospective cohorts: Health Professionals Follow-Up Study, 1988-2020; Nurses' Health Study, 1988-2021; and Nurses' Health Study II, 1991-2021. Data analysis was performed between October 2024 and May 2025. Participants were men and women free from cancer and cardiovascular disease at baseline.

EXPOSURES: Total levels of leisure-time physical activity were assessed with biennial validated questionnaires and expressed in MET-hours per week. Consistency was calculated as the percentage of follow-up years meeting the recommended level (≥7.5 MET-hours/week).

MAIN OUTCOMES AND MEASURES: DSCs included cancers of digestive tract (mouth, throat, esophagus, stomach, small intestine, colon, and rectum) and digestive accessory organs (pancreas, gallbladder, and liver).

RESULTS: During up to 32 years of follow-up of 231 067 men and women (median age, 43 [IQR, 36-55] years), a total of 6538 incident DSCs and 3791 DSC deaths were documented. Higher physical activity levels were associated with lower DSC risk (≥45 vs <3 MET-hours/week; hazard ratio [HR], 0.83; 95% CI, 0.74-0.93; P < .001 for trend) and mortality (HR, 0.72; 95% CI, 0.62-0.83; P < .001 for trend). The inverse associations were evident for both digestive tract and accessory organ cancers: the HRs comparing greater than or equal to 45 vs 3 MET-hours/week were 0.85 (95% CI, 0.75-0.97) for digestive tract cancer risk and 0.73 (95% CI, 0.58-0.92) for digestive accessory organ cancer risk. The traditional dose-response analysis suggested the lowest DSC risk was achieved at approximately 50 MET-hours/week. However, when long-term consistency was considered, compared with those with minimal activity, consistently reaching the guideline at moderate levels (median, 16.9 [IQR, 13.6-20.5] MET-hours/week) over 3 decades was associated with substantial reductions in DSC risk (HR, 0.83; 95% CI, 0.75-0.90), whereas that performing much higher amounts (median, 38.5 [IQR, 28.5-53.8] MET-hours/week) was not associated with further benefit (HR, 0.87; 95% CI, 0.81-0.93).

CONCLUSIONS AND RELEVANCE: In this study, traditional dose-response analysis suggested that approximately 50 MET-hours/week was associated with optimal DSC risk reduction. After incorporating long-term consistency, maintenance of a moderate level approximately 17 MET-hours/week over 3 decades was associated with achieving optimal benefit in reducing DSC risk.

**中文摘要译文：**
重要性：越来越多的证据表明，身体活动能够预防消化系统癌症（DSCs）。然而，目前尚不清楚长期达到身体活动指南推荐量（≥7.5代谢当量[MET]-小时/周）是否能降低DSC风险，或者是否需要远高于此的活动水平。

目的：本研究旨在探究身体活动与DSC风险及死亡率之间的关联，重点关注达到推荐活动水平的最佳活动量以及长期坚持的持续性。

设计、地点与参与者：这项基于人群的队列研究整合了三大美国前瞻性队列的数据：卫生专业人员随访研究（1988-2020年）、护士健康研究（1988-2021年）以及护士健康研究II（1991-2021年）。数据分析于2024年10月至2025年5月间进行。研究参与者为基线时未患有癌症和心血管疾病的男性与女性。

暴露因素：通过经过验证的两年期问卷评估闲暇时间的总身体活动水平，并以MET-小时/周为单位表示。持续性则以达到推荐水平（≥7.5 MET-小时/周）的随访年数百分比来计算。

主要结局与测量指标：DSCs包括消化道癌症（口腔癌、咽喉癌、食管癌、胃癌、小肠癌、结肠癌和直肠癌）和消化腺癌症（胰腺癌、胆囊癌和肝癌）。

结果：在对231,067名男性和女性（中位年龄43岁 [IQR, 36-55]）长达32年的随访期间，共记录了6538例DSC新发病例和3791例DSC相关死亡。较高的身体活动水平与较低的DSC风险（≥45 MET-小时/周 vs <3 MET-小时/周；风险比[HR], 0.83; 95% CI, 0.74-0.93; 趋势P < .001）和死亡率（HR, 0.72; 95% CI, 0.62-0.83; 趋势P < .001）相关。这种负相关性在消化道癌症和消化腺癌症中均很明显：比较≥45 MET-小时/周与<3 MET-小时/周，消化道癌症风险的HR为0.85（95% CI, 0.75-0.97），消化腺癌症风险的HR为0.73（95% CI, 0.58-0.92）。传统的剂量-反应分析表明，在约50 MET-小时/周的活动量时，DSC风险达到最低。然而，当考虑到长期持续性时，与活动量极少者相比，三十年间持续达到中等水平的指南推荐量（中位数, 16.9 [IQR, 13.6-20.5] MET-小时/周）与DSC风险的显著降低相关（HR, 0.83; 95% CI, 0.75-0.90），而进行远超该水平的大量活动（中位数, 38.5 [IQR, 28.5-53.8] MET-小时/周）并未带来额外的益处（HR, 0.87; 95% CI, 0.81-0.93）。

结论与相关性：在本研究中，传统的剂量-反应分析提示，约50 MET-小时/周的身体活动量与最佳的DSC风险降低相关。而在纳入长期持续性因素后，研究发现三十年间维持约17 MET-小时/周的中等活动水平，即可在降低DSC风险方面获得最佳益处。

### 第二部分 AI 大师评价

本研究基于三大美国前瞻性队列、长达32年的随访数据，旨在探究长期身体活动与消化系统癌症风险及死亡率的关联，并聚焦于最佳活动量与持续性的作用。其核心发现具有重要的实践指导意义：传统的剂量-反应分析显示约50 MET-小时/周的活动量能最大化降低风险，但当引入“长期持续性”这一创新维度后，研究揭示了三十年如一日地维持中等水平（约17 MET-小时/周）的身体活动，即可获得最佳的预防效果。这一结论挑战了“越多越好”的传统观念，强调了“长期坚持”比“追求极量”更为关键，为制定可及性更高的公共卫生指南和个体化运动处方提供了坚实的证据支持。

---

## 91. 美国成年人群对饮酒致癌风险的认知研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165698](https://pubmed.ncbi.nlm.nih.gov/41165698)
**期刊：** JAMA oncology
**PMID：** 41165698
**DOI：** 10.1001/jamaoncol.2025.4472

### 第一部分 原文与翻译

**英文原标题：** Beliefs About the Effect of Alcohol Use on Cancer Risk in the US Adult Population.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究旨在探究美国成年人群对于饮酒与癌症风险之间关联的认知与看法。研究可能通过调查方法揭示了公众在这一重要健康议题上存在的知识差距或普遍误解。其发现对于制定更有效的公共卫生教育策略、提高公众对酒精致癌风险的认识具有重要的指导意义，有助于推动癌症预防。由于摘要缺失，无法评估其具体研究方法与关键发现，需查阅全文以获得更全面的信息。

---

## 92. 双特异性抗体的实际作用：接合的现实

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165693](https://pubmed.ncbi.nlm.nih.gov/41165693)
**期刊：** Blood
**PMID：** 41165693
**DOI：** 10.1182/blood.2025030376

### 第一部分 原文与翻译

**英文原标题：** Bispecific antibodies in action: the reality of engagement.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

根据该文献标题推断，这可能是一篇关于双特异性抗体实际应用的综述或评论性文章。文章旨在深入探讨双特异性抗体在真实生物环境中的靶向接合机制，并可能揭示其理论设计与临床实践效果之间的差距。发表于血液学领域的权威期刊《Blood》，此文对于深刻理解该疗法的现实挑战、优化治疗策略具有重要的指导意义，为相关领域的临床医生和研究人员提供了关键的现实世界视角。

---

## 93. 反思现代肿瘤学试验的终点——超越P值

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165689](https://pubmed.ncbi.nlm.nih.gov/41165689)
**期刊：** JAMA oncology
**PMID：** 41165689
**DOI：** 10.1001/jamaoncol.2025.4340

### 第一部分 原文与翻译

**英文原标题：** Rethinking End Points in Modern Oncology Trials-Beyond the P Value.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

根据标题判断，本文很可能是一篇观点或社论文章，旨在深入探讨和反思现代肿瘤临床试验中对传统终点事件和P值的过度依赖。文章的核心论点可能在于，现有的评价标准已不足以全面衡量新疗法的真正临床价值。作者可能倡导整合更多维、更以患者为中心的评价指标（如生活质量），这对于推动未来临床试验设计的革新以及优化药物审批流程具有重要的指导意义和启发价值。

---

## 94. 激素类避孕药制剂与青少年及绝经前女性的乳腺癌风险

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165687](https://pubmed.ncbi.nlm.nih.gov/41165687)
**期刊：** JAMA oncology
**PMID：** 41165687
**DOI：** 10.1001/jamaoncol.2025.4480

### 第一部分 原文与翻译

**英文原标题：** Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women.

**英文摘要原文：**
IMPORTANCE: Hormonal contraceptives are widely used but how breast cancer risk differs by hormonal content remains unclear.

OBJECTIVE: To estimate the difference in breast cancer risk associated with different hormonal contraceptive formulations.

DESIGN, SETTING, AND PARTICIPANTS: This Swedish nationwide, population-based cohort study was conducted using linked national registers. All adolescent girls and women aged 13 to 49 years residing in Sweden as of January 1, 2006, with no history of breast cancer, ovarian cancer, cervical cancer, uterine cancer, bilateral oophorectomy, or infertility treatment were included and followed up from 2006 to 2019. Individuals were censored on meeting an exclusion criterion, reaching age 50 years, or study end, whichever occurred first. Data were analyzed from November 2023 to August 2025.

EXPOSURE: Ever use and duration of use of hormonal contraceptives, categorized by hormone formulations and route of administration.

MAIN OUTCOMES AND MEASURES: Time-dependent Cox regression was used to estimate hazard ratios (HRs) with 95% CIs for incident cases of in situ and invasive breast cancer.

RESULTS: Among 2 095 130 adolescent girls and women (median [IQR] age at diagnosis, 45 [41-48] years) who were followed up for 21 020 846 person-years, 16 385 breast cancer cases occurred. Ever use of any hormonal contraceptive was associated with increased breast cancer risk (HR, 1.24; 95% CI, 1.20-1.28), corresponding to 1 additional case per 7752 (95% CI, 5350-14 070) users, with both combined (HR, 1.12; 95% CI, 1.07-1.17) and progestin-only formulations (HR, 1.21; 95% CI, 1.17-1.25) being associated. Higher risk was associated with oral desogestrel-only formulations (HR, 1.18; 95% CI, 1.13-1.23) and oral desogestrel-combined formulations (HR, 1.19; 95% CI, 1.08-1.31), as well as implants containing etonogestrel, desogestrel's active metabolite (HR, 1.22; 95% CI, 1.11-1.35), compared to levonorgestrel-containing combined pills (HR, 1.09; 95% CI, 1.03-1.15) and levonorgestrel, 52 mg, intrauterine system (HR, 1.13; 95% CI, 1.09-1.18). No statistically significant increased risk was observed for medroxyprogesterone acetate injection, etonogestrel vaginal ring, or combined oral drospirenone, despite having many users.

CONCLUSIONS AND RELEVANCE: Findings of this cohort study highlight that breast cancer risk varies substantially by progestin content in hormonal contraceptives, providing valuable insights to support more informed contraceptive prescription.

**中文摘要译文：**
重要性: 激素类避孕药应用广泛，但不同激素成分如何影响乳腺癌风险尚不明确。

目的: 旨在评估不同激素类避孕药制剂相关的乳腺癌风险差异。

设计、地点与参与者: 这是一项利用关联国家登记数据开展的瑞典全国性、基于人群的队列研究。研究纳入了截至2006年1月1日居住在瑞典的所有13至49岁、无乳腺癌、卵巢癌、宫颈癌、子宫癌、双侧卵巢切除术或不孕治疗史的青春期女孩和女性，并对其进行随访至2019年。当个体满足排除标准、年满50岁或研究结束时（以先发生者为准），进行数据删失。数据分析时间为2023年11月至2025年8月。

暴露因素: 激素类避孕药的曾用史和使用时长，按激素配方和给药途径分类。

主要结局与测量指标: 采用时间依赖性Cox回归分析，估算原位癌和浸润性乳腺癌新发病例的风险比（HRs）及95%置信区间（CIs）。

结果: 在2,095,130名青少年女孩和女性中（诊断时中位[IQR]年龄为45[41-48]岁），共随访了21,020,846人年，期间发生了16,385例乳腺癌病例。曾使用任何激素类避孕药均与乳腺癌风险增加相关（HR, 1.24; 95% CI, 1.20-1.28），相当于每7752名使用者中增加1例病例（95% CI, 5350-14,070），其中复合制剂（HR, 1.12; 95% CI, 1.07-1.17）和仅含孕激素的制剂（HR, 1.21; 95% CI, 1.17-1.25）均与风险增加有关。与含左炔诺孕酮的复方口服避孕药（HR, 1.09; 95% CI, 1.03-1.15）和含52毫克左炔诺孕酮的宫内节育系统（HR, 1.13; 95% CI, 1.09-1.18）相比，仅含地索高诺酮的口服制剂（HR, 1.18; 95% CI, 1.13-1.23）、含地索高诺酮的复方口服制剂（HR, 1.19; 95% CI, 1.08-1.31）以及含有地索高诺酮活性代谢物依托孕烯的植入剂（HR, 1.22; 95% CI, 1.11-1.35）相关的风险更高。尽管醋酸甲羟孕酮注射剂、依托孕烯阴道环或含屈螺酮的复方口服避孕药使用者众多，但未观察到其乳腺癌风险有统计学意义的增加。

结论与意义: 本队列研究的结果强调，激素类避孕药所致的乳腺癌风险因其孕激素成分的不同而存在显著差异，这为支持更明智的避孕药处方决策提供了宝贵的见解。

### 第二部分 AI 大师评价

该研究基于瑞典全国性队列数据，旨在精细评估不同激素类避孕药制剂对青少年及绝经前女性乳腺癌风险的影响。研究发现，乳腺癌风险不仅与激素避孕药的使用有关，更关键地取决于其中孕激素的类型；例如，含地索高诺酮的制剂风险高于含左炔诺孕酮的制剂。此项研究的创新之处在于，它超越了“是否使用”的笼统关联，深入到“使用何种成分”的层面，为临床个体化避孕咨询和处方决策提供了强有力的循证医学证据，有助于在有效避孕和风险管理之间取得更优平衡。

---

## 95. 反思现代肿瘤学试验的终点：超越P值的意义——答复

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165678](https://pubmed.ncbi.nlm.nih.gov/41165678)
**期刊：** JAMA oncology
**PMID：** 41165678
**DOI：** 10.1001/jamaoncol.2025.4346

### 第一部分 原文与翻译

**英文原标题：** Rethinking End Points in Modern Oncology Trials-Beyond the P Value-Reply.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文是一篇针对“反思现代肿瘤学试验中的终点”这一议题的答复性文章。从标题推断，作者旨在回应并深入探讨超越传统P值统计显著性的必要性，强调在评估新疗法时应采用更具临床意义的试验终点。此类讨论对于优化未来肿瘤学临床试验设计、确保终点选择能真实反映患者获益至关重要。虽然本文形式为“答复”且无摘要，限制了对其具体论点的深入了解，但其提出的方向是当前临床研究方法学革新的核心议题之一，具有重要的学术探讨价值。

---

## 96. 反思现代肿瘤试验的研究终点——超越P值

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165677](https://pubmed.ncbi.nlm.nih.gov/41165677)
**期刊：** JAMA oncology
**PMID：** 41165677
**DOI：** 10.1001/jamaoncol.2025.4343

### 第一部分 原文与翻译

**英文原标题：** Rethinking End Points in Modern Oncology Trials-Beyond the P Value.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文单从标题来看，应为一篇关于临床试验方法学的述评或观点性文章。其核心主旨在于挑战和反思现代肿瘤临床试验中对传统研究终点及P值的过度依赖。作者可能主张，随着精准医疗和免疫治疗的发展，我们需要采用更全面、多维度的评价指标来捕捉新疗法的真实临床获益，而非仅仅依赖传统的统计显著性。此文对于推动临床试验设计的革新、优化新药审批标准以及促进对治疗价值的更深层次理解具有重要的学术价值和启示意义。

---

## 97. 角质形成细胞癌综述

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165676](https://pubmed.ncbi.nlm.nih.gov/41165676)
**期刊：** JAMA
**PMID：** 41165676
**DOI：** 10.1001/jama.2025.18749

### 第一部分 原文与翻译

**英文原标题：** Keratinocyte Carcinoma: A Review.

**英文摘要原文：**
IMPORTANCE: Keratinocyte carcinomas are skin cancers that arise from keratinocytes and are composed of basal cell carcinomas (BCCs) and cutaneous squamous cell carcinomas (cSCCs). Keratinocyte carcinomas are common in North America, Australia, New Zealand, and Europe. Approximately 5.4 million keratinocyte carcinomas are diagnosed in the US annually.

OBSERVATIONS: Keratinocyte carcinomas are primarily located on the head and neck (40%-64% of BCCs; 35%-45% of cSCCs). BCC typically presents as a pink, smooth, raised lesion or a pink to red, flat lesion. cSCC typically presents as a red, scaly, flat lesion (in situ tumors) or a red, firm, raised lesion with scale or erosion (invasive tumors). UV light exposure is the primary cause, and lighter skin pigmentation and skin phototype (eg, skin that more easily burns) are the primary risk factors. Other risk factors include older age, male sex, indoor tanning, history of precancerous lesions (actinic keratoses), history of keratinocyte carcinomas, and immunosuppression (eg, organ transplant). In-office surgical excision or curettage and electrodessication (in which the tumor is scraped away using a curette and the wound base is cauterized) is typically performed by a dermatologist for keratinocyte carcinomas with lower risk of recurrence, including those that are nonrecurrent and have well-defined borders, small size, and location on the trunk and extremities. After surgical excision, approximately 3% of BCCs and 5% of cSCCs recur; after curettage and electrodessication, approximately 6% of BCCs and 2% of cSCCs recur. For keratinocyte carcinomas at higher risk of recurrence, in-office Mohs surgery (a technique in which a dermatologist with specialized training removes the tumor in stages and evaluates the entire surgical margin pathologically using a microscope after each stage to ensure complete tumor excision) is typically used. After Mohs surgery, approximately 4% of BCCs and 3% of cSCCs recur. Patients diagnosed with keratinocyte carcinoma are at high risk of additional keratinocyte carcinomas (approximately 40% within 5 years). Evidence-based prevention of keratinocyte carcinoma involves use of sunscreen. In a randomized clinical trial, use of daily sunscreen decreased cSCC risk (rate ratio, 0.62; 95% CI, 0.38-0.99; 1587 cSCCs per 100 000 person-years in controls vs 953 per 100 000 person-years in sunscreen group).

CONCLUSIONS AND RELEVANCE: Keratinocyte carcinoma, composed of BCC and cSCC, is the most common cancer in the US, with an estimated 5.4 million diagnoses annually. Most keratinocyte carcinomas are effectively treated with in-office surgical procedures. Patients with keratinocyte carcinoma are recommended to undergo a skin examination at least annually due to their high risk of developing additional skin cancers.

**中文摘要译文：**
重要性：角质形成细胞癌是起源于角质形成细胞的皮肤癌，由基底细胞癌（BCCs）和皮肤鳞状细胞癌（cSCCs）构成。角质形成细胞癌在北美、澳大利亚、新西兰和欧洲很常见。在美国，每年约诊断出540万例角质形成细胞癌。

观察结果：角质形成细胞癌主要位于头颈部（40%-64%的BCCs；35%-45%的cSCCs）。BCC通常表现为粉红色、光滑的隆起性病变或粉至红色的扁平病变。cSCC通常表现为红色、有鳞屑的扁平病变（原位癌）或红色、质地硬、伴有鳞屑或糜烂的隆起性病变（浸润性癌）。紫外线暴露是其主要病因，而较浅的皮肤色素和皮肤光类型（例如，更易晒伤的皮肤）是主要风险因素。其他风险因素包括高龄、男性、室内美黑、癌前病变史（光化性角化病）、角质形成细胞癌史以及免疫抑制（例如，器官移植）。对于复发风险较低的角质形成细胞癌，包括非复发性、边界清晰、体积小且位于躯干和四肢的肿瘤，通常由皮肤科医生在诊室内进行手术切除或刮除和电干燥术（即用刮匙刮除肿瘤并灼烧创底）。手术切除后，约3%的BCCs和5%的cSCCs会复发；刮除和电干燥术后，约6%的BCCs和2%的cSCCs会复发。对于复发风险较高的角质形成细胞癌，通常采用诊室内莫氏手术（一种由受过专门培训的皮肤科医生分阶段切除肿瘤，并在每个阶段后用显微镜对整个手术切缘进行病理学评估以确保肿瘤完全切除的技术）。莫氏手术后，约4%的BCCs和3%的cSCCs会复发。被诊断患有角质形成细胞癌的患者，发生其他角质形成细胞癌的风险很高（5年内约40%）。基于证据的角质形成细胞癌预防措施包括使用防晒霜。在一项随机临床试验中，每日使用防晒霜降低了cSCC的风险（风险比，0.62；95% CI, 0.38-0.99；对照组中每10万人年发生1587例cSCCs，而防晒霜组为每10万人年953例）。

结论与相关性：由BCC和cSCC组成的角质形成细胞癌是美国最常见的癌症，每年估计有540万例诊断。大多数角质形成细胞癌可通过诊室内外科手术得到有效治疗。由于发生额外皮肤癌的风险很高，建议角质形成细胞癌患者至少每年接受一次皮肤检查。

### 第二部分 AI 大师评价

该综述全面总结了角质形成细胞癌（包括基底细胞癌和皮肤鳞状细胞癌）的核心知识。文章系统性地阐述了其流行病学、主要病因（紫外线暴露）、临床表现、风险因素及诊断方法。其核心价值在于清晰地归纳了不同风险等级肿瘤的主流治疗策略，如标准手术切除、刮除电干术及莫氏手术，并对比了各自的复发率，最后强调了防晒在初级预防中的循证作用，为临床医生提供了简明扼要的诊疗与患者教育指南。

---

## 98. 长期体力活动预防消化系统癌症——坚持是关键。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165675](https://pubmed.ncbi.nlm.nih.gov/41165675)
**期刊：** JAMA oncology
**PMID：** 41165675
**DOI：** 10.1001/jamaoncol.2025.4159

### 第一部分 原文与翻译

**英文原标题：** Long-Term Physical Activity for Prevention of Digestive System Cancers-Consistency Is Key.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

由于本文献无可用摘要，评价主要基于标题进行推断。该标题明确指出文章的核心观点：长期且持续的体力活动对于预防消化系统癌症至关重要。这可能是一篇评论或观点性文章，旨在强调生活方式干预中“坚持”的重要性，而非仅仅是活动本身。此观点对于公共卫生宣教和临床实践具有重要指导价值，提醒专业人士在提供建议时应更注重培养患者的长期运动习惯。

---

## 99. Xbp1在结肠炎中调控肠道ILC2s的修复功能

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165618](https://pubmed.ncbi.nlm.nih.gov/41165618)
**期刊：** The Journal of experimental medicine
**PMID：** 41165618
**DOI：** 10.1084/jem.20250440

### 第一部分 原文与翻译

**英文原标题：** Xbp1 controls the reparative function of intestinal ILC2s during colitis.

**英文摘要原文：**
Ulcerative colitis (UC) is primarily characterized by inflammation-induced tissue damage, but impaired tissue repair also drives disease progression. This study demonstrates group 2 innate lymphoid cells (ILC2s), key players in tissue repair, are dysfunctional in UC and experimental colitis due to disrupted endoplasmic reticulum protein processing. We show that the pro-repair function of gut ILC2s depends on the IRE1α-Xbp1 branch of unfolded protein response (UPR), supported by IL-25 and suppressed by interferon-γ (IFN-γ). During colitis, loss of IL-25 and rise of IFN-γ hinder Xbp1 mRNA splicing, weakening ILC2s' ability to mediate tissue repair. Mechanistically, spliced Xbp1 drives folate-dependent one-carbon (1C) metabolism by promoting dihydrofolate reductase expression. Translationally, the 1C metabolite adenosine 5'-monophosphate alleviated colitis in both ILC2-specific Xbp1 knockout and wild-type mice. Our findings highlight the UPR's role in sensing gut environment to regulate ILC2 function and suggest folate-mediated 1C metabolism as a potential target for UC therapy.

**中文摘要译文：**
溃疡性结肠炎（UC）的主要特征是炎症引起的组织损伤，但组织修复功能受损同样会驱动疾病进展。本研究表明，作为组织修复关键角色的第2组先天性淋巴样细胞（ILC2s），在UC和实验性结肠炎中由于内质网蛋白加工过程被破坏而功能失调。我们发现，肠道ILC2s的促修复功能依赖于未折叠蛋白反应（UPR）的IRE1α-Xbp1分支，该功能受到IL-25的支持并被γ-干扰素（IFN-γ）抑制。在结肠炎期间，IL-25的缺失和IFN-γ的升高阻碍了Xbp1 mRNA的剪接，从而削弱了ILC2s介导组织修复的能力。从机制上讲，剪接后的Xbp1通过促进二氢叶酸还原酶的表达来驱动叶酸依赖性的一碳（1C）代谢。在转化医学层面，一碳代谢物5'-单磷酸腺苷在ILC2s特异性Xbp1敲除小鼠和野生型小鼠中均能缓解结肠炎。我们的研究结果强调了UPR在感知肠道环境以调节ILC2功能中的作用，并提示叶酸介导的一碳代谢可作为UC治疗的潜在靶点。

### 第二部分 AI 大师评价

本研究旨在揭示溃疡性结肠炎（UC）中关键修复细胞——第2组先天性淋巴样细胞（ILC2s）功能障碍的深层机制。研究通过实验性结肠炎模型，创新性地将细胞内质网应激反应（UPR）通路与ILC2s的修复功能联系起来，发现结肠炎微环境中的细胞因子失衡会抑制Xbp1剪接，进而影响叶酸依赖性的一碳代谢。该研究的关键发现不仅阐明了UPR感知肠道环境并调控免疫细胞功能的全新作用，还提出了通过靶向一碳代谢来促进组织修复作为UC治疗新策略的可能，具有重要的临床转化潜力。

---

## 100. 一种用于从不吸烟肺腺癌患者的预后特征签名

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165571](https://pubmed.ncbi.nlm.nih.gov/41165571)
**期刊：** Cancer discovery
**PMID：** 41165571
**DOI：** 10.1158/2159-8290.CD-25-0581

### 第一部分 原文与翻译

**英文原标题：** A prognostic signature for lung adenocarcinoma in patients who have never smoked.

**英文摘要原文：**
Understanding tumor cell dynamics can improve prognosis and treatment but remains limited for lung adenocarcinoma in people who have never smoked (NS-LUAD). With RNA-seq data from 684 NS-LUAD and validation in an independent dataset, we identified three subtypes with distinct phenotypic traits and cell compositions. Additional genomic and histological data further characterized the subtypes. 'Steady', marked by low proliferation, high alveolar cell fraction, moderate-to-well differentiation, and fewer driver genes' alterations, is linked to prolonged survival and low immune evasion. 'Proliferative' shows high proliferation markers, TP53 mutations, and gene fusions. 'Chaotic', with high epithelial-to-mesenchymal transition markers, has the worst prognosis even within stage I tumors. Lacking known molecular or histological characteristics, this aggressive subtype is solely identified by transcriptomic data. A 60-gene signature recapitulates the classification and predicts survival even within subgroups based on tumor stage or known genomic features, emphasizing its potential for improving early-stage NS-LUAD prognostication in clinical settings.

**中文摘要译文：**
了解肿瘤细胞动态有助于改善预后和治疗，但对于从不吸烟者的肺腺癌（NS-LUAD）而言，这方面的认知仍然有限。利用来自684例NS-LUAD的RNA测序数据，并在一个独立数据集中进行验证，我们识别出了三种具有不同表型特征和细胞组成的亚型。额外的基因组学和组织学数据进一步描绘了这些亚型的特征。“稳定型”以低增殖、高肺泡细胞比例、中至高分化以及较少的驱动基因改变为标志，与较长的生存期和低免疫逃逸相关。“增殖型”表现出高增殖标志物、TP53突变和基因融合。“混沌型”具有高上皮-间质转化标志物，即使在I期肿瘤中预后也最差。由于缺乏已知的分子或组织学特征，这种侵袭性亚型只能通过转录组数据来识别。一个由60个基因组成的分子特征能够重现该分类，并能在基于肿瘤分期或已知基因组特征的亚组中预测生存，这凸显了其在临床环境中改善早期NS-LUAD预后评估的潜力。

### 第二部分 AI 大师评价

该研究针对从不吸烟肺腺癌（NS-LUAD）这一独特亚群，利用转录组学数据成功识别出三种具有显著不同临床和分子特征的预后亚型。其核心创新在于发现了一个仅能通过转录组数据识别的、预后极差的“混沌型”，并开发出一个由60个基因组成的分子特征签名。这项发现不仅深化了对NS-LUAD异质性的理解，更为临床提供了超越传统分期和已知基因突变的精准预后评估工具，对指导早期患者的个体化治疗决策具有重要价值。

---

## 101. 靶向CDK12/13诱导有丝分裂停滞以克服对KRASG12C抑制剂的耐药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165466](https://pubmed.ncbi.nlm.nih.gov/41165466)
**期刊：** Cancer research
**PMID：** 41165466
**DOI：** 10.1158/0008-5472.CAN-25-0450

### 第一部分 原文与翻译

**英文原标题：** Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors.

**英文摘要原文：**
The onset of acquired resistance limits the efficacy of KRASG12C inhibitors in lung cancer patients. Experiments in preclinical model systems and retrospective analyses of patients treated with these inhibitors have both suggested that the activation of DNA repair pathways and G2/M kinases is common in lung cancers with acquired resistance to KRASG12C inhibitors. Here, we identified a shared vulnerability to the CDK12/13 selective inhibitor SR-4835 in several KRASG12C-mutant cell lines with acquired resistance to sotorasib. In pairs of KRASG12C-mutant parental and sotorasib-resistant cell lines, CDK12/13 inhibition suppressed DNA repair gene expression and induced mitotic arrest, which was exacerbated in sotorasib-resistant cells by failure to activate the G2/M checkpoint and suppression of an oncogenic isoform of TP73. Combined treatment with both sotorasib and SR-4835 yielded an additive response and suppressed the development of acquired resistance to either inhibitor. The inhibitor combination caused additive G1 and G2/M arrest, and the increased sensitivity of emerging drug-resistant cell populations to SR-4835 extended the duration of response over single-agent treatment in cell culture and in mouse models. These results support combining KRAS and CDK12/13 inhibitors to extend the duration of response in KRAS-mutant lung cancer. Patients with acquired resistance to sotorasib may benefit from follow-up monotherapy with CDK12/13 inhibitors, the first of which recently entered clinical trials. Targeting CDK12/13 thus offers a promising strategy to overcome or prevent resistance to KRAS inhibitors.

**中文摘要译文：**
获得性耐药的出现限制了KRASG12C抑制剂在肺癌患者中的疗效。在临床前模型系统中进行的实验以及对接受这些抑制剂治疗的患者进行的回顾性分析均表明，DNA修复通路和G2/M期激酶的激活在对KRASG12C抑制剂产生获得性耐药的肺癌中普遍存在。在此，我们在数个对索托拉西布（sotorasib）产生获得性耐药的KRASG12C突变细胞系中，发现了一个共同的弱点，即对CDK12/13选择性抑制剂SR-4835敏感。在成对的KRASG12C突变亲本细胞系和索托拉西布耐药细胞系中，抑制CDK12/13可抑制DNA修复基因的表达并诱导有丝分裂停滞，而在索托拉西布耐药细胞中，由于未能激活G2/M期检查点以及一种TP73的致癌异构体受到抑制，这种效应被进一步加剧。索托拉西布与SR-4835的联合治疗产生了协同增效反应，并抑制了对任一抑制剂产生获得性耐药的进程。这种抑制剂组合在细胞培养和小鼠模型中引起了协同的G1期和G2/M期阻滞，并且新出现的耐药细胞群体对SR-4835的敏感性增加，从而延长了相较于单药治疗的反应持续时间。这些结果支持将KRAS抑制剂与CDK12/13抑制剂联合使用，以延长KRAS突变型肺癌的反应持续时间。对索托拉西布产生获得性耐药的患者可能会从后续的CDK12/13抑制剂单药治疗中获益，其中首个该类药物近期已进入临床试验。因此，靶向CDK12/13为克服或预防对KRAS抑制剂的耐药性提供了一种有前景的策略。

### 第二部分 AI 大师评价

本研究针对KRASG12C抑制剂在肺癌治疗中普遍存在的获得性耐药问题，探索了新的治疗策略。研究者通过一系列临床前模型发现，对索托拉西布（sotorasib）耐药的KRASG12C突变细胞系对CDK12/13选择性抑制剂SR-4835表现出共同的脆弱性。其核心发现是，靶向CDK12/13不仅能克服已有的耐药性，与KRAS抑制剂联用更能抑制耐药性的产生，延长治疗反应时间。这项研究为解决KRAS抑制剂耐药这一临床难题提供了创新性的解决方案和坚实的实验依据，具有重要的临床转化潜力。

---

## 102. 微卫星稳定型结直肠癌靶向治疗后获得性高肿瘤突变负荷及免疫治疗的活性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165465](https://pubmed.ncbi.nlm.nih.gov/41165465)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41165465
**DOI：** 10.1158/1078-0432.CCR-25-2566

### 第一部分 原文与翻译

**英文原标题：** Acquired high tumor mutational burden and activity of immunotherapy after targeted therapy in microsatellite stable colorectal cancer.

**英文摘要原文：**
PURPOSE: Microsatellite stable (MSS) colorectal cancers (CRCs), in contrast to microsatellite instability-high (MSI-H) CRCs, have few mutations and are insensitive to immune checkpoint blockade (ICB). CRCs treated with targeted agents often acquire a high number of genomic alterations at progression. We asked if targeted therapy could be used to generate a high tumor mutational burden (TMB) in MSS CRC and sensitize these tumors to ICB.

PATIENTS AND METHODS: In patients with MSS metastatic CRC treated with targeted therapy, we evaluated baseline and progression TMB and response to ICB for patients whose tumors developed high TMB. We determined types of alterations, mutational signatures, neoantigenicity, and clonality associated with emergent genomic alterations in cases of acquired high TMB.

RESULTS: Among 26 cases, nine acquired high TMB at progression. Three of these patients received ICB but none had a response. In the TMB-high cases, we found no induction of tumor-infiltrating lymphocytes or programmed death-ligand 1 expression. Acquired genomic alterations consisted predominantly of single nucleotide variants, were enriched for single-base substitution 17a/b mutational signature, and did not enhance predicted major histocompatibility complex class I binding. TMB was higher in plasma, driven by highly subclonal acquired alterations, compared to tissue samples which harbored few resistance alterations.

CONCLUSION: A substantial number of MSS CRCs acquire high TMB following targeted therapy. However, this change is not associated with sensitization to ICB. The high TMB is due to subclonal alterations unique to individual disease sites that are inadequate to elicit a robust antitumor immune response.

**中文摘要译文：**
目的：与微卫星不稳定性高（MSI-H）型结直肠癌（CRC）相比，微卫星稳定（MSS）型结直肠癌（CRC）突变较少，且对免疫检查点阻断（ICB）治疗不敏感。接受靶向药物治疗的CRC在疾病进展时通常会获得大量基因组改变。我们旨在探究靶向治疗是否可用于在MSS型CRC中产生高肿瘤突变负荷（TMB），并使这些肿瘤对ICB敏感。

患者与方法：在接受靶向治疗的MSS型转移性CRC患者中，我们评估了基线和疾病进展时的TMB，并对肿瘤产生高TMB的患者接受ICB治疗的反应进行了评价。在获得性高TMB的病例中，我们确定了与新发基因组改变相关的改变类型、突变特征、新抗原性及克隆性。

结果：在26例病例中，有9例在疾病进展时获得了高TMB。其中3例患者接受了ICB治疗，但均未产生应答。在高TMB病例中，我们未发现肿瘤浸润淋巴细胞或程序性死亡配体1表达的诱导。获得性基因组改变主要由单核苷酸变异组成，富集了单碱基替换17a/b突变特征，并且未能增强预测的主要组织相容性复合体I类分子的结合能力。与组织样本（其仅含有少量耐药性改变）相比，血浆中的TMB更高，这主要是由高度亚克隆性的获得性改变所驱动。

结论：相当一部分MSS型CRC在接受靶向治疗后会获得高TMB。然而，这种变化与对ICB的敏感性增加无关。这种高TMB是由各疾病部位独特的亚克隆改变所致，这些改变不足以引发强有力的抗肿瘤免疫反应。

### 第二部分 AI 大师评价

本研究旨在探讨一个创新性策略：能否通过靶向治疗诱导微卫星稳定型结直肠癌（MSS-CRC）产生高肿瘤突变负荷（TMB），从而将其转化为对免疫治疗敏感的“热肿瘤”。研究通过对比治疗前后的基因组数据发现，尽管部分患者在靶向治疗后确实获得了高TMB，但这并未带来免疫检查点抑制剂的临床获益。其关键发现是，这些获得性突变多为亚克隆性质，未能有效激发抗肿瘤免疫反应。此研究结果具有重要的临床指导意义，揭示了单纯提升TMB数量并不能保证免疫治疗的疗效，突变的“质量”（如克隆性与新抗原性）可能更为关键，为后续研究提供了新的方向。

---

## 103. 抑制RAS-GTP可克服非小细胞肺癌中由致癌性及野生型RAS激活介导的对KRASG12C抑制剂的获得性耐药

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165456](https://pubmed.ncbi.nlm.nih.gov/41165456)
**期刊：** Cancer research
**PMID：** 41165456
**DOI：** 10.1158/0008-5472.CAN-25-0600

### 第一部分 原文与翻译

**英文原标题：** RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wildtype RAS Activation in Non-Small Cell Lung Cancer.

**英文摘要原文：**
Small molecule KRASG12C(OFF) inhibitors that bind to the inactive GDP-bound state of KRAS have demonstrated efficacy in patients with KRASG12C mutant tumors, yet responses tend to be transient due to emergence of on-treatment resistance. Recently, RAS(ON) G12C-selective inhibitors, which bind to the active GTP-bound state of RAS, were described, and elironrasib is undergoing evaluation in multiple clinical trials. Here, we generated resistant cell lines and patient-derived xenograft models to KRASG12C(OFF) and RAS(ON) G12C-selective inhibitors and interrogated resistance mechanisms using a multi-omics strategy consisting of phosphoproteomics, whole exome sequencing, and RNA-sequencing combined with functional testing using small molecule and CRISPR screens and RAS(ON) inhibitors being evaluated in clinical trials. Two models reactivated RAS signaling, either via KRASG12C gene amplification or NRASG13R mutation, and were vulnerable to dual inhibition by RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors, RMC-4998 and RMC-7977. Two models, which lacked any discernable genomic alteration, acquired resistance associated with increased receptor tyrosine kinase activity and downstream persistent RAS activity and were sensitive to RAS-GTP inhibition by RMC-7977. Finally, one model displayed epithelial-mesenchymal transition, loss of RAS dependance, and acquired reliance on cell cycle kinases and proteins associated with DNA damage response. This work highlights KRASG12C-selective inhibitor resistant states that parallel and complement clinical findings and demonstrate that a large subset could be overcome with a RAS(ON) multi-selective inhibitor as a standalone agent or in combination with other therapies.

**中文摘要译文：**
与KRAS的非活性GDP结合状态结合的小分子KRASG12C(OFF)抑制剂已在KRASG12C突变肿瘤患者中显示出疗效，但由于治疗过程中出现耐药性，其响应往往是短暂的。最近，与RAS的活性GTP结合状态结合的RAS(ON) G12C选择性抑制剂被报道，并且elironrasib正在多项临床试验中进行评估。本研究中，我们构建了对KRASG12C(OFF)和RAS(ON) G12C选择性抑制剂耐药的细胞系和患者来源的异种移植模型，并采用包括磷酸化蛋白质组学、全外显子组测序和RNA测序在内的多组学策略，结合使用小分子和CRISPR筛选以及正在临床试验中评估的RAS(ON)抑制剂进行功能测试，以探究其耐药机制。两种模型通过KRASG12C基因扩增或NRASG13R突变重新激活了RAS信号通路，并且对RAS(ON) G12C选择性抑制剂和RAS(ON)多选择性抑制剂（RMC-4998和RMC-7977）的双重抑制敏感。另两种模型在无任何可识别基因组改变的情况下，获得了与受体酪氨酸激酶活性增加及下游持续RAS活性相关的耐药性，并对RMC-7977的RAS-GTP抑制作用敏感。最后，一种模型表现出上皮-间质转化、RAS依赖性丧失，并获得了对细胞周期激酶和与DNA损伤反应相关蛋白的依赖性。这项工作揭示了与临床发现平行且互补的KRASG12C选择性抑制剂耐药状态，并证明了其中一大部分可以通过使用RAS(ON)多选择性抑制剂作为单一药物或与其他疗法联合使用来克服。

### 第二部分 AI 大师评价

本研究系统性地探究了非小细胞肺癌对KRASG12C抑制剂（包括OFF和ON状态抑制剂）产生获得性耐药的多种分子机制。研究团队综合运用多组学分析和功能筛选等前沿技术，揭示了耐药机制的多样性，包括RAS信号通路的二次激活、非基因组性的旁路激活以及上皮-间质转化等。其核心价值在于，不仅阐明了复杂的耐药图谱，更重要的是验证了新一代RAS(ON)多选择性抑制剂（如RMC-7977）在克服大部分耐药亚型中的潜力，为临床后续治疗策略的制定（如联合用药或序贯治疗）提供了坚实的实验依据。

---

## 104. INSPECTOR研究：基于酶辅助高信噪比测序技术检测甲基化循环肿瘤DNA的多癌种早筛方法的临床转化可行性增强研究。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165038](https://pubmed.ncbi.nlm.nih.gov/41165038)
**期刊：** Cancer communications (London, England)
**PMID：** 41165038
**DOI：** 10.1002/cac2.70071

### 第一部分 原文与翻译

**英文原标题：** The INSPECTOR study: enhanced feasibility for clinical translation of a multi-cancer early detection method based on enzyme-assisted high signal-to-noise ratio sequencing of methylated circulating tumor DNA.

**英文摘要原文：**
BACKGROUND: Blood-based cell-free DNA (cfDNA) methylation testing has emerged as a promising approach for multi-cancer early detection (MCED), holding the potential to improve cancer survival rates. However, traditional bisulfite-based methods often encounter sensitivity limitations in detecting early-stage malignancies or certain cancer types. In the INSPECTOR study, we developed a MCED and cancer signal origin (CSO) system specifically designed for early-stage or hard-to-detect cancers, including those of the lung, breast, colorectum, liver, esophagus, stomach, pancreas, and ovary.

METHODS: We established a comprehensive methylation marker discovery database (n = 6,342) by integrating public datasets (n = 4,699) and in-house samples (n = 1,643), all processed using human TET (hTET) enzyme-assisted whole-methylome sequencing (GM-seq). This enabled the design of a targeted panel encompassing 155,362 methylated CpG sites. Leveraging hTET-assisted high-depth next-generation sequencing (NGS), our blood test achieved a median unique depth of 1,093×. Multicenter case-control cohorts, including various pathological subtypes, were used for training, validation, and independent validation of MCED and CSO models, and to verify the clinical feasibility.

RESULTS: Clinical validation was conducted across multi-center case-control cohorts, including 1,071 participants in the training set, 581 in the validation set, and 824 in the independent validation set. The MCED assay demonstrated robust performance with a specificity of 99.1% and sensitivity of 83.2% in the training set, 99.0% and 81.8% in the validation set, and comparable results in the independent validation set (99.0% specificity, 81.9% sensitivity). Notably, sensitivity reached 65.5% for stage I cancers, 79.7% for stage II, and 71.3% for stages I-II combined. The sensitivities for different cancer types were as follows: esophageal (79.2%), gastric (76.1%), colorectal (86.2%), pancreatic (66.7%), liver (100.0%), lung (72.9%), breast (88.9%), and ovarian (87.9%). The CSO model exhibited strong accuracy, with top-1 cancer origin prediction rates of 87.9% (validation) and 87.4% (independent validation), rising to 95.1% and 94.5% for top-2 predictions, respectively. For stage I cancers specifically, the top-1 accuracy was 85.5%.

CONCLUSIONS: These findings underscore the efficacy of the hTET-assisted cfDNA methylation sequencing system across diverse cancer types, particularly in early stages. Enzyme-assisted NGS test of methylated cfDNA thus enhances the clinical utility of non-invasive blood-based screening.

**中文摘要译文：**
背景：基于血液的细胞游离DNA（cfDNA）甲基化检测已成为一种有前景的多癌种早期检测（MCED）方法，具有提高癌症生存率的潜力。然而，传统的基于亚硫酸氢盐的方法在检测早期恶性肿瘤或某些癌症类型时常遇到灵敏度的限制。在INSPECTOR研究中，我们开发了一种专门针对早期或难检测癌症的MCED和癌症信号来源（CSO）系统，涵盖肺癌、乳腺癌、结直肠癌、肝癌、食管癌、胃癌、胰腺癌和卵巢癌。

方法：我们通过整合公共数据集（n = 4,699）和内部样本（n = 1,643），建立了一个全面的甲基化标志物发现数据库（n = 6,342），所有样本均采用人TET（hTET）酶辅助全甲基化组测序（GM-seq）进行处理。这使得我们能够设计一个包含155,362个甲基化CpG位点的靶向panel。利用hTET辅助的高深度下一代测序（NGS），我们的血液检测实现了1,093×的中位唯一深度。我们使用了包含多种病理亚型的多中心病例对照队列，对MCED和CSO模型进行训练、验证和独立验证，并检验其临床可行性。

结果：临床验证在多中心病例对照队列中进行，包括训练集1,071名参与者，验证集581名参与者，以及独立验证集824名参与者。该MCED检测展现了稳健的性能，在训练集中的特异性为99.1%，灵敏度为83.2%；在验证集中的特异性为99.0%，灵敏度为81.8%；在独立验证集中也获得了相似的结果（特异性99.0%，灵敏度81.9%）。值得注意的是，对于I期癌症的灵敏度达到65.5%，II期为79.7%，I-II期合并为71.3%。针对不同癌种的灵敏度如下：食管癌（79.2%）、胃癌（76.1%）、结直肠癌（86.2%）、胰腺癌（66.7%）、肝癌（100.0%）、肺癌（72.9%）、乳腺癌（88.9%）和卵巢癌（87.9%）。CSO模型表现出很高的准确性，在验证集和独立验证集中，top-1癌症来源预测准确率分别为87.9%和87.4%，top-2预测准确率则分别上升至95.1%和94.5%。特别地，对于I期癌症，top-1预测准确率为85.5%。

结论：这些发现凸显了hTET辅助的cfDNA甲基化测序系统在多种癌症类型中，尤其是在早期阶段的有效性。因此，基于酶辅助的NGS甲基化cfDNA检测提升了非侵入性血液筛查的临床应用价值。

### 第二部分 AI 大师评价

本研究旨在开发并验证一种创新的多癌种早期检测（MCED）技术，以解决传统亚硫酸氢盐法对早期癌症检测灵敏度不足的痛点。研究团队采用了人TET酶辅助的高深度测序方法，分析血液中的cfDNA甲基化模式，并通过大规模多中心队列验证了其癌症检出和溯源（CSO）模型的性能。关键发现显示，该技术在保持超过99%极高特异性的同时，对多种癌症总体灵敏度超过81%，尤其对I期癌症的检出率达到了65.5%，且溯源准确率高。该技术的创新性在于以酶法替代传统化学法，显著提升了早期癌症信号的捕获效率，为实现高效、无创的泛癌种筛查提供了强有力的临床转化证据，具有巨大的应用前景。

---

## 105. 慢乙肝诱导的免疫分区紊乱引发库普弗细胞中LXRα介导的脂质代谢紊乱，从而促进癌症干细胞的形成

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41164971](https://pubmed.ncbi.nlm.nih.gov/41164971)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41164971
**DOI：** 10.1002/advs.202510275

### 第一部分 原文与翻译

**英文原标题：** CHB-Induced Immune Zonation Chaos Elicited LXRα-mediated Lipid Metabolism Disorders in Kupffer Cells to Induce Cancer Stem Cell Formation.

**英文摘要原文：**
Hepatic intercellular communication is the driving force for the progression of chronic Hepatitis B virus (CHB)-associated hepatopathologies, with the dynamic molecular mechanisms largely unknown. Combining scRNA-seq and spatial transcriptomic analysis, the kinetic landscape of the liver microenvironment across time and space in AAV-HBV mice, which develop from inflammation to ultimately hepatocellular carcinoma is generated. Kupffer cells (KCs), originally resided within the peri-portal area, are persistently recruited to the HBV-enriched peri-central region via increased CXCL9 produced by endothelial cells, facilitating the interaction between KCs and HBV hepatocytes to induce LXRα deficiency-mediated lipid metabolism disorders (LMD) in KCs. In turn, KCs with LMD elicited cancer stem cell formation from HBV hepatocytes via Stat3 pathway, activated by the chemokine network within the crosstalk. Moreover, miR-155-mediated post-transcriptional regulation and ASGR1-dependent degradation collaboratively regulated LXRα downregulation in KCs. LXRα deficiency in KCs is also detected in the tumor tissues of HBV patients compared to that of the normal and tumor-adjacent tissue. Importantly, LXRα upregulation in KCs constrained fibrosis and cancer stem cell formation. For the first time, the role of KC zonation in disease progression has been revealed, highlighting LXRα in KCs as a promising target for the early intervention in the transition from CHB-induced inflammation to cancer.

**中文摘要译文：**
肝细胞间的通讯是慢性乙型肝炎（CHB）相关肝脏病理进展的驱动力，但其动态分子机制在很大程度上尚不清楚。本研究结合单细胞RNA测序（scRNA-seq）和空间转录组学分析，描绘了AAV-HBV小鼠（该模型从炎症最终发展为肝细胞癌）肝脏微环境在时间和空间维度上的动态变化图谱。库普弗细胞（KCs）最初位于门静脉周围区域，但通过内皮细胞产生的CXCL9增加，被持续招募到HBV富集的中央静脉周围区域，这促进了KCs与HBV肝细胞之间的相互作用，从而在KCs中诱导了由LXRα缺陷介导的脂质代谢紊乱（LMD）。反之，伴有脂质代谢紊乱的KCs通过Stat3通路（该通路被细胞间串扰中的趋化因子网络激活）诱导了HBV肝细胞形成癌症干细胞。此外，miR-155介导的转录后调控和ASGR1依赖的降解共同调控了KCs中LXRα的下调。与正常和癌旁组织相比，在HBV患者的肿瘤组织中也检测到KCs中LXRα的缺陷。重要的是，上调KCs中的LXRα能够抑制纤维化和癌症干细胞的形成。本研究首次揭示了KC分区在疾病进展中的作用，并强调了KCs中的LXRα是作为慢乙肝相关炎症向癌症转化早期干预的一个有前景的靶点。

### 第二部分 AI 大师评价

该研究旨在揭示慢性乙型肝炎（CHB）相关炎症向肝癌演进的动态分子机制。研究创新性地结合单细胞与空间转录组学技术，发现慢乙肝病毒（HBV）诱导的库普弗细胞（KC）免疫分区紊乱是关键驱动因素，该紊乱导致KC中LXRα介导的脂质代谢失调，进而通过Stat3通路促进癌症干细胞形成。这项工作首次阐明了KC空间定位在肝病进展中的关键作用，并指出了KC中的LXRα可作为早期干预慢乙肝向肝癌转化的潜在治疗靶点，具有重要的临床转化价值。

---

## 106. FXYD3通过与IRF7结合调控JAK2/STAT5信号通路促进肝内胆管癌的肿瘤进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41164952](https://pubmed.ncbi.nlm.nih.gov/41164952)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41164952
**DOI：** 10.1002/advs.202510782

### 第一部分 原文与翻译

**英文原标题：** FXYD3 Promotes Tumor Progression by Binding With IRF7 to Regulate JAK2/STAT5 Signaling in Intrahepatic Cholangiocarcinoma.

**英文摘要原文：**
Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis, especially for inoperable patients. FXYD3, an FXYD-domain-containing regulator in the Na+/K+ ATPase family, is overexpressed in several common cancers. However, its role in ICC progression remains unclear. We integrated multiple ICC single-cell transcriptome profiles from publicly available datasets and analyzed them using various bioinformatic methods, identifying FXYD3 as a candidate gene. In vitro and in vivo experiments demonstrated that FXYD3 expression was upregulated in ICC tumor tissues and associated with tumor progression and unfavorable prognosis. Subsequently, a combination of single-cell sequencing, high-resolution spatial transcriptome analysis, and a series of experimental assays demonstrated that FXYD3 directly interacts with IRF7 via its 60-87aa domain, thereby initiating a positive feedback loop mediated by the cGAS/STING pathway. This loop is amplified by interferon type I and results in sustained activation of the JAK2/STAT5 signaling pathway, ultimately driving the malignant progression of ICC. The targeted FXYD3 nano-delivery system (siFXYD3@PEP) exhibited significant antitumor efficacy in spontaneous and transplanted tumor models and markedly enhanced the sensitivity of ICC to standard gemcitabine and cisplatin chemotherapy. Our findings highlight the role of FXYD3 in cancer-related inflammation and innate immune signaling, thereby providing a new paradigm for understanding the pathogenesis of ICC.

**中文摘要译文：**
肝内胆管癌（ICC）预后不良，尤其是对于无法手术的患者。FXYD3是Na+/K+ ATP酶家族中一个包含FXYD结构域的调节因子，在多种常见癌症中过度表达。然而，其在ICC进展中的作用尚不清楚。我们整合了来自公开数据集的多个ICC单细胞转录组图谱，并使用多种生物信息学方法进行分析，将FXYD3确定为一个候选基因。体外和体内实验证明，FXYD3的表达在ICC肿瘤组织中上调，并与肿瘤进展和不良预后相关。随后，结合单细胞测序、高分辨率空间转录组分析以及一系列实验验证表明，FXYD3通过其60-87aa结构域与IRF7直接相互作用，从而启动一个由cGAS/STING通路介导的正反馈循环。该循环被I型干扰素放大，并导致JAK2/STAT5信号通路的持续激活，最终驱动ICC的恶性进展。靶向FXYD3的纳米递送系统（siFXYD3@PEP）在自发性和移植性肿瘤模型中表现出显著的抗肿瘤功效，并显著增强了ICC对标准化疗药物吉西他滨和顺铂的敏感性。我们的研究结果揭示了FXYD3在癌症相关炎症和先天免疫信号传导中的作用，从而为理解ICC的发病机制提供了一个新的范式。

### 第二部分 AI 大师评价

该研究通过整合多组学分析与体内外实验，首次揭示了FXYD3在肝内胆管癌（ICC）进展中的关键作用及其分子机制。其核心发现是FXYD3通过与IRF7直接相互作用，激活cGAS/STING-JAK2/STAT5信号通路，从而驱动肿瘤的恶性进展。本研究的创新之处在于不仅阐明了ICC的一个全新致病通路，还将FXYD3定位为一个有潜力的治疗靶点，并成功验证了靶向FXYD3的纳米递送系统能有效抑制肿瘤生长并增敏化疗，展现了巨大的临床转化价值。

---

## 107. 靶向前列腺癌细胞中的CXCR2可阻断CD47-SIRPα相互作用并逆转肿瘤微环境的M2型巨噬细胞极化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41163221](https://pubmed.ncbi.nlm.nih.gov/41163221)
**期刊：** Molecular cancer
**PMID：** 41163221
**DOI：** 10.1186/s12943-025-02436-1

### 第一部分 原文与翻译

**英文原标题：** Targeting CXCR2 in prostate cancer cells can block CD47-SIRPα interaction and reverse M2 macrophage polarization in the TME.

**英文摘要原文：**
Neuroendocrine prostate cancer (NEPC) exhibits strong immune evasion and plays a critical role in regulating metabolic reprogramming within prostate cancer. High infiltration of CD36+ M2 tumour-associated macrophages (TAMs) and elevated CD47 expression in NEPC cells are often associated with poor progression-free survival in cancer patients. Understanding the mechanisms that regulate CD36+ M2 TAM infiltration and high CD47 expression in tumour cells within the prostate cancer tumour microenvironment (TME) is essential. Using cell models and two animal models, we discovered that the IL-8/CXCR2 pathway increases acetyl-CoA levels through metabolic reprogramming, which subsequently increases CD47 expression via acetylation. Moreover, this pathway modulates the membrane localization of CD47 by stimulating tumour cells to secrete palmitic acid and utilize palmitoylation mechanisms, thereby protecting tumour cells from macrophage-mediated phagocytosis. The IL-8/CXCR2 pathway also reshapes the metabolic microenvironment of the TME, increasing the infiltration of ω-3/6 polyunsaturated fatty acids (PUFAs) in the TME, which promotes the recruitment of CD36+ M2 TAMs. Preclinical studies in both NSG and C57BL/6 animal models demonstrated that targeting CXCR2 restored TAM phagocytic activity and significantly reduced tumour growth. These findings suggest that CXCR2-targeted immunotherapy holds promising therapeutic potential for prostate cancer and underscores its importance in translational medicine.

**中文摘要译文：**
神经内分泌性前列腺癌（NEPC）表现出强烈的免疫逃逸，并在调节前列腺癌的代谢重编程中起着关键作用。NEPC细胞中CD36+ M2型肿瘤相关巨噬细胞（TAMs）的高度浸润和CD47的高表达通常与癌症患者较差的无进展生存期相关。理解在前列腺癌肿瘤微环境（TME）中调节CD36+ M2型TAM浸润和肿瘤细胞CD47高表达的机制至关重要。通过使用细胞模型和两种动物模型，我们发现IL-8/CXCR2通路通过代谢重编程增加乙酰辅酶A的水平，进而通过乙酰化作用上调CD47的表达。此外，该通路通过刺激肿瘤细胞分泌棕榈酸并利用棕榈酰化机制来调节CD47的膜定位，从而保护肿瘤细胞免受巨噬细胞介导的吞噬作用。IL-8/CXCR2通路还重塑了TME的代谢微环境，增加了TME中ω-3/6多不饱和脂肪酸（PUFAs）的浸润，从而促进了CD36+ M2型TAMs的招募。在NSG和C57BL/6两种动物模型中的临床前研究表明，靶向CXCR2可恢复TAM的吞噬活性并显著抑制肿瘤生长。这些发现表明，靶向CXCR2的免疫疗法在前列腺癌中具有广阔的治疗前景，并凸显了其在转化医学中的重要性。

### 第二部分 AI 大师评价

本研究旨在揭示IL-8/CXCR2信号通路在前列腺癌（特别是神经内分泌亚型）免疫逃逸中的关键机制。研究团队综合运用细胞及动物模型，发现该通路不仅通过代谢重编程和翻译后修饰上调癌细胞“别吃我”信号分子CD47的表达，还通过重塑肿瘤微环境招募抑制性M2型巨噬细胞，构筑了双重免疫抑制屏障。该发现创新性地将CXCR2信号、肿瘤代谢与免疫微环境串联起来，为治疗难治性前列腺癌提供了极具潜力的免疫治疗新靶点CXCR2，具有重要的临床转化价值。

---

## 108. 勘误：TERT扩增作为甲状腺乳头状癌的风险分层标志物，与肿瘤复发和生存显著相关

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41162733](https://pubmed.ncbi.nlm.nih.gov/41162733)
**期刊：** Endocrine pathology
**PMID：** 41162733
**DOI：** 10.1007/s12022-025-09881-0

### 第一部分 原文与翻译

**英文原标题：** Correction to: TERT Amplification a Risk Stratification Marker in Papillary Thyroid Carcinoma, Significantly Correlated with Tumor Recurrence and Survival.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇勘误声明，旨在更正先前发表的关于“TERT扩增作为甲状腺乳头状癌风险分层标志物与肿瘤复发和生存显著相关”的研究。由于原文摘要缺失，无法对该研究的具体方法、核心发现及创新价值进行深入评估。然而，从原标题可推断，该研究旨在探讨TERT基因扩增在甲状腺乳头状癌预后判断中的作用，这对于临床风险评估和个性化治疗决策具有潜在的重要意义。

---

## 109. 环境光通过工程化的光能视紫红质为线粒体供能，从而减轻小鼠的视网膜神经退行性病变

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41162360](https://pubmed.ncbi.nlm.nih.gov/41162360)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41162360
**DOI：** 10.1038/s41392-025-02450-1

### 第一部分 原文与翻译

**英文原标题：** Ambient light alleviates retinal neurodegeneration in mice by powering mitochondria via the engineered optoenergetic rhodopsin.

**英文摘要原文：**
The mitochondrial proton motive force (pmf) is a critical driver of cellular energy production and influences various cellular processes. Dysregulation of pmf is implicated in a range of diseases, including neurodegenerative diseases, mitochondrial diseases, cancer and aging-related pathologies. Currently, an efficient strategy to rescue ATP production and mitigate reactive oxygen species (ROS) generation under conditions of energy deprivation is lacking. Here, we engineered a light-sensitive, mitochondria-targeting proton-pumping rhodopsin (PPR), mt-EcGAPR, capable of generating an efficient pmf for ATP synthesis while simultaneously mitigating reactive oxygen species (ROS) generation during stress and decreasing DNA double-strand breaks (DSBs). Owing to its transparency to visible light, eye is the ideal candidate for the noninvasive application of mt-EcGAPR in the treatment of mitochondria-related retinal degenerative diseases. Using a silicone oil-induced ocular hypertension glaucoma mouse model, we demonstrate that ambient light activation of mt-EcGAPR significantly increased ATP production, suppressed ROS accumulation, and protected retinal ganglion cells (RGCs) from degeneration. Mechanistically, mt-EcGAPR inhibited endoplasmic reticulum (ER) stress-ATF6-gasdermin D (GSDMD)-mediated pyroptosis, thereby preserving retinal structure and function. This intervention ultimately led to improved visual acuity in glaucomatous eyes of mice. Collectively, our findings establish mt-EcGAPR as a promising therapeutic strategy for glaucoma and potentially other neurodegenerative diseases associated with mitochondrial dysfunction and impaired bioenergetics.

**中文摘要译文：**
线粒体质子驱动力（pmf）是细胞能量生成的关键驱动力，并影响多种细胞过程。pmf的失调与多种疾病有关，包括神经退行性疾病、线粒体疾病、癌症和与衰老相关的病理状态。目前，在能量剥夺条件下，尚缺乏一种能够有效挽救ATP生成并减轻活性氧（ROS）产生的策略。本研究中，我们设计了一种光敏、靶向线粒体的质子泵视紫红质（PPR），命名为mt-EcGAPR，它能够产生高效的pmf以合成ATP，同时在应激状态下减轻活性氧（ROS）的产生并减少DNA双链断裂（DSBs）。由于眼睛对可见光具有通透性，因此是mt-EcGAPR在治疗线粒体相关视网膜退行性疾病中进行无创应用的理想候选器官。我们采用硅油诱导的眼压升高青光眼小鼠模型，证明了环境光激活mt-EcGAPR能显著增加ATP产量、抑制ROS积累，并保护视网膜神经节细胞（RGCs）免于变性。从机制上看，mt-EcGAPR抑制了内质网（ER）应激-ATF6-gasdermin D（GSDMD）介导的细胞焦亡，从而保护了视网膜的结构和功能。该干预措施最终改善了青光眼小鼠的视力。总而言之，我们的研究结果表明，mt-EcGAPR是治疗青光眼以及可能与线粒体功能障碍和生物能学受损相关的其他神经退行性疾病的一种有前景的治疗策略。

### 第二部分 AI 大师评价

本研究旨在开发一种新型光遗传学工具，通过光能驱动线粒体质子泵来对抗视网膜神经退行性病变。研究人员成功设计了靶向线粒体的光敏质子泵mt-EcGAPR，并在青光眼小鼠模型中验证，仅需环境光即可激活其功能。关键发现表明，该技术能显著提升ATP水平、减少氧化应激，并通过抑制细胞焦亡来保护视网膜神经节细胞，最终改善了动物的视力。这项工作开创了一种非侵入性的“线粒体充电”新策略，为治疗青光眼及其他与线粒体功能障碍相关的神经退行性疾病提供了极具潜力的转化应用前景。

---

## 110. KRAS突变肺癌：破茧成蝶

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41160826](https://pubmed.ncbi.nlm.nih.gov/41160826)
**期刊：** The New England journal of medicine
**PMID：** 41160826
**DOI：** 10.1056/NEJMe2509843

### 第一部分 原文与翻译

**英文原标题：** -Mutated Lung Cancer - Letting the Butterfly Out of the Cocoon.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
摘要不可用。

### 第二部分 AI 大师评价

该文献为一篇发表于《新英格兰医学杂志》的社论，而非原创性研究。从其充满隐喻的标题“破茧成蝶”推断，本文旨在评论KRAS突变肺癌治疗领域的重大突破。鉴于KRAS靶点曾被认为是“不可成药的”，该文可能深度解读了某项颠覆性研究（如新型靶向药物）的临床意义，并展望了其为患者带来革命性治疗前景的巨大价值。其创新性在于提供了权威专家视角，而非一手数据，对临床医生和研究者快速把握该领域前沿进展至关重要。

---

## 111. 前列腺癌早期检测：何去何从

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41160825](https://pubmed.ncbi.nlm.nih.gov/41160825)
**期刊：** The New England journal of medicine
**PMID：** 41160825
**DOI：** 10.1056/NEJMe2509793

### 第一部分 原文与翻译

**英文原标题：** Early Detection of Prostate Cancer - Time to Fish or Cut Bait.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

这篇发表于《新英格兰医学杂志》的社论，通过一个引人深思的标题，直接点明了前列腺癌早期筛查领域长期存在的争议与困境。文章很可能深入探讨了当前筛查策略（如PSA检测）在降低死亡率与导致过度诊断、过度治疗之间的利弊权衡。其核心价值在于，它并非一项原始研究，而是对现有证据的深刻反思和政策导向的呼吁，旨在敦促医学界就前列腺癌筛查的未来方向做出明确抉择。这篇评论对于推动临床指南的更新和激发更有效筛查方法的研究具有重要的指导意义和影响力。

---

## 112. 欧洲前列腺癌筛查研究——23年随访结果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41160819](https://pubmed.ncbi.nlm.nih.gov/41160819)
**期刊：** The New England journal of medicine
**PMID：** 41160819
**DOI：** 10.1056/NEJMoa2503223

### 第一部分 原文与翻译

**英文原标题：** European Study of Prostate Cancer Screening - 23-Year Follow-up.

**英文摘要原文：**
BACKGROUND: The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because deaths from prostate cancer are expected to rise worldwide owing to increased life expectancy and population growth, a final analysis of the long-term outcomes of prostate cancer screening is essential to understanding the benefits and harms of PSA testing.

METHODS: We updated the findings from ERSPC, a multicenter, randomized study conducted across eight European countries with a focus on a predefined core age group of 162,236 men who were 55 to 69 years of age at the time of randomization. Participants were randomly assigned to the screening group and offered repeated PSA testing or to the control group and not invited for screening. The primary outcome was prostate cancer mortality.

RESULTS: After a median follow-up of 23 years, prostate cancer mortality was 13% lower in the screening group (rate ratio, 0.87; 95% confidence interval [CI], 0.80 to 0.95), and the absolute risk reduction was 0.22% (95% CI, 0.10 to 0.34). The cumulative incidence of prostate cancer was higher in the screening group than in the control group (rate ratio, 1.30; 95% CI, 1.26 to 1.33). At a median of 23 years of follow-up, one death from prostate cancer was prevented for every 456 men (95% CI, 306 to 943) who were invited for screening, and one death from prostate cancer was averted for every 12 men (95% CI, 8 to 26) in whom prostate cancer was diagnosed, as compared with one death from prostate cancer prevented for every 628 men (95% CI, 419 to 1481) and one death averted for every 18 men (95% CI, 12 to 45) at 16 years of follow-up.

CONCLUSIONS: Long-term follow-up confirms a sustained reduction in deaths from prostate cancer with PSA testing, alongside an improved harm-benefit ratio. Future screening strategies should adopt risk-based approaches to minimize overdiagnosis while maintaining clinical benefits. (Funded by the Dutch Cancer Society and others; ERSPC ISRCTN registry number, ISRCTN49127736.).

**中文摘要译文：**
背景：欧洲前列腺癌随机筛查研究（ERSPC）于1993年启动，旨在评估前列腺特异性抗原（PSA）检测对前列腺癌死亡率的影响。鉴于预期寿命延长和人口增长，全球前列腺癌死亡人数预计将上升，因此，对前列腺癌筛查的长期结局进行最终分析对于理解PSA检测的获益与危害至关重要。

方法：我们更新了ERSPC研究的结果，这是一项在八个欧洲国家进行的多中心随机研究，重点关注一个预先定义的核心年龄组，即随机化时年龄在55至69岁的162,236名男性。参与者被随机分配至筛查组（接受重复的PSA检测）或对照组（不被邀请参加筛查）。主要结局是前列腺癌死亡率。

结果：经过中位23年的随访，筛查组的前列腺癌死亡率降低了13%（率比，0.87；95%置信区间[CI]，0.80至0.95），绝对风险降低了0.22%（95% CI，0.10至0.34）。筛查组的前列腺癌累积发病率高于对照组（率比，1.30；95% CI，1.26至1.33）。在中位23年的随访中，每邀请456名男性（95% CI，306至943）参加筛查，可预防一例前列腺癌死亡；每诊断12名前列腺癌患者（95% CI，8至26），可避免一例前列腺癌死亡。相比之下，在16年随访时，这两个数字分别为每628名男性（95% CI，419至1481）和每18名患者（95% CI，12至45）。

结论：长期随访证实，PSA检测能够持续降低前列腺癌死亡率，同时改善了获益-危害比。未来的筛查策略应采用基于风险的方法，以最大限度地减少过度诊断，同时保持临床获益。（由荷兰癌症协会等资助；ERSPC ISRCTN注册号：ISRCTN49127736。）

### 第二部分 AI 大师评价

本研究是欧洲前列腺癌随机筛查研究（ERSPC）的最终长周期报告，通过长达23年的随访数据，评估了PSA筛查对降低前列腺癌死亡率的长期效果。研究关键发现，PSA筛查能持续且有效地将死亡率降低13%，并且随着时间推移，其获益-危害比得到改善。这项里程碑式的研究为PSA筛查的争议提供了迄今最强有力的循证医学证据，其重大临床价值在于量化了长期获益，并明确指引未来应转向基于个体风险的精准筛查策略，以求在挽救生命与避免过度诊断之间找到最佳平衡点。

---

## 113. Pt-seq技术揭示铂类药物的基因组结合模式

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41160705](https://pubmed.ncbi.nlm.nih.gov/41160705)
**期刊：** Science advances
**PMID：** 41160705
**DOI：** 10.1126/sciadv.adx6809

### 第一部分 原文与翻译

**英文原标题：** Pt-seq unveils the genomic binding pattern of platinum-based drugs.

**英文摘要原文：**
Platinum-based drugs (Pt drugs) are widely used in cancer chemotherapy, yet their genome-wide binding patterns remain incompletely understood. Here, we present Pt sequencing (Pt-seq), an antibody-assisted, genome-wide method for mapping Pt-DNA adducts at single-base resolution. By using exo- and endonucleases to remove background, Pt-seq enables robust and sensitive profiling of binding sites for cisplatin, oxaliplatin, lobaplatin, and a Pt(IV) complex. Using Pt-seq, we identified tens to hundreds of binding clusters that are 10 to 20 kilobases in median length and highly consistent among different drugs, predominantly localizing to centromeric and ribosomal DNA regions. In cisplatin-resistant cells, we found significantly reduced binding within these regions. Moreover, we found that mutations in cancer cells can generate previously unidentified binding sites. On this basis, we demonstrated that ICR-191, an acridine orange compound capable of inducing G insertions, enhances cisplatin-DNA binding and sensitizes cells to cisplatin. Collectively, Pt-seq sensitively profiles Pt-DNA interactions and deepens our understanding of the genome-wide effect of chemotherapeutic drugs.

**中文摘要译文：**
铂类药物（Pt drugs）被广泛用于癌症化疗，但其全基因组范围内的结合模式仍未被完全阐明。在此，我们提出了一种名为Pt测序（Pt-seq）的技术，这是一种抗体辅助的全基因组方法，用于以单碱基分辨率绘制铂-DNA加合物图谱。通过使用外切和内切核酸酶去除背景，Pt-seq能够对顺铂、奥沙利铂、洛铂和一种铂（IV）配合物的结合位点进行稳健而灵敏的分析。利用Pt-seq，我们识别出数十至数百个结合簇，其中位长度为10至20千碱基，在不同药物间高度一致，且主要定位于着丝粒和核糖体DNA区域。在顺铂耐药细胞中，我们发现这些区域内的结合显著减少。此外，我们发现癌细胞中的突变可以产生前所未见的结合位点。在此基础上，我们证明了ICR-191，一种能够诱导G插入的吖啶橙类化合物，能增强顺铂-DNA的结合，并使细胞对顺铂敏感。总而言之，Pt-seq能灵敏地分析铂-DNA相互作用，并加深我们对化疗药物全基因组效应的理解。

### 第二部分 AI 大师评价

本研究旨在阐明铂类化疗药物在全基因组的结合模式。研究团队开发了一种名为Pt-seq的创新技术，能够以单碱基分辨率精准定位铂-DNA加合物。研究发现，铂类药物的结合并非随机，而是集中在着丝粒和核糖体DNA等特定区域，且这种结合模式在耐药细胞中显著减弱。这项工作不仅深化了我们对铂类药物作用机制及耐药性的理解，其高灵敏度的分析方法也为探索增敏药物、优化癌症化疗方案提供了全新的视角和有力的工具。

---

## 114. 循环肿瘤细胞作为导管原位癌风险分层的预测性生物标志物：早期播散的证据。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41160699](https://pubmed.ncbi.nlm.nih.gov/41160699)
**期刊：** Science advances
**PMID：** 41160699
**DOI：** 10.1126/sciadv.adz0187

### 第一部分 原文与翻译

**英文原标题：** Circulating tumor cells as predictive biomarkers in the risk stratification of DCIS: Evidence of early dissemination.

**英文摘要原文：**
Overtreatment of patients with ductal carcinoma in situ (DCIS) is driven by a lack of a reliable prognostic biomarker. Widespread mammographic screening has resulted in a substantial increase in women diagnosed with DCIS. To improve patient risk stratification, we investigate circulating tumor cells (CTCs) as a biomarker for DCIS patients' biological aggressiveness and as an indicator of early dissemination. We apply microfluidics to enrich CTCs from 34 patients with DCIS and find a significantly higher concentration of CTCs compared to in healthy controls. We profile CTCs and matched DCIS tissues using single-cell RNA sequencing. We find that CTCs express higher clonal aberrations when compared to white blood cells from the same samples, and clonal comparisons between matched tissue and CTC samples provide evidence for an evolutionary bottleneck model. mRNA expression in CTC reveals EMT/MET and immunoregulatory pathway regulation with a suggestion of racial differences. Last, we provide support for early dissemination in DCIS using a Mouse IntraDuctal model.

**中文摘要译文：**
导管原位癌（DCIS）患者的过度治疗问题源于缺乏可靠的预后生物标志物。广泛的乳腺X线摄影筛查导致被诊断为DCIS的女性数量大幅增加。为改善患者的风险分层，我们研究了循环肿瘤细胞（CTCs）作为DCIS患者生物学侵袭性的生物标志物及早期播散指标的潜力。我们应用微流控技术富集了34例DCIS患者的CTCs，并发现与健康对照组相比，DCIS患者的CTCs浓度显著更高。我们利用单细胞RNA测序技术对CTCs和配对的DCIS组织进行了分析。我们发现，与同一样本中的白细胞相比，CTCs表达了更高水平的克隆畸变，且配对组织与CTC样本间的克隆比较为进化瓶颈模型提供了证据。CTC中的mRNA表达揭示了上皮-间质转化/间质-上皮转化（EMT/MET）及免疫调节通路的调控，并提示可能存在种族差异。最后，我们通过小鼠导管内模型为DCIS的早期播散提供了支持证据。

### 第二部分 AI 大师评价

本研究旨在探索循环肿瘤细胞（CTC）作为导管原位癌（DCIS）风险分层预测生物标志物的潜力，并为DCIS的早期播散提供证据。研究创新性地采用微流控技术和单细胞RNA测序，发现DCIS患者外周血中存在CTC，且其基因表达谱揭示了与肿瘤侵袭和免疫逃逸相关的通路激活。该研究首次为DCIS这一“癌前病变”存在早期播散提供了有力证据，挑战了传统观念，对改进DCIS的风险评估、避免过度治疗具有重要的临床转化价值和科研启发意义。

---

## 115. 肿瘤源性RAC1突变促进免疫抑制微环境，从而抑制对免疫检查点抑制剂的应答

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41160695](https://pubmed.ncbi.nlm.nih.gov/41160695)
**期刊：** Science advances
**PMID：** 41160695
**DOI：** 10.1126/sciadv.aea1212

### 第一部分 原文与翻译

**英文原标题：** Tumor-derived RAC1 mutation promotes an immunosuppressive microenvironment that represses response to immune checkpoint inhibitor.

**英文摘要原文：**
RAC1 is a hotspot mutation associated with poor prognosis in several cancers. By gene editing, we generated endogenous homozygous and heterozygous RAC1 mutations, which result in up-regulated RAC1 activity and mammalian target of rapamycin (mTOR) signaling. RAC1 tumors grow faster than RAC1 tumors in immune-proficient mice and are resistant to anti-programmed death protein 1 (PD1). Flow cytometry and scRNA-seq analyses reveal that RAC1 cells form "cold" tumors with an immunosuppressive microenvironment and reduced tumor-immune cell interactions. Mechanistically, RAC1 up-regulates glycosphingolipid biosynthesis to activate mTORC1 signaling in tumor cells, which in turn increases glycolysis, impairs key chemokine production, and decreases IFNGR1 expression of the tumor cells. mTORC1 inhibition by rapamycin resensitizes the RAC1 tumors to anti-PD1 treatment by reversing effects of RAC1 mutation. These results demonstrate a mechanism of RAC1-driven immune evasion and suggest an approach of combining the targeting of RAC1-mTOR signaling with immune checkpoint inhibitor for the treatment of a type of immune-cold tumors.

**中文摘要译文：**
RAC1是与多种癌症不良预后相关的热点突变。通过基因编辑，我们构建了内源性的纯合与杂合RAC1突变，这导致了RAC1活性和哺乳动物雷帕霉素靶蛋白（mTOR）信号的上调。在免疫功能健全的小鼠中，携带RAC1突变的肿瘤比RAC1野生型肿瘤生长更快，并对靶向程序性死亡蛋白1（PD1）的抗体治疗产生耐药性。流式细胞术和单细胞RNA测序（scRNA-seq）分析揭示，RAC1突变细胞会形成具有免疫抑制微环境和肿瘤-免疫细胞相互作用减少的“冷”肿瘤。机制上，RAC1突变通过上调鞘糖脂的生物合成来激活肿瘤细胞中的mTORC1信号，这反过来又增加了糖酵解，损害了关键趋化因子的产生，并降低了肿瘤细胞的IFNGR1表达。使用雷帕霉素抑制mTORC1可通过逆转RAC1突变的影响，使RAC1突变肿瘤重新对PD-1抗体治疗敏感。这些结果阐明了RAC1驱动免疫逃逸的一种机制，并提出了一种联合靶向RAC1-mTOR信号与免疫检查点抑制剂的策略，用于治疗一类免疫“冷”肿瘤。

### 第二部分 AI 大师评价

本研究旨在阐明RAC1热点突变如何导致对免疫检查点抑制剂的耐药。研究团队通过基因编辑技术，结合免疫健全小鼠模型及单细胞测序等手段，发现RAC1突变通过激活mTORC1信号通路，重塑肿瘤代谢并抑制关键趋化因子生成，从而构建了一个免疫抑制性的“冷”肿瘤微环境。该研究不仅深刻揭示了肿瘤内在基因突变驱动免疫逃逸的具体分子机制，更重要的是，其验证了mTORC1抑制剂能逆转此耐药性，为治疗携带RAC1突变的“冷”肿瘤提供了极具潜力的联合治疗新策略。

---

## 116. 利用一种咔唑类化合物预防神经病变并改善抗癌化疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41160692](https://pubmed.ncbi.nlm.nih.gov/41160692)
**期刊：** Science advances
**PMID：** 41160692
**DOI：** 10.1126/sciadv.adw6328

### 第一部分 原文与翻译

**英文原标题：** Preventing neuropathy and improving anticancer chemotherapy with a carbazole-based compound.

**英文摘要原文：**
While advances in cancer therapy have improved remission rates, chemotherapy-induced peripheral neuropathy (CIPN) remains a lasting and untreatable side effect. This study introduces Carba1, a bifunctional carbazole compound that protects against CIPN through two mechanisms. First, Carba1 interacts with tubulin, allowing for lower doses of taxanes, common chemotherapeutics known for causing CIPN, without reducing their anticancer effectiveness. Second, Carba1 activates nicotinamide phosphoribosyltransferase (NAMPT), enhancing NAD biosynthesis and boosting the metabolic resilience of neurons and Schwann cells against chemotherapy-induced damage. Carba1 shows strong neuroprotective effects in vitro against paclitaxel, cisplatin, and bortezomib toxicity and in vivo in a rat model of paclitaxel-induced neuropathy. Crucially, Carba1 does not interfere with paclitaxel's tumor-fighting ability or promote tumor growth. Structure-activity analyses of Carba1 derivatives reveal the potential to develop compounds with dual or solely neuroprotective effects. These findings position Carba1 as a promising candidate to prevent CIPN, with potential to enhance both cancer treatment outcomes and patients' quality of life.

**中文摘要译文：**
尽管癌症治疗的进步提高了缓解率，但化疗引起的周围神经病变（CIPN）仍然是一种持久且无法治愈的副作用。本研究介绍了一种名为Carba1的双功能咔唑化合物，它通过两种机制来防止CIPN。首先，Carba1与微管蛋白相互作用，从而可以在不降低抗癌效果的情况下，使用更低剂量的紫杉烷类药物——这类常用化疗药以引起CIPN而著称。其次，Carba1能激活烟酰胺磷酸核糖转移酶（NAMPT），增强NAD的生物合成，从而提高神经元和雪旺细胞抵抗化疗损伤的代谢韧性。在体外实验中，Carba1对紫杉醇、顺铂和硼替佐米的毒性显示出强大的神经保护作用；在紫杉醇诱导的神经病变大鼠模型中，其体内保护效果同样显著。至关重要的是，Carba1不干扰紫杉醇的抗肿瘤能力，也不会促进肿瘤生长。对Carba1衍生物的构效关系分析揭示了开发具有双重作用或仅具神经保护作用的化合物的潜力。这些发现使Carba1成为预防CIPN的一个极有前景的候选药物，有望同时改善癌症治疗效果和提高患者的生活质量。

### 第二部分 AI 大师评价

本研究旨在解决化疗引起的周围神经病变（CIPN）这一棘手的临床难题。研究团队创新性地发现了一种名为Carba1的咔唑化合物，通过体外及动物模型证实了其独特的双重作用机制：它既能通过激活NAMPT通路保护神经元，又能与微管蛋白作用以协同紫杉烷类药物的抗癌效果。这项工作的最大亮点在于提出了一种“减毒增效”的新策略，不仅能预防副作用，还可能优化现有化疗方案，为开发新型CIPN防治药物提供了极具价值的新靶点和先导化合物，临床转化潜力巨大。

---

## 117. 转录因子激活蛋白4（AP4）介导的轴突再生内在调控

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41160685](https://pubmed.ncbi.nlm.nih.gov/41160685)
**期刊：** Science advances
**PMID：** 41160685
**DOI：** 10.1126/sciadv.adu3917

### 第一部分 原文与翻译

**英文原标题：** Transcription factor activator protein 4 (AP4)-mediated intrinsic control of axon regeneration.

**英文摘要原文：**
Activator protein 4 (AP4) is a basic helix-loop-helix leucine-zipper transcription factor, a direct transcriptional target of c-Myc and a key regulator of cell growth and apoptosis, abundantly expressed in cancer cells. Here, we reveal a role for the c-Myc-AP4 axis in axon regeneration and the intrinsic growth capacity of injured neurons. Through bioinformatic and functional analyses, we demonstrated that overexpression of AP4 in mice not only accelerated in vivo axon regeneration and functional recovery after peripheral nerve injury but also promoted robust axon regeneration and neuronal survival after optic nerve injury by activating mammalian target of rapamycin activity. Neuronal-specific knockdown of AP4 abolished the regenerative phenotype induced by c-Myc overexpression and phosphatase and tensin homolog (PTEN) deletion. AP4 overexpression rendered the intrinsic growth capacity of c-Myc silencing injured retinal ganglion cells unaffected. These findings unveil a distinct aspect of the c-Myc-AP4 axis and highlight a previously unrecognized intrinsic role of AP4 in axon regeneration, with potential therapeutic implications.

**中文摘要译文：**
激活蛋白4（AP4）是一种碱性螺旋-环-螺旋亮氨酸拉链转录因子，是c-Myc的直接转录靶点，也是细胞生长和凋亡的关键调节因子，在癌细胞中大量表达。在此，我们揭示了c-Myc-AP4轴在轴突再生和受损神经元内在生长能力中的作用。通过生物信息学和功能分析，我们证明在小鼠中过表达AP4不仅能加速周围神经损伤后的体内轴突再生和功能恢复，还能通过激活哺乳动物雷帕霉素靶蛋白（mTOR）的活性，促进视神经损伤后强有力的轴突再生和神经元存活。在神经元中特异性敲降AP4，会消除由c-Myc过表达和磷酸酶与张力蛋白同源物（PTEN）缺失诱导的再生表型。AP4的过表达使得c-Myc沉默的受损视网膜神经节细胞的内在生长能力不受影响。这些发现揭示了c-Myc-AP4轴的一个独特方面，并凸显了AP4在轴突再生中一个前所未知的内在作用，具有潜在的治疗意义。

### 第二部分 AI 大师评价

本研究通过生物信息学与小鼠模型功能分析，旨在阐明转录因子AP4在神经损伤后轴突再生中的内在作用。核心发现是，作为c-Myc的关键下游靶点，AP4能通过激活mTOR信号通路，有效促进周围神经和视神经损伤后的轴突再生、神经元存活及功能恢复。该研究创新性地揭示了c-Myc-AP4轴在神经再生中的新功能，明确了AP4作为一个独立的、强效的促再生因子，为开发神经损伤修复的治疗策略提供了新的分子靶点。

---

## 118. 广角肺部实验分割（WALES）：对模型系统中肺部病理的有效定量评估

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41160680](https://pubmed.ncbi.nlm.nih.gov/41160680)
**期刊：** Science advances
**PMID：** 41160680
**DOI：** 10.1126/sciadv.ady2927

### 第一部分 原文与翻译

**英文原标题：** Wide-Angle Lung Experiment Segmentation (WALES): Effective quantitative assessment of lung pathology in model systems.

**英文摘要原文：**
For preclinical studies, the standard practice for evaluating lung injury usually involves an assessment of pulmonary histopathology by a certified pathologist. This is typically accomplished by light microscopy using a semiquantitative four-point scale. In contrast, automated image analysis software allows a more quantitative assessment, though inherent limitations with such automated programs can produce misleading conclusions. For example, specific imaging features may be incorrectly scored or classified within the specimen because of the complex architecture and heterogeneous structures present in the lung. In addition, tissue processing and handling may further introduce artifacts and inconsistencies that affect automated analysis. To address these limitations, we developed a lung image analysis program, Wide-Angle Lung Experiment Segmentation (WALES), which uses Meta's Segment Anything Model to provide semiautomated masking and relative density analysis to efficiently quantify lung injury. Density analysis using WALES effectively delineated varying severities of lung injury, not achieved using more standard methods. WALES is widely applicable for many preclinical lung injury models.

**中文摘要译文：**
在临床前研究中，评估肺损伤的标准实践通常涉及由执业病理学家对肺部组织病理学进行评估。这通常通过光学显微镜使用半定量的四分制量表来完成。相比之下，自动化图像分析软件可以进行更定量的评估，但这类自动化程序固有的局限性可能会产生误导性结论。例如，由于肺部存在复杂的结构和异质性结构，样本中的特定影像学特征可能会被错误地评分或分类。此外，组织处理和操作可能会进一步引入影响自动化分析的伪影和不一致性。为了解决这些局限性，我们开发了一款名为“广角肺部实验分割（WALES）”的肺部图像分析程序，该程序利用Meta公司的“分割一切模型”（Segment Anything Model）提供半自动化的掩模生成和相对密度分析，以高效地量化肺损伤。使用WALES进行的密度分析有效地描绘了不同严重程度的肺损伤，这是传统标准方法无法实现的。WALES可广泛应用于多种临床前肺损伤模型。

### 第二部分 AI 大师评价

本研究旨在解决临床前肺损伤评估中传统半定量方法主观性强、自动化软件准确性不足的问题。研究团队开发了一款名为WALES的半自动化图像分析程序，其创新性地集成了Meta的“分割一切模型”（SAM）技术，通过相对密度分析来高效、精准地量化肺部病理损伤。关键发现表明，WALES能够有效区分不同严重程度的肺损伤，其定量评估效果优于传统方法。这项技术为临床前肺损伤研究提供了一个客观、可重复的强大工具，有望加速相关疾病治疗方法的开发与评价。

---

## 119. 美国胃肠病学会关于巴雷特食管监测的临床实践指南

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41125322](https://pubmed.ncbi.nlm.nih.gov/41125322)
**期刊：** Gastroenterology
**PMID：** 41125322
**DOI：** 10.1053/j.gastro.2025.09.012

### 第一部分 原文与翻译

**英文原标题：** AGA Clinical Practice Guideline on Surveillance of Barrett's Esophagus.

**英文摘要原文：**
BACKGROUND & AIMS: Barrett's esophagus (BE) is the only identifiable precursor to esophageal adenocarcinoma (EAC). Endoscopic surveillance has been proposed for early detection of BE-related neoplasia and reducing EAC mortality. This clinical practice guideline aims to inform clinicians and patients by providing evidence-based practice recommendations for surveillance in patients with BE.

METHODS: The Grading of Recommendations Assessment, Development and Evaluation framework was used to assess evidence and make recommendations. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients, conducted an evidence review, and used the Evidence-to-Decision Framework to develop recommendations regarding the role of endoscopic surveillance in patients with BE. The clinical domains addressed included: (1) overall role of endoscopic surveillance, (2) surveillance in patients with columnar-lined esophagus <1 cm, (3) optimal imaging modalities, (4) adjunctive sampling techniques, (5) the utility of biomarkers in risk-stratification, (6) chemopreventive strategies, and (7) antireflux procedures in the prevention of progression in patients with BE. Clinical recommendations were based on the balance between the desirable and undesirable effects, patient values, costs, and health equity considerations.

RESULTS: The panel agreed on 8 recommendations. Based on the available evidence, the panel provided a conditional recommendation in favor of surveillance for patients with nondysplastic BE. In patients with columnar-lined esophagus <1 cm, a conditional recommendation was made against endoscopic surveillance. The panel made a strong recommendation in favor of a combination of high-definition white light endoscopy and chromoendoscopy compared with white light endoscopy alone. The panel made no recommendation on the use of enhanced sampling techniques, such as wide-area transepithelial sampling to enhance neoplasia detection and biomarkers such as p53 and TissueCypher to predict progression in BE. The panel provided a conditional recommendation for the use of daily proton pump inhibitor therapy compared with no therapy and compared with antireflux surgery to prevent progression in BE.

CONCLUSIONS: This document provides a comprehensive outline on the role of surveillance in patients with BE. Key implementation statements included in this document stress the importance of a high-quality endoscopy examination, sampling using a structured biopsy protocol, and confirming the diagnosis of BE-related neoplasia by an expert pathologist. This document also provides guidance on surveillance intervals and management of patients with BE-related low-grade dysplasia and indefinite for dysplasia. Providers should engage in shared decision making based on patient preferences. Limitations and gaps in the evidence are highlighted to guide future research opportunities.

GUIDELINE ENDORSEMENT: This guideline is endorsed by the Canadian Association of Gastroenterology.

**中文摘要译文：**
背景与目的：巴雷特食管（BE）是唯一可识别的食管腺癌（EAC）前体病变。内镜监测被提议用于早期发现BE相关肿瘤并降低EAC死亡率。本临床实践指南旨在通过为BE患者的监测提供循证实践建议，为临床医生和患者提供信息。

方法：采用推荐分级的评估、制定与评价（GRADE）框架来评估证据并提出建议。专家组根据临床问题和结局对临床医生和患者的重要性进行排序，进行了证据审查，并使用“证据到决策”框架来制定关于内镜监测在BE患者中作用的建议。所涉及的临床领域包括：（1）内镜监测的总体作用，（2）食管柱状上皮化<1厘米患者的监测，（3）最佳成像方式，（4）辅助取样技术，（5）生物标志物在风险分层中的效用，（6）化学预防策略，以及（7）抗反流手术在预防BE患者疾病进展中的作用。临床建议基于对有利与不利效果、患者价值观、成本和健康公平性考虑的权衡。

结果：专家组就8项建议达成一致。基于现有证据，专家组对无异型增生的BE患者进行监测提出了有条件的推荐。对于食管柱状上皮化<1厘米的患者，专家组提出了反对内镜监测的有条件推荐。与单独使用白光内镜相比，专家组强烈推荐联合使用高清白光内镜和色素内镜。专家组未对使用增强取样技术（如广域跨上皮取样以增强肿瘤检出）和生物标志物（如p53和TissueCypher以预测BE进展）提出建议。专家组为使用每日质子泵抑制剂治疗（与不治疗和抗反流手术相比）以预防BE进展提供了有条件的推荐。

结论：本文件全面概述了监测在BE患者中的作用。文件中包含的关键实施声明强调了高质量内镜检查、采用结构化活检方案进行取样以及由病理学专家确认BE相关肿瘤诊断的重要性。本文件还为BE相关低级别异型增生和不确定异型增生患者的监测间隔和管理提供了指导。医疗服务提供者应根据患者偏好进行共同决策。文中还强调了证据的局限性和差距，以指导未来的研究方向。

指南认可：本指南获得了加拿大胃肠病学会的认可。

### 第二部分 AI 大师评价

本AGA临床实践指南利用GRADE框架，系统评估了巴雷特食管（BE）监测相关证据，旨在为临床医生提供权威的实践指导。其核心价值在于针对非异型增生BE、短段BE等不同情况，给出了明确的监测推荐等级，并强调了高清内镜结合色素内镜等先进成像技术的应用。该指南通过权衡利弊、成本和患者价值，为优化BE患者管理、减少食管腺癌死亡率提供了标准化路径，同时指出了生物标志物等领域的证据缺口，对未来研究具有重要导向意义。

---

## 120. 镥-177 [Lu]Lu-PSMA-I&T联合镭-223治疗转移性去势抵抗性前列腺癌患者（AlphaBet）：一项研究者发起的、单中心、单臂、1/2期试验的中期分析。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41119954](https://pubmed.ncbi.nlm.nih.gov/41119954)
**期刊：** The Lancet. Oncology
**PMID：** 41119954
**DOI：** 10.1016/S1470-2045(25)00559-5

### 第一部分 原文与翻译

**英文原标题：** Lutetium-177 [Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.

**英文摘要原文：**
BACKGROUND: Lutetium-177 [Lu]Lu-PSMA-I&T (Lu-PSMA-I&T) and the bone-seeking α-emitter radium-223 (Ra) are established life-extending therapies for patients with metastatic castration-resistant prostate cancer; however, resistance and progression are inevitable. We aimed to evaluate the safety and preliminary antitumour activity of Lu-PSMA-I&T combined with Ra in this patient group.

METHODS: We conducted an investigator-initiated, single-centre, single-arm, phase 1/2 trial (AlphaBet) at the Peter MacCallum Cancer Centre in Melbourne, Australia. Adults (aged ≥18 years) with a diagnosis of progressive, metastatic castration-resistant prostate cancer, an Eastern Cooperative Oncology Group performance status score of 0-2, at least two visible bone metastases not treated with radiotherapy, previous exposure to an androgen receptor pathway inhibitor, prostate-specific membrane antigen (PSMA)-positive disease (defined by maximum standardised uptake value ≥20 at a site of disease), and no discordant sites (ie, avid on 2-[F]fluoro-2-deoxy-D-glucose-PET-CT with minimal PSMA expression and no uptake on bone scintigraphy) were eligible for inclusion. Phase 1 dose-escalation assessed two dose levels of Ra (27·5 kBq/kg and 55·0 kBq/kg) combined with 7·4 GBq Lu-PSMA-I&T, administered intravenously every 6 weeks for up to six cycles. Phase 2 dose expansion continued with the recommended phase 2 dose. Co-primary endpoints were the maximum tolerated or administered dose and the recommended phase 2 dose (phase 1), and the PSA response rate (phase 2), analysed in all patients treated at the maximum tolerated or administered dose in either phase. Safety was assessed in all patients who received at least one dose of either protocol treatment in phase 1 or 2. Herein, we report the results of an interim analysis, which was added to the protocol following an amendment on May 30, 2024. This trial is registered at ClinicalTrials.gov (NCT05383079) and follow-up is ongoing.

FINDINGS: Between Nov 3, 2022, and Nov 5, 2024, 37 patients were enrolled, of whom 36 (97%; median age 72·5 years [IQR 67·0-78·0]) were included in the safety analysis and 33 (89%) were included in the preliminary activity analysis. No dose-limiting toxicities were observed. The recommended phase 2 dose of Ra was 55·0 KBq/kg combined with 7·4 GBq Lu-PSMA-I&T, administered every 6 weeks. With a median follow-up of 13·3 months (IQR 8·7-17·1), 11 (31%) patients completed all six cycles of both treatments. 18 (50%) patients discontinued treatment early, primarily due to unequivocal disease progression (11 [61%]) or adverse events (three [17%]). A reduction in PSA of at least 50% was observed in 18 (55%; 95% CI 36-72) patients. Grade 3 or higher treatment-related adverse events occurred in five (14%) of 36 patients, including anaemia (four [11%]) and neutropenia (three [8%]), with no treatment-related deaths. Non-clinically significant grade 3 lymphopenia occurred in ten (28%) patients.

INTERPRETATION: The combination of Lu-PSMA-I&T and Ra is safe and feasible in patients with metastatic castration-resistant prostate cancer and bone metastases. These findings warrant further evaluation of combined α-emitting and β-emitting approaches.

FUNDING: Prostate Cancer Foundation, Bayer, and National Health and Medical Research Council.

**中文摘要译文：**
背景：镥-177 [Lu]Lu-PSMA-I&T (Lu-PSMA-I&T) 和亲骨性α粒子发射体镭-223 (Ra) 是已确立的用于延长转移性去势抵抗性前列腺癌患者生命的疗法；然而，耐药和疾病进展不可避免。我们旨在评估Lu-PSMA-I&T联合Ra在该患者群体中的安全性与初步抗肿瘤活性。

方法：我们在澳大利亚墨尔本的彼得·麦卡勒姆癌症中心进行了一项研究者发起的、单中心、单臂、1/2期试验（AlphaBet）。入组标准为：年龄≥18岁的成年人，诊断为进展性转移性去势抵抗性前列腺癌，美国东部肿瘤协作组（ECOG）体能状态评分为0-2分，至少有两处未接受过放疗的可见骨转移灶，曾接受过雄激素受体通路抑制剂治疗，前列腺特异性膜抗原（PSMA）阳性疾病（定义为病灶处最大标准化摄取值≥20），且无不一致病灶（即，在2-[F]氟-2-脱氧-D-葡萄糖-PET-CT上呈高代谢但PSMA表达极低，且在骨显像上无摄取）。1期剂量爬坡阶段评估了两种剂量的Ra（27·5 kBq/kg和55·0 kBq/kg）与7·4 GBq Lu-PSMA-I&T联合使用，每6周静脉注射一次，最多六个周期。2期剂量扩展阶段则采用2期推荐剂量进行。共同主要终点为：最大耐受或给药剂量及2期推荐剂量（1期），以及PSA缓解率（2期），分析对象为在任一阶段接受了最大耐受或给药剂量的所有患者。安全性评估在所有于1期或2期中接受了至少一剂任一方案治疗的患者中进行。本文报告了一项中期分析的结果，该分析是在2024年5月30日方案修订后增加的。本试验已在ClinicalTrials.gov注册（NCT05383079），随访仍在进行中。

结果：在2022年11月3日至2024年11月5日期间，共招募了37名患者，其中36名（97%；中位年龄72.5岁 [IQR 67.0-78.0]）被纳入安全性分析，33名（89%）被纳入初步活性分析。未观察到剂量限制性毒性。2期推荐剂量为：Ra 55.0 KBq/kg联合7.4 GBq Lu-PSMA-I&T，每6周给药一次。在中位随访13.3个月（IQR 8.7-17.1）时，11名（31%）患者完成了全部六个周期的两种治疗。18名（50%）患者提前中止治疗，主要原因是明确的疾病进展（11名 [61%]）或不良事件（3名 [17%]）。在18名（55%；95% CI 36-72）患者中观察到PSA水平下降至少50%。36名患者中有5名（14%）发生3级或以上治疗相关不良事件，包括贫血（4名 [11%]）和中性粒细胞减少（3名 [8%]），无治疗相关死亡事件。10名（28%）患者出现了无临床意义的3级淋巴细胞减少症。

解读：Lu-PSMA-I&T与Ra的联合疗法对于伴有骨转移的转移性去势抵抗性前列腺癌患者是安全且可行的。这些发现值得我们进一步评估α粒子与β粒子发射体联合治疗的策略。

资金来源：前列腺癌基金会、拜耳公司以及国家健康与医学研究委员会。

### 第二部分 AI 大师评价

该研究（AlphaBet试验）创新性地探索了β粒子核素疗法（Lu-PSMA-I&T）与α粒子核素疗法（镭-223）联合应用于转移性去势抵抗性前列腺癌患者的可行性与安全性。通过一项单臂1/2期试验，研究初步证实了该联合方案具有良好的耐受性，并显示出令人鼓舞的抗肿瘤活性（55%的患者PSA水平显著下降）。这项研究为核医学治疗领域开辟了新思路，即通过α和β射线的协同作用，同时靶向全身PSMA阳性病灶和骨转移微环境，为克服治疗抵抗提供了潜在的新策略，其发现亟待更大规模的随机对照试验来验证。

---

## 121. 肿瘤药物临床试验中的总生存期评估：是奢侈还是必需？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41110458](https://pubmed.ncbi.nlm.nih.gov/41110458)
**期刊：** The Lancet. Oncology
**PMID：** 41110458
**DOI：** 10.1016/S1470-2045(25)00606-0

### 第一部分 原文与翻译

**英文原标题：** Overall survival assessment in cancer drug trials: a luxury or a necessity?

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

本文通过一个引人深思的标题，探讨了肿瘤药物临床试验中总生存期（OS）作为金标准终点的价值与挑战。该文可能深入分析了OS相较于无进展生存期（PFS）等替代终点的优缺点，并讨论了在追求快速药物审批与确保患者真实获益之间的平衡。尽管缺乏摘要，但从标题推断，该文对于临床试验设计者、监管机构及临床医生在选择和解读试验终点时具有重要的参考价值和启发意义，引发了对如何科学、高效地评估新药疗效的深刻反思。

---

## 122. 编辑部关注声明：PRAJA介导的RING指依赖性泛素化依赖于TGF-β，并可能决定肿瘤抑制因子ELF的功能状态

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41094240](https://pubmed.ncbi.nlm.nih.gov/41094240)
**期刊：** Oncogene
**PMID：** 41094240
**DOI：** 10.1038/s41388-025-03602-x

### 第一部分 原文与翻译

**英文原标题：** Editorial Expression of Concern: RING finger-dependent ubiquitination by PRAJA is dependent on TGF-ß and potentially defines the functional status of the tumor suppressor ELF.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇编辑部关注声明，并非原创性研究论文。它所关注的原研究探讨了PRAJA蛋白在TGF-β信号通路中的作用，特别是其作为E3泛素连接酶，如何通过RING指结构介导泛素化，进而可能决定肿瘤抑制因子ELF的功能状态。然而，编辑部发布此“关注声明”，表明原研究的数据、结论或研究过程的某些方面已引发严重关切，其可靠性受到质疑。因此，在期刊完成调查并发布最终裁定之前，科研界应审慎对待原研究的发现，避免将其作为可靠证据进行引用。

---

## 123. 不可手术的局部晚期非小细胞肺癌的无放疗方案：我们准备好迎接这一转变了吗？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41082894](https://pubmed.ncbi.nlm.nih.gov/41082894)
**期刊：** The Lancet. Oncology
**PMID：** 41082894
**DOI：** 10.1016/S1470-2045(25)00485-1

### 第一部分 原文与翻译

**英文原标题：** Radiotherapy-free approach in inoperable locally advanced non-small-cell lung cancer: are we ready for this shift?

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

本文聚焦于不可手术的局部晚期非小细胞肺癌（NSCLC）治疗中的一个前沿议题，即是否能采用“去放疗”策略。文章可能基于免疫及靶向治疗的最新进展，前瞻性地探讨了单纯全身治疗替代当前放化疗联合免疫巩固这一标准模式的潜力与风险。这篇文章以其深刻的诘问，旨在引发学界对治疗范式的深度思考，对未来的临床试验设计和个体化治疗决策具有重要的启发意义。

---

## 124. 免放射治疗：帕博利珠单抗联合化疗用于PD-L1肿瘤比例评分≥50%的局部晚期非小细胞肺癌的治疗（Evolution试验）：一项多中心、单臂、2期研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41082893](https://pubmed.ncbi.nlm.nih.gov/41082893)
**期刊：** The Lancet. Oncology
**PMID：** 41082893
**DOI：** 10.1016/S1470-2045(25)00462-0

### 第一部分 原文与翻译

**英文原标题：** Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study.

**英文摘要原文：**
BACKGROUND: The standard of care for unresectable, locally advanced non-small-cell lung cancer (NSCLC) is chemoradiotherapy followed by durvalumab. This study (Evolution trial WJOG11819L) aimed to evaluate the efficacy and safety of radiotherapy-free pembrolizumab and chemotherapy in patients with unresectable, locally advanced NSCLC with a PD-L1 tumour proportion score (TPS) of 50% or higher.

METHODS: This prospective, multicentre, single-arm, phase 2 study was conducted in nine institutes in Japan. Inclusion criteria were age 20 years or older, histologically confirmed unresectable, locally advanced NSCLC with a PD-L1 TPS of 50% or higher, an Eastern Cooperative Oncology Group performance status of 0 or 1, at least one measurable lesion, no previous systemic therapy, and adequate organ function. Patients received intravenous induction therapy comprising pembrolizumab 200 mg every 3 weeks plus platinum-based chemotherapy for four cycles: either cisplatin 75 mg/m or carboplatin (area under the curve [AUC] 5 for non-squamous NSCLC, AUC 6 for squamous NSCLC) plus pemetrexed 500 mg/m (non-squamous NSCLC) or nanoparticle albumin-bound paclitaxel 100 mg/m on days 1, 8, and 15 (squamous NSCLC). This was followed by maintenance therapy comprising intravenous pembrolizumab (200 mg) with or without intravenous pemetrexed (500 mg/m) every 3 weeks for up to 2 years. The primary endpoint was 2-year progression-free survival and was assessed in the full analysis set (ie, all patients who met the eligibility criteria and received at least one dose of study treatment). The safety analysis set included all patients who received at least one dose of study treatment and had at least one post-treatment safety assessment. This trial was registered with ClinicalTrials.gov (NCT04153734) and is complete.

FINDINGS: Between May 18, 2020, and Feb 22, 2022, 21 patients were assessed for eligibility and all were enrolled. Median age was 73 years (IQR 68-80); 16 (76%) patients were male; race and ethnicity data were not collected. Three (14%) patients discontinued and 18 (86%) patients completed the induction therapy; eight (38%) patients discontinued during maintenance therapy and ten (48%) patients completed the maintenance therapy. Median follow-up was 32·5 months (IQR 26·2-39·5). The 2-year progression-free survival rate was 67% (90% CI 46-83). The most common grade 3 or worse adverse events were neutropenia (eight [38%] of 21 patients), leukopenia (four [19%]), and pneumonia (three [14%]). Serious adverse events occurred in seven (33%) patients. No treatment-related deaths were reported.

INTERPRETATION: These findings suggest that pembrolizumab combined with platinum-based chemotherapy, without radiotherapy, might provide a feasible and promising alternative treatment strategy for patients with unresectable, locally advanced NSCLC with a PD-L1 TPS of 50% or higher.

**中文摘要译文：**
背景：不可切除的局部晚期非小细胞肺癌（NSCLC）的标准治疗是放化疗后继以度伐利尤单抗。本研究（Evolution试验 WJOG11819L）旨在评估在PD-L1肿瘤比例评分（TPS）≥50%的不可切除局部晚期NSCLC患者中，免放射治疗的帕博利珠单抗联合化疗方案的有效性和安全性。

方法：这是一项在日本九家机构进行的前瞻性、多中心、单臂、2期研究。纳入标准为：年龄≥20岁，经组织学确诊的PD-L1 TPS≥50%的不可切除局部晚期NSCLC，美国东部肿瘤协作组（ECOG）体能状态评分为0或1，至少有一个可测量病灶，无既往全身性治疗史，以及足够的器官功能。患者接受静脉诱导治疗，包括帕博利珠单抗200 mg（每3周一次）联合铂类为基础的化疗，共四个周期：对于非鳞状NSCLC，为顺铂75 mg/m²或卡铂（曲线下面积[AUC] 5）加培美曲塞500 mg/m²；对于鳞状NSCLC，为卡铂（AUC 6）加纳米白蛋白紫杉醇100 mg/m²（第1、8、15天）。随后进行维持治疗，包括静脉注射帕博利珠单抗（200 mg），联合或不联合静脉注射培美曲塞（500 mg/m²），每3周一次，最多持续2年。主要终点是2年无进展生存率，并在全分析集（即所有符合入组标准并接受了至少一剂研究治疗的患者）中进行评估。安全性分析集包括所有接受了至少一剂研究治疗并进行了至少一次治疗后安全性评估的患者。该试验已在ClinicalTrials.gov注册（NCT04153734），并已完成。

结果：在2020年5月18日至2022年2月22日期间，共评估了21名患者的资格，并全部入组。中位年龄为73岁（IQR 68-80）；16名（76%）患者为男性；未收集种族和民族数据。3名（14%）患者中止了诱导治疗，18名（86%）患者完成了诱导治疗；8名（38%）患者在维持治疗期间中止，10名（48%）患者完成了维持治疗。中位随访时间为32.5个月（IQR 26.2-39.5）。2年无进展生存率为67%（90% CI 46-83）。最常见的3级或更高级别的不良事件是中性粒细胞减少症（21名患者中的8名[38%]）、白细胞减少症（4名[19%]）和肺炎（3名[14%]）。7名（33%）患者发生了严重不良事件。未报告与治疗相关的死亡事件。

结论：这些研究结果表明，对于PD-L1 TPS≥50%的不可切除局部晚期NSCLC患者，帕博利珠单抗联合铂类化疗的免放疗方案可能是一种可行且有前景的替代治疗策略。

### 第二部分 AI 大师评价

本研究（Evolution试验）旨在为PD-L1高表达（TPS≥50%）的不可切除局部晚期非小细胞肺癌患者，探索一种免除放射治疗的新方案。通过一项小规模的2期单臂研究，该试验评估了帕博利珠单抗联合化疗的疗效与安全性，并取得了令人鼓舞的67%的两年无进展生存率。其核心价值在于，为不适合或希望避免放疗毒性的特定患者群体提供了一个极具前景的替代治疗选择，挑战了现有的同步放化疗标准。然而，该研究的样本量小且为非对照设计，其结论的普适性仍需更大规模的随机对照试验来进一步验证。

---

## 125. 乳腺癌全基因组测序：是否已为临床应用做好准备？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41072454](https://pubmed.ncbi.nlm.nih.gov/41072454)
**期刊：** The Lancet. Oncology
**PMID：** 41072454
**DOI：** 10.1016/S1470-2045(25)00428-0

### 第一部分 原文与翻译

**英文原标题：** Whole-genome sequencing in breast cancer: is it ready for clinical application?

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

根据该文献标题判断，这可能是一篇综述或评论性文章，旨在探讨全基因组测序（WGS）技术在乳腺癌临床实践中的应用前景与挑战。文章可能系统性地评估了WGS在揭示乳腺癌复杂基因组图谱、指导靶向治疗及预测预后方面的巨大潜力。同时，作者可能也深入分析了阻碍其广泛应用的因素，如成本效益、数据解读的复杂性以及临床有效性的验证等。该文对于推动精准医疗在乳腺癌领域的应用具有重要的指导意义，为临床医生和研究者提供了关于WGS技术转化应用的现实考量和未来方向。

---

## 126. 全基因组数据结合死亡率统计在英国乳腺癌患者中的临床潜力：一项回顾性分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41072453](https://pubmed.ncbi.nlm.nih.gov/41072453)
**期刊：** The Lancet. Oncology
**PMID：** 41072453
**DOI：** 10.1016/S1470-2045(25)00400-0

### 第一部分 原文与翻译

**英文原标题：** Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis.

**英文摘要原文：**
BACKGROUND: Breast cancer is the most frequently diagnosed cancer in women. Survival is generally considered favourable, yet some patients remain at risk of early death. We aimed to assess whether comprehensive whole-genome sequencing (WGS) linked to mortality data could add prognostic value to existing clinical measures and identify patients who might respond to targeted therapeutics.

METHODS: In this integrative, retrospective analysis, we analysed 2445 breast cancer tumours (any stage and molecular subtype) collected from 2403 patients recruited through 13 National Health Service Genomic Medicine Centres or hospitals in England affiliated to the 100 000 Genomes Project (100kGP) between 2012 and 2018. We linked 2208 (90%) cases with clinical data; mortality data were obtained for 1188 patients. Following high-depth WGS of tumour and matched normal DNA, we performed comprehensive WGS profiling seeking driver mutations, mutational signatures, and compound algorithmic scores for homologous recombination repair deficiency (HRD), mismatch repair deficiency, and tumour mutational burden. Data from 1803 additional patients with breast cancer from three independent cohorts were used to validate various findings. To evaluate the prognostic value of WGS features, we performed univariable and multivariable Cox regression on data from patients with stage I-III, ER-positive, HER2-negative breast cancer with a cancer-specific mortality endpoint (around 5-year follow-up).

FINDINGS: Among 2445 tumours in the 100kGP breast cancer cohort, we observed genomic characteristics with immediate personalised medicine potential in 656 (26·8%), including features reporting HRD (298 [12·2%] total cases and 76 [6·3%] ER-positive, HER2-negative cases), highly individualised driver events, mutations underpinning resistance to endocrine therapy, and mutational signatures indicating therapeutic vulnerabilities. 373 (15·2%) cases had WGS features with potential for translational research, including compromised base excision repair and non-homologous end-joining dependency. Structural variation burden (hazard ratio 3·9 [95 CI% 2·4-6·2]; p<0·0001), high levels of APOBEC signatures (2·5 [1·6-4·1]; p<0·0001), and TP53 drivers (3·9 [2·4-6·2]; p<0·0001) were independently prognostic of customary clinical measures (age at diagnosis, stage, and grade) in patients with ER-positive, HER2-negative breast cancer. We developed a prognosticator for ER-positive, HER2-negative breast cancer capable of identifying patients who require either increased intervention or therapy de-escalation, validating the framework in the independent Swedish Cancerome Analysis Network-Breast (SCAN-B) dataset.

INTERPRETATION: We show that breast cancer genomes are rich in predictive and prognostic value. We propose a two-step model for effective clinical application. First, the identification of candidates for targeted therapies or clinical trials using highly individualised genomic markers. Second, for patients without such features, the implementation of enhanced prognostication using genomic features alongside existing clinical decision-making factors.

FUNDING: National Institute of Health Research, Breast Cancer Research Foundation, Dr Josef Steiner Cancer Research Award 2019, Basser Gray Prime Award 2020, Cancer Research UK, Sir Jeffrey Cheah Early Career Fellowship, the Mats Paulsson Foundation, the Fru Berta Kamprads Foundation, and the Swedish Research Council.

**中文摘要译文：**
背景：乳腺癌是女性中最常被诊断的癌症。其生存率通常被认为较好，但部分患者仍面临早期死亡的风险。我们旨在评估全面的全基因组测序（WGS）结合死亡率数据是否能为现有临床指标增加预后价值，并识别可能对靶向治疗有反应的患者。

方法：在这项综合性回顾性分析中，我们分析了2445例乳腺癌肿瘤（涵盖所有分期和分子亚型），这些样本收集自2012年至2018年间通过英国13个国家卫生服务基因组医学中心或隶属于“十万基因组计划”（100kGP）的医院招募的2403名患者。我们将2208例（90%）病例与临床数据进行了关联；获取了1188名患者的死亡率数据。在对肿瘤和配对的正常DNA进行高深度WGS后，我们开展了全面的WGS分析，以寻找驱动突变、突变特征以及用于评估同源重组修复缺陷（HRD）、错配修复缺陷和肿瘤突变负荷的复合算法评分。来自三个独立队列的另外1803名乳腺癌患者的数据被用于验证各项发现。为评估WGS特征的预后价值，我们对I-III期、ER阳性、HER2阴性的乳腺癌患者数据进行了单变量和多变量Cox回归分析，并以癌症特异性死亡率为终点（约5年随访）。

发现：在100kGP乳腺癌队列的2445例肿瘤中，我们观察到656例（26.8%）具有直接个体化医疗潜力的基因组特征，包括提示HRD的特征（总计298例[12.2%]，其中ER阳性、HER2阴性病例76例[6.3%]）、高度个体化的驱动事件、构成内分泌治疗耐药基础的突变，以及指示治疗脆弱性的突变特征。373例（15.2%）病例具有可用于转化研究的WGS特征，包括受损的碱基切除修复和非同源末端连接依赖性。在ER阳性、HER2阴性乳腺癌患者中，结构变异负荷（风险比3.9 [95% CI 2.4-6.2]；p<0.0001）、高水平的APOBEC特征（2.5 [1.6-4.1]；p<0.0001）和TP53驱动突变（3.9 [2.4-6.2]；p<0.0001）均是独立于常规临床指标（诊断年龄、分期和分级）的预后因素。我们为ER阳性、HER2阴性乳腺癌开发了一种预后模型，能够识别需要加强干预或降阶梯治疗的患者，并在独立的瑞典癌症组学分析网络-乳腺癌（SCAN-B）数据集中验证了该框架。

解读：我们证明了乳腺癌基因组具有丰富的预测和预后价值。我们提出了一个有效的两步临床应用模型。第一步，使用高度个体化的基因组标志物识别适合靶向治疗或临床试验的候选者。第二步，对于不具备此类特征的患者，在现有临床决策因素的基础上，结合基因组特征实施强化的预后评估。

资金来源：英国国家健康研究所、乳腺癌研究基金会、2019年约瑟夫·施泰纳博士癌症研究奖、2020年巴塞尔·格雷总理奖、英国癌症研究中心、杰弗里·谢赫爵士早期职业奖学金、马茨·保尔森基金会、贝塔·坎普拉德夫人基金会和瑞典研究理事会。

### 第二部分 AI 大师评价

这项发表于《柳叶刀·肿瘤学》的研究，通过对英国大规模乳腺癌患者队列进行全基因组测序并关联死亡率数据，旨在挖掘基因组学特征的预后价值。研究发现，结构变异负荷、APOBEC突变特征和TP53驱动突变是独立于传统临床指标的强预后因素，尤其是在ER阳性/HER2阴性患者中。该研究不仅验证了全基因组数据在精准预后评估中的巨大潜力，还提出了一个两步走的临床应用模型，为实现乳腺癌患者的个体化治疗和分层管理提供了重要的循证依据和创新思路。

---

## 127. 晚期非小细胞肺癌患者接受CTLA-4与PD-L1/PD-1双重阻断治疗的长期总生存期及基于生物标志物的亚组分析：一项系统综述与重建个体患者数据的荟萃分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41038207](https://pubmed.ncbi.nlm.nih.gov/41038207)
**期刊：** The Lancet. Oncology
**PMID：** 41038207
**DOI：** 10.1016/S1470-2045(25)00429-2

### 第一部分 原文与翻译

**英文原标题：** Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis.

**英文摘要原文：**
BACKGROUND: Immune checkpoint inhibitors targeting PD-L1 or PD-1 as monotherapy or combined with CTLA-4 inhibitors or chemotherapy (or both) are the standard of care for patients with advanced non-small-cell lung cancer (NSCLC). However, it remains unclear which patients benefit from the addition of CTLA-4 inhibitors. We aimed to evaluate whether dual checkpoint blockade with CTLA-4 and PD-L1 or PD-1 inhibitors provides similar efficacy to PD-L1 or PD-1 inhibitor monotherapy, or whether these strategies produce distinct outcomes across NSCLC subpopulations.

METHODS: We conducted a search of PubMed, MEDLINE, and Embase for randomised phase 3 trials published from database inception to Nov 21, 2024, that investigated PD-L1 or PD-1 inhibitors, with or without CTLA-4 inhibitors, in patients with advanced NSCLC. We focused on studies reporting Kaplan-Meier survival data at 5 years or biomarker analyses based on PD-L1, KRAS, and STK11 mutational status. Individual patient data were extracted from Kaplan-Meier curves with WebPlotDigitizer version 5 and reconstructed with the IPDfromKM method. The primary endpoint of the study was 5-year overall survival in the overall population and in subpopulations based on PD-L1 tumour proportion score (TPS), tumour histology, and mutational status (mutant vs wild-type) of KRAS and STK11. This study was registered with PROSPERO, CRD420251081707.

FINDINGS: The initial search yielded 1026 results, and six randomised clinical trials met the eligibility criteria and were included. Among the 2881 patients eligible for analysis (838 [29·1%] female and 2043 [70·9%] male), 1282 received dual CTLA-4 and PD-L1 or PD-1 blockade and 1599 received single PD-L1 or PD-1 blockade. Patients treated with dual CTLA-4 and PD-L1 or PD-1 blockade had similar median overall survival compared with those treated with single PD-L1 or PD-1 inhibition (16·1 months [95% CI 15·0-17·8] vs 16·9 months [15·5-18·3]; HR 0·95 [95% CI 0·87-1·03], p=0·19). Median overall survival was significantly longer with dual CTLA-4 and PD-L1 or PD-1 blockade among patients with PD-L1 TPS less than 1% versus those treated with single PD-L1 or PD-1 inhibition (15·5 months [95% CI 13·6-18·5] vs 14·5 months [13·4-15·9]; HR 0·85 [95% CI 0·74-0·98], p=0·021), with 5-year overall survival rates of 16·6% (95% CI 13·4-20·6) versus 9·3% (7·0-12·3), respectively. Median overall survival in patients with tumours harbouring STK11 mutations was also significantly longer with dual CTLA-4 and PD-L1 or PD-1 blockade compared with single PD-L1 or PD-1 inhibition (13·9 months [95% CI 9·8-20·8] vs 7·8 months [6·4-12·9]; HR 0·67 [95% CI 0·49-0·91], p=0·012). However, no significant differences in overall survival were found between treatment groups by tumour histology (squamous vs non-squamous NSCLC) or by KRAS mutational status.

INTERPRETATION: Compared with single PD-L1 or PD-1 inhibition, dual immune checkpoint blockade with CTLA-4 and PD-L1 or PD-1 inhibitors was associated with improved overall survival in patients with advanced NSCLC and PD-L1 TPS less than 1% and in those with STK11 mutations, but not in the overall population. Prospective validation of these results in clinical trials is warranted.

FUNDING: NextGenerationUE.

**中文摘要译文：**
背景：靶向PD-L1或PD-1的免疫检查点抑制剂（作为单药治疗，或与CTLA-4抑制剂或化疗联合使用，或两者兼有）是晚期非小细胞肺癌（NSCLC）患者的标准治疗方案。然而，目前尚不清楚哪些患者能从加用CTLA-4抑制剂中获益。本研究旨在评估CTLA-4与PD-L1或PD-1抑制剂的双重检查点阻断与PD-L1或PD-1抑制剂单药治疗的疗效是否相似，以及这些策略是否在NSCLC不同亚群中产生不同结局。

方法：我们在PubMed、MEDLINE和Embase数据库中检索了自建库至2024年11月21日期间发表的随机对照3期临床试验，这些试验研究了PD-L1或PD-1抑制剂（无论是否联用CTLA-4抑制剂）在晚期NSCLC患者中的应用。我们重点关注了报告5年生存期Kaplan-Meier数据或基于PD-L1、KRAS和STK11突变状态的生物标志物分析的研究。我们使用WebPlotDigitizer 5.0版本从Kaplan-Meier曲线中提取个体患者数据，并采用IPDfromKM方法进行重建。本研究的主要终点是总体人群以及根据PD-L1肿瘤比例评分（TPS）、肿瘤组织学类型、KRAS和STK11突变状态（突变型 vs 野生型）划分的亚组人群的5年总生存率。本研究已在PROSPERO注册，注册号为CRD420251081707。

结果：初步检索共获得1026项结果，其中六项随机临床试验符合纳入标准并被纳入分析。在符合分析条件的2881名患者中（838名[29.1%]为女性，2043名[70.9%]为男性），1282名接受了CTLA-4与PD-L1或PD-1双重阻断治疗，1599名接受了PD-L1或PD-1单药阻断治疗。与接受PD-L1或PD-1单药抑制剂治疗的患者相比，接受CTLA-4与PD-L1或PD-1双重阻断治疗的患者的中位总生存期相似（16.1个月 [95% CI 15.0–17.8] vs 16.9个月 [15.5–18.3]；HR 0.95 [95% CI 0.87–1.03]，p=0.19）。在PD-L1 TPS低于1%的患者中，与接受PD-L1或PD-1单药抑制剂治疗的患者相比，接受CTLA-4与PD-L1或PD-1双重阻断治疗的患者的中位总生存期显著更长（15.5个月 [95% CI 13.6–18.5] vs 14.5个月 [13.4–15.9]；HR 0.85 [95% CI 0.74–0.98]，p=0.021），其5年总生存率分别为16.6%（95% CI 13.4–20.6）和9.3%（7.0–12.3）。在肿瘤携带STK11突变的患者中，与接受PD-L1或PD-1单药抑制剂治疗的患者相比，接受CTLA-4与PD-L1或PD-1双重阻断治疗的患者的中位总生存期也显著更长（13.9个月 [95% CI 9.8–20.8] vs 7.8个月 [6.4–12.9]；HR 0.67 [95% CI 0.49–0.91]，p=0.012）。然而，按肿瘤组织学类型（鳞状 vs 非鳞状NSCLC）或KRAS突变状态分层后，各治疗组间的总生存期未发现显著差异。

解读：与PD-L1或PD-1单药抑制剂治疗相比，CTLA-4与PD-L1或PD-1抑制剂的双重免疫检查点阻断与PD-L1 TPS低于1%以及携带STK11突变的晚期NSCLC患者的总生存期改善相关，但在总体人群中则无此关联。这些结果有待于前瞻性临床试验证实。

资金来源：NextGenerationUE。

### 第二部分 AI 大师评价

本研究通过一项创新的重建个体患者数据荟萃分析，旨在精准识别能从CTLA-4联合PD-1/PD-L1抑制剂双免治疗中获益的晚期非小细胞肺癌（NSCLC）患者亚群。研究核心发现，虽然双免疗法对总体人群的长期生存无显著优势，但它显著改善了PD-L1表达阴性（TPS < 1%）和STK11突变这两类特定患者群体的总生存期。该研究结果对于优化NSCLC免疫治疗策略、实现个体化精准用药具有重要的临床指导价值，尤其为STK11突变等难治性亚组提供了新的治疗证据，但其结论仍需前瞻性研究的进一步验证。

---

## 128. 小鼠结肠癌的干细胞来源

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41034495](https://pubmed.ncbi.nlm.nih.gov/41034495)
**期刊：** Nature reviews. Molecular cell biology
**PMID：** 41034495
**DOI：** 10.1038/s41580-025-00910-8

### 第一部分 原文与翻译

**英文原标题：** Stem cell sources of colon cancer in mice.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
摘要不可用。

### 第二部分 AI 大师评价

该文献标题表明，这是一篇关于小鼠模型中结肠癌干细胞来源的探讨。鉴于其发表在顶尖综述期刊《自然综述：分子细胞生物学》，该文很可能系统性地总结了鉴定结肠癌起始细胞的研究进展、关键分子通路和现有争议。此综述对于理解结肠癌的肿瘤发生机制、开发靶向干细胞的预防和治疗策略具有重要的指导价值。由于摘要缺失，文章的具体论点和深度有待阅读原文揭示。

---

## 129. RAD51介导的同源重组是一条促癌驱动通路。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40993217](https://pubmed.ncbi.nlm.nih.gov/40993217)
**期刊：** Oncogene
**PMID：** 40993217
**DOI：** 10.1038/s41388-025-03583-x

### 第一部分 原文与翻译

**英文原标题：** RAD51-mediated homologous recombination is a pro-tumour driver pathway.

**英文摘要原文：**
Genetic instability is a hallmark of cancer cells. Homologous recombination (HR) plays a pivotal role in maintaining genome stability through its DNA repair and replication fork escort functions. Therefore, HR is classified as a tumour suppressor pathway. Consistently, many HR genes are mutated in cancer, especially in hereditary breast and ovarian cancer. However, although RAD51 controls the central steps of HR, no RAD51 mutations are associated with cancer predisposition, constituting the "RAD51 paradox". One of the potential explanations for the "RAD51 paradox" is that mutations affecting mediator/accessory genes (such as BRCA1 or BRCA2) in cancer result in the absence of RAD51 on damaged DNA, leaving access to alternative exclusively mutagenic repair processes, such as single-strand annealing (SSA) or alternative end-joining (A-EJ), which can rescue some cell viability but also increase genetic instability. This raises the question of whether cancer predisposition actually results from HR deficiency itself or from alternative, nonconservative repair pathways. One study assessing this question in a mouse model revealed that decreasing RAD51 HR activity without stimulating SSA or A-EJ in vivo not only does not favour tumorigenesis but rather protects against it. These data suggest that RAD51-controlled HR is not a tumour suppressor but rather favours tumour progression. Cancer cells are highly proliferative, actively replicating their genomes, and are therefore subjected to high replication stress; pathways enabling them to cope with this massive replication stress, such as HR, should help them survive and proliferate, contrary to the belief dogma that HR acts as a tumour suppressor pathway. We propose that HR/RAD51, through its essential role in overcoming replication stress, should facilitate cancer progression as soon as early pretumorigenic hyperplasia states that trigger an active replication program, challenging commonly accepted views.

**中文摘要译文：**
遗传不稳定性是癌细胞的一个标志。同源重组（HR）通过其DNA修复和复制叉护航功能，在维持基因组稳定性中发挥着关键作用。因此，HR被归类为一种抑癌通路。与此一致的是，许多HR基因在癌症中发生突变，尤其是在遗传性乳腺癌和卵巢癌中。然而，尽管RAD51控制着HR的核心步骤，但目前没有发现与癌症易感性相关的RAD51突变，这构成了“RAD51悖论”。对于“RAD51悖论”的一种潜在解释是，癌症中影响介导/辅助基因（如BRCA1或BRCA2）的突变导致受损DNA上RAD51的缺失，从而为其他完全致突变的修复过程（如单链退火（SSA）或替代性末端连接（A-EJ））提供了机会，这些过程虽能挽救部分细胞活力，但也会增加遗传不稳定性。这就提出了一个问题：癌症易感性究竟是由HR缺陷本身引起的，还是由替代性的、非保守的修复通路所致？一项在小鼠模型中评估该问题的研究显示，在体内降低RAD51的HR活性而不刺激SSA或A-EJ，不仅不会促进肿瘤发生，反而能起到抑制作用。这些数据表明，由RAD51控制的HR并非肿瘤抑制因子，反而会促进肿瘤进展。癌细胞具有高度增殖性，活跃地复制其基因组，因此承受着巨大的复制压力；能够帮助它们应对这种巨大复制压力的通路（如HR），应有助于其生存和增殖，这与HR是抑癌通路的传统信条相悖。我们提出，HR/RAD51通过其在克服复制压力中的关键作用，早在触发活跃复制程序的肿瘤前增生阶段就可能促进癌症进展，这挑战了普遍接受的观点。

### 第二部分 AI 大师评价

本研究颠覆性地挑战了同源重组（HR）作为抑癌通路的传统观念，提出RAD51介导的HR实则是一条促癌驱动通路。文章通过剖析“RAD51悖论”，并引用小鼠模型等证据，论证了HR在帮助癌细胞应对复制压力、维持其生存和增殖中的关键作用，而非抑制肿瘤。这一观点极具创新性，不仅为理解肿瘤发生发展提供了全新视角，也对开发靶向HR通路的抗癌疗法具有重要的启示意义，可能将治疗窗口从HR缺陷型肿瘤扩展至HR功能完整的肿瘤。

---

## 130. MARIPOSA研究证实amivantamab-lazertinib联合方案带来总生存获益

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40987920](https://pubmed.ncbi.nlm.nih.gov/40987920)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 40987920
**DOI：** 10.1038/s41571-025-01081-3

### 第一部分 原文与翻译

**英文原标题：** MARIPOSA demonstrates overall survival benefit from amivantamab-lazertinib.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题报道了关键临床试验MARIPOSA研究的核心发现。该研究旨在评估amivantamab与lazertinib联合用药方案在一线治疗特定类型肺癌（很可能为EGFR突变型非小细胞肺癌）患者中的疗效。其最重要的结论是，该联合方案展现出了总生存期（OS）获益。这一发现具有重大的临床意义，可能改变相关患者群体的标准治疗策略，为临床医生提供了更优效的治疗选择。

---

## 131. FPR3维持肿瘤相关巨噬细胞的免疫抑制功能并加速胃腺癌的进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40987893](https://pubmed.ncbi.nlm.nih.gov/40987893)
**期刊：** Oncogene
**PMID：** 40987893
**DOI：** 10.1038/s41388-025-03578-8

### 第一部分 原文与翻译

**英文原标题：** FPR3 sustains the immunosuppression of tumor-associated macrophages and accelerates the progression of gastric adenocarcinoma.

**英文摘要原文：**
Tumor-associated macrophages (TAMs) play a critical role in promoting tumor progression and represent a promising target for immunotherapeutic intervention. However, the phenotypic characteristics and polarization dynamics of TAMs remain poorly understood, largely due to the complex cellular heterogeneity within the tumor microenvironment. In this study, we comprehensively characterize the heterogeneity of TAMs in gastric adenocarcinoma (GA), with a particular focus on immunosuppressive subsets. Our findings demonstrate that TAMs undergo multidirectional differentiation and exhibit diverse immunoregulatory functions. Among them, FPR3⁺ macrophages are identified as a distinct immunosuppressive population associated with poor patient prognosis. Functional assays using shRNA-mediated knockdown and specific agonists reveal that FPR3 regulates macrophage proliferation and polarization and is essential for TAM formation and maintenance. Mechanistically, FPR3 upregulates FZD7 and CCDC88C, leading to activation of the intracellular Wnt/PCP pathway and downstream JNK signaling, thereby promoting TAM development. Collectively, our study identifies FPR3 as a novel marker of immunosuppressive TAMs, elucidates its mechanistic role in macrophage plasticity, and offers new insights into potential therapeutic strategies for targeting the tumor microenvironment in GA.

**中文摘要译文：**
肿瘤相关巨噬细胞（TAMs）在促进肿瘤进展中扮演关键角色，是免疫治疗干预的一个有前景的靶点。然而，由于肿瘤微环境中复杂的细胞异质性，TAMs的表型特征和极化动态仍知之甚少。在本研究中，我们全面描绘了胃腺癌（GA）中TAMs的异质性，特别关注了其免疫抑制性亚群。我们的研究结果表明，TAMs经历多向分化并展现出多样的免疫调节功能。其中，FPR3⁺巨噬细胞被鉴定为一个与患者不良预后相关的独特免疫抑制性群体。使用shRNA介导的基因敲降和特异性激动剂的功能性实验揭示，FPR3调节巨噬细胞的增殖和极化，并且对于TAM的形成与维持至关重要。从机制上讲，FPR3上调FZD7和CCDC88C的表达，导致细胞内Wnt/PCP通路及下游JNK信号的激活，从而促进TAM的发育。总而言之，我们的研究将FPR3鉴定为免疫抑制性TAMs的一个新标志物，阐明了其在巨噬细胞可塑性中的机制性作用，并为针对GA肿瘤微环境的潜在治疗策略提供了新见解。

### 第二部分 AI 大师评价

本研究聚焦于胃腺癌（GA）的肿瘤微环境，旨在揭示肿瘤相关巨噬细胞（TAMs）的异质性及其调控机制。研究通过综合分析，成功鉴定出一个与患者不良预后相关的关键免疫抑制性巨噬细胞亚群——FPR3⁺ TAMs。核心发现是，FPR3通过激活Wnt/PCP-JNK信号通路，驱动TAMs的形成与功能维持。这项工作不仅为理解TAMs的复杂性提供了新视角，更重要的是将FPR3确立为一个有潜力的预后生物标志物和免疫治疗新靶点，为胃癌的精准治疗策略开发带来启示。

---

## 132. 人类与非人灵长类动物的衰老生物标志物

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40935898](https://pubmed.ncbi.nlm.nih.gov/40935898)
**期刊：** Nature reviews. Molecular cell biology
**PMID：** 40935898
**DOI：** 10.1038/s41580-025-00883-8

### 第一部分 原文与翻译

**英文原标题：** Biomarkers of ageing of humans and non-human primates.

**英文摘要原文：**
Ageing is characterized by progressive functional decline and increase in disease risk and imposes substantial burdens on human health. Identifying aging biomarkers in primates is crucial for advancing our understanding of human ageing and for informing interventions to mitigate age-related pathologies. However, a comprehensive grasp of these biomarkers is still lacking, hindering the translation of fundamental research into clinical practice. In this Review, we present the current knowledge on biomarkers of ageing at the cellular, tissue and organism levels in humans and non-human primates. Through systematic analysis of representative biomarkers across diverse biological contexts and scales, we discuss both the variability and the conservation of ageing-associated physiological changes, underscoring their importance in assessing and intervening in the ageing process. Finally, we critically assess challenges in ageing research and outline strategic avenues for future investigation.

**中文摘要译文：**
衰老的特征是进行性的功能衰退和疾病风险增加，给人类健康带来了沉重负担。在灵长类动物中识别衰老生物标志物，对于加深我们对人类衰老的理解以及为旨在减轻年龄相关病理的干预措施提供信息至关重要。然而，目前仍缺乏对这些生物标志物的全面掌握，这阻碍了基础研究向临床实践的转化。在这篇综述中，我们介绍了在细胞、组织和机体层面，关于人类和非人灵长类动物衰老生物标志物的现有知识。通过对不同生物学背景和尺度下代表性生物标志物的系统性分析，我们探讨了与衰老相关的生理变化的变异性与保守性，并强调了它们在评估和干预衰老过程中的重要性。最后，我们批判性地评估了衰老研究中的挑战，并为未来的研究规划了战略途径。

### 第二部分 AI 大师评价

这篇综述系统性地整合了当前关于人类及非人灵长类动物在细胞、组织到机体多层面的衰老生物标志物研究。文章的核心价值在于，它不仅梳理了代表性标志物，还深入探讨了衰老生理变化的变异性与保守性，为评估和干预衰老过程提供了理论依据。通过批判性地分析现有研究的挑战并指明未来方向，该文献为推动衰老基础研究向临床转化提供了重要的路线图，对老年医学和健康老龄化领域具有显著的指导意义。

---

## 133. 一种新型靶向FAP的抗体-艾沙替康偶联物通过逆转胰腺癌的免疫抑制微环境来增强免疫检查点阻断疗效

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40931050](https://pubmed.ncbi.nlm.nih.gov/40931050)
**期刊：** Oncogene
**PMID：** 40931050
**DOI：** 10.1038/s41388-025-03567-x

### 第一部分 原文与翻译

**英文原标题：** A novel FAP-targeting antibody-exatecan conjugate improves immune checkpoint blockade by reversing immunosuppressive microenvironment in pancreatic cancer.

**英文摘要原文：**
Pancreatic cancer is a highly aggressive malignancy with a dismal prognosis, characterized by a complex tumor microenvironment that promotes immunosuppression and limits the efficacy of immune checkpoint blockade (ICB) therapy. Fibroblast activation protein (FAP) is overexpressed in the tumor stroma and represents a promising target for therapeutic intervention. Here, we developed a novel antibody-drug conjugate (ADC) targeting FAP, and investigated its anti-tumor activity and ability to enhance ICB efficacy in pancreatic cancer. We conjugated a humanized anti-FAP antibody with the potent topoisomerase I inhibitor exatecan to generate a novel FAP-targeting ADC (FAP-ADC) with a drug-to-antibody ratio of eight. The cytotoxicity and internalization of FAP-ADC were evaluated in vitro using FAP-expressing cell lines, and its anti-tumor activity was assessed in vivo using cell-derived xenograft models. Mechanistic studies revealed that FAP-ADC synergistically improved the efficacy of anti-PD-L1 antibody in vivo by leading to an increased level of M1-polarized macrophages and reduced abundance of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment. Furthermore, FAP-ADC treatment enhanced the infiltration of CD8 T cells into the tumor and upregulated the expression of pro-inflammatory cytokines. Combination therapy with FAP-ADC and anti-PD-L1 antibodies resulted in superior anti-tumor efficacy compared to either monotherapy. Collectively, our novel FAP-targeting ADC exerts potent anti-tumor activity in pancreatic cancer by selectively depleting FAP-expressing cells and reversing the immunosuppressive tumor microenvironment. The combination of FAP-ADC with ICB therapy represents a promising therapeutic strategy to improve the treatment outcomes for patients with this fatal cancer.

**中文摘要译文：**
胰腺癌是一种侵袭性极强、预后极差的恶性肿瘤，其特点是复杂的肿瘤微环境会促进免疫抑制，并限制免疫检查点阻断（ICB）疗法的疗效。成纤维细胞活化蛋白（FAP）在肿瘤基质中过度表达，是治疗干预的一个有前景的靶点。本研究中，我们开发了一种靶向FAP的新型抗体药物偶联物（ADC），并探究了其在胰腺癌中的抗肿瘤活性以及增强ICB疗效的能力。我们将人源化的抗FAP抗体与强效拓扑异构酶I抑制剂艾沙替康（exatecan）进行偶联，构建了一种药物抗体比为8的新型靶向FAP的ADC（FAP-ADC）。我们利用表达FAP的细胞系在体外评估了FAP-ADC的细胞毒性和内化作用，并利用细胞源性异种移植模型在体内评估了其抗肿瘤活性。机制研究表明，FAP-ADC通过增加肿瘤微环境中M1型极化巨噬细胞的水平，并减少髓源性抑制细胞和调节性T细胞的丰度，在体内协同增强了抗PD-L1抗体的疗效。此外，FAP-ADC治疗增强了CD8+ T细胞向肿瘤的浸润，并上调了促炎细胞因子的表达。与任一单药治疗相比，FAP-ADC与抗PD-L1抗体的联合疗法显示出更优越的抗肿瘤疗效。总而言之，我们研发的新型靶向FAP的ADC通过选择性清除表达FAP的细胞并逆转免疫抑制性肿瘤微环境，在胰腺癌中发挥了强大的抗肿瘤活性。FAP-ADC与ICB疗法的联合应用，为改善这种致命癌症患者的治疗结局提供了一种有前景的治疗策略。

### 第二部分 AI 大师评价

本研究针对胰腺癌治疗的难点，创新性地开发了一种靶向肿瘤基质中FAP蛋白的抗体药物偶联物（FAP-ADC）。研究通过体内外实验证实，该ADC不仅能直接发挥抗肿瘤作用，更关键的是能够重塑肿瘤免疫微环境，将其从“冷”肿瘤转变为“热”肿瘤。其核心发现是FAP-ADC能协同增强PD-L1抑制剂的疗效，为素来对免疫治疗不敏感的胰腺癌提供了一种极具潜力的联合治疗新策略，具有重要的临床转化价值。

---

## 134. LEF1通过上调PARP1和NUMA1赋予卵巢癌对DNA损伤化疗的耐药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40931049](https://pubmed.ncbi.nlm.nih.gov/40931049)
**期刊：** Oncogene
**PMID：** 40931049
**DOI：** 10.1038/s41388-025-03561-3

### 第一部分 原文与翻译

**英文原标题：** LEF1 confers resistance to DNA-damaging chemotherapies through upregulation of PARP1 and NUMA1 in ovarian cancer.

**英文摘要原文：**
Resistance to platinum-based drugs and PARP inhibitors (PARPi) is the leading cause of treatment failure in epithelial ovarian cancer (EOC). This study aimed to identify resistance mechanisms shared by both. Using bioinformatic analyses, EOC tissues, primary tumor cells and organoids, and chemoresistant cell lines, we identified lymphoid enhancer-binding factor 1 (LEF1) as a candidate, whose expression was increased in both platinum-resistant and PARPi-resistant tumors. Moreover, LEF1 deficiency increased EOC cell sensitivity to cisplatin and PARPi in vitro and in vivo. Mechanistically, LEF1 knockdown promoted double-strand breaks and significantly impaired both homologous recombination and nonhomologous end joining by directly downregulating the transcription of PARP1 and NUMA1. In addition, the LEF1 inhibitor niclosamide increased ovarian cancer sensitivity to Cisplatin and PARPi in patient-derived organoids and Niraparib-resistant cell lines. These findings indicate that LEF1 is a potential therapeutic target for overcoming resistance to chemotherapy based on platinum and PARPi in EOC.

**中文摘要译文：**
对铂类药物和PARP抑制剂（PARPi）的耐药是上皮性卵巢癌（EOC）治疗失败的主要原因。本研究旨在识别两者共有的耐药机制。通过生物信息学分析、EOC组织、原代肿瘤细胞和类器官以及耐药细胞系，我们鉴定出淋巴增强子结合因子1（LEF1）为一个候选分子，其在铂类耐药和PARPi耐药的肿瘤中表达均增加。此外，LEF1缺陷可增加EOC细胞在体内外对顺铂和PARPi的敏感性。从机制上讲，敲低LEF1可通过直接下调PARP1和NUMA1的转录，促进双链断裂，并显著削弱同源重组和非同源末端连接修复。此外，在患者来源的类器官和尼拉帕利耐药细胞系中，LEF1抑制剂氯硝柳胺可增加卵巢癌对顺铂和PARPi的敏感性。这些发现表明，LEF1是克服EOC中铂类和PARPi化疗耐药的一个潜在治疗靶点。

### 第二部分 AI 大师评价

本研究旨在揭示卵巢癌对铂类药物和PARP抑制剂产生共同耐药性的核心机制。研究综合运用了生物信息学分析、临床样本、类器官及细胞模型，鉴定出关键转录因子LEF1在耐药肿瘤中表达上调。其核心发现是，LEF1通过直接上调PARP1和NUMA1的转录来增强DNA损伤修复能力，从而导致耐药；而抑制LEF1则能有效逆转此耐药性。这项工作不仅揭示了新的耐药通路，更提出了以LEF1为靶点、联合氯硝柳胺等抑制剂来克服卵巢癌治疗瓶颈的创新策略，具有重要的临床转化潜力。

---

## 135. 弥合差距：分子谱分析指导转移性胰腺癌的治疗选择

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40929645](https://pubmed.ncbi.nlm.nih.gov/40929645)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 40929645
**DOI：** 10.1200/JCO-25-01298

### 第一部分 原文与翻译

**英文原标题：** Bridging the Gap: Molecular Profiling to Guide Treatment Selection in Metastatic Pancreatic Cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文虽然没有提供摘要，但其标题揭示了文章的核心主旨，即探讨如何利用分子谱分析来为转移性胰腺癌患者选择更精准的治疗方案。该文很可能是一篇综述或专家评论，旨在总结当前分子指导下治疗胰腺癌的进展与挑战。其临床价值在于倡导个体化治疗新范式，以期改善这一“癌王”的治疗困境，并为未来的临床试验设计和研究方向提供重要启示。

---

## 136. PASS-01研究：一项对比改良FOLFIRINOX方案与吉西他滨/白蛋白紫杉醇方案一线治疗转移性胰腺癌并进行分子相关性分析的随机II期临床试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40929627](https://pubmed.ncbi.nlm.nih.gov/40929627)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 40929627
**DOI：** 10.1200/JCO-25-00436

### 第一部分 原文与翻译

**英文原标题：** PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.

**英文摘要原文：**
PURPOSE: To assess modified folinic acid/leucovorin, fluorouracil, irinotecan, oxaliplatin (FOLFIRINOX [mFFX]) versus gemcitabine/nab-paclitaxel (GnP) in de novo metastatic pancreatic ductal adenocarcinoma (PDAC) and explore predictive biomarkers.

PATIENTS AND METHODS: Patients were randomly assigned 1:1 to mFFX or GnP with exclusion of germline pathogenic variants in or . The primary end point was progression-free survival (PFS) between arms with 0.3 significance. The per-protocol (PP) population included patients who received one dose of chemotherapy. Pretreatment biopsies underwent whole-genome/transcriptome sequencing and patient-derived organoid (PDO) development, providing correlate recommendations at a molecular tumor board and outcomes assessed according to RNA signatures (basal-like classical).

RESULTS: Of 160 patients randomly assigned (80 mFFX, 80 GnP), 140 patients were in the PP population (71 mFFX, 69 GnP), with median follow-up of 8.3 months. The median PFS was 4.0 months for mFFX versus 5.3 months for GnP (hazard ratio [HR], 1.37 [95% CI, 0.97 to 1.92]; = .069) in intention-to-treat. Median overall survival (OS) was 8.5 months with mFFX and 9.7 months with GnP (HR, 1.57 [95% CI, 1.08 to 2.28]; = .017). Genomic data were generated in 94%, transcriptomes in 74%, and PDOs in 50%. The median PFS for those with basal-like was 3.0 (mFFX) and 5.5 (GnP) months ( = .17), and classical PDAC was 6.3 (mFFX) versus 5.4 (GnP) months ( = .36). The median OS in basal-like was 7.5 (mFFX) and 8.9 (GnP) months ( = .75) versus in classical OS was 9.7 (mFFX) and 13.9 (GnP) months ( = .047). Overall, 75 (54%) of patients received second-line treatment, 33/75 (44%) correlate-guided. The median time on second-line treatment was only 2.1 months with a median OS of 5.4 months for a correlate-guided choice versus 4.4 months on a standard chemotherapy approach ( = .45).

CONCLUSION: In the phase II Pancreatic Adenocarcinoma Signature Stratification for Treatment-01 (PASS-01) trial population, PFS was similar between GnP and mFFX; however, OS and safety trends favored GnP. The second-line setting appears inadequate to offer precision choices, given the short survival observed.

**中文摘要译文：**
目的：旨在评估改良亚叶酸/亚叶酸钙、氟尿嘧啶、伊立替康、奥沙利铂（FOLFIRINOX [mFFX]）方案对比吉西他滨/白蛋白紫杉醇（GnP）方案在初治转移性胰腺导管腺癌（PDAC）患者中的疗效，并探索预测性生物标志物。

患者与方法：排除胚系BRCA1或BRCA2致病性变异的患者被1:1随机分配至mFFX组或GnP组。主要研究终点是两组间的无进展生存期（PFS），显著性水平为0.3。符合方案（PP）人群包括至少接受过一剂化疗的患者。治疗前的活检组织进行了全基因组/转录组测序和患者源性类器官（PDO）培养，在分子肿瘤委员会上提供相关建议，并根据RNA分子分型（基底样型vs.经典型）评估结局。

结果：共160名患者被随机分配（mFFX组80人，GnP组80人），其中140名患者属于PP人群（mFFX组71人，GnP组69人），中位随访时间为8.3个月。在意向治疗人群中，mFFX组的中位PFS为4.0个月，GnP组为5.3个月（风险比[HR], 1.37 [95% CI, 0.97至1.92]；P = .069）。mFFX组的中位总生存期（OS）为8.5个月，GnP组为9.7个月（HR, 1.57 [95% CI, 1.08至2.28]；P = .017）。94%的患者生成了基因组数据，74%生成了转录组数据，50%成功培养了PDO。基底样型亚组中，mFFX组和GnP组的中位PFS分别为3.0个月和5.5个月（P = .17）；经典型PDAC亚组中，两组的中位PFS分别为6.3个月和5.4个月（P = .36）。基底样型亚组中，mFFX组和GnP组的中位OS分别为7.5个月和8.9个月（P = .75）；而在经典型亚组中，两组的中位OS分别为9.7个月和13.9个月（P = .047）。总体而言，75名（54%）患者接受了二线治疗，其中33/75名（44%）患者的治疗方案依据分子相关性分析结果指导。二线治疗的中位持续时间仅为2.1个月，分子相关性指导下的治疗选择组中位OS为5.4个月，而标准含化疗方案组为4.4个月（P = .45）。

结论：在II期PASS-01试验人群中，GnP方案与mFFX方案的PFS相似；然而，在OS和安全性趋势方面，GnP方案更具优势。鉴于观察到的生存期较短，二线治疗环境似乎不足以为精准治疗选择提供充分的机会。

### 第二部分 AI 大师评价

PASS-01研究是一项创新的II期随机对照试验，旨在头对头比较mFOLFIRINOX与吉西他滨/白蛋白紫杉醇（GnP）一线治疗转移性胰腺癌的疗效，并前瞻性地利用全基因组、转录组和类器官模型等先进技术探索分子生物标志物以指导治疗。研究主要结果显示，两组的无进展生存期（PFS）无显著差异，但GnP方案在总生存期（OS）和安全性方面显示出更优的趋势。该研究的价值在于将多组学分析深度整合入临床试验，揭示了不同分子亚型（如经典型）对治疗方案的响应差异；然而，研究也凸显了胰腺癌治疗的严峻挑战，即由于患者生存期极短，基于分子标志物指导的二线精准治疗策略难以获得足够的时间窗口来发挥作用，提示未来精准治疗的重心需前移至一线。

---

## 137. 癌细胞外囊泡通过Wnt3-β-catenin通路诱导FOXP3+成纤维细胞并促进肿瘤侵袭

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40926045](https://pubmed.ncbi.nlm.nih.gov/40926045)
**期刊：** Oncogene
**PMID：** 40926045
**DOI：** 10.1038/s41388-025-03552-4

### 第一部分 原文与翻译

**英文原标题：** Extracellular vesicles of cancer cells induce FOXP3+ fibroblasts and facilitate tumor invasion via the Wnt3-β-catenin pathway.

**英文摘要原文：**
Forkhead-box-protein P3 (FOXP3) is a key transcription factor in T regulatory cells (Tregs). However, its expression and significance in non-immune stromal cells in the tumor microenvironment remain unclear. Here, we demonstrated FOXP3 expression in stromal fibroblasts of mouse and human gastrointestinal tumors. Immunohistological examination revealed FOXP3 expression in αSMA collagen I myofibroblasts. In the mouse omentum inoculated with gastric cancer cells, cytokeratin/CD45/FoxP3 stromal cells were identified via flow-cytometry, and high FOXP3 expression was noted in fibroblasts surrounding the tumor glands, where CD8 T cells were exclusively infiltrated. Extracellular vesicles (EVs) from mouse gastric cancer cells upregulated Foxp3 transcription in fibroblasts, which partly depends on increase of transcription factors including NFAT1 and c-Rel, and activation of TGF-β and STAT5 pathways. In FOXP3 fibroblasts, immunosuppressive cytokines including IL-10 and CCL2 were upregulated. FOXP3 overexpression in NIH/3T3 fibroblasts enhanced Wnt3a-induced β-catenin responses, accompanied by cell growth and tumor invasion in mice stomach. As the mechanism, FOXP3 induced CDH11 expression in fibroblasts, which augmented the Wnt3/β-catenin pathway, and blocking of CDH11 suppressed tumor invasion mediated by FOXP3 fibroblasts. Our results suggest that cancer cell-derived EVs regulate FOXP3 expression in stromal fibroblasts, attenuating antitumor immunity, and facilitating tumor invasion.

**中文摘要译文：**
叉头框蛋白P3（FOXP3）是调节性T细胞（Tregs）中的一个关键转录因子。然而，其在肿瘤微环境中的非免疫基质细胞中的表达和意义仍不清楚。在本研究中，我们证实了FOXP3在小鼠和人类胃肠道肿瘤的基质成纤维细胞中存在表达。免疫组织学检查显示，FOXP3在αSMA胶原I型肌成纤维细胞中表达。在接种了胃癌细胞的小鼠网膜中，通过流式细胞术鉴定了细胞角蛋白/CD45/FoxP3基质细胞，并注意到在肿瘤腺体周围的成纤维细胞中FOXP3高表达，而CD8 T细胞仅浸润于此处。来自小鼠胃癌细胞的细胞外囊泡（EVs）上调了成纤维细胞中Foxp3的转录，这部分依赖于包括NFAT1和c-Rel在内的转录因子的增加，以及TGF-β和STAT5通路的激活。在FOXP3成纤维细胞中，包括IL-10和CCL2在内的免疫抑制性细胞因子表达上调。在NIH/3T3成纤维细胞中过表达FOXP3，增强了Wnt3a诱导的β-catenin反应，并伴随着小鼠胃内的细胞生长和肿瘤侵袭。在机制方面，FOXP3诱导了成纤维细胞中CDH11的表达，从而增强了Wnt3/β-catenin通路，而阻断CDH11则抑制了由FOXP3成纤维细胞介导的肿瘤侵袭。我们的研究结果表明，癌细胞来源的细胞外囊泡调节基质成纤维细胞中FOXP3的表达，从而削弱抗肿瘤免疫并促进肿瘤侵袭。

### 第二部分 AI 大师评价

本研究揭示了转录因子FOXP3在肿瘤微环境中的一个全新角色，创新性地证实了癌细胞可通过释放细胞外囊泡诱导基质成纤维细胞表达FOXP3。研究通过体内外实验，清晰地阐明了FOXP3+成纤维细胞不仅能营造免疫抑制微环境，还能通过上调CDH11激活Wnt/β-catenin通路，从而直接促进肿瘤的侵袭。这项发现不仅加深了我们对肿瘤基质互作复杂性的理解，也为抗肿瘤治疗提供了如CDH11等潜在的新靶点。

---

## 138. 靶向放射性核素治疗的分子蓝图

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40926013](https://pubmed.ncbi.nlm.nih.gov/40926013)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 40926013
**DOI：** 10.1038/s41571-025-01069-z

### 第一部分 原文与翻译

**英文原标题：** The molecular blueprint of targeted radionuclide therapy.

**英文摘要原文：**
Targeted radionuclide therapy (TRT) is a cutting-edge treatment approach in oncology that combines the molecular precision of targeted agents with the effect of radiotherapy to selectively deliver cytotoxic radiation to cancer cells. Research efforts from the past few decades have led to a diverse molecular landscape of TRT and have provided lessons for further rational development of targeted radiopharmaceuticals and expansion of the clinical applications of this treatment modality. In this Review, we discuss TRT in the context of therapeutic approaches currently available in oncology, describe the broad range of established and emerging targets for TRT including innovative approaches to exploit vulnerabilities presented by the tumour microenvironment, and address the challenges for clinical translation and molecular optimization. By bridging technological innovation and preclinical discoveries with real-world clinical implementation, ongoing research on TRT is seeking to provide effective and safe treatment options for patients across a variety of cancer types and treatment settings. Overall, we emphasize the transformative potential of TRT and highlight how a comprehensive understanding of what constitutes an optimal target can redefine clinical practice, fostering the evolution of TRT as a highly individualized and adaptable therapeutic option that improves outcomes across a broad range of cancer types.

**中文摘要译文：**
靶向放射性核素治疗（TRT）是肿瘤学领域一种前沿的治疗方法，它将靶向药物的分子精准性与放射治疗的效应相结合，从而选择性地将细胞毒性辐射递送至癌细胞。过去几十年的研究工作已经塑造了TRT多样化的分子格局，并为进一步合理开发靶向放射性药物以及扩展该治疗模式的临床应用提供了经验。在这篇综述中，我们结合当前肿瘤学中可用的治疗方法来讨论TRT，描述了TRT广泛的已确立和新兴靶点，包括利用肿瘤微环境弱点的创新方法，并探讨了其临床转化和分子优化所面临的挑战。通过将技术创新、临床前发现与真实世界的临床实践相结合，当前关于TRT的研究旨在为各种癌症类型和治疗背景下的患者提供有效且安全的治疗选择。总而言之，我们强调TRT的变革潜力，并阐明了对最佳靶点的全面理解如何能够重新定义临床实践，从而促进TRT发展成为一种高度个性化和适应性强的治疗选择，以改善广泛癌症类型的患者预后。

### 第二部分 AI 大师评价

这篇发表于顶级期刊的综述文章，系统性地描绘了靶向放射性核素治疗（TRT）的“分子蓝图”。文章全面梳理了TRT的已确立及新兴分子靶点，探讨了其在临床转化中面临的挑战与机遇，并展望了未来的发展方向。该综述的创新性在于其前瞻性地整合了从基础研究到临床应用的完整知识链条，为开发新型放射性药物和优化治疗策略提供了理论框架。对于肿瘤学研究者和临床医生而言，此文具有极高的指导价值，有力地推动了TRT作为一种精准、个性化癌症疗法的发展。

---

## 139. 阿米万塔单抗-拉泽替尼治疗EGFR突变晚期非小细胞肺癌的总生存期

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40923797](https://pubmed.ncbi.nlm.nih.gov/40923797)
**期刊：** The New England journal of medicine
**PMID：** 40923797
**DOI：** 10.1056/NEJMoa2503001

### 第一部分 原文与翻译

**英文原标题：** Overall Survival with Amivantamab-Lazertinib in -Mutated Advanced NSCLC.

**英文摘要原文：**
BACKGROUND: Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated  (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC) was significantly improved with amivantamab-lazertinib as compared with osimertinib. Results of the protocol-specified final overall survival analysis in this trial have not been reported.

METHODS: We randomly assigned, in a 2:2:1 ratio, participants with previously untreated -mutated (exon 19 deletion or L858R substitution), locally advanced or metastatic NSCLC to receive amivantamab-lazertinib, osimertinib, or lazertinib. Overall survival (assessed in an analysis of the time from randomization to death from any cause) in the amivantamab-lazertinib group as compared with the osimertinib group was a key secondary end point. Additional end points included safety.

RESULTS: A total of 429 participants each were assigned to receive amivantamab-lazertinib or osimertinib. Over a median follow-up of 37.8 months, amivantamab-lazertinib led to significantly longer overall survival than osimertinib (hazard ratio for death, 0.75; 95% confidence interval, 0.61 to 0.92; P = 0.005); 3-year overall survival was 60% and 51%, respectively. At the clinical cutoff date, 38% of participants in the amivantamab-lazertinib group and 28% in the osimertinib group were still receiving the assigned treatment. Adverse events of grade 3 or higher were more common with amivantamab-lazertinib (in 80% of participants) than with osimertinib (in 52%), particularly skin-related events, venous thromboembolism, and infusion-related events; these findings were consistent with the established safety profile of each treatment. No new safety signals were observed with additional follow-up.

CONCLUSIONS: Amivantamab-lazertinib led to significantly longer overall survival among participants with previously untreated -mutated advanced NSCLC than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher. (Funded by Janssen Research and Development; MARIPOSA ClinicalTrials.gov number, NCT04487080.).

**中文摘要译文：**
背景：该项3期试验的既往结果表明，在未经治疗的EGFR（表皮生长因子受体）突变晚期非小细胞肺癌（NSCLC）患者中，与奥希替尼相比，阿米万塔单抗-拉泽替尼能显著改善无进展生存期。该试验方案规定的最终总生存期分析结果尚未报道。

方法：我们将未经治疗的、携带EGFR突变（19号外显子缺失或L858R突变）的局部晚期或转移性NSCLC患者，按2:2:1的比例随机分配接受阿米万塔单抗-拉泽替尼、奥希替尼或拉泽替尼治疗。总生存期（定义为从随机分组到因任何原因死亡的时间）是阿米万塔单抗-拉泽替尼组与奥希替尼组比较的一项关键次要终点。其他终点包括安全性。

结果：共有429名参与者分别被分配接受阿米万塔单抗-拉泽替尼或奥希替尼治疗。在中位随访37.8个月后，阿米万塔单抗-拉泽替尼组的总生存期显著长于奥希替尼组（死亡风险比为0.75；95%置信区间为0.61至0.92；P=0.005）；两组的3年总生存率分别为60%和51%。在临床数据截止日期，阿米万塔单抗-拉泽替尼组中有38%的参与者、奥希替尼组中有28%的参与者仍在接受指定的治疗。3级及以上不良事件在阿米万塔单抗-拉泽替尼组（80%的参与者）中比奥希替尼组（52%）更常见，特别是皮肤相关事件、静脉血栓栓塞和输液相关事件；这些发现与每种治疗已知的安全性特征一致。在额外的随访中未观察到新的安全性信号。

结论：对于未经治疗的EGFR突变晚期NSCLC患者，阿米万塔单抗-拉泽替尼相比奥希替尼能带来更长的总生存期，但与3级及以上不良事件风险增加相关。（由杨森研发部门资助；MARIPOSA试验，ClinicalTrials.gov编号：NCT04487080。）

### 第二部分 AI 大师评价

本研究是针对EGFR突变晚期非小细胞肺癌一线治疗的里程碑式MARIPOSA 3期临床试验的最终总生存期分析。研究通过头对头比较，关键性地发现阿米万塔单抗-拉泽替尼联合疗法相较于当前标准治疗奥希替尼，首次证实了总生存期的显著获益。这一发现极具临床价值，可能改变该领域的一线治疗格局。然而，联合疗法也带来了更高的3级及以上不良事件发生率，提示临床应用中需密切权衡其疗效与安全性。

---

## 140. 肿瘤抗原PRAME通过SIRT1-DBC1轴失活p53以促进黑色素瘤生长

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40921759](https://pubmed.ncbi.nlm.nih.gov/40921759)
**期刊：** Oncogene
**PMID：** 40921759
**DOI：** 10.1038/s41388-025-03565-z

### 第一部分 原文与翻译

**英文原标题：** Tumor antigen PRAME promotes melanoma growth by inactivating p53 through the SIRT1-DBC1 axis.

**英文摘要原文：**
Preferentially expressed antigen in melanoma (PRAME), which is highly expressed in melanoma, is associated with tumor progression and malignancy. Notably, melanoma cells often exhibit inactivation of the tumor suppressor p53 despite carrying the wild-type p53 gene. Here, we investigated the functional interplay between PRAME and p53. Consistent with our analysis of human databases, PRAME overexpression promoted melanoma cell proliferation. Conversely, PRAME downregulation produced the opposite effects, accompanied by an increase in apoptosis. RNA sequencing revealed aberrant regulation of p53 target genes following PRAME depletion, which was further supported by reverse transcription-quantitative polymerase chain reaction and luciferase reporter assays. To explore the underlying mechanism, we isolated the PRAME protein complex and identified DBC1, an SIRT1 suppressor, as a component of the complex. Furthermore, we observed that PRAME promoted p53 deacetylation. The interaction of PRAME with DBC1 releases SIRT1 from DBC1, enabling SIRT1 activation and subsequent p53 deacetylation. The combination of PRAME depletion and SIRT1 inhibition can significantly promote the growth retardation of melanoma cells, as demonstrated by xenograft analysis in nude mice. Collectively, these findings suggest that the acquired elevation of the PRAME level during melanoma pathogenesis may suppress p53 pathways, thereby promoting tumor growth. We propose that PRAME silencing combined with the use of SIRT1 inhibitors is a promising therapeutic strategy for melanoma by restoring p53 activity.

**中文摘要译文：**
黑色素瘤优先表达抗原（PRAME）在黑色素瘤中高表达，并与肿瘤的进展和恶性程度相关。值得注意的是，尽管携带野生型p53基因，黑色素瘤细胞常表现出肿瘤抑制因子p53的失活。在本研究中，我们探究了PRAME与p53之间的功能性相互作用。与我们对人类数据库的分析结果一致，PRAME的过表达促进了黑色素瘤细胞的增殖。相反，下调PRAME则产生相反效果，并伴随着细胞凋亡的增加。RNA测序显示，在PRAME耗尽后，p53靶基因出现异常调控，这得到了逆转录-定量聚合酶链式反应和荧光素酶报告基因实验的进一步证实。为探索其潜在机制，我们分离了PRAME蛋白复合物，并鉴定出SIRT1的抑制因子DBC1是该复合物的一个组分。此外，我们观察到PRAME促进了p53的去乙酰化。PRAME与DBC1的相互作用将SIRT1从DBC1中释放出来，从而激活SIRT1，并随后导致p53的去乙酰化。裸鼠异种移植分析表明，PRAME耗尽联合SIRT1抑制可以显著促进黑色素瘤细胞的生长迟滞。总而言之，这些发现表明，在黑色素瘤发病过程中PRAME水平的获得性升高可能会抑制p53通路，从而促进肿瘤生长。我们提出，通过沉默PRAME并联用SIRT1抑制剂来恢复p53的活性，是一种有前景的黑色素瘤治疗策略。

### 第二部分 AI 大师评价

该研究精准揭示了肿瘤抗原PRAME在黑色素瘤中促进肿瘤生长的关键分子机制。研究团队创新性地发现，PRAME通过与DBC1相互作用，释放并激活SIRT1，进而导致p53去乙酰化失活，从而阐明了野生型p53在黑色素瘤中功能抑制的一条重要通路。此项发现不仅深化了对黑色素瘤发病机制的理解，更重要的是，其提出的沉默PRAME与抑制SIRT1相结合的联合治疗策略，为恢复p53抑癌功能提供了坚实的实验依据，具有重要的临床转化潜力。

---

## 141. 对《超越1个月：更广视角审视ROBOMET试验结果》和《重访ROBOMET：立体定向体部放疗对疼痛性骨转移是否真正有效？》的回应

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40921011](https://pubmed.ncbi.nlm.nih.gov/40921011)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 40921011
**DOI：** 10.1200/JCO-25-01686

### 第一部分 原文与翻译

**英文原标题：** Reply to: "Beyond 1 Month: A Broader Look at the ROBOMET Trial Results" and "ROBOMET Revisited: Is Stereotactic Body Radiotherapy Truly Effective for Painful Bone Metastases?".

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文并非一项原创性研究，而是ROBOMET试验研究者对两篇评论文章的官方回应。文章的核心在于澄清和辩护其原始研究中关于立体定向体部放疗（SBRT）治疗疼痛性骨转移的疗效结论，特别是针对超过一个月的长期效果及临床真实有效性的质疑。此类学术回应对于促进严谨的科学讨论、澄清研究细节至关重要，有助于读者更全面、辩证地理解原始试验的价值与局限性。

---

## 142. 不止于1个月：对ROBOMET试验结果的更广阔审视

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40920997](https://pubmed.ncbi.nlm.nih.gov/40920997)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 40920997
**DOI：** 10.1200/JCO-25-01179

### 第一部分 原文与翻译

**英文原标题：** Beyond 1 Month: A Broader Look at the ROBOMET Trial Results.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
摘要不可用。

### 第二部分 AI 大师评价

根据标题推断，这篇文献很可能是对ROBOMET临床试验结果的一篇深度评论或二次分析。其核心目的在于超越原始研究可能关注的1个月短期终点，从更长期的视角来审视试验数据，探讨其更深远的临床意义。由于摘要缺失，无法得知具体发现，但这类分析对于全面理解一项重要试验的长期疗效与安全性、充分发掘数据价值以及指导未来临床实践具有至关重要的作用。

---

## 143. 泌尿外科领域Meta分析与系统评价指南

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40914655](https://pubmed.ncbi.nlm.nih.gov/40914655)
**期刊：** European urology
**PMID：** 40914655
**DOI：** 10.1016/j.eururo.2025.07.021

### 第一部分 原文与翻译

**英文原标题：** Guidelines for Meta-analyses and Systematic Reviews in Urology.

**英文摘要原文：**
Our guideline comprises points addressing the conduct and interpretation of systematic reviews and meta-analyses in urology. Application of the guideline would lead to a more considered interpretation of a smaller number of systematic reviews and meta-analyses, and could thus help in translating evidence into better decision-making for doctors and patients.

**中文摘要译文：**
本指南包含的要点旨在阐述泌尿外科领域系统评价与 Meta 分析的实施与解读。应用本指南将有助于对数量更少但更为审慎的系统评价与 Meta 分析进行解读，从而帮助将证据转化为更有利于医生和患者的决策。

### 第二部分 AI 大师评价

本指南旨在为泌尿外科领域的系统评价与Meta分析提供规范化的操作与解读标准。其核心目的在于提升该领域证据合成研究的质量与可靠性，强调通过严谨的方法论进行审慎解读，而非追求研究数量。该指南的发布对于推动泌尿外科学的循证医学实践具有重要价值，有助于研究人员产出高质量的证据，并辅助临床医生和患者做出更优的医疗决策。

---

## 144. 融合单细胞基因组与转录组信息解析乳腺癌进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40912251](https://pubmed.ncbi.nlm.nih.gov/40912251)
**期刊：** Cell
**PMID：** 40912251
**DOI：** 10.1016/j.cell.2025.08.012

### 第一部分 原文与翻译

**英文原标题：** Coalescing single-cell genomes and transcriptomes to decode breast cancer progression.

**英文摘要原文：**
Understanding epithelial lineages of breast cancer and genotype-phenotype relationships requires direct measurements of the genome and transcriptome of the same single cells at scale. To achieve this, we developed wellDR-seq, a high-genomic-resolution, high-throughput method to simultaneously profile the genome and transcriptome of thousands of single cells. We profiled 33,646 single cells from 12 estrogen-receptor-positive breast cancers and identified ancestral subclones in multiple patients that showed a luminal hormone-responsive lineage, indicating a potential cell of origin. In contrast to bulk studies, wellDR-seq enabled the study of subclone-level gene-dosage relationships, which showed near-linear correlations in large chromosomal segments and extensive variation at the single-gene level. We identified dosage-sensitive and dosage-insensitive genes, including many breast cancer genes as well as sporadic copy-number aberrations in non-cancer cells. Overall, these data reveal complex relationships between copy number and gene expression in single cells, improving our understanding of breast cancer progression.

**中文摘要译文：**
要理解乳腺癌的上皮谱系以及基因型与表型的关系，需要对同一个单细胞的基因组和转录组进行大规模的直接测量。为实现这一目标，我们开发了wellDR-seq技术，这是一种高基因组分辨率、高通量的方法，可同时对数千个单细胞的基因组和转录组进行分析。我们对来自12例雌激素受体阳性乳腺癌的33,646个单细胞进行了分析，并在多名患者中鉴定出了具有管腔型激素应答谱系的祖先亚克隆，这揭示了其潜在的起源细胞。与批量研究不同，wellDR-seq能够研究亚克隆水平的基因剂量关系，结果显示在大的染色体片段上存在近乎线性的相关性，而在单个基因水平上则存在广泛的变异。我们识别出了剂量敏感和剂量不敏感的基因，其中包括许多乳腺癌基因以及非癌细胞中的散发性拷贝数畸变。总的来说，这些数据揭示了单细胞中拷贝数与基因表达之间的复杂关系，加深了我们对乳腺癌进展的理解。

### 第二部分 AI 大师评价

本研究旨在通过同步分析单个细胞的基因组与转录组，深入解析乳腺癌的进展机制。研究团队为此开发了一项名为wellDR-seq的高通量、高分辨率创新技术。利用该技术，研究者成功揭示了雌激素受体阳性乳腺癌中潜在的起源细胞谱系，并阐明了亚克隆水平上基因拷贝数与表达之间的复杂剂量关系。这项工作不仅为理解肿瘤异质性和进化提供了强有力的工具，也为精准医疗和靶向治疗策略的开发开辟了新途径。

---

## 145. 肿瘤通过劫持巨噬细胞获取铁供应促进骨转移和贫血

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40907490](https://pubmed.ncbi.nlm.nih.gov/40907490)
**期刊：** Cell
**PMID：** 40907490
**DOI：** 10.1016/j.cell.2025.08.013

### 第一部分 原文与翻译

**英文原标题：** Tumors hijack macrophages for iron supply to promote bone metastasis and anemia.

**英文摘要原文：**
Bone marrow is both a primary site for hematopoiesis and a fertile niche for metastasis. The mechanism of the common occurrence of anemia among patients with bone metastasis remains poorly understood. Here, we show that a specialized population of VCAM1CD163CCR3 macrophages, normally essential for erythropoiesis by transporting iron to erythroblasts, are highly enriched in the bone metastatic niche in mouse models. Tumor cells hijack these macrophages for iron supply, reducing iron availability for erythroblasts, impairing erythropoiesis, and contributing to anemia. Increased iron supply enables tumor cells to produce hemoglobin in response to hypoxia, mimicking erythroblasts. We identify macrophages with similar iron-transporting features in human bone metastases and show that elevated HBB expression correlates with increased risk of bone metastasis. These findings establish iron-transporting macrophages as an essential component of the metastatic bone niche, revealing a critical interplay between immune cells, metal metabolism, and tumor cell plasticity in driving metastasis and anemia.

**中文摘要译文：**
骨髓既是主要的造血场所，也是转移的沃土。骨转移患者中贫血的普遍发生机制尚不清楚。本研究发现，在小鼠模型的骨转移微环境中，一种特殊的VCAM1CD163CCR3巨噬细胞亚群高度富集，该细胞群通常通过向红系祖细胞转运铁而对红细胞生成至关重要。肿瘤细胞劫持这些巨噬细胞以获取铁供应，这减少了红系祖细胞可用的铁，损害了红细胞生成，并导致了贫血。增加的铁供应使肿瘤细胞能够在缺氧反应中产生血红蛋白，从而模拟红系祖细胞。我们在人类骨转移病灶中鉴定出具有相似铁转运特征的巨噬细胞，并发现HBB表达升高与骨转移风险增加相关。这些发现确立了转运铁的巨噬细胞是转移性骨微环境的重要组成部分，揭示了在驱动转移和贫血过程中，免疫细胞、金属代谢和肿瘤细胞可塑性之间的关键相互作用。

### 第二部分 AI 大师评价

该研究旨在阐明骨转移患者并发贫血的核心机制。通过小鼠模型和人体样本分析，研究团队发现肿瘤细胞会“劫持”一类特殊的铁转运巨噬细胞，与机体正常的红细胞生成过程“竞争”铁资源。这一过程不仅导致贫血，还反向增强了肿瘤细胞在缺氧微环境下的生存和转移能力。此项发现创新性地将肿瘤免疫、金属代谢与肿瘤可塑性联系起来，为理解肿瘤与宿主的相互作用提供了全新视角，并为治疗骨转移及相关贫血症开辟了潜在的新靶点。

---

## 146. NeuroD1通过组蛋白H3K27乙酰化驱动KAT2A-FDFT1信号轴，从而促进胆固醇生物合成和肝细胞癌的进展。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40890513](https://pubmed.ncbi.nlm.nih.gov/40890513)
**期刊：** Oncogene
**PMID：** 40890513
**DOI：** 10.1038/s41388-025-03534-6

### 第一部分 原文与翻译

**英文原标题：** NeuroD1 drives a KAT2A-FDFT1 signaling axis to promote cholesterol biosynthesis and hepatocellular carcinoma progression via histone H3K27 acetylation.

**英文摘要原文：**
Abnormal lipid metabolism is one of the hallmarks of cancer. Lipid metabolic reprogramming, which has been observed in various tumors, could participate in tumor occurrence, invasion, and metastasis of tumors by regulating various carcinogenic signaling pathways. However, the molecular mechanism that regulates tumor cell lipid metabolic reprogramming has not been fully elucidated. Recent studies revealed that neurogenic differentiation factor 1 (NeuroD1) is upregulated in a variety of tumor cells, and is associated with tumorigenesis and poor prognosis. However, its role in tumor cell lipid metabolism remains unclear. Here, we found that NeuroD1 is highly expressed in hepatocellular carcinoma (HCC) cells and is associated with tumor cell cholesterol biosynthesis. We found that NeuroD1 enhances HCC cell cholesterol biosynthesis, leading to an increase in their viability. Mechanistically, NeuroD1 binds to the promoter of farnesyl diphosphate farnesyl transferase 1 (FDFT1), thereby activating its transcription activity. Furthermore, NeuroD1 can promote FDFT1 transcription through lysine acetyltransferase 2A-mediated H3K27 acetylation. Subsequently, we found that NeuroD1/FDFT1-mediated cholesterol biosynthesis is critical to the tumorigenic potential of HCC cells. These findings not only identify NeuroD1 as a regulator of lipid metabolism in tumor cells, but also reveal a novel molecular mechanism underlying its carcinogenic function.

**中文摘要译文：**
脂质代谢异常是癌症的标志之一。在多种肿瘤中观察到的脂质代谢重编程，可通过调控多种致癌信号通路参与肿瘤的发生、侵袭和转移。然而，调控肿瘤细胞脂质代谢重编程的分子机制尚未被完全阐明。近期研究表明，神经源性分化因子1（NeuroD1）在多种肿瘤细胞中表达上调，并与肿瘤发生及不良预后相关。然而，其在肿瘤细胞脂质代谢中的作用仍不清楚。在本研究中，我们发现NeuroD1在肝细胞癌（HCC）细胞中高表达，并与肿瘤细胞的胆固醇生物合成相关。我们发现NeuroD1能增强HCC细胞的胆固醇生物合成，从而提高其细胞活力。从机制上讲，NeuroD1与法尼基二磷酸法尼基转移酶1（FDFT1）的启动子结合，从而激活其转录活性。此外，NeuroD1还可通过赖氨酸乙酰转移酶2A介导的H3K27乙酰化促进FDFT1的转录。随后，我们发现NeuroD1/FDFT1介导的胆固醇生物合成对HCC细胞的致瘤潜力至关重要。这些发现不仅确定了NeuroD1是肿瘤细胞脂质代谢的一个调控因子，也揭示了其致癌功能背后一种新的分子机制。

### 第二部分 AI 大师评价

本研究旨在揭示神经源性分化因子1（NeuroD1）在肝细胞癌（HCC）进展中的新作用机制，特别聚焦于其对胆固醇代谢的调控。研究通过系列分子实验发现，NeuroD1不仅能直接结合并激活关键胆固醇合成酶FDFT1的转录，还创新性地揭示了该过程依赖于KAT2A介导的组蛋白H3K27乙酰化修饰。这一发现首次将NeuroD1、表观遗传调控与HCC的脂质代谢重编程联系起来，为理解HCC的致病机理提供了全新视角，并提示NeuroD1-FDFT1信号轴可能成为HCC治疗的潜在新靶点。

---

## 147. 靶向细胞凋亡的BH3模拟物：革新急性髓系白血病患者的治疗模式

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40890352](https://pubmed.ncbi.nlm.nih.gov/40890352)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 40890352
**DOI：** 10.1038/s41571-025-01068-0

### 第一部分 原文与翻译

**英文原标题：** Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia.

**英文摘要原文：**
Acute myeloid leukaemia (AML) remains a challenging haematological malignancy, with most patients developing resistance to standard-of-care (SOC) treatments. This resistance is often attributed to the overexpression of anti-apoptotic BCL-2 family proteins, which regulate the intrinsic apoptotic pathway by inhibiting pro-apoptotic effector proteins such as BAX and BAK. AML cells exploit this imbalance to evade apoptosis and sustain survival, necessitating the development of novel therapeutic strategies. BH3 mimetics are small-molecule inhibitors targeting the pro-survival BCL-2 family proteins and have emerged as promising agents in patients with AML who are unable to receive high-intensity induction chemotherapy. Co-treatment with the BCL-2-specific inhibitor venetoclax and various SOC therapies has been proven effective, with several combinations now approved by the US Food and Drug Administration for adults with AML who are ≥75 years of age and/or are ineligible for intensive induction chemotherapy, on the basis of improved response rates and survival outcomes compared with the previous SOC. In this Review, we highlight the transformative potential of BH3 mimetics in AML therapy, including ongoing studies investigating novel combination regimens and efforts to further refine treatment strategies, with the ultimate goal of improving outcomes for patients with AML.

**中文摘要译文：**
急性髓系白血病（AML）仍然是一种具有挑战性的血液系统恶性肿瘤，大多数患者会对标准治疗（SOC）产生耐药性。这种耐药性通常归因于抗凋亡BCL-2家族蛋白的过表达，这些蛋白通过抑制BAX和BAK等促凋亡效应蛋白来调节内源性细胞凋亡途径。AML细胞利用这种失衡来逃避细胞凋亡并维持生存，因此有必要开发新的治疗策略。BH3模拟物是靶向促生存BCL-2家族蛋白的小分子抑制剂，对于无法接受高强度诱导化疗的AML患者，它已成为一种有前景的药物。BCL-2特异性抑制剂维奈克拉与多种标准治疗方案的联合用药已被证明有效，基于与既往标准治疗相比更高的缓解率和生存获益，其中数种联合方案已被美国食品药品监督管理局批准用于年龄≥75岁和/或不适合接受强化诱导化疗的AML成人患者。在这篇综述中，我们重点阐述了BH3模拟物在AML治疗中的变革性潜力，包括正在进行的新型联合方案研究以及为进一步优化治疗策略所做的努力，其最终目标是改善AML患者的预后。

### 第二部分 AI 大师评价

这篇综述深刻阐述了靶向细胞凋亡的BH3模拟物在急性髓系白血病（AML）治疗中的核心作用。文章系统总结了BH3模拟物（如维奈克拉）通过抑制抗凋亡BCL-2蛋白、恢复细胞凋亡通路来克服AML耐药性的机制。其关键价值在于，明确了这些药物联合标准化疗方案为老年或不耐受高强度化疗的患者带来了显著的生存获益，标志着AML治疗模式的重大革新。该文为临床医生提供了最新的治疗证据和未来研究方向，对推动AML精准治疗具有重要的指导意义。

---

## 148. 瞬时基因解链调控少突胶质细胞的成熟时机

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40858115](https://pubmed.ncbi.nlm.nih.gov/40858115)
**期刊：** Cell
**PMID：** 40858115
**DOI：** 10.1016/j.cell.2025.07.039

### 第一部分 原文与翻译

**英文原标题：** Transient gene melting governs the timing of oligodendrocyte maturation.

**英文摘要原文：**
Cellular maturation is a crucial step for tissue formation and function, distinct from the initial steps of differentiation and cell fate specification. In the central nervous system, failure of oligodendrocyte maturation is linked to diseases such as multiple sclerosis. Here, we report a transcriptional mechanism that governs the timing of oligodendrocyte maturation. After progenitor cells differentiate into immature oligodendrocytes, the transcription factor SOX6 redistributes from super-enhancers to cluster across specific gene bodies. These sites exhibit extensive chromatin decondensation and transcription, which abruptly turn off upon maturation. Suppression of SOX6 deactivates these immaturity loci, accelerating the transition to mature, myelinating oligodendrocytes. Notably, cells harboring this immature SOX6 gene signature are enriched in multiple sclerosis patient brains and antisense oligonucleotide-mediated Sox6 knockdown drives oligodendrocyte maturation in mice. Our findings establish SOX6 as a key regulator of oligodendrocyte maturation and highlight its potential as a therapeutic target to promote myelination in disease.

**中文摘要译文：**
细胞成熟是组织形成和功能的关键步骤，有别于分化和细胞命运决定的初始阶段。在中枢神经系统中，少突胶质细胞成熟障碍与多发性硬化等疾病相关。本研究报道了一种调控少突胶质细胞成熟时机的转录机制。在祖细胞分化为不成熟的少突胶质细胞后，转录因子SOX6会从超级增强子重新分布并聚集在特定的基因体上。这些位点表现出广泛的染色质去凝集和转录活动，而这些活动在细胞成熟时会突然关闭。抑制SOX6会使这些未成熟基因位点失活，从而加速向成熟、可形成髓鞘的少突胶质细胞的转变。值得注意的是，在多发性硬化症患者的大脑中，携带这种不成熟SOX6基因特征的细胞富集，并且通过反义寡核苷酸介导的Sox6基因敲降可驱动小鼠少突胶质细胞的成熟。我们的研究结果确立了SOX6作为少突胶质细胞成熟的关键调控因子，并凸显了其作为促进疾病中髓鞘形成的潜在治疗靶点。

### 第二部分 AI 大师评价

本研究旨在揭示调控少突胶质细胞成熟时机的关键转录机制。研究发现，转录因子SOX6通过在特定基因体上瞬时聚集，引发染色质去凝集（即“基因解链”）和转录，从而扮演了抑制细胞成熟的“刹车”角色。该研究的创新之处在于阐明了一个控制细胞成熟时间进程的新颖分子开关，而非仅仅关注细胞分化本身，并将SOX6确立为促进多发性硬化等脱髓鞘疾病再髓鞘化的潜力治疗靶点，为相关疾病的治疗提供了新的思路与实验依据。

---

## 149. 将天然细胞因子受体转化为正交合成生物传感器

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40846994](https://pubmed.ncbi.nlm.nih.gov/40846994)
**期刊：** Nature chemical biology
**PMID：** 40846994
**DOI：** 10.1038/s41589-025-01986-1

### 第一部分 原文与翻译

**英文原标题：** Conversion of natural cytokine receptors into orthogonal synthetic biosensors.

**英文摘要原文：**
Synthetic receptors enable bioengineers to build cell-based therapies that perform therapeutic functions in a targeted or conditional fashion to enhance specificity and efficacy. Although many synthetic receptors exist, it remains challenging to generate new receptors that sense soluble cues and relay that detection through orthogonal mechanisms independent of native pathways. Here we co-opt natural cytokine receptor ectodomains into modular extracellular sensor architecture (MESA) receptors to form natural ectodomain (NatE) MESA receptors. We generated multiple functional, orthogonal synthetic cytokine receptors, identified design principles and constraints and propose guidance for extending this approach to other natural receptors. We demonstrate the utility of NatE MESA by engineering T cells to sense an immunosuppressive cue and respond with customized transcriptional output to support chimeric antigen receptor T cell activity. Lastly, we multiplex NatE MESA to logically evaluate multiple cues associated with the tumor microenvironment. These technologies and learnings will enable engineering cellular functions for new applications.

**中文摘要译文：**
合成受体使生物工程师能够构建细胞疗法，这类疗法以靶向或条件性的方式执行治疗功能，从而提高其特异性和疗效。尽管已存在多种合成受体，但在开发能够感知可溶性信号、并通过独立于内源性通路的正交机制来传递检测信号的新型受体方面，仍然充满挑战。本研究中，我们将天然细胞因子受体的胞外域整合入模块化胞外传感器架构（MESA）受体中，从而构建了天然胞外域（NatE）MESA受体。我们生成了多种功能性的正交合成细胞因子受体，明确了其设计原则和限制因素，并为将此方法推广至其他天然受体提供了指导。我们通过改造T细胞，使其能够感知免疫抑制信号并以定制的转录输出作出响应，从而支持嵌合抗原受体T细胞的活性，以此展示了NatE MESA的实用价值。最后，我们将NatE MESA进行多路复用，以对与肿瘤微环境相关的多种信号进行逻辑评估。这些技术和认知将为面向新应用的细胞功能工程化提供可能。

### 第二部分 AI 大师评价

本研究旨在解决合成生物学中的一个关键挑战：如何创建能感知可溶性信号分子且不干扰细胞内源通路的新型正交受体。研究团队创新性地将天然细胞因子受体的胞外域与模块化传感器架构（MESA）相结合，成功构建了一系列名为NatE MESA的功能性合成生物传感器。该研究不仅阐明了其设计原则与局限，更通过在T细胞中验证其感知并响应肿瘤微环境信号的能力，展示了其在增强CAR-T等细胞疗法精准性和有效性方面的巨大潜力。此项技术为开发更智能、更能适应复杂疾病环境的细胞疗法提供了一个通用且强大的平台。

---

## 150. 腺苷激酶与ADAL协同对修饰性腺苷进行解毒以保障代谢稳态

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40840445](https://pubmed.ncbi.nlm.nih.gov/40840445)
**期刊：** Cell
**PMID：** 40840445
**DOI：** 10.1016/j.cell.2025.07.041

### 第一部分 原文与翻译

**英文原标题：** Adenosine kinase and ADAL coordinate detoxification of modified adenosines to safeguard metabolism.

**英文摘要原文：**
RNA contains diverse post-transcriptional modifications, and its catabolic breakdown yields numerous modified nucleosides requiring correct processing, but the mechanisms remain unknown. Here, we demonstrate that three RNA-derived modified adenosines, N-methyladenosine (mA), N,N-dimethyladenosine (mA), and N-isopentenyladenosine (iA), are sequentially metabolized into inosine monophosphate (IMP) to mitigate their intrinsic cytotoxicity. After phosphorylation by adenosine kinase (ADK), they undergo deamination by adenosine deaminase-like (ADAL). In Adal knockout mice, N-modified adenosine monophosphates (AMPs) accumulate and allosterically inhibit AMP-activated protein kinase (AMPK), dysregulating glucose metabolism. Furthermore, ADK deficiency, linked to human inherited disorders of purine metabolism, elevates levels of the three modified adenosines, resulting in early lethality in mice. Mechanistically, excessive mA, mA, and iA impair lysosomal function by interfering with lysosomal membrane proteins, thereby disrupting lipid metabolism and causing cellular toxicity. Through this nucleotide metabolism pathway and mechanism, cells detoxify modified adenosines, linking modified RNA metabolism to human disease.

**中文摘要译文：**
RNA包含多种转录后修饰，其分解代谢会产生大量需要正确处理的修饰性核苷，但其具体机制仍不清楚。在此，我们证明了三种源自RNA的修饰性腺苷，即N-甲基腺苷（mA）、N,N-二甲基腺苷（mA）和N-异戊烯基腺苷（iA），会依次代谢为单磷酸肌苷（IMP），以减轻其内在的细胞毒性。它们经腺苷激酶（ADK）磷酸化后，再由腺苷脱氨酶样蛋白（ADAL）进行脱氨基作用。在Adal基因敲除小鼠中，N-修饰的单磷酸腺苷（AMPs）会累积，并变构抑制AMP活化蛋白激酶（AMPK），从而导致葡萄糖代谢失调。此外，与人类遗传性嘌呤代谢紊乱相关的ADK缺陷，会导致这三种修饰性腺苷水平升高，并引起小鼠的早期死亡。从机制上看，过量的mA、mA和iA会通过干扰溶酶体膜蛋白来损害溶酶体功能，进而破坏脂质代谢并引发细胞毒性。通过这一核苷酸代谢通路和机制，细胞能够对修饰性腺苷进行解毒，从而将修饰RNA代谢与人类疾病联系起来。

### 第二部分 AI 大师评价

本研究旨在阐明细胞如何处理RNA分解代谢产生的有毒修饰性腺苷。研究团队通过运用基因敲除小鼠模型等手段，揭示了一条由腺苷激酶（ADK）和腺苷脱氨酶样蛋白（ADAL）协同作用的关键解毒通路。该研究的关键发现是，此通路的缺陷会导致有毒代谢物累积，进而通过抑制AMPK或损害溶酶体功能，分别干扰糖代谢和脂质代谢。这项工作创新性地将RNA修饰物的分解代谢与核心代谢调控及人类遗传病直接联系起来，为理解相关疾病的发病机制提供了深刻见解。

---

## 151. 液体活检在泌尿生殖系统恶性肿瘤患者管理中的作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40829964](https://pubmed.ncbi.nlm.nih.gov/40829964)
**期刊：** European urology
**PMID：** 40829964
**DOI：** 10.1016/j.eururo.2025.07.016

### 第一部分 原文与翻译

**英文原标题：** The Role of Liquid Biopsy in the Management of Patients with Genitourinary Malignancies.

**英文摘要原文：**
BACKGROUND AND OBJECTIVE: Liquid biopsy testing refers to the use of specific analytical methods to detect disease-related biomarkers in blood or its components. These tests can be either qualitative or quantitative. Liquid biopsy testing is increasingly used in patient care. Here, we explore all the current Food and Drug Administration (FDA)-approved indications for liquid biopsies related to genitourinary oncology. The secondary objective is to describe a few other potential uses of this technology that may become approved soon.

METHODS: We conducted a systematic review of all FDA approvals from 2015 through 2025. We interrogated multiple FDA databases to capture both tumor-specific and tissue-agnostic approvals. We limited the search to indications related to or requiring biomarker testing to assess the value of liquid biopsy testing. A total of 1119 approvals were identified. Of these, nine unique drug approvals related to genitourinary cancers require molecular testing. We then identified the registrational trials used for those approvals through PubMed and present the results here. For the secondary endpoints, we identified examples published within the past 10 yr.

KEY FINDINGS AND LIMITATIONS: The current use for liquid biopsy testing based on regulatory approval is for predicting treatment response. There are nine FDA-approved drugs or drug combinations applicable to clinical practice for patients with genitourinary malignancies. Liquid biopsy testing is currently available to identify patients for most of these indications. We highlight the limitations associated with current liquid biopsy testing.

CONCLUSIONS AND CLINICAL IMPLICATIONS: Currently, there are multiple clinical indications for liquid biopsy in routine clinical practice. These FDA-approved indications can significantly improve the outcomes for biomarker-selected patients. All providers treating patients with a genitourinary malignancy are encouraged to use these tools regularly when indicated to improve patient care. Additional applications are expected to become available for routine clinical use in the future.

**中文摘要译文：**
背景与目的：液体活检检测指利用特定的分析方法检测血液或其成分中与疾病相关的生物标志物。这些检测可以是定性的，也可以是定量的。液体活检检测在患者治疗中的应用日益增多。本文旨在探讨目前所有经美国食品药品监督管理局（FDA）批准的、与泌尿生殖系统肿瘤学相关的液体活检适应证。次要目的在于描述该技术未来可能很快获批的其他一些潜在用途。

方法：我们对2015年至2025年间FDA批准的所有项目进行了一项系统性综述。我们检索了多个FDA数据库，以捕获肿瘤特异性和组织不限的批准项目。我们将检索范围限定于需要生物标志物检测的相关适应证，以评估液体活检检测的价值。总计识别出1119项批准项目。其中，九项与泌尿生殖系统癌症相关的独特药物批准需要进行分子检测。随后，我们通过PubMed确定了用于这些批准的注册性试验，并在此呈现其结果。为实现次要目标，我们检索了过去10年内发表的相关实例。

主要发现与局限性：基于监管批准，液体活检检测目前的用途是预测治疗反应。对于泌尿生殖系统恶性肿瘤患者，临床实践中现有九种经FDA批准的药物或药物组合可供应用。目前，液体活检检测可用于筛选适用于这些适应证中的大多数患者。我们在此强调了当前液体活检检测相关的局限性。

结论与临床意义：当前，液体活检在常规临床实践中已拥有多种临床适应证。这些经FDA批准的适应证能够显著改善经生物标志物筛选的患者的预后。我们鼓励所有治疗泌尿生殖系统恶性肿瘤的医疗服务提供者，在有适应证的情况下，常规使用这些工具以改善患者的治疗效果。预计未来将有更多应用进入常规临床使用。

### 第二部分 AI 大师评价

该研究通过系统性综述，全面梳理了2015至2025年间美国FDA批准的液体活检在泌尿生殖系统肿瘤领域的应用现状。核心发现指出，液体活检目前主要用于预测治疗反应，并明确了九项相关的药物批准适应证，为临床实践提供了清晰的指导。本综述的价值在于为临床医生提供了权威且及时的监管信息汇总，极大地促进了液体活检技术在泌尿生殖肿瘤精准治疗中的规范化应用。同时，文章也指出了当前技术的局限性并展望了未来发展方向，兼具临床指导意义与科研前瞻性。

---

## 152. EZH2抑制所致的表观遗传学变化增加了高AID活性或DNA修复缺陷B细胞中的染色体易位

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40825195](https://pubmed.ncbi.nlm.nih.gov/40825195)
**期刊：** Blood
**PMID：** 40825195
**DOI：** 10.1182/blood.2024026131

### 第一部分 原文与翻译

**英文原标题：** Epigenetic changes by EZH2 inhibition increase translocations in B cells with high AID activity or DNA repair deficiency.

**英文摘要原文：**
The enhancer of zeste homolog 2 (EZH2) histone methyltransferase inhibitors tazemetostat and valemetostat recently have received approval for clinical use in follicular lymphoma and adult T-cell leukemia/lymphoma, respectively. In follicular lymphoma, the expression of activation-induced cytidine deaminase (AID) is responsible for increased mutational signatures and genomic instability. Because EZH2 inhibitors induce epigenetic and transcriptional changes in normal and lymphoma B cells, we studied whether these inhibitors could alter the pattern of AID-mediated chromosomal translocations. In this study, we showed that treatment with EZH2 inhibitors did not significantly change AID expression or AID-dependent chromosomal translocation frequency when used as monotherapy in either CH12F3 mouse B cells or MEC-1 human B cells. In contrast, when combined with phosphoinositide 3-kinase δ (PI3Kδ) inhibition, which enhances AID expression, EZH2 inhibition significantly increased the frequency of chromosomal translocations when compared with either EZH2 or PI3Kδ inhibition alone both in mouse CH12F3 cells and human MEC-1 cells. EZH2 inhibition also further enhanced translocation formation in mouse B cells that were DNA ligase IV (Ligase4) deficient. Mechanistically, EZH2 inhibition in B cells depletes the repressive histone modification H3 trimethylation at lysine 27 (H3K27me3) while concurrently enhancing the active histone modification H3 acetylation at lysine 27 (H3K27ac), thereby selectively increasing transcriptional activity and facilitating chromosomal translocation formation in the presence of high AID activity or Ligase4 deficiency. These findings highlight the impact of drugs that induce epigenetic changes to influence chromosomal translocations, and demonstrate the genetic safety of EZH2 inhibitors as monotherapy while highlighting the increased risk of genomic instability when used in cells prone to translocations, such as B cells with high AID levels or DNA repair deficiency.

**中文摘要译文：**
zeste同源物增强子2 (EZH2) 组蛋白甲基转移酶抑制剂tazemetostat和valemetostat近期分别被批准用于滤泡性淋巴瘤和成人T细胞白血病/淋巴瘤的临床治疗。在滤泡性淋巴瘤中，活化诱导的胞苷脱氨酶 (AID) 的表达是导致突变特征增加和基因组不稳定的原因。由于EZH2抑制剂会诱导正常和淋巴瘤B细胞发生表观遗传学和转录变化，我们研究了这些抑制剂是否能改变AID介导的染色体易位模式。在本研究中，我们发现，在CH12F3小鼠B细胞或MEC-1人B细胞中，当作为单药治疗时，EZH2抑制剂并未显著改变AID的表达或AID依赖性染色体易位的频率。相反，当与可增强AID表达的磷脂酰肌醇3-激酶δ (PI3Kδ) 抑制剂联合使用时，与单独使用EZH2或PI3Kδ抑制剂相比，EZH2抑制显著增加了小鼠CH12F3细胞和人MEC-1细胞中染色体易位的频率。EZH2抑制也进一步促进了DNA连接酶IV (Ligase4) 缺陷型小鼠B细胞中易位的形成。从机制上讲，B细胞中的EZH2抑制会耗尽抑制性组蛋白修饰——赖氨酸27位三甲基化H3 (H3K27me3)，同时增强活性组蛋白修饰——赖氨酸27位乙酰化H3 (H3K27ac)，从而在高AID活性或Ligase4缺陷存在的情况下，选择性地增加转录活性并促进染色体易位的形成。这些发现凸显了诱导表观遗传学变化的药物对染色体易位的影响，并证明了EZH2抑制剂作为单药治疗时的遗传安全性，同时也强调了当其用于易发生易位的细胞（如具有高AID水平或DNA修复缺陷的B细胞）时，基因组不稳定的风险会增加。

### 第二部分 AI 大师评价

本研究旨在探究EZH2抑制剂对B细胞染色体易位的影响，特别是在激活诱导性胞苷脱氨酶（AID）高表达或DNA修复功能缺陷的背景下。研究通过细胞实验发现，尽管EZH2抑制剂单药治疗是安全的，但当与能提高AID活性的PI3Kδ抑制剂联用或在DNA修复缺陷细胞中使用时，会显著增加染色体易位的风险。该研究揭示了EZH2抑制剂通过改变组蛋白修饰（降低H3K27me3，增加H3K27ac）来促进易位的分子机制，为评估其临床应用中的遗传毒性风险提供了重要的实验依据，对指导联合用药策略具有重要的临床警示意义。

---

## 153. RNA聚合酶II的抑制以不依赖于转录功能丧失的方式激活细胞死亡

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40818455](https://pubmed.ncbi.nlm.nih.gov/40818455)
**期刊：** Cell
**PMID：** 40818455
**DOI：** 10.1016/j.cell.2025.07.034

### 第一部分 原文与翻译

**英文原标题：** RNA Pol II inhibition activates cell death independently from the loss of transcription.

**英文摘要原文：**
RNA Pol II-mediated transcription is essential for eukaryotic life. Although loss of transcription is thought to be universally lethal, the associated mechanisms promoting cell death are not yet known. Here, we show that death following the loss of RNA Pol II activity does not result from dysregulated gene expression. Instead, it occurs in response to loss of the hypophosphorylated form of Rbp1 (also called RNA Pol IIA). Loss of RNA Pol IIA exclusively activates apoptosis, and expression of a transcriptionally inactive version of Rpb1 rescues cell viability. Using functional genomics, we identify the mechanisms driving lethality following the loss of RNA Pol IIA, which we call the Pol II degradation-dependent apoptotic response (PDAR). Using the genetic dependencies of PDAR, we identify clinically used drugs that owe their lethality to a PDAR-dependent mechanism. Our findings unveil an apoptotic signaling response that contributes to the efficacy of a wide array of anti-cancer therapies.

**中文摘要译文：**
RNA聚合酶II介导的转录对真核生物的生命至关重要。尽管转录功能的丧失被普遍认为是致命的，但其促进细胞死亡的相关机制尚不清楚。在此，我们证明了RNA聚合酶II活性丧失后所导致的细胞死亡并非源于基因表达失调。相反，这种死亡是响应于Rbp1（亦称为RNA聚合酶IIA）的低磷酸化形式的丢失而发生的。RNA聚合酶IIA的丢失特异性地激活细胞凋亡，而表达一个无转录活性的Rpb1版本则能挽救细胞的生存能力。通过功能基因组学，我们识别出了在RNA聚合酶IIA丢失后驱动细胞致死的机制，我们将其命名为“聚合酶II降解依赖性凋亡反应”（PDAR）。利用PDAR的遗传依赖性，我们发现了一些临床上使用的药物，其致死效应归因于PDAR依赖的机制。我们的研究结果揭示了一种凋亡信号反应，该反应有助于多种抗癌疗法的疗效。

### 第二部分 AI 大师评价

本研究旨在探究RNA聚合酶II（RNA Pol II）抑制所导致的细胞死亡机制。研究团队通过功能基因组学等方法，颠覆性地发现细胞死亡并非由转录功能丧失直接引起，而是源于RNA Pol IIA（Rbp1的低磷酸化形式）的减少，从而激活了一个名为“聚合酶II降解依赖性凋亡反应”（PDAR）的新型凋亡通路。这项发现不仅揭示了RNA Pol II超越其转录功能的非经典信号作用，还阐明了多种现有抗癌药物的潜在作用机制，为开发靶向PDAR通路的新型抗癌疗法提供了重要的理论基础和新靶点。

---

## 154. 推进放射蛋白质组学：在前列腺癌中整合前列腺特异性膜抗原PET/CT、多参数磁共振成像与局部蛋白质组学分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40796480](https://pubmed.ncbi.nlm.nih.gov/40796480)
**期刊：** European urology
**PMID：** 40796480
**DOI：** 10.1016/j.eururo.2025.07.003

### 第一部分 原文与翻译

**英文原标题：** Advancing Radioproteomics: Integration of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging with Localized Proteomic Profiling in Prostate Cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该研究标题揭示了一项前沿的探索性工作，旨在通过整合多模态影像学（PSMA PET/CT和mpMRI）与局部蛋白质组学分析，推动前列腺癌的放射蛋白质组学研究。其核心创新在于将宏观的影像学表型与微观的分子特征直接关联，可能为非侵入性地预测肿瘤的生物学行为和治疗反应提供新的生物标志物。尽管缺乏摘要信息，但该研究方向代表了精准医疗的重要发展趋势，有望加深对前列腺癌异质性的理解，并为个体化诊疗策略的制定开辟新途径。

---

## 155. 术后肠外瘘根治性手术时机的选择：一项包含200例患者的回顾性队列研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40794442](https://pubmed.ncbi.nlm.nih.gov/40794442)
**期刊：** Annals of surgery
**PMID：** 40794442
**DOI：** 10.1097/SLA.0000000000006897

### 第一部分 原文与翻译

**英文原标题：** Timing of Curative Surgery in Postoperative Enterocutaneous Fistulas: A Retrospective Cohort Study of 200 Patients.

**英文摘要原文：**
OBJECTIVE: Evaluate the feasibility of early radical enterocutaneous fistula (ECF) surgery.

BACKGROUND: After failure of medical treatment for ECF, the optimal timing of surgical reintervention remains debated.

METHODS: Patients undergoing radical ECF surgery to treat postoperative small bowel- ECFs and/or colon-ECFs (2005-2024) were retrospectively included. Success was defined as no remnant ECF or ECF-related stoma at the most recent follow-up and absence of 90-day postoperative mortality. Early ECF surgery was defined as planned surgery (urgent procedures excluded) occurring within 4 months of the last abdominal procedure.

RESULTS: Among 200 patients (median 62 years; 43% female; 40% American Society of Anesthesiologists ≥ 3), 77% had small bowel-ECF only, 12% colon-ECF only and 11%. both. Eighty-two percent were referred, with a median delay of 48 days [interquartile range (IQR): 8-200] after ECF diagnosis. Referral center management lasted 34 days (IQR: 3-90), with 10% exceeding 120 days. After excluding 22 emergency procedures, early ECF surgery was performed in 39% (70/178). Early-surgery patients had fewer respiratory comorbidities (9% vs 21%; P = 0.036) and shorter ECF diagnosis-to-transfer interval (16 days vs 145; P = 0.001). Early surgery did not impact operative time ( P = 0.312), mortality ( P = 0.091), severe morbidity ( P = 0.867), and reoperations ( P = 0.511). After a median follow-up of 12 months, the success rate was 74% (permanent stomas = 11%; recurrence = 17%). American Society of Anesthesiologists ≥ 3 ( P = 0.012) and malignancies ( P = 0.010) were independently associated with failure on multivariate analysis, whereas ECF-origin ( P = 0.924) and surgical timing ( P = 0.438) were not.

CONCLUSIONS: For postoperative small bowel/colon ECF, the success rate of radical surgery is 74%. Early surgery seems feasible (39%) and does not compromise success. Further prospective studies are needed.

**中文摘要译文：**
目的：评估早期施行肠外瘘（ECF）根治性手术的可行性。

背景：在ECF内科治疗失败后，再次手术干预的最佳时机仍存在争议。

方法：本研究回顾性纳入了在2005年至2024年间因术后小肠ECF和/或结肠ECF而接受根治性ECF手术的患者。成功定义为在最近一次随访中无残留ECF或ECF相关造口，并且术后90天内无死亡。早期ECF手术定义为在末次腹部手术后4个月内进行的择期手术（急诊手术除外）。

结果：在200名患者中（中位年龄62岁；43%为女性；40%美国麻醉医师协会分级≥3级），77%仅为小肠ECF，12%仅为结肠ECF，11%为两者兼有。82%的患者为转诊而来，从ECF诊断到转诊的中位延迟时间为48天[四分位距(IQR): 8-200]。转诊中心的治疗持续了34天（IQR: 3-90），其中10%的患者超过120天。排除22例急诊手术后，39%（70/178）的患者接受了早期ECF手术。早期手术患者的呼吸系统合并症较少（9% vs 21%；P = 0.036），且从ECF诊断到转院的间隔时间更短（16天 vs 145天；P = 0.001）。早期手术对总手术时间（P = 0.312）、死亡率（P = 0.091）、严重并发症发生率（P = 0.867）和再次手术率（P = 0.511）没有影响。中位随访12个月后，总体成功率为74%（永久性造口=11%；复发=17%）。多变量分析显示，美国麻醉医师协会分级≥3级（P = 0.012）和恶性肿瘤（P = 0.010）是与失败独立相关的因素，而ECF来源（P = 0.924）和手术时机（P = 0.438）则不是。

结论：对于术后小肠/结肠ECF，根治性手术的成功率为74%。早期手术（39%）似乎是可行的，且不影响手术成功率。未来仍需进一步的前瞻性研究。

### 第二部分 AI 大师评价

本研究通过一项大规模回顾性队列分析，旨在探讨术后肠外瘘（ECF）患者接受根治性手术的最佳时机问题。研究关键发现，在末次腹部手术后4个月内进行早期手术是可行的，且与传统延期手术相比，并未增加死亡率、严重并发症或影响最终成功率。这项发现对传统临床实践中倾向于长期等待（通常超过6个月）的观念提出了挑战，提示对于特定患者群体，积极的早期手术干预或为一种安全有效的策略，具有重要的临床指导价值。

---

## 156. 胰腺内胆管切除术治疗I型先天性胆管扩张症的疗效与安全性：一项多中心对照队列研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40794433](https://pubmed.ncbi.nlm.nih.gov/40794433)
**期刊：** Annals of surgery
**PMID：** 40794433
**DOI：** 10.1097/SLA.0000000000006898

### 第一部分 原文与翻译

**英文原标题：** The Efficacy and Safety of Intrapancreatic Bile Duct Resection Applied in Type I of Congenital Bile Duct Dilation: A Multicenter Control Cohort Study.

**英文摘要原文：**
OBJECTIVE: To compare the efficacy and safety of radical extrahepatic cyst excision (REC), which includes the intrapancreatic bile duct (IPBD), and subtotal extrahepatic cyst excision (SEC), which preserves the IPBD, in treating Todani type I congenital bile duct dilation with IPBD involvement (I-IPBD).

BACKGROUND: The application of REC and SEC in I-IPBD remains debated.

METHODS: The multicenter study recruited I-IPBDs who underwent REC or SEC from 5 centers between 2006 and 2024. The primary endpoint was occurrence of long-term complications, including recurrent cholangitis, pancreatitis, and IPBD stones. The secondary outcomes included readmission, reoperation, life quality assessed by Mayo score, carcinogenesis, and perioperative complications categorized as overall, severe, pancreas-related, and severe pancreas-related.

RESULTS: Three hundred fifty-five I-IPBDs were included and divided into the REC group (175 cases) and SEC (180 cases) from 722 type I congenital bile duct dilations. The REC group demonstrated better long-term complication-free survival compared with SEC group (log-rank P < 0.001; hazard ratio = 0.08, 95% CI: 0.04-0.15, P < 0.001). The REC group had lower rates of readmission, reoperation, and carcinogenesis, and achieved a superior Mayo score ( P < 0.05). No significant differences were observed between the REC and SEC groups in overall perioperative complications, severe perioperative complications, and severe pancreas-related perioperative complications ( P > 0.05). Furthermore, subgroup analysis by age demonstrated similar trends in primary and secondary outcomes compared with the overall analysis.

CONCLUSIONS: REC was an effective and safe surgical approach for I-IPBD compared with SEC, thus it should be recommended routinely for these patients.

**中文摘要译文：**
目的：旨在比较包含胰腺内胆管（IPBD）切除的肝外囊肿根治性切除术（REC）与保留IPBD的肝外囊肿次全切除术（SEC）在治疗合并IPBD受累的Todani I型先天性胆管扩张症（I-IPBD）中的疗效与安全性。

背景：REC与SEC在I-IPBD中的应用仍存在争议。

方法：这项多中心研究招募了2006年至2024年间来自5个中心的接受REC或SEC治疗的I-IPBD患者。主要终点是远期并发症的发生，包括复发性胆管炎、胰腺炎和胰腺内胆管结石。次要结局包括再入院、再次手术、通过梅奥评分评估的生活质量、癌变以及分为总体、重度、胰腺相关和重度胰腺相关的围手术期并发症。

结果：从722例I型先天性胆管扩张症患者中，共纳入355例I-IPBD患者，并分为REC组（175例）和SEC组（180例）。与SEC组相比，REC组展现出更优的远期无并发症生存率（log-rank P < 0.001; 风险比 = 0.08, 95% CI: 0.04-0.15, P < 0.001）。REC组的再入院率、再次手术率和癌变率更低，并获得了更优的梅奥评分（P < 0.05）。在总体围手术期并发症、重度围手术期并发症以及重度胰腺相关围手术期并发症方面，REC组与SEC组之间未观察到显著差异（P > 0.05）。此外，按年龄进行的亚组分析显示，其主要和次要结局与总体分析呈现相似趋势。

结论：与SEC相比，REC是治疗I-IPBD的一种有效且安全的手术方法，因此应作为常规推荐给此类患者。

### 第二部分 AI 大师评价

本研究通过一项大规模多中心对照队列研究，精准地比较了两种手术方式（肝外囊肿根治性切除术REC vs. 次全切除术SEC）在治疗特定类型先天性胆管扩张症（I-IPBD）中的远期疗效与安全性。研究的关键发现是，更为彻底的REC手术在不增加围手术期风险的前提下，显著降低了远期并发症、再手术率和癌变风险。这项研究以其高质量的证据，有力地解决了临床实践中的一个重要争议，为将REC确立为该类患者的标准术式提供了强有力的支持，具有重要的临床指导价值。

---

## 157. 超越P值：综合并发症指数（CCI®）最小重要差异新探——一项反映重大腹部手术患者有意义结局的研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40793921](https://pubmed.ncbi.nlm.nih.gov/40793921)
**期刊：** Annals of surgery
**PMID：** 40793921
**DOI：** 10.1097/SLA.0000000000006877

### 第一部分 原文与翻译

**英文原标题：** Beyond P Values : Novel Minimal Important Difference of the Comprehensive Complication Index That Reflects a Meaningful Outcome for Patients Undergoing Major Abdominal Surgery.

**英文摘要原文：**
OBJECTIVE: To estimate the minimal important difference (MID) of the Comprehensive Complication Index (CCI ® ) in patients undergoing abdominal surgery.

BACKGROUND: The CCI ® is a validated metric that quantifies cumulative surgical morbidity. While the CCI ® is a sensitive endpoint to detect treatment effects, a statistically significant effect does not necessarily translate into clinical relevance. Relevant differences from the patients' perspective are best captured by the MID.

METHODS: Individual patient data were extracted from surgical studies reporting CCI ® at 30 days and using patient-reported outcome measures with established MIDs at baseline and 30 days. To determine the MID for the CCI ® , we used an anchor-based approach as recommended by methods guidelines. A patient-reported outcome measure was selected as an anchor only if the Spearman correlation coefficient between its change in score (baseline to 30 days postoperative) and the CCI ® was ≥|0.30|. We used linear regression to estimate the MID of the CCI ® across different anchors, and triangulation to determine a single MID.

RESULTS: Data were extracted from 3 published randomized controlled trials and 1 prospective observational study (n = 1583 patients) in major abdominal surgery. In colorectal surgery cohorts, 2 subscores of the Short Form-36, 2 subscores of the Multidimensional Fatigue Inventory-20, the EuroQol-5-Dimension Index Score, and the EuroQol Visual Analog Scale showed a correlation with the CCI ® of ≥|0.30|. This resulted in MID estimates for the CCI ® ranging from 6.1 to 22.2. In hepato-pancreato-biliary surgery, 1 subscore of the Short Form-36, and 2 subscores of the Patient Reported Outcome Measure Information System-29 questionnaire qualified as anchors providing MID estimates ranging from 6.2 to 13.8.

CONCLUSIONS: We propose a mean difference of 12 points in the CCI ® between treatment groups as a relevant difference in patients undergoing abdominal surgery. This MID provides an important foundation for sample size calculations and interpretation of randomized controlled trials and large real-world observational studies.

**中文摘要译文：**
目的：评估接受腹部手术患者的综合并发症指数（CCI®）的最小重要差异（MID）。

背景：CCI®是一项经过验证的、用于量化累积手术并发症的指标。尽管CCI®是检测治疗效果的敏感终点，但统计学上的显著差异并不一定转化为临床相关性。从患者角度看，有意义的差异最好通过MID来捕捉。

方法：本研究从报告了术后30天CCI®、并使用了在基线和术后30天有既定MID的患者报告结局指标的外科研究中提取了单个患者数据。为确定CCI®的MID，我们采用了方法学指南推荐的锚定法。只有当某项患者报告结局指标的评分变化（从基线到术后30天）与CCI®之间的斯皮尔曼相关系数≥|0.30|时，该指标才被选为锚点。我们使用线性回归来估计不同锚点下的CCI® MID，并采用三角测量法来确定一个单一的MID值。

结果：数据提取自3项已发表的随机对照试验和1项前瞻性观察性研究，共涉及1583名接受重大腹部手术的患者。在结直肠手术队列中，简明健康状况调查表-36（Short Form-36）的2个子评分、多维疲劳量表-20（Multidimensional Fatigue Inventory-20）的2个子评分、欧洲五维健康量表（EuroQol-5-Dimension）指数评分以及欧洲视觉模拟量表（EuroQol Visual Analog Scale）与CCI®的相关性均≥|0.30|。由此得出的CCI® MID估计值范围为6.1至22.2。在肝胆胰手术中，简明健康状况调查表-36的1个子评分和患者报告结局测量信息系统-29（Patient Reported Outcome Measure Information System-29）问卷的2个子评分符合锚点资格，其提供的MID估计值范围为6.2至13.8。

结论：我们建议，在接受腹部手术的患者中，治疗组间CCI®的12分平均差值可被视为一个有意义的差异。该MID为随机对照试验和大型真实世界观察性研究的样本量计算和结果解读提供了重要基础。

### 第二部分 AI 大师评价

本研究旨在为量化术后并发症的“综合并发症指数（CCI®）”建立一个具有临床意义的“最小重要差异”（MID），从而超越传统统计学P值的局限性。研究创新性地采用锚定法，通过分析大型临床研究数据，将CCI®这一客观指标与患者报告的结局（PROs）这一主观感受相关联，最终提出12分可作为重大腹部手术患者CCI®变化的临床重要阈值。这一发现极具价值，它为未来临床试验的样本量计算和结果解读提供了更贴近患者真实感受的标尺，有力地推动了临床研究从“统计学显著”向“临床有意义”的转化。

---

## 158. 感染性坏死性胰腺炎单独使用抗生素治疗成功的预测因素：一项全国性前瞻性队列研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40792644](https://pubmed.ncbi.nlm.nih.gov/40792644)
**期刊：** Annals of surgery
**PMID：** 40792644
**DOI：** 10.1097/SLA.0000000000006902

### 第一部分 原文与翻译

**英文原标题：** Predictors for Successful Treatment of Infected Necrotizing Pancreatitis With Antibiotics Alone: A Nationwide Prospective Cohort.

**英文摘要原文：**
OBJECTIVE: To identify predictors for successful treatment of patients with infected necrotizing pancreatitis with antibiotics alone.

BACKGROUND: Infected necrotizing pancreatitis is associated with mortality ranging from 15% to 35%. Recent studies have shown that in some patients, treatment with antibiotics alone is successful, thus avoiding invasive procedures.

METHODS: We performed a post hoc analysis of a prospective cohort of 305 patients with suspected or proven infected necrotizing pancreatitis from 22 Dutch hospitals. The primary outcome was successful treatment with antibiotics alone (ie, survival without radiologic, endoscopic, or surgical intervention). All computed tomography images were reviewed to classify the pattern of pancreatic necrosis. A prediction model using clinical and radiologic predictors was created using multivariable logistic regression. A prognostic nomogram was developed based on the final predictors.

RESULTS: Overall, 86 out of 305 patients (28%) with infected necrotizing pancreatitis were successfully treated with antibiotics alone. Our final prediction model included presence of organ failure at the start of antibiotics [odds ratio (OR): 0.46, 95% CI: 0.22-0.99, P =0.046], presence of central necrosis (OR: 0.11, 95% CI: 0.05-0.23, P <0.001) and presence of subtotal necrosis (OR: 0.12, 95% CI: 0.03-0.36, P <0.001). The area under the curve was 0.74 (95% CI: 0.70-0.75). The prognostic nomogram yielded a probability of successful antibiotic treatment of 5% when organ failure and central necrosis were present and 47% when all predictors were absent.

CONCLUSIONS: In patients with infected necrotizing pancreatitis, predictors negatively impacting successful treatment with antibiotics are organ failure at the start of antibiotics, and the presence of central or subtotal necrosis on imaging.

**中文摘要译文：**
目的：旨在识别感染性坏死性胰腺炎患者仅凭抗生素治疗成功的预测因素。

背景：感染性坏死性胰腺炎的死亡率在15%至35%之间。近期研究表明，在部分患者中，仅使用抗生素治疗即可成功，从而避免了侵入性操作。

方法：我们对一项来自荷兰22家医院、包含305名疑似或确诊感染性坏死性胰腺炎患者的前瞻性队列进行了事后分析。主要结局是仅凭抗生素治疗成功（即未经放射学、内镜或外科干预而存活）。所有计算机断层扫描（CT）图像均被重新审阅，以对胰腺坏死的模式进行分类。我们采用多变量逻辑回归方法，利用临床和影像学预测因素建立了一个预测模型。基于最终的预测因素，我们开发了一个预后列线图。

结果：总体而言，305名感染性坏死性胰腺炎患者中有86名（28%）仅通过抗生素治疗即获成功。我们的最终预测模型包含了抗生素启用时的器官功能衰竭[比值比（OR）：0.46，95% CI：0.22-0.99，P =0.046]、中央型坏死（OR：0.11，95% CI：0.05-0.23，P <0.001）以及次全坏死（OR：0.12，95% CI：0.03-0.36，P <0.001）。曲线下面积为0.74（95% CI：0.70-0.75）。该预后列线图显示，当存在器官功能衰竭和中央型坏死时，抗生素治疗成功的概率为5%；而当所有预测因素均不存在时，成功概率为47%。

结论：对于感染性坏死性胰腺炎患者，对抗生素单独治疗成功产生负面影响的预测因素是：抗生素启用时的器官功能衰竭，以及影像学上存在的中央型或次全坏死。

### 第二部分 AI 大师评价

本研究通过对一项全国性前瞻性队列的事后分析，精准探究了感染性坏死性胰腺炎（INP）患者仅凭抗生素治疗成功的关键预测因素。研究创新性地结合了临床（器官衰竭）与影像学（坏死模式）指标，构建了一个实用的预测模型和列线图。其核心发现——器官衰竭、中央型及次全坏死是治疗失败的强预测因子——为临床医生提供了明确的决策依据，有助于筛选出可避免侵入性干预的患者，对优化INP的阶梯式治疗策略具有重要的指导价值。

---

## 159. 回复

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40759342](https://pubmed.ncbi.nlm.nih.gov/40759342)
**期刊：** Gastroenterology
**PMID：** 40759342
**DOI：** 10.1053/j.gastro.2025.07.036

### 第一部分 原文与翻译

**英文原标题：** Reply.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题为“回复”，且无摘要，表明这并非一篇原创性研究论文，而很可能是一封作者对先前发表文章的评论或读者来信所做的回应。此类文章在学术期刊中通常用于澄清研究细节、回应质疑或参与学术讨论。因此，无法基于现有信息评估其具体的研究方法或发现，但其价值在于促进学术交流和保证科学研究的严谨性。

---

## 160. 持续性雄激素剥夺疗法联合或不联合转移灶导向治疗在寡转移性前列腺癌中的应用：多中心2期随机EXTEND试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40750497](https://pubmed.ncbi.nlm.nih.gov/40750497)
**期刊：** European urology
**PMID：** 40750497
**DOI：** 10.1016/j.eururo.2025.07.006

### 第一部分 原文与翻译

**英文原标题：** Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial.

**英文摘要原文：**
BACKGROUND AND OBJECTIVE: Oligometastatic prostate cancer (omPC) is characterized by limited metastases. We hypothesized that metastasis-directed therapy (MDT) to all sites of omPC combined with androgen deprivation therapy (ADT) would improve clinical outcomes.

METHODS: In the multicenter phase 2 EXTEND trial, patients with omPC were randomized 1:1 to ADT versus MDT + ADT in two independently powered and randomized baskets, one using intermittent ADT and one using continuous ADT. The primary endpoint was progression-free survival (PFS). The secondary endpoints included radiologic PFS (rPFS) and castration resistance-free survival (CRFS). Here, the primary results of the continuous ADT basket, the combined analysis of both baskets, and translational immune correlatives are reported.

KEY FINDINGS AND LIMITATIONS: From September 2018 through August 2022, 174 patients were randomized and were eligible for the primary analysis. In the continuous ADT basket (N = 87), the median PFS was 47 mo with MDT + ADT versus 22 mo with ADT (hazard ratio [HR], 0.50; one-sided p = 0.036). In the combined analysis, the median PFS was 36 mo with MDT + ADT versus 17 mo with ADT (HR, 0.45; p < 0.001). Radiologic PFS and CRFS were also superior with MDT + ADT. Durable clinical responses after MDT + ADT were associated with systemic Th1-polarizing cytokine upregulation and CD8 T-cell proliferation. Compared with ADT, MDT + ADT induced greater systemic immune activation, including T-cell receptor expansion/contraction, which we also observed in the independent ORIOLE trial of MDT. The greatest PFS benefit after MDT + ADT was observed in patients with systemic T-cell receptor expansion/contraction.

CONCLUSIONS AND CLINICAL IMPLICATIONS: MDT + ADT improves PFS compared with ADT in omPC patients, meriting phase 3 confirmation. Hypothesis-generating immune responses warrant mechanistic validation and future trials with T-cell-targeted immunotherapies.

**中文摘要译文：**
背景与目的：寡转移性前列腺癌（omPC）的特征是转移灶数量有限。我们假设，对所有寡转移性前列腺癌病灶进行转移灶导向治疗（MDT）联合雄激素剥夺疗法（ADT）能够改善临床结局。

方法：在这项多中心2期EXTEND试验中，寡转移性前列腺癌患者被1:1随机分配至ADT组或MDT + ADT组，该试验包含两个独立设计和随机化的研究队列，一个采用间歇性ADT，另一个采用持续性ADT。主要终点是无进展生存期（PFS）。次要终点包括影像学无进展生存期（rPFS）和去势抵抗无进展生存期（CRFS）。本报告呈现了持续性ADT队列的主要结果、两个队列的合并分析以及转化性免疫相关性研究的结果。

主要发现与局限性：从2018年9月至2022年8月，共有174名患者被随机分组并符合主要分析条件。在持续性ADT队列中（N = 87），MDT + ADT组的中位PFS为47个月，而ADT组为22个月（风险比[HR]为0.50；单侧p = 0.036）。在合并分析中，MDT + ADT组的中位PFS为36个月，而ADT组为17个月（HR为0.45；p < 0.001）。MDT + ADT组的影像学无进展生存期和去势抵抗无进展生存期同样更优。MDT + ADT治疗后持久的临床反应与全身性Th1极化细胞因子上调及CD8 T细胞增殖相关。与单纯ADT相比，MDT + ADT诱导了更强的全身性免疫激活，包括T细胞受体扩增/收缩，这一现象在独立的ORIOLE MDT试验中也曾观察到。在出现全身性T细胞受体扩增/收缩的患者中，观察到了MDT + ADT带来的最大PFS获益。

结论与临床意义：对于寡转移性前列腺癌患者，MDT联合ADT相较于单纯ADT能够改善无进展生存期，这一结论值得通过3期试验加以证实。本研究中产生的关于免疫应答的假设，有待通过机制验证以及未来结合T细胞靶向免疫疗法的试验进行探索。

### 第二部分 AI 大师评价

该研究是一项多中心2期随机对照试验，旨在评估对于寡转移性前列腺癌（omPC）患者，在雄激素剥夺疗法（ADT）基础上增加转移灶导向治疗（MDT）的疗效。研究关键发现表明，联合治疗显著延长了患者的无进展生存期（PFS）、影像学PFS及去势抵抗无进展生存期。其创新之处在于，不仅证实了MDT的临床价值，还通过转化性研究揭示了其疗效可能与诱导全身性T细胞免疫激活有关，为未来探索免疫联合治疗提供了重要依据，并强调了进行3期临床试验以确认该策略的必要性。

---

## 161. 三肝段切除术能否改善局限性Bismuth-Corlette II/III型肝门部胆管癌的预后？一项法国全国性队列研究的启示

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40747928](https://pubmed.ncbi.nlm.nih.gov/40747928)
**期刊：** Annals of surgery
**PMID：** 40747928
**DOI：** 10.1097/SLA.0000000000006868

### 第一部分 原文与翻译

**英文原标题：** Do Trisectionectomies Improve Outcomes for Localized Bismuth-Corlette Type II and III Perihilar Cholangiocarcinoma? Insights From a Nationwide French Cohort Study.

**英文摘要原文：**
OBJECTIVE: To determine whether extending resections to trisectionectomies (TS) improves long-term outcomes in Bismuth-Corlette (BC) type II-III perihilar cholangiocarcinomas (PHC).

BACKGROUND: Extended (segment 1) hemihepatectomy (EH) is the standard surgical approach for BC type II-III PHC.

METHODS: This nationwide French retrospective study compared patients undergoing right/left-sided TS and EH for BC II-III PHC between 2010 and 2020. The primary endpoint was overall survival (OS) with secondary endpoints including disease-free survival, R0-resection rate and postoperative outcomes. Propensity score and inverse probability treatment weighting were applied to balance confounders. Kaplan-Meier curves and log-rank tests were used for survival analysis, with adjusted hazard ratios (aHRs) derived from mixed-effect multivariable Cox models clustered within hospitals.

RESULTS: Among 443 patients (median age: 66, 57.1% men), 286 (64.6%) underwent TS and 157 (35.4%) EH. TS achieved more frequently R0 resection (83.9% vs 75.8%, P = 0.037), had more frequent grade B-C liver failure (23.4% vs 11.3%, P = 0.002) but similar 90-day severe morbidity (Clavien-Dindo ≥3) and mortality rates with EH (51.6% vs 50.7%, P = 0.85 and 12.9% vs 14.0%, P = 0.55). TS significantly improved OS and disease-free survival [52.4 months (42.5-104.5) vs 31 months (24.3-42.3), P < 0.001 and 39.9 months (26.2-66.2) vs 24.3 months (20.7-36.3), P = 0.01] and was independently associated with improved OS in the original cohort [aHR: 0.63 (0.46-0.88), P = 0.007], inverse probability treatment weighting pseudo-population [aHR: 0.63 (0.41-0.95), P = 0.029] and across different BC subtypes and side of resection.

CONCLUSIONS: TS improves oncological outcomes compared with EH in BC II-III PHC resection and should be strongly considered when feasible.

**中文摘要译文：**
目的：旨在确定扩大手术范围至三肝段切除术（TS）是否能改善Bismuth-Corlette（BC）II-III型肝门部胆管癌（PHC）患者的长期预后。

背景：扩大（含尾状叶）半肝切除术（EH）是BC II-III型PHC的标准手术方式。

方法：这项法国全国性回顾性研究比较了2010年至2020年间因BC II-III型PHC接受右/左侧TS和EH治疗的患者。主要终点为总生存期（OS），次要终点包括无病生存期、R0切除率及术后结局。研究应用了倾向性评分和逆概率治疗加权法以平衡混杂因素。采用Kaplan-Meier曲线和对数秩检验进行生存分析，并通过以医院为聚类的混合效应多变量Cox模型得出调整后的风险比（aHRs）。

结果：在443名患者（中位年龄：66岁，57.1%为男性）中，286名（64.6%）接受了TS，157名（35.4%）接受了EH。与EH组相比，TS组更频繁地实现了R0切除（83.9% vs 75.8%, P = 0.037），B-C级肝功能衰竭的发生率更高（23.4% vs 11.3%, P = 0.002），但两组的90天内严重并发症（Clavien-Dindo ≥3级）发生率和死亡率相似（分别为51.6% vs 50.7%, P = 0.85；12.9% vs 14.0%, P = 0.55）。TS显著改善了患者的OS和无病生存期[分别为52.4个月 (42.5-104.5) vs 31个月 (24.3-42.3), P < 0.001；39.9个月 (26.2-66.2) vs 24.3个月 (20.7-36.3), P = 0.01]，并且在原始队列[aHR: 0.63 (0.46-0.88), P = 0.007]、逆概率治疗加权伪人群[aHR: 0.63 (0.41-0.95), P = 0.029]以及不同BC分型和切除侧别中，均是改善OS的独立相关因素。

结论：对于BC II-III型PHC的切除，与EH相比，TS能改善肿瘤学结局，在可行的情况下应予以强烈考虑。

### 第二部分 AI 大师评价

该研究通过一项大规模的法国全国性回顾性队列研究，直接比较了三肝段切除术（TS）与标准扩大半肝切除术（EH）治疗Bismuth-Corlette II-III型肝门部胆管癌的长期效果。研究关键发现，尽管TS术后肝衰竭风险更高，但其并未增加90天严重并发症或死亡率，反而显著提高了R0切除率，并带来了更优的总生存期和无病生存期。本研究的价值在于，它为挑战现有手术标准提供了强有力的证据，揭示了更扩大的切除范围能够转化为明确的生存获益。尽管存在回顾性研究的固有局限，但其严谨的统计分析和全国性数据使其结论具有重要的临床指导意义，可能推动在可行情况下将三肝段切除术作为此类患者优先考虑的术式。

---

## 162. 血液结直肠癌筛查结果异常后的结肠镜随访

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40744392](https://pubmed.ncbi.nlm.nih.gov/40744392)
**期刊：** Gastroenterology
**PMID：** 40744392
**DOI：** 10.1053/j.gastro.2025.07.019

### 第一部分 原文与翻译

**英文原标题：** Colonoscopic Follow-Up After Abnormal Blood-Based Colorectal Cancer Screening Results.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究聚焦于一个重要且前沿的临床问题：对于通过血液检测筛查出结直肠癌风险异常的患者，其后续结肠镜检查的执行情况及诊断结果。研究可能通过分析真实的临床数据，揭示了筛查阳性人群的结肠镜依从率以及镜下病变的检出率，为优化筛查后管理流程提供了关键证据。随着液体活检等新型筛查手段的普及，该研究对于完善结直肠癌筛查-诊断路径、制定相关临床指南具有重要的现实指导意义。

---

## 163. XPO1驱动对eprenetapopt和阿扎胞苷的耐药性，并可作为TP53突变型骨髓恶性肿瘤的治疗靶点。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40737597](https://pubmed.ncbi.nlm.nih.gov/40737597)
**期刊：** Blood
**PMID：** 40737597
**DOI：** 10.1182/blood.2025028803

### 第一部分 原文与翻译

**英文原标题：** XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies.

**英文摘要原文：**
TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are among the most aggressive and chemotherapy-refractory myeloid neoplasms, with a median overall survival of <6 months. An enormous unmet need exists to develop novel therapeutic strategies, and understand resistance mechanisms to suboptimal existing therapies for this disease. In 2 parallel, phase 2 clinical trials that combined eprenetapopt with azacitidine in TP53-mutated MDS/AML, we observed complete remission rates of 40% to 50%, and molecular remission rates of 38%. However, unless allogeneic stem cell transplant was performed, relapse inevitably occurred. To understand the mechanisms of secondary resistance responsible for this, we genotyped sequential clinical trial samples, conducted a genome-wide CRISPR screen in TP53-mutated leukemia cells, and identified XPO1 as a therapeutically tractable mediator of resistance. We demonstrate that XPO1 is overexpressed in patient samples after eprenetapopt and azacitidine treatment, elucidate the mechanism by which this occurs, and determine that it is necessary and sufficient for resistance to combination therapy. Finally, we validate in a variety of model systems, including a novel patient-derived xenograft model of TP53 mutant MDS, that eprenetapopt in combination with XPO1 inhibitors can overcome this resistance, providing preclinical rationale that this novel combination strategy is a viable therapeutic approach in patients with TP53 mutant MDS/AML.

**中文摘要译文：**
TP53突变的骨髓增生异常综合征（MDS）和急性髓系白血病（AML）属于侵袭性最强、对化疗最耐药的骨髓肿瘤，其中位总生存期不足6个月。因此，开发新的治疗策略并理解对此类疾病现有次优疗法的耐药机制，存在着巨大的未满足的临床需求。在两项平行的II期临床试验中，我们联合使用eprenetapopt与阿扎胞苷治疗TP53突变的MDS/AML患者，观察到40%至50%的完全缓解率和38%的分子学缓解率。然而，除非进行异基因干细胞移植，否则复发不可避免。为探究导致此现象的继发性耐药机制，我们对临床试验的序贯样本进行了基因分型，在TP53突变的白血病细胞中开展了全基因组CRISPR筛选，并最终将XPO1鉴定为一种可作为治疗靶点的耐药介导因子。我们证明了在接受eprenetapopt和阿扎胞苷治疗后，患者样本中的XPO1表达上调，阐明了其发生机制，并确定了它是联合治疗产生耐药性的充分必要条件。最后，我们通过多种模型系统，包括一种新型TP53突变MDS的患者来源异种移植模型，验证了eprenetapopt联合XPO1抑制剂能够克服这种耐药性，从而为这一新颖的联合策略作为TP53突变MDS/AML患者的可行治疗方法提供了临床前依据。

### 第二部分 AI 大师评价

本研究聚焦于TP53突变型骨髓恶性肿瘤这一临床难题，旨在揭示eprenetapopt联合阿扎胞苷治疗后产生继发性耐药的关键机制。研究团队综合运用了临床样本基因分型、全基因组CRISPR筛选及患者来源异种移植模型等前沿技术，精准锁定了XPO1是驱动耐药的核心分子。此项发现不仅深刻阐释了治疗失败的分子机理，更具突破性地提出了靶向XPO1的联合用药新策略以克服耐药，为改善这类高危患者的预后提供了坚实的临床前证据和明确的治疗方向，具有重大的临床转化潜力。

---

## 164. RESONATE-2研究的最终分析：伊布替尼一线治疗CLL/SLL长达10年的随访结果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40737596](https://pubmed.ncbi.nlm.nih.gov/40737596)
**期刊：** Blood
**PMID：** 40737596
**DOI：** 10.1182/blood.2024028205

### 第一部分 原文与翻译

**英文原标题：** Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.

**英文摘要原文：**
With up to 10 years of follow-up, we report results from the final analysis of RESONATE- 2, a phase 3 study of first-line ibrutinib vs chlorambucil for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Patients aged ≥65 years with previously untreated CLL/SLL without del(17p) were randomly assigned to receive either single-agent ibrutinib (420 mg/d; n = 136) or chlorambucil (0.5-0.8 mg/kg; ≤12 cycles; n = 133). With a median follow-up of 9.6 years in the ibrutinib arm, the median progression-free survival (PFS) was 8.9 years (95% confidence interval [CI], 7.0 to not estimable [NE]) vs 1.3 years (95% CI, 0.9-1.6) for the chlorambucil arm. Among patients with unmutated immunoglobulin heavy chain variable (uIGHV), del (11q), mutated TP53, or complex karyotype, the median PFS was 8.4 years (95% CI, 6.8 to NE) with ibrutinib and 0.7 years (95% CI, 0.4-1.2) with chlorambucil. Median overall survival (OS) with ibrutinib was not reached. The most common adverse events (AEs) of any grade included diarrhea (52%), fatigue (41%), cough (39%), nausea (32%), arthralgia (31%), peripheral edema (31%), and hypertension (30%). During the entire study period, 34 of 136 patients (25%) had an ibrutinib dose reduction due to AEs; these AEs improved in 30 of 34 patients (88%). At study completion, 27% of patients remained on first-line ibrutinib treatment. This landmark RESONATE-2 study defines median PFS and demonstrates continued OS benefit of first-line ibrutinib treatment for patients with CLL/SLL, including those with high-risk genomic features. Sustained efficacy and tolerability of ibrutinib reemphasize the favorable benefit-risk profile. This trial was registered at www.ClinicalTrials.gov as NCT01722487/NCT01724346.

**中文摘要译文：**
本报告提供了RESONATE-2研究的最终分析结果，这是一项关于伊布替尼对比苯丁酸氮芥一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）的3期研究，随访时间长达10年。年龄≥65岁、既往未接受治疗且无del(17p)的CLL/SLL患者被随机分配接受单药伊布替尼（420 mg/d；n = 136）或苯丁酸氮芥（0.5-0.8 mg/kg；≤12个周期；n = 133）治疗。在伊布替尼组中位随访9.6年的情况下，其中位无进展生存期（PFS）为8.9年（95%置信区间[CI]，7.0至无法评估[NE]），而苯丁酸氮芥组为1.3年（95% CI，0.9-1.6）。在伴有免疫球蛋白重链可变区未突变（uIGHV）、del(11q)、TP53突变或复杂核型的患者中，伊布替尼组的中位PFS为8.4年（95% CI，6.8至NE），而苯丁酸氮芥组为0.7年（95% CI，0.4-1.2）。伊布替尼组的中位总生存期（OS）尚未达到。最常见的任何级别的不良事件（AEs）包括腹泻（52%）、疲劳（41%）、咳嗽（39%）、恶心（32%）、关节痛（31%）、外周水肿（31%）和高血压（30%）。在整个研究期间，136名患者中有34名（25%）因不良事件而减少了伊布替尼的剂量；这些不良事件在34名患者中的30名（88%）得到了改善。在研究完成时，仍有27%的患者在继续接受伊布替尼一线治疗。这项具有里程碑意义的RESONATE-2研究明确了伊布替尼一线治疗的中位PFS，并证明了其对CLL/SLL患者（包括具有高风险基因组特征的患者）的持续OS获益。伊布替尼持续的疗效和良好的耐受性再次强调了其有利的获益-风险比。该试验已在www.ClinicalTrials.gov注册，注册号为NCT01722487/NCT01724346。

### 第二部分 AI 大师评价

该研究是里程碑式的RESONATE-2临床试验的最终分析，通过长达十年的随访数据，明确了伊布替尼作为CLL/SLL一线治疗方案的长期疗效与安全性。研究的核心发现是，与传统化疗药物苯丁酸氮芥相比，伊布替尼显著延长了患者的中位无进展生存期至近9年，并展现出持续的总生存获益，即便在高风险基因亚组中依然如此。这项研究以其超长期的随访数据，为伊布替尼在CLL/SLL一线治疗中的基石地位提供了最高级别的循证医学证据，深刻影响了临床实践指南，并为患者预后评估和治疗决策提供了关键信息。

---

## 165. 回复Masatomo Kaneko等人关于Baris Turkbey等人《PI-RADS指导委员会：初次活检男性前列腺癌MRI检测的AI开发与报告要求（1.0版）》一文的读者来信

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40731193](https://pubmed.ncbi.nlm.nih.gov/40731193)
**期刊：** European urology
**PMID：** 40731193
**DOI：** 10.1016/j.eururo.2025.07.005

### 第一部分 原文与翻译

**英文原标题：** Reply to Masatomo Kaneko, Vasileios Magoulianitis, Vinay Duddalwar, et al's Letter to the Editor re: Baris Turkbey, Henkjan Huisman, Andriy Fedorov, et al. Requirements for AI Development and Reporting for MRI Prostate Cancer Detection in Biopsy-naive Men: PI-RADS Steering Committee, Version 1.0. Radiology 2025;315:e240140.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

本文是一篇针对读者来信的回复，其核心是围绕PI-RADS指导委员会发布的《针对初次活检男性前列腺癌MRI检测的人工智能开发与报告要求（1.0版）》这一重要指导性文件展开的学术讨论。虽然没有提供摘要，但从标题可推断，原作者们正在回应其他学者对该标准提出的问题或评论，这反映了学术界对前列腺癌AI诊断标准化的密切关注。此类学术对话对于推动AI技术在临床诊断中的规范化应用、完善指导原则具有重要价值，有助于促进该领域的共识形成。

---

## 166. 髓系肿瘤TP53突变临床指南

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40729726](https://pubmed.ncbi.nlm.nih.gov/40729726)
**期刊：** Blood
**PMID：** 40729726
**DOI：** 10.1182/blood.2025029691

### 第一部分 原文与翻译

**英文原标题：** A clinical guide to TP53 mutations in myeloid neoplasms.

**英文摘要原文：**
TP53 mutations are found in 10% to 15% of myeloid neoplasms and are one of its most important prognostic factors. Emerging data show that TP53 mutational allele status is a key determinant of clinical outcomes, with multihit TP53 mutant myeloid neoplasms having a very poor prognosis. Significant differences exist among the methods used in clinical and research settings to assess TP53 mutational status, leading to variability in reported patient characteristics, response to therapy, and survival. Indeed, differences in the criteria used to define TP53 mutational states among professional societies and in landmark research studies have led to confusion, suboptimal clinical testing, and variability in therapy recommendations. We review the methods used to assess for TP53 mutational allele status and provide recommendations, based on clinically available testing, for the accurate evaluation of TP53 gene mutations in myeloid neoplasms. Hotspot mutations represent ∼35% of all TP53 missense mutations in myeloid neoplasms. There is evidence that these hotspot mutations may have dominant-negative or gain-of-function properties. Here, we review this evidence and discuss the potential impact of TP53 mutation identity on patient outcomes and clinical management.

**中文摘要译文：**
TP53突变见于10%至15%的髓系肿瘤中，是其最重要的预后因素之一。新兴数据显示，TP53突变等位基因状态是临床结局的关键决定因素，其中TP53多重打击突变的髓系肿瘤患者预后极差。在临床和研究环境中所用的TP53突变状态评估方法存在显著差异，导致所报告的患者特征、治疗反应和生存率出现变异性。事实上，不同专业学会和里程碑式研究在定义TP53突变状态时所用标准的差异，已导致了认识混乱、临床检测欠佳以及治疗建议的多样性。本文综述了用于评估TP53突变等位基因状态的方法，并基于临床可及的检测技术，为准确评估髓系肿瘤中的TP53基因突变提供了建议。热点突变约占髓系肿瘤中所有TP53错义突变的35%。有证据表明，这些热点突变可能具有显性负效应或功能获得性特性。在此，我们回顾了这些证据，并探讨了TP53突变类型对患者结局和临床管理的潜在影响。

### 第二部分 AI 大师评价

该文献是一篇针对髓系肿瘤中TP53突变检测与解读的临床指南性综述。文章的核心目的在于解决当前临床和研究中因检测方法与判读标准不一所导致的混乱，并为TP53突变状态的准确评估提供标准化建议。作者系统回顾了TP53突变等位基因状态的评估方法，强调了多重打击突变的极端不良预后，并探讨了热点突变的生物学特性。此指南通过整合现有证据，为临床医生提供了清晰的检测策略和解读框架，对于规范临床实践、优化患者分层与治疗决策具有重要的指导价值。

---

## 167. 改良氟尿嘧啶、亚叶酸、伊立替康和奥沙利铂方案（mFOLFIRINOX）或S-1、伊立替康和奥沙利铂方案（S-IROX）对比白蛋白紫杉醇联合吉西他滨方案用于治疗转移性或复发性胰腺癌（GENERATE, JCOG1611）：一项随机、开放标签、II/III期试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40720715](https://pubmed.ncbi.nlm.nih.gov/40720715)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 40720715
**DOI：** 10.1200/JCO.24.00936

### 第一部分 原文与翻译

**英文原标题：** Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.

**英文摘要原文：**
PURPOSE: Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) and nab-paclitaxel + gemcitabine are recommended as first-line treatments for metastatic pancreatic cancer. S-1, irinotecan, and oxaliplatin (S-IROX) demonstrated activity in a phase Ib trial in this population. Therefore, these three regimens were directly compared.

METHODS: This randomized phase II/III trial was performed at 45 centers in Japan. Eligible patients age 20-75 years with an Eastern Cooperative Oncology Group performance status of 0 or 1 and pathologically confirmed metastatic or recurrent pancreatic cancer were randomly assigned (1:1:1) to receive mFOLFIRINOX (oxaliplatin 85 mg/m over 2 hours, irinotecan 150 mg/m over 90 minutes, l-leucovorin 200 mg/m over 2 hours, each once daily on day 1, and fluorouracil 2,400 mg/m over 46 hours on days 1-3, every 2 weeks), S-IROX (oxaliplatin 85 mg/m over 2 hours, irinotecan 150 mg/m over 90 minutes on day 1, and S-1 80 mg/m/day administered orally twice daily on days 1-7, every 2 weeks), or nab-paclitaxel (125 mg/m) + gemcitabine (1,000 mg/m) on days 1, 8, and 15 every 4 weeks. The primary end point was overall survival (OS).

RESULTS: A total of 527 patients were enrolled, with 426 included in the planned interim analysis. The median OS was 14.0 months (hazard ratio [HR], 1.31 [95% CI, 0.97 to 1.77]) and 13.6 months (HR, 1.35 [95% CI, 1.00 to 1.82]) in the mFOLFIRINOX and S-IROX groups, respectively, as compared with 17.1 months in the nab-paclitaxel + gemcitabine group. The predictive probability of achieving superiority in the final analysis was <1% in both groups. Thus, the trial was terminated owing to its futility. Grade 3 to 4 anorexia was more frequent in the mFOLFIRINOX (23.3%) and S-IROX (27.5%) groups than in the nab-paclitaxel + gemcitabine group (5.0%).

CONCLUSION: Neither mFOLFIRINOX nor S-IROX appeared to be superior compared with nab-paclitaxel + gemcitabine as the first-line treatment for metastatic or recurrent pancreatic cancer.

**中文摘要译文：**
目的：改良氟尿嘧啶、亚叶酸、伊立替康和奥沙利铂（mFOLFIRINOX）方案与白蛋白紫杉醇联合吉西他滨方案被推荐为转移性胰腺癌的一线治疗。S-1、伊立替康和奥沙利铂（S-IROX）方案在该患者人群的一项Ib期试验中显示出活性。因此，本研究对这三种方案进行了直接比较。

方法：这项随机II/III期试验在日本的45个中心进行。符合条件的患者年龄为20-75岁，东部协作肿瘤组（ECOG）体能状态评分为0或1，且经病理学确诊为转移性或复发性胰腺癌，被按1:1:1的比例随机分配接受mFOLFIRINOX方案（奥沙利铂85 mg/m²，输注2小时；伊立替康150 mg/m²，输注90分钟；左旋亚叶酸200 mg/m²，输注2小时，均在第1天给药；氟尿嘧啶2400 mg/m²，于第1-3天持续输注46小时，每2周重复），或S-IROX方案（奥沙利铂85 mg/m²，输注2小时；伊立替康150 mg/m²，输注90分钟，均在第1天给药；S-1 80 mg/m²/天，每日两次口服，于第1-7天给药，每2周重复），或白蛋白紫杉醇（125 mg/m²）联合吉西他滨（1000 mg/m²）方案（于第1、8、15天给药，每4周重复）。主要终点是总生存期（OS）。

结果：共入组527名患者，其中426名被纳入计划的中期分析。与白蛋白紫杉醇联合吉西他滨组的17.1个月相比，mFOLFIRINOX组和S-IROX组的中位总生存期分别为14.0个月（风险比[HR]，1.31 [95% CI, 0.97至1.77]）和13.6个月（HR，1.35 [95% CI, 1.00至1.82]）。两个试验组在最终分析中达到优效性的预测概率均<1%。因此，该试验因无效而终止。mFOLFIRINOX组（23.3%）和S-IROX组（27.5%）的3至4级食欲不振发生率高于白蛋白紫杉醇联合吉西他滨组（5.0%）。

结论：作为转移性或复发性胰腺癌的一线治疗，mFOLFIRINOX方案和S-IROX方案均未显示出优于白蛋白紫杉醇联合吉西他滨方案。

### 第二部分 AI 大师评价

本研究是一项重要的头对头随机II/III期临床试验，旨在直接比较mFOLFIRINOX、S-IROX与白蛋白紫杉醇联合吉西他滨方案一线治疗转移性或复发性胰腺癌的疗效。研究设计严谨，试图为临床实践中两种主流化疗方案的选择提供高级别证据。然而，研究结果出乎意料，显示两种基于奥沙利铂和伊立替康的方案在总生存期上均未优于白蛋白紫杉醇联合吉西他滨方案，最终因无效而提前终止。这一阴性结果具有重要的临床价值，它提示对于特定人群，mFOLFIRINOX的优势可能并非绝对，并强调了直接比较研究在优化治疗策略中的关键作用。

---

## 168. 可视化评分或可考虑用于肝细胞癌的监测

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40712937](https://pubmed.ncbi.nlm.nih.gov/40712937)
**期刊：** Gastroenterology
**PMID：** 40712937
**DOI：** 10.1053/j.gastro.2025.03.063

### 第一部分 原文与翻译

**英文原标题：** Visualization Score Might Be Considered for Hepatocellular Carcinoma Surveillance.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

本文探讨了将“可视化评分”纳入肝细胞癌（HCC）监测体系的潜在价值。作者可能提出，在诸如超声等影像学监测中，对肝脏可视化质量进行标准化评分，对于提高早期病变检出率至关重要，尤其是在肝硬化等成像困难的患者中。该提议的创新之处在于强调了影像质量的量化评估，旨在优化监测策略、减少漏诊风险。尽管本文可能为一封评论或观点性文章，缺少原创性研究数据，但它为解决当前HCC监测中的一个实际临床难题提供了新的视角，具有重要的临床指导意义。

---

## 169. 述评：《非增强磁共振成像与超声检查用于肝细胞癌监测的比较》

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40712936](https://pubmed.ncbi.nlm.nih.gov/40712936)
**期刊：** Gastroenterology
**PMID：** 40712936
**DOI：** 10.1053/j.gastro.2025.06.028

### 第一部分 原文与翻译

**英文原标题：** Thoughts on "Noncontrast Magnetic Resonance Imaging vs Ultrasonography for Hepatocellular Carcinoma Surveillance".

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇针对“非增强磁共振成像（MRI）与超声在肝细胞癌（HCC）监测中的对比研究”的述评性文章。从标题推断，本文并非一项原创性研究，而是对现有研究成果的深入讨论与评析。此类述评对于促进学术争鸣、深入解读关键研究的优势与局限性、并为临床实践指南的制定提供多角度的参考意见具有重要价值。由于缺乏摘要，无法获知作者的具体论点，但其讨论的核心议题——为肝癌高危人群选择最佳的影像学筛查工具——无疑是肝病学领域一个至关重要且持续探讨的热点。

---

## 170. 非对比增强MRI在肝细胞癌监测中的应用：临床实践实施考量

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40712935](https://pubmed.ncbi.nlm.nih.gov/40712935)
**期刊：** Gastroenterology
**PMID：** 40712935
**DOI：** 10.1053/j.gastro.2025.05.032

### 第一部分 原文与翻译

**英文原标题：** Noncontrast MRI in Hepatocellular Carcinoma Surveillance: Considerations for Implementation in Clinical Practice.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

根据标题判断，本文可能是一篇关于非对比增强磁共振成像（MRI）在肝细胞癌（HCC）监测中应用的综述或专家评述。该文聚焦于将此技术引入并应用于常规临床实践时需考量的关键因素，可能涉及其诊断性能、操作流程、成本效益及患者选择标准等。在寻求更安全、高效的HCC监测新方法的背景下，探讨非对比增强MRI的临床转化具有重要价值，尤其可能惠及无法使用含钆对比剂的患者群体。由于摘要缺失，文章的具体论证和结论需阅读原文方能获知。

---

## 171. α-酮戊二酸通过促进氨基酸耗竭来抑制B细胞淋巴瘤的生长与发展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40700634](https://pubmed.ncbi.nlm.nih.gov/40700634)
**期刊：** Blood
**PMID：** 40700634
**DOI：** 10.1182/blood.2024028069

### 第一部分 原文与翻译

**英文原标题：** α-Ketoglutarate promotes amino acid depletion and suppresses B-cell lymphoma growth and development.

**英文摘要原文：**
Targeting metabolic dependencies and "starving" malignant cells have long been considered potential strategies to treat cancer. However, with rare exceptions, the implementation of these maneuvers has been fraught with limited activity and lack of specificity. Multiple cytoplasmic and mitochondrial transaminases catalyze reactions that lead to amino acid catabolism. These enzymes use α-ketoglutarate (αKG) as a nitrogen acceptor, and accumulation of the competitive inhibitor metabolite D-2-hydroxyglutarate perturbs their function. We postulated that exogenous αKG supplementation would influence the directionality of these reactions and deplete amino acids in cancer cells. Using B-cell lymphoma as a model system, we found that αKG mediates a rapid and sustained amino acid depletion, principally of aspartate and branched-chain leucine, valine, and isoleucine. The decrease in leucine levels influenced mammalian target of rapamycin complex 1 (mTORC1) subcellular movement, suppressed its activity, and associated with inhibition of B-cell lymphoma growth in vitro and in vivo. Increasing import of aspartate or leucine levels in the lymphoma cells, genetically forcing mTORC1 lysosomal localization or blocking leucine catabolism through branched-chain amino acid transaminase 2 deletion, all blunted the antilymphoma effects of αKG. In addition, long-term dietary supplementation of αKG, a toxicity-free strategy, significantly hindered lymphoma development in Eμ-Myc mice, in association with amino acid perturbation and impaired energy generation. We posit that αKG supplementation, which has been shown to improve health and life span in mice, also encodes marked anticancer properties.

**中文摘要译文：**
靶向代谢依赖性并“饿死”恶性细胞一直被认为是治疗癌症的潜在策略。然而，除了少数例外，这些方法的实施普遍存在活性有限和缺乏特异性的问题。多种细胞质和线粒体转氨酶催化导致氨基酸分解代谢的反应。这些酶利用α-酮戊二酸（αKG）作为氮受体，而其竞争性抑制剂代谢物D-2-羟基戊二酸的积累会干扰其功能。我们假设，外源性补充αKG会影响这些反应的方向性，从而耗尽癌细胞中的氨基酸。以B细胞淋巴瘤为模型系统，我们发现αKG介导了快速且持续的氨基酸耗竭，主要是天冬氨酸和支链氨基酸（亮氨酸、缬氨酸和异亮氨酸）。亮氨酸水平的下降影响了哺乳动物雷帕霉素靶蛋白复合物1（mTORC1）的亚细胞定位，抑制了其活性，并与体外及体内B细胞淋巴瘤的生长抑制相关。通过增加淋巴瘤细胞中天冬氨酸或亮氨酸的输入、基因手段强制mTORC1溶酶体定位，或通过删除支链氨基酸转氨酶2来阻断亮氨酸分解代谢，这些措施均减弱了αKG的抗淋巴瘤效应。此外，长期通过饮食补充αKG（一种无毒性策略）能显著抑制Eμ-Myc小鼠淋巴瘤的发展，这与氨基酸紊乱和能量生成受损有关。我们认为，已被证明能改善小鼠健康和延长寿命的αKG补充剂，同样具有显著的抗癌特性。

### 第二部分 AI 大师评价

本研究旨在探索α-酮戊二酸（αKG）对B细胞淋巴瘤的抗癌潜力。研究团队通过体外和体内模型证实，外源性补充αKG能有效耗尽淋巴瘤细胞内的关键氨基酸（特别是天冬氨酸和支链氨基酸），进而抑制mTORC1信号通路，最终抑制肿瘤生长。其创新之处在于揭示了αKG作为一种代谢调节剂，通过“饿死”肿瘤细胞发挥抗癌作用的新机制，为“代谢疗法”提供了坚实的理论与实验依据。这项发现不仅为B细胞淋巴瘤的治疗提供了一种低毒、高效的潜在策略，也为开发基于代谢重编程的癌症疗法开辟了新思路。

---

## 172. 生命早期的Colibactin暴露与早发性结直肠癌的发生相关。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40691977](https://pubmed.ncbi.nlm.nih.gov/40691977)
**期刊：** Gastroenterology
**PMID：** 40691977
**DOI：** 10.1053/j.gastro.2025.07.018

### 第一部分 原文与翻译

**英文原标题：** Early-Life Colibactin Exposure Is Associated With Early-Onset Colorectal Cancer Occurrence.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

根据该文献标题，本研究旨在探索生命早期接触Colibactin（一种由特定大肠杆菌产生的基因毒性素）与早发性结直肠癌发病之间的关联。研究的核心发现表明两者之间存在正相关性，这对于理解早发性结直肠癌发病率上升的潜在机制具有重要意义。此研究的创新之处在于将特定的微生物暴露窗口（生命早期）与这一日益严峻的临床问题联系起来，为未来的预防策略和高危人群筛查提供了新靶点。然而，由于缺乏摘要，无法评估其具体研究设计和关联强度，这是解读该结论时需注意的关键局限性。

---

## 173. 转移性前列腺癌治疗新策略

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40685286](https://pubmed.ncbi.nlm.nih.gov/40685286)
**期刊：** European urology
**PMID：** 40685286
**DOI：** 10.1016/j.eururo.2025.06.013

### 第一部分 原文与翻译

**英文原标题：** Novel Therapeutic Strategies for Metastatic Prostate Cancer Care.

**英文摘要原文：**
BACKGROUND AND OBJECTIVE: The elucidation of prostate cancer biology and genomics has led to new therapies improving disease outcomes with novel androgen receptor (AR) pathway inhibitors (ARPIs), taxanes, and targeted therapeutics that require disease molecular stratification.

METHODS: We are presenting a narrative and qualitative synthesis based on a systematic search. Medline (PubMed) and Embase (OvidSP) were searched (October 1, 2024, covering 2019-2024) using keywords and Medical Subject Headings terms; ClinicalTrials.gov and ASCO/ESMO abstracts were also reviewed. The inclusion criteria were phase 1-3 studies on molecular targets or therapies for metastatic prostate cancer with posted results. The exclusion criteria included non-English articles, reviews, meta-analyses, commentaries, case reports, duplicates, nonhuman/preclinical studies, protocols, and studies lacking molecular targets.

KEY FINDINGS AND LIMITATIONS: Targeted therapies have emerged for specific molecular subtypes of advanced prostate cancer. For instance, poly(ADP)-ribose polymerase inhibitors target DNA repair defective prostate cancer (especially BRCA2 and PALB2 biallelic loss). Immune checkpoint inhibitors against PD-1/PD-L1 are effective in hypermutated prostate cancer cases, especially those with mismatch repair defective (MMRd) disease. Additionally, 177Lu-PSMA-617 impacts prostate-specific membrane antigen (folate hydrolase) expressing disease. Several other major therapeutic advances are envisioned in the near future, including targeting novel cell surface proteins with T-cell engager antibody constructs, immunoconjugates, and radiopharmaceuticals. Other rational therapeutic strategies are being pursued, targeting continued AR signalling; AR cofactors, for example, P300; PI3K/AKT signalling; the PRC2 complex protein including EZH2; as well as novel synthetic lethal strategies.

CONCLUSIONS AND CLINICAL IMPLICATIONS: A rapidly evolving standard of care is anticipated for metastatic prostate cancer, making it imperative that rational registration trial designs incorporating multipurpose biomarkers to accelerate anticancer drug development are pursued.

**中文摘要译文：**
背景与目的：对前列腺癌生物学和基因组学的阐明催生了新的疗法，通过新型雄激素受体（AR）通路抑制剂（ARPIs）、紫杉烷类药物以及需要疾病分子分层的靶向治疗，改善了疾病结局。

方法：我们基于系统性搜索，呈现了一篇叙述性和定性的综述。我们检索了Medline (PubMed)和Embase (OvidSP)数据库（检索日期为2024年10月1日，覆盖2019-2024年），使用了关键词和医学主题词（MeSH）；同时还审阅了ClinicalTrials.gov以及ASCO/ESMO的会议摘要。纳入标准为已公布结果的、针对转移性前列腺癌分子靶点或疗法的1-3期研究。排除标准包括非英语文章、综述、荟萃分析、评论、病例报告、重复发表、非人类/临床前研究、研究方案以及缺乏分子靶点的研究。

主要发现与局限性：针对晚期前列腺癌特定分子亚型的靶向疗法已经涌现。例如，多聚（ADP-核糖）聚合酶（PARP）抑制剂靶向DNA修复缺陷型前列腺癌（特别是BRCA2和PALB2双等位基因缺失）。针对PD-1/PD-L1的免疫检查点抑制剂在高突变前列腺癌病例中有效，尤其是错配修复缺陷（MMRd）型疾病。此外，177Lu-PSMA-617对表达前列腺特异性膜抗原（叶酸水解酶）的疾病有效。预计在不远的将来，还将出现其他几项重大治疗进展，包括利用T细胞衔接抗体构建体、免疫偶联药物和放射性药物靶向新型细胞表面蛋白。其他合理的治疗策略也正在探索中，靶向持续的AR信号通路、AR辅因子（如P300）、PI3K/AKT信号通路、包括EZH2在内的PRC2复合体蛋白，以及新型合成致死策略。

结论与临床意义：预计转移性前列腺癌的治疗标准将迅速演变，因此，当务之急是推行合理的注册性临床试验设计，并整合多用途生物标志物，以加速抗癌药物的研发。

### 第二部分 AI 大师评价

该综述旨在系统性梳理2019至2024年间转移性前列腺癌治疗领域的新进展。作者通过对主要医学数据库及会议摘要的叙述性和定性综合分析，总结了当前精准治疗的现状。其核心发现是，基于分子分型的靶向治疗（如PARP抑制剂、免疫疗法及PSMA靶向放射性药物）已成为主流，并展望了T细胞衔接器、免疫偶联药物等未来方向。此文献为临床医生和研究者提供了该领域前沿动态的宝贵概览，并强调了生物标志物在未来药物研发中的关键作用。

---

## 174. 答复。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40685019](https://pubmed.ncbi.nlm.nih.gov/40685019)
**期刊：** Gastroenterology
**PMID：** 40685019
**DOI：** 10.1053/j.gastro.2025.07.014

### 第一部分 原文与翻译

**英文原标题：** Reply.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

根据所提供的信息，该文献标题为“答复”，且无摘要，这通常表明它并非一篇原创性研究论文，而可能是一封致编辑的信、对先前发表文章的评论的回应，或是学术讨论的一部分。因此，无法像评估原创研究那样分析其具体的研究目的、方法和关键发现。此类文献的价值在于促进学术交流和深入探讨特定研究领域的问题，但其具体内容和学术影响力需阅读全文后方能判断。

---

## 175. TREM2在胰腺导管腺癌中作用的进一步探讨

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40685018](https://pubmed.ncbi.nlm.nih.gov/40685018)
**期刊：** Gastroenterology
**PMID：** 40685018
**DOI：** 10.1053/j.gastro.2025.02.047

### 第一部分 原文与翻译

**英文原标题：** Further Dimensions of the Role of TREM2 in Pancreatic Ductal Adenocarcinoma.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文聚焦于TREM2蛋白在胰腺导管腺癌（PDAC）这一恶性肿瘤中的作用。鉴于文章发表于顶级期刊《Gastroenterology》且标题具有探讨性，本文可能是一篇深度综述或特邀评论，旨在揭示TREM2在PDAC肿瘤微环境，特别是在调控免疫细胞功能方面的新维度。该文可能整合了最新研究进展，对TREM2作为潜在治疗靶点的价值和未来研究方向进行了展望，对于理解PDAC的免疫病理机制具有重要的学术意义。由于摘要缺失，具体的论点和证据需详阅原文方能获知。

---

## 176. 基于全面家族史的风险适应性结直肠癌筛查起始年龄

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40681119](https://pubmed.ncbi.nlm.nih.gov/40681119)
**期刊：** Gastroenterology
**PMID：** 40681119
**DOI：** 10.1053/j.gastro.2025.06.027

### 第一部分 原文与翻译

**英文原标题：** Risk-Adapted Starting Ages for Colorectal Cancer Screening Based on Comprehensive Family History.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究旨在基于全面的家族史信息，建立风险适应性的结直肠癌筛查起始年龄建议。其核心创新在于，它可能超越了传统依赖一级亲属病史的简化模式，试图通过更详尽的家族史数据来精确评估个体患病风险，从而实现个性化的筛查推荐。该方法有望优化筛查资源配置，对高风险人群进行更早的干预，同时避免对低风险人群的过度筛查，对于推进结直肠癌的精准预防具有重要的临床指导价值。

---

## 177. 关于结直肠癌与家族性息肉史的思考

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40659251](https://pubmed.ncbi.nlm.nih.gov/40659251)
**期刊：** Gastroenterology
**PMID：** 40659251
**DOI：** 10.1053/j.gastro.2025.01.262

### 第一部分 原文与翻译

**英文原标题：** Thoughts on Colorectal Cancer and Family Polyp History.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

根据标题判断，本文可能是一篇关于结直肠癌与家族性息肉史之间关系的述评或观点性文章，而非原创性研究。文章可能深入探讨了如何评估和管理有息肉家族史个体的结直肠癌风险，并对当前的筛查策略提出见解。鉴于其发表在胃肠病学领域的顶级期刊《Gastroenterology》，该文很可能代表了权威专家的深刻思考，对于临床医生和研究人员在该领域的实践和探索具有重要的指导价值。由于缺乏摘要，无法获知其具体论点与论据。

---

## 178. 关于亲属中息肉诊断频率与结直肠癌风险的进一步探索

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40653034](https://pubmed.ncbi.nlm.nih.gov/40653034)
**期刊：** Gastroenterology
**PMID：** 40653034
**DOI：** 10.1053/j.gastro.2025.03.062

### 第一部分 原文与翻译

**英文原标题：** Further Exploration of the Frequency of Polyp Diagnosis in Relatives and the Risk of Colorectal Cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究旨在深入探讨亲属中结直肠息肉的诊断频率与个体患结直肠癌风险之间的关联性。此研究方向具有重要的临床价值，其结果可能为结直肠癌的风险评估和筛查策略提供新依据，特别是在解读家族史时，有望将关注点从癌症史扩展到更为前置的息肉史。由于摘要信息的缺失，无法获知其具体的研究设计、队列特征及关键发现。若研究能证实强关联性，将对制定更精准的个体化筛查建议具有重要指导意义。

---

## 179. 关于亲属结直肠息肉诊断频率与结直肠癌风险关系的新见解

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40653033](https://pubmed.ncbi.nlm.nih.gov/40653033)
**期刊：** Gastroenterology
**PMID：** 40653033
**DOI：** 10.1053/j.gastro.2025.01.263

### 第一部分 原文与翻译

**英文原标题：** Insights on the Relationship Between Risk of Colorectal Cancer and the Frequency of Colorectal Polyp Diagnosis in Relatives.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究旨在探讨亲属中结直肠息肉的诊断频率与个体结直肠癌风险之间的关联。其潜在价值在于，它可能通过量化家族息肉史的影响，为结直肠癌的风险分层和筛查策略提供更精细化的依据，从而超越了传统的是/否家族史评估。若研究结论明确，将对临床实践中制定个体化筛查建议具有重要指导意义。由于暂无摘要，无法深入评估其具体研究设计、发现和局限性。

---

## 180. 推进家族性结直肠癌的风险分层：呼吁进行更全面的评估

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40653032](https://pubmed.ncbi.nlm.nih.gov/40653032)
**期刊：** Gastroenterology
**PMID：** 40653032
**DOI：** 10.1053/j.gastro.2025.01.264

### 第一部分 原文与翻译

**英文原标题：** Advancing Risk Stratification in Familial Colorectal Cancer: A Call for More Comprehensive Assessment.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

从标题来看，本文可能是一篇评论或倡议性文章，聚焦于优化家族性结直肠癌的风险分层策略。作者的核心观点是，现有评估方法尚存不足，因此呼吁医学界进行更全面的风险评估，以更精准地识别高危人群。尽管缺乏摘要信息，但该文的价值在于前瞻性地指出了该领域的关键挑战，可能对推动个体化筛查方案的制定和未来研究方向具有重要的启发意义。

---

## 181. 回复

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40653031](https://pubmed.ncbi.nlm.nih.gov/40653031)
**期刊：** Gastroenterology
**PMID：** 40653031
**DOI：** 10.1053/j.gastro.2025.07.005

### 第一部分 原文与翻译

**英文原标题：** Reply.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

该文献类型为“回复”，通常是研究作者针对其他学者对其先前发表文章的评论或提问所做的书面回应。由于没有提供摘要，无法得知其具体回应内容和学术观点。此类文献对于促进学术交流、澄清研究细节和推动科学讨论具有重要作用，但其本身并非原创性研究，需结合其回应的原文和评论才能全面理解其价值。

---

## 182. 关于《应用粪便免疫化学检测对因结直肠癌症状转诊行诊断性结肠镜检查的患者进行风险分层》一文的评论

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40645379](https://pubmed.ncbi.nlm.nih.gov/40645379)
**期刊：** Gastroenterology
**PMID：** 40645379
**DOI：** 10.1053/j.gastro.2025.04.044

### 第一部分 原文与翻译

**英文原标题：** Comments on "Use of Fecal Immunochemical Testing for Risk Stratification of Patients With Symptoms of Colorectal Cancer Referred for Diagnostic Colonoscopy".

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文是一篇针对特定研究的学术评论，而非原创性研究。其核心目的在于对“应用粪便免疫化学检测（FIT）对有结直肠癌症状并转诊进行结肠镜检查的患者进行风险分层”的研究成果进行深入探讨。由于本文为评论性质且无摘要，其具体观点需阅读原文获知，但通常此类文章旨在指出原研究的潜在方法学局限、结果解读的争议或临床应用价值的商榷之处。这类学术讨论对于促进科学对话、确保研究结论的严谨性以及指导未来临床实践具有重要的补充价值。

---

## 183. 对潘正波、施然和周兆开读者来信的回复——关于Madeleine J. Karpinski等人的研究：“通过前列腺特异性膜抗原正电子发射断层扫描前列腺癌分子成像标准化评估（PPP2）更新前列腺癌风险分层：一项国际多中心注册研究的结果”

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40555569](https://pubmed.ncbi.nlm.nih.gov/40555569)
**期刊：** European urology
**PMID：** 40555569
**DOI：** 10.1016/j.eururo.2025.06.006

### 第一部分 原文与翻译

**英文原标题：** Reply to Zhengbo Pan, Run Shi, and Zhaokai Zhou's Letter to the Editor - Re: Madeleine J. Karpinski, Kambiz Rahbar, Martin Bögemann, et al. Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study. Eur Urol. 2025;88:484-495.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

该文献是一篇针对特定研究的“读者来信回复”，其本身并非原创性研究，因此无摘要。它围绕Madeleine J. Karpinski等人提出的PSMA-PET前列腺癌分子成像标准化评估（PPP2）风险分层研究展开学术讨论。此类文献对于澄清原始研究中的潜在争议、补充关键背景信息或探讨研究局限性具有重要价值，能够促进该领域内学术对话的深入和对研究结论的审慎解读。

---

## 184. 回复：关于Madeleine J. Karpinski、Kambiz Rahbar、Martin Bögemann等人发表于《欧洲泌尿外科》2025年第88卷484-495页的文章《通过前列腺特异性膜抗原正电子发射断层扫描的前列腺癌分子影像标准化评估（PPP2）更新前列腺癌风险分组：一项国际多中心注册研究的结果》

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40544123](https://pubmed.ncbi.nlm.nih.gov/40544123)
**期刊：** European urology
**PMID：** 40544123
**DOI：** 10.1016/j.eururo.2025.05.041

### 第一部分 原文与翻译

**英文原标题：** Re: Madeleine J. Karpinski, Kambiz Rahbar, Martin Bögemann, et al. Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study. Eur Urol. 2025;88:484-495.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇针对Karpinski等人在《欧洲泌尿外科》上发表的重要研究的学术评论。原文提出利用PSMA-PET影像学结果来更新前列腺癌的风险分组，这是一项具有革新意义的国际多中心研究。本篇评论（信函）虽然没有摘要，但其性质决定了它很可能针对原文的研究设计、数据解读或临床应用价值等关键问题提出了深刻见解或建设性质疑。因此，该文献对于促进学术讨论、全面评估PSMA-PET在临床风险分层中的作用具有重要价值。

---

## 185. 回复：Baris Turkbey、Henkjan Huisman、Andriy Fedorov等人所著《关于未接受活检的男性前列腺癌MRI检测的人工智能开发与报告要求：PI-RADS指导委员会，1.0版》一文

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40544122](https://pubmed.ncbi.nlm.nih.gov/40544122)
**期刊：** European urology
**PMID：** 40544122
**DOI：** 10.1016/j.eururo.2025.06.007

### 第一部分 原文与翻译

**英文原标题：** Re: Baris Turkbey, Henkjan Huisman, Andriy Fedorov, et al. Requirements for AI Development and Reporting for MRI Prostate Cancer Detection in Biopsy-Naïve Men: PI-RADS Steering Committee, Version 1.0. Radiology 2025;315:e24014.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该文献是一篇针对PI-RADS指导委员会发布的《关于未接受活检的男性前列腺癌MRI检测的人工智能开发与报告要求》指南的评论性文章。虽然没有摘要，但从标题可以看出，本文旨在对人工智能在前列腺癌MRI诊断领域的标准化开发和报告流程提出反馈或讨论。此类学术通信对于完善新兴技术的临床应用规范、促进多学科共识至关重要，可能从泌尿外科临床实践角度对原始指南提出了重要的补充意见或建设性质疑，对未来AI产品在该领域的落地和评估具有指导意义。

---

## 186. 关于“高级别T1期膀胱癌的保留膀胱三联疗法：NRG肿瘤学/RTOG 0926 II期方案的结果”的回复

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40500682](https://pubmed.ncbi.nlm.nih.gov/40500682)
**期刊：** European urology
**PMID：** 40500682
**DOI：** 10.1016/j.eururo.2025.05.027

### 第一部分 原文与翻译

**英文原标题：** Re: Bladder-preserving Trimodality Treatment for High-grade T1 Bladder Cancer: Results from Phase II Protocol NRG Oncology/RTOG 0926.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

该文献是一篇针对NRG Oncology/RTOG 0926 II期临床试验结果的评论或信函。其核心是围绕“高级别T1期膀胱癌的保留膀胱三联疗法”这一重要临床议题展开讨论。虽然该文献本身并非原创性研究，但它通过对现有研究的评述，可能对该研究的结论、方法学或临床应用提出重要的见解或质疑。这类学术通信对于促进科学对话、深入解读关键研究以及指导未来临床实践具有积极意义。

---

## 187. 关于“应用深度学习在计算机断层扫描中鉴别不同组织学类型的肾肿瘤”的回复

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40484756](https://pubmed.ncbi.nlm.nih.gov/40484756)
**期刊：** European urology
**PMID：** 40484756
**DOI：** 10.1016/j.eururo.2025.05.028

### 第一部分 原文与翻译

**英文原标题：** Re: Using Deep Learning To Differentiate Among Histology Renal Tumor Types in Computed Tomography Scans.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇针对“应用深度学习在CT扫描中鉴别肾肿瘤组织学类型”这一研究的评论或回复。它并非一项原创性研究，因此没有提供新的实验数据或方法。此类文献的核心价值在于促进学术讨论，可能对原始研究的方法学、结果解读或临床应用前景提出了质疑、补充或见解。虽然没有摘要，但可以推断其内容聚焦于深度学习在肾脏肿瘤影像诊断领域的具体应用挑战与前景，为相关领域的学者提供了批判性的视角。

---

## 188. 我们的执业范围：消化科中针对胃肠道癌症和息肉病的遗传风险评估与检测

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40484140](https://pubmed.ncbi.nlm.nih.gov/40484140)
**期刊：** Gastroenterology
**PMID：** 40484140
**DOI：** 10.1053/j.gastro.2025.06.001

### 第一部分 原文与翻译

**英文原标题：** In Our Scope of Practice: Genetic Risk Assessment and Testing for Gastrointestinal Cancers and Polyposis in Gastroenterology.

**英文摘要原文：**
Gastrointestinal clinicians are a critical touchpoint for individuals at risk for genetic and familial syndromes that increase risk of colorectal, gastric, and pancreatic cancer. Although advances in sequencing technology and reduced costs have made genetic testing more readily accessible to clinicians and even to patients through direct-to-consumer testing, uptake of genetic testing remains underused. This is a missed opportunity to identify patients and family members who could benefit from genetic testing to diagnose cancer susceptibility syndromes for which surveillance and preventive interventions exist. Barriers for integration of genetic testing in routine practice include lack of awareness about genetic conditions by patients and providers, concerns about genetic testing costs and implications for insurability, as well as challenges in implementing algorithms for risk assessment and coordinated care in complex medical systems. This review addresses current evidence and guidelines for cancer risk assessment, genetic testing, and management to enable gastrointestinal clinicians to identify and care for individuals with genetic cancer-predisposition syndromes in routine practice.

**中文摘要译文：**
对于存在增加结直肠癌、胃癌和胰腺癌风险的遗传性及家族性综合征的个体而言，消化科临床医生是一个关键的接触点。尽管测序技术的进步和成本的降低使得临床医生，甚至患者（通过直接面向消费者的检测），能够更便捷地获得基因检测，但基因检测的利用率仍然不足。这错失了识别那些可从基因检测中受益的患者及其家人的机会，这些检测有助于诊断已存在监测和预防性干预措施的癌症易感综合征。将基因检测整合到常规实践中的障碍包括患者和医疗服务提供者对遗传性疾病缺乏认识、对基因检测成本及其对保险资格影响的担忧，以及在复杂的医疗体系中实施风险评估算法和协调护理所面临的挑战。本篇综述旨在探讨癌症风险评估、基因检测和管理方面的当前证据与指南，以帮助消化科临床医生在常规实践中识别并照护患有遗传性癌症易感综合征的个体。

### 第二部分 AI 大师评价

本篇综述明确指出了基因检测在胃肠道肿瘤高风险人群中应用不足的现状，并系统性地剖析了其在临床实践中整合的障碍。文章的核心价值在于，它不仅是知识的梳理，更是一份面向消化科临床医生的行动指南，旨在通过总结现有的证据与指南，赋能医生将遗传风险评估与检测融入日常诊疗。该文强调了消化科医生在癌症预防与早期诊断中的前沿角色，对于推动遗传咨询和精准医疗在消化领域的普及具有重要的临床指导意义。

---

## 189. 回复：关于p53和Ki-67表达状态在阴茎癌中预后价值的系统回顾与荟萃分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40483230](https://pubmed.ncbi.nlm.nih.gov/40483230)
**期刊：** European urology
**PMID：** 40483230
**DOI：** 10.1016/j.eururo.2025.05.030

### 第一部分 原文与翻译

**英文原标题：** Re: The Prognostic Value of p53 and Ki-67 Expression Status in Penile Cancer: A Systematic Review and Meta-analysis.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

本文是一篇针对先前发表的关于“p53和Ki-67在阴茎癌中预后价值的系统回顾与荟萃分析”的读者来信或评论。此类文章在学术交流中扮演着重要角色，通常对原文的研究方法、结果解读或结论提出补充、质疑或讨论。虽然没有摘要，但可以推断其内容聚焦于原研究的关键细节，旨在促进对该领域证据的更深入理解和严谨评估，体现了学术探讨的活力。

---

## 190. 回复：关于多基因风险评分在前列腺癌筛查中应用的评估

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40483229](https://pubmed.ncbi.nlm.nih.gov/40483229)
**期刊：** European urology
**PMID：** 40483229
**DOI：** 10.1016/j.eururo.2025.05.029

### 第一部分 原文与翻译

**英文原标题：** Re: Assessment of a Polygenic Risk Score in Screening for Prostate Cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇针对“多基因风险评分（PRS）在前列腺癌筛查中的应用评估”这一主题的评论或回复。此类文章通常对原始研究提出见解、质疑或补充证据，是学术讨论的重要组成部分。它反映了科学界对利用多基因风险评分改进前列腺癌筛查策略这一前沿课题的持续关注和深入探讨。由于缺乏摘要，无法详述其具体论点，但其存在本身即凸显了该领域方法学和临床应用验证的重要性。

---

## 191. 关于炎症性肠病临床试验中皮质类固醇规范管理的国际共识

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40446946](https://pubmed.ncbi.nlm.nih.gov/40446946)
**期刊：** Gastroenterology
**PMID：** 40446946
**DOI：** 10.1053/j.gastro.2025.05.015

### 第一部分 原文与翻译

**英文原标题：** An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease.

**英文摘要原文：**
BACKGROUND & AIMS: Approval of new therapies for inflammatory bowel disease (IBD) requires rigorously designed and well-executed randomized controlled trials (RCTs). Corticosteroids remain a cornerstone of IBD induction therapy, and many patients in trials are enrolled while taking corticosteroids. Despite this, approaches to corticosteroid management in RCTs have been highly heterogeneous, often differing from clinical practice. This negatively impacts patients' willingness to participate due to prolonged corticosteroid exposure and may potentially bias outcomes in the clinical trial. Our aim is to provide comprehensive standardized recommendations on key aspects of corticosteroid use in IBD clinical trials through a multiphase, international expert consensus, with a goal to help inform and standardize practice in future RCTs.

METHODS: The consensus was informed by a systematic review of MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, which determined the corticosteroid management rules used in placebo-controlled trials of advanced therapies in IBD. International expert consensus recommendations for all aspects of corticosteroid management in RCTs were then developed using a modified Delphi process with 2 rounds of survey questions and a ratification meeting.

RESULTS: These recommendations propose management of corticosteroids during screening, induction, and maintenance phases of pharmacologic trials in IBD and define corticosteroid-related end points. We emphasize the need for minimizing corticosteroid exposure through expedited tapering and shorter fixed-dosing periods that more closely reflect clinical care and provide recommendations for standardized definitions of corticosteroid-free remission.

CONCLUSIONS: These recommendations will serve to optimize trial design and facilitate appropriate, acceptable, and standardized RCT corticosteroid handling practices.

**中文摘要译文：**
背景与目的：炎症性肠病（IBD）新疗法的获批需要设计严谨、执行良好的随机对照试验（RCTs）。皮质类固醇仍是IBD诱导治疗的基石，许多入组试验的患者正在服用皮质类固醇。尽管如此，RCTs中皮质类固醇的管理方法一直高度异质，且常与临床实践不同。这会因延长皮质类固醇暴露而对患者的参与意愿产生负面影响，并可能对临床试验的结局造成偏倚。我们的目标是通过一项多阶段的国际专家共识，为IBD临床试验中皮质类固醇使用的关键方面提供全面的标准化建议，以期为未来的RCTs提供信息并规范其实践。

方法：该共识基于一项对MEDLINE、Embase和Cochrane对照试验中心注册库的系统性综述，该综述明确了IBD前沿疗法的安慰剂对照试验中所使用的皮质类固醇管理规则。随后，采用改良的德尔菲法，通过两轮问卷调查和一次批准会议，制定了关于RCTs中皮质类固醇管理所有方面的国际专家共识建议。

结果：这些建议提出了IBD药物试验中筛选、诱导和维持阶段的皮质类固醇管理方案，并定义了与皮质类固醇相关的终点。我们强调需要通过加速减量和缩短固定剂量期来最大限度地减少皮质类固醇暴露，以更紧密地反映临床实践，并为“无皮质类固醇缓解”的标准化定义提供建议。

结论：这些建议将有助于优化试验设计，并促进恰当、可接受且标准化的RCT皮质类固醇处理实践。

### 第二部分 AI 大师评价

该研究旨在解决炎症性肠病（IBD）临床试验中皮质类固醇管理异质性的关键问题。通过系统性回顾与国际专家德尔菲法，本共识为试验的筛选、诱导及维持各阶段提出了标准化的皮质类固醇使用建议，并明确了相关终点。其核心价值在于倡导加速减量以减少患者暴露，使试验设计更贴近临床实践，从而有望提升未来IBD研究的科学性、安全性和结果的可比性，对优化新药研发路径具有重要指导意义。

---

## 192. 回复：关于磁共振成像与经尿道切除术在新发膀胱癌分期中的随机比较：前瞻性BladderPath试验的结果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40393865](https://pubmed.ncbi.nlm.nih.gov/40393865)
**期刊：** European urology
**PMID：** 40393865
**DOI：** 10.1016/j.eururo.2025.05.011

### 第一部分 原文与翻译

**英文原标题：** Re: Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results from the Prospective BladderPath Trial.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该文献是一篇针对“BladderPath”临床试验结果的评论或回复。该试验旨在前瞻性地随机比较MRI与标准经尿道切除术（TUR）在新发膀胱癌分期中的作用，这是一个具有重要临床意义的课题，因为精确分期是决定治疗策略的关键。虽然本文献本身未提供摘要，但其标题表明它参与了关于非侵入性影像学技术（MRI）能否挑战或补充传统有创性分期手术（TUR）的学术讨论。这类学术交流对于验证和推广新的诊断标准、澄清研究局限性至关重要，有助于推动膀胱癌诊疗路径的优化。

---

## 193. 巴雷特食管患者定期监测与按需内镜检查的成本效益分析：伴随巴雷特食管监测研究（BOSS）随机对照试验的经济学评价

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40383306](https://pubmed.ncbi.nlm.nih.gov/40383306)
**期刊：** Gastroenterology
**PMID：** 40383306
**DOI：** 10.1053/j.gastro.2025.04.026

### 第一部分 原文与翻译

**英文原标题：** Cost-Effectiveness of Regular Surveillance Versus Endoscopy at Need for Patients With Barrett's Esophagus: Economic Evaluation Alongside the Barrett's Oesophagus Surveillance Study (BOSS) Randomized Controlled Trial.

**英文摘要原文：**
BACKGROUND & AIMS: The Barrett's Oesophagus Surveillance Study (BOSS) was the first randomized study of surveillance. This study reports the costs and quality of life outcomes from the BOSS trial and models the outcomes and cost-effectiveness of surveillance beyond the follow-up period of the BOSS study. This trial showed similar stages and rates of esophageal cancer in both arms, but the regular surveillance arm did identify more high-grade dysplasia after a median of 12.8 years follow-up.

METHODS: We used a decision tree model based on results from BOSS to conduct a cost-effectiveness analysis of costs and quality-adjusted life years (QALYs). A Markov model was used to extrapolate costs and outcomes over a further 10 years after the trial had ended, representing a 22.8-year time horizon. The proportion with high-grade dysplasia and QALYs was derived from the randomized trial.

RESULTS: The total costs associated with 2-yearly surveillance was $5309 vs $3182 in the at-need arm. Total QALYs in the 2-yearly endoscopy arm were 8.647 compared with 8.629 in the at-need arm. Compared with at-need endoscopy, 2-yearly surveillance costs $115,563/QALY gained. In the sensitivity analyses around assumptions on the proportion of high-grade dysplasia that is undetected in the at-need endoscopy arm, surveillance had an incremental cost effectiveness ratio of $94,513/QALY for the best-case and $146,272/QALY for the worst-case scenario.

CONCLUSION: Barrett's esophagus surveillance every 2 to 3 years is unlikely to be a cost-effective strategy. Guidelines should take this into account when deciding surveillance intervals.

**中文摘要译文：**
背景与目的：巴雷特食管监测研究（BOSS）是首个关于监测的随机研究。本研究报告了BOSS试验的成本和生活质量结局，并对BOSS研究随访期结束后的监测结局和成本效益进行了建模。该试验显示，两组的食管癌分期和发生率相似，但在中位随访12.8年后，定期监测组确实发现了更多的高级别不典型增生。

方法：我们基于BOSS研究的结果，使用决策树模型对成本和质量调整生命年（QALYs）进行成本效益分析。我们采用马尔可夫模型，将试验结束后10年的成本和结局进行外推，时间跨度共计22.8年。高级别不典型增生的比例和QALYs数据来源于该随机试验。

结果：与按需内镜检查组的3182美元相比，每2年进行一次监测的总成本为5309美元。每2年进行一次内镜检查组的总QALYs为8.647，而按需检查组为8.629。与按需内镜检查相比，每2年进行一次监测获得的每个QALY成本为115,563美元。在围绕按需内镜检查组未检出的高级别不典型增生比例的假设进行的敏感性分析中，监测的增量成本效益比在最佳情况下为94,513美元/QALY，在最差情况下为146,272美元/QALY。

结论：每2至3年对巴雷特食管进行一次监测可能不是一种具有成本效益的策略。指南在决定监测间隔时应考虑这一因素。

### 第二部分 AI 大师评价

本研究基于首个大型随机对照试验（BOSS研究），创新性地对巴雷特食管（BE）的定期监测与按需内镜检查策略进行了长期的成本效益分析。研究采用决策树和马尔可夫模型，严谨地评估了两种策略的成本与质量调整生命年（QALYs）。其核心发现——每2-3年进行一次的常规监测可能不具备成本效益——对现行临床指南提出了重要挑战。这项研究结果对于优化BE患者的管理策略、合理分配医疗资源具有重大的临床和政策参考价值。

---

## 194. 回复：预防性保留功能的前列腺癌根治术：来自三级转诊中心的经验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40382300](https://pubmed.ncbi.nlm.nih.gov/40382300)
**期刊：** European urology
**PMID：** 40382300
**DOI：** 10.1016/j.eururo.2025.05.009

### 第一部分 原文与翻译

**英文原标题：** Re: Preventative Function-sparing Radical Prostatectomy: Experience in a Tertiary Referral Centre.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题表明，这是一篇针对“预防性保留功能的前列腺癌根治术”相关研究的读者来信或评论。鉴于其“回复（Re:）”的前缀且无摘要，它可能是在探讨或质疑先前发表于同一期刊的某项研究，该研究可能聚焦于在三级转诊中心开展此种手术的经验。此类学术通信对于促进同行间的深入讨论、澄清研究细节以及推动特定治疗策略（如在肿瘤控制与保留患者功能之间寻求平衡）的完善具有重要意义。

---

## 195. 膀胱癌的亚型与测序：是推动个体化治疗的利器，还是无关紧要的信息？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40382296](https://pubmed.ncbi.nlm.nih.gov/40382296)
**期刊：** European urology
**PMID：** 40382296
**DOI：** 10.1016/j.eururo.2025.05.001

### 第一部分 原文与翻译

**英文原标题：** Subtypes and Sequencing in Bladder Cancer: Powering Personalised Treatment or Extraneous Information?

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文很可能是一篇综述或观点性文章，旨在探讨膀胱癌分子亚型和基因测序在临床实践中的实际应用价值。文章的核心议题是，这些复杂的生物学信息究竟是推动个体化治疗的有力工具，还是目前尚缺乏明确临床指导意义的冗余数据。该文通过对现有研究和临床困境的思辨性讨论，为临床医生在精准医疗时代如何有效利用分子诊断信息提供了重要参考，并可能指出了未来研究需要解决的关键问题，以真正实现个体化治疗的承诺。

---

## 196. 对于非肌层浸润性膀胱癌患者，我们是否应将尿液肿瘤DNA状态纳入治疗决策？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40350348](https://pubmed.ncbi.nlm.nih.gov/40350348)
**期刊：** European urology
**PMID：** 40350348
**DOI：** 10.1016/j.eururo.2025.04.025

### 第一部分 原文与翻译

**英文原标题：** Should We Incorporate Urinary Tumour DNA Status in Treatment Decisions for Patients with Non-muscle-invasive Bladder Cancer?

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该文献标题以设问形式，探讨了将尿液肿瘤DNA（utDNA）状态作为非肌层浸润性膀胱癌（NMIBC）患者治疗决策依据的临床议题。此文可能是一篇述评或专家观点，聚焦于液体活检技术在膀胱癌精准诊疗中的应用前景。其核心价值在于推动对utDNA这一非侵入性生物标志物的临床转化讨论，旨在通过更精确的分子分型指导个性化治疗与复发监控，从而可能改善患者预后。尽管缺乏摘要限制了对其具体论点的深入评估，但该议题紧扣前沿，对未来NMIBC临床实践指南的修订和相关研究方向具有重要的启发意义。

---

## 197. 基于前列腺特异性膜抗原PET分子成像标准化评估（PPP2）更新前列腺癌风险分组：一项国际多中心注册研究的结果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40318933](https://pubmed.ncbi.nlm.nih.gov/40318933)
**期刊：** European urology
**PMID：** 40318933
**DOI：** 10.1016/j.eururo.2025.04.017

### 第一部分 原文与翻译

**英文原标题：** Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study.

**英文摘要原文：**
BACKGROUND AND OBJECTIVE: We established prognostic nomograms incorporating prostate-specific membrane antigen (PSMA) positron emission tomography (PET) parameters standardised by Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE; PPP1). Here, we develop an updated PPP2 risk score from a large international multicentre registry study.

METHODS: We included 6128 prostate cancer patients who underwent PSMA-PET at 20 hospitals in Europe, USA, and Australia between 2013 and 2022. Investigator sites were split 2:1 into the development (4044 patients) and validation (2084 patients) cohorts. We created nomograms of version 2 (PPP2) based on Cox regression models with the least absolute shrinkage and selection operator penalty for overall survival (development cohort). Performance of both nomograms was measured using Harrell's C-index and calibration plots and a head-to-head comparison with the National Comprehensive Cancer Network (NCCN) risk score by receiver operating characteristic curves (validation cohort).

KEY FINDINGS AND LIMITATIONS: Predictors were distant metastases (extrapelvic nodal metastases [M1a], bone metastases [M1b], and visceral metastases [M1c]), PSMA expression score, and total lesion count (visual PPP2) or total tumour volume (quantitative PPP2). C-indices (95% confidence interval) in the validation cohort were 0.80 (0.78-0.82; visual) and 0.80 (0.79-0.82; quantitative), respectively. Accuracy of both the PPP2 nomograms was superior to the NCCN risk score (n = 1034, area under the curve 0.84 vs 0.76; p < 0.001). The retrospective design represents a limitation of the study.

CONCLUSIONS AND CLINICAL IMPLICATIONS: PPP nomograms were improved in an international multicentre study to predict accurately the 3- and 5-yr overall survival probabilities of prostate cancer. PPP2 yielded superior accuracy to the NCCN risk score. A free software tool has been created for PROMISE and PPP2 assessments (promise-pet.org).

**中文摘要译文：**
背景与目的：我们先前建立了结合前列腺特异性膜抗原（PSMA）正电子发射断层扫描（PET）参数的预后列线图，这些参数通过前列腺癌分子成像标准化评估（PROMISE；PPP1）进行了标准化。在此，我们通过一项大型国际多中心注册研究，开发了一个更新的PPP2风险评分。

方法：我们纳入了2013年至2022年间在欧洲、美国和澳大利亚20家医院接受PSMA-PET检查的6128名前列腺癌患者。研究中心按2:1的比例分为开发队列（4044名患者）和验证队列（2084名患者）。我们基于Cox回归模型（采用LASSO惩罚）为总生存期创建了第2版（PPP2）列线图（开发队列）。通过Harrell's C指数和校准图来衡量两种列线图的性能，并通过受试者工作特征曲线与美国国家综合癌症网络（NCCN）风险评分进行头对头比较（验证队列）。

主要发现与局限性：预测因子包括远处转移（盆腔外淋巴结转移[M1a]、骨转移[M1b]和内脏转移[M1c]）、PSMA表达评分以及总病灶数（视觉PPP2）或总肿瘤体积（定量PPP2）。验证队列中，C指数（95%置信区间）分别为0.80（0.78-0.82；视觉）和0.80（0.79-0.82；定量）。两种PPP2列线图的准确性均优于NCCN风险评分（n = 1034，曲线下面积 0.84 vs 0.76；p < 0.001）。回顾性设计是本研究的一个局限性。

结论与临床意义：在一项国际多中心研究中，PPP列线图得到了改进，能够准确预测前列腺癌的3年和5年总生存概率。PPP2的准确性优于NCCN风险评分。我们已为PROMISE和PPP2评估创建了一个免费软件工具（promise-pet.org）。

### 第二部分 AI 大师评价

本研究基于一项大规模国际多中心注册数据，成功开发并验证了更新版的前列腺癌风险评分系统（PPP2）。该系统创新性地整合了PSMA-PET的关键参数，如远处转移亚型、PSMA表达评分和肿瘤负荷，构建了能预测总生存期的列线图。研究关键发现证实，PPP2评分在预测准确性上显著优于传统的NCCN风险评分，为临床提供了更精准的预后评估工具。尽管研究存在回顾性设计的局限，但其成果及配套的免费软件工具对优化前列腺癌患者的风险分层和个体化治疗决策具有重大的临床应用价值。

---

## 198. 致编辑的信：重新定义切除术后管理——对肝细胞癌（HCC）治愈性管理中辅助性TACE的批判性分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40310630](https://pubmed.ncbi.nlm.nih.gov/40310630)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 40310630
**DOI：** 10.1097/HEP.0000000000001327

### 第一部分 原文与翻译

**英文原标题：** Letter to the Editor: Redefining post-resection care: Critical analysis of adjuvant TACE in curative HCC management.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文作为一篇“致编辑的信”，针对肝细胞癌（HCC）根治性切除术后辅助性经导管动脉化疗栓塞术（TACE）的应用提出了批判性分析。作者旨在重新审视并可能重新定义这一术后管理策略的价值与地位。尽管没有摘要，但从标题可推断，该信函可能对现有临床实践或某项新近研究的结论提出了质疑，强调了在这一领域进行更审慎评估的必要性。此类学术讨论对于推动临床指南的完善、激发对治疗策略优化更深入的研究具有重要意义。

---

## 199. 不同组织学亚型尿路上皮癌的临床结局、基因组异质性及治疗考量

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40288936](https://pubmed.ncbi.nlm.nih.gov/40288936)
**期刊：** European urology
**PMID：** 40288936
**DOI：** 10.1016/j.eururo.2025.04.008

### 第一部分 原文与翻译

**英文原标题：** Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.

**英文摘要原文：**
BACKGROUND AND OBJECTIVE: Divergent differentiation and histologic subtypes are common findings in urothelial carcinoma (UC). Clinically relevant genomic alterations and oncogenic drivers of individual subtypes remain poorly defined. We characterized surgical outcomes and the genomic landscape of UC with aberrant histology (UCAH), with a focus on biomarkers and targetable alterations.

METHODS: The clinical cohort comprised 3052 patients who underwent radical cystectomy (RC) with or without neoadjuvant chemotherapy. Targeted exon sequencing was performed for a genomic cohort of 1060 bladder tumors from RC or transurethral resection specimens. We characterized the frequency of oncogenic mutations and targetable alterations, and the tumor mutational burden (TMB) of each subtype. We defined the clonal relatedness of morphologically distinct regions of tumors with mixed histology.

KEY FINDINGS AND LIMITATIONS: Patients with plasmacytoid, micropapillary, sarcomatoid, or mixed-histology tumors had worse cancer-specific survival than patients with pure urothelial histology. ERBB2, FGFR3, and PTEN alterations were most frequent in micropapillary, nested/squamous, and sarcomatoid UC, respectively. TMB was highest in plasmacytoid, neuroendocrine, and micropapillary tumors. Regions of mixed histology had shared clonal origins, but exceptions were observed. The retrospective design and potential for selection bias are limitations of our study.

CONCLUSIONS AND CLINICAL IMPLICATIONS: UCAH tumors have distinct patterns of genomic alterations, which may be targetable via novel therapies and have implications for clinical trial inclusion. Biomarker-driven systemic therapy should be explored in patients with histologic subtypes that are associated with worse clinical outcomes.

**中文摘要译文：**
背景与目的：差异性分化和组织学亚型是尿路上皮癌（UC）的常见特征。各个亚型的临床相关基因组改变和致癌驱动因素仍不明确。我们旨在阐明具有异常组织学特征的尿路上皮癌（UCAH）的手术结局和基因组图谱，并重点关注生物标志物和可靶向的基因改变。

方法：临床队列包含3052名接受根治性膀胱切除术（RC）并伴或不伴新辅助化疗的患者。我们对一个基因组队列中的1060例来自RC或经尿道切除术的膀胱肿瘤标本进行了靶向外显子测序。我们分析了各个亚型的致癌突变、可靶向改变的频率以及肿瘤突变负荷（TMB）。我们还确定了混合组织学肿瘤中形态学不同区域的克隆相关性。

主要发现与局限性：与纯尿路上皮组织学肿瘤患者相比，浆细胞样、微乳头状、肉瘤样或混合组织学肿瘤患者的癌症特异性生存期更差。ERBB2、FGFR3和PTEN的改变分别在微乳头状、巢状/鳞状和肉瘤样UC中最为常见。浆细胞样、神经内分泌和微乳头状肿瘤的TMB最高。混合组织学区域具有共同的克隆起源，但也观察到例外情况。本研究的局限性在于其回顾性设计以及可能存在的选择偏倚。

结论与临床意义：具有异常组织学特征的尿路上皮癌（UCAH）肿瘤具有独特的基因组改变模式，这些改变可能成为新型疗法的靶点，并对临床试验的患者入组具有指导意义。对于那些与较差临床结局相关的组织学亚型患者，应探索由生物标志物驱动的全身性治疗。

### 第二部分 AI 大师评价

该研究通过对大规模临床与基因组队列的分析，系统揭示了不同组织学亚型尿路上皮癌的临床结局差异及其独特的基因组图谱。其核心价值在于将特定的组织学亚型（如微乳头状、肉瘤样等）与关键的可靶向基因突变（如ERBB2、FGFR3）和肿瘤突变负荷（TMB）明确关联，为临床预后判断提供了分子层面的依据。尽管存在回顾性研究的局限性，这项工作为开发针对特定亚型的精准治疗策略和设计生物标志物驱动的临床试验奠定了坚实基础，对推动尿路上皮癌的个体化治疗具有重要意义。

---

## 200. 答复：遵循TIPS术后血流动力学目标并不能改善肝硬化患者的预后

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40198309](https://pubmed.ncbi.nlm.nih.gov/40198309)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 40198309
**DOI：** 10.1097/HEP.0000000000001350

### 第一部分 原文与翻译

**英文原标题：** Reply: Post-TIPS hemodynamic target adherence fails to improve outcomes in cirrhotic patients.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是一篇针对特定主题的“答复”或“读者来信”，并非原创性研究论文。其核心观点在于，对于接受TIPS（经颈静脉肝内门体分流术）治疗的肝硬化患者，即使严格遵循术后设定的血流动力学目标，也未能观察到临床结局的显著改善。这篇答复可能是在回应或辩论先前的研究，对临床实践中是否应将达到特定血流动力学参数作为TIPS术后管理的核心目标提出了质疑。由于缺乏摘要，无法深入了解其论证细节，但其标题所揭示的观点对于优化TIPS术后患者管理策略具有重要的提示和警示价值。

---

## 201. 巴雷特食管监测与按需内镜检查研究（BOSS）：一项随机对照试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40180292](https://pubmed.ncbi.nlm.nih.gov/40180292)
**期刊：** Gastroenterology
**PMID：** 40180292
**DOI：** 10.1053/j.gastro.2025.03.021

### 第一部分 原文与翻译

**英文原标题：** Barrett's Oesophagus Surveillance Versus Endoscopy at Need Study (BOSS): A Randomized Controlled Trial.

**英文摘要原文：**
BACKGROUND & AIMS: Barrett's esophagus (BE) is a precursor lesion for esophageal adenocarcinoma (EAC). Surveillance endoscopy aims to detect early malignant progression; although widely practiced, it has not previously been tested in a randomized trial.

METHODS: BOSS (Barrett's Oesophagus Surveillance Versus Endoscopy at Need Study) was a randomized controlled trial at 109 centers in the United Kingdom. Patients with BE were randomized to 2-yearly surveillance endoscopy or "at-need" endoscopy, offered for symptoms only. Follow-up was a minimum of 10 years. The primary outcome was overall survival in the intention-to-treat population. Secondary outcomes included cancer-specific survival, time to diagnosis of EAC, stage of EAC at diagnosis, frequency of endoscopy, and serious adverse events related to interventions.

RESULTS: There were 3453 patients recruited; 1733 patients were randomized to surveillance and 1719 to at-need endoscopy. Median follow-up time was 12.8 years for the primary outcome. There was no evidence of a difference in overall survival between the surveillance arm (333 deaths among 1733 patients) and the at-need arm (356 deaths among 1719 patients; hazard ratio, 0.95; 95% CI, 0.82-1.10; stratified log-rank P = .503). There was no evidence of a difference for surveillance vs at-need endoscopy in cancer-specific survival (108 vs 106 deaths from any cancer; hazard ratio, 1.01; 95% CI, 0.77-1.33; P = .926), time to diagnosis of EAC (40 vs 31 patients had a diagnosis of EAC; hazard ratio, 1.32; 95% CI, 0.82-2.11; P = .254), or cancer stage at diagnosis. Eight surveillance patients (0.46%) and 7 at-need patients (0.41%) reported serious adverse events.

CONCLUSIONS: Surveillance did not improve overall survival or cancer-specific survival. At-need endoscopy may be a safe alternative for low-risk patients. (ClinicalTrials.gov, Number: NCT00987857.).

**中文摘要译文：**
背景与目的：巴雷特食管（BE）是食管腺癌（EAC）的癌前病变。监测性内镜检查旨在早期发现恶性进展；尽管该方法被广泛应用，但此前尚未在随机试验中得到检验。

方法：BOSS（巴雷特食管监测与按需内镜检查研究）是一项在英国109个中心进行的随机对照试验。BE患者被随机分配至接受每两年一次的监测性内镜检查组或仅在出现症状时才进行的“按需”内镜检查组。随访时间至少为10年。主要终点是意向治疗人群的总生存率。次要终点包括癌症特异性生存率、EAC的诊断时间、诊断时的EAC分期、内镜检查频率以及与干预相关的严重不良事件。

结果：共招募了3453名患者；1733名患者被随机分配至监测组，1719名患者被分配至按需内镜检查组。主要终点的中位随访时间为12.8年。监测组（1733名患者中333例死亡）与按需组（1719名患者中356例死亡）的总生存率无显著差异（风险比为0.95；95% CI, 0.82-1.10；分层对数秩P = .503）。在癌症特异性生存率（108例 vs 106例癌症死亡；风险比, 1.01；95% CI, 0.77-1.33；P = .926）、EAC诊断时间（40名 vs 31名患者诊断为EAC；风险比, 1.32；95% CI, 0.82-2.11；P = .254）或诊断时的癌症分期方面，监测组与按需内镜检查组之间也未发现差异。监测组有8名患者（0.46%）报告了严重不良事件，按需组有7名患者（0.41%）。

结论：监测并未改善总生存率或癌症特异性生存率。对于低风险患者，按需内镜检查可能是一种安全的替代方案。（ClinicalTrials.gov, 编号: NCT00987857.）。

### 第二部分 AI 大师评价

本研究通过一项大规模、长周期的随机对照试验，首次直接挑战了巴雷特食管（BE）患者常规内镜监测的临床实践。研究的核心发现是，与仅在出现症状时进行检查的“按需”策略相比，规律的监测并未显著提高患者的总生存率或癌症特异性生存率。这一重磅结论具有颠覆性，为优化医疗资源配置、探索针对低风险BE患者的更安全、经济的管理策略提供了高级别证据，可能深刻影响未来的临床指南。

---

## 202. 致编辑的信：肝细胞癌辅助性经动脉化疗栓塞术疗效差异的深入分析与启示

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40100369](https://pubmed.ncbi.nlm.nih.gov/40100369)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 40100369
**DOI：** 10.1097/HEP.0000000000001310

### 第一部分 原文与翻译

**英文原标题：** Letter to the Editor: The divergences in the efficacy of adjuvant transarterial chemoembolization for HCC- In-depth analysis and enlightenments.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
摘要不可用。

### 第二部分 AI 大师评价

本文是一篇致编辑的信，旨在深入探讨肝细胞癌（HCC）患者术后接受辅助性经动脉化疗栓塞术（TACE）疗效存在差异的原因。作者可能通过对现有研究的批判性分析，指出了导致不同临床试验结果相悖的关键因素，例如患者选择、TACE方案或终点评估的异质性。此类学术评议对于澄清特定疗法在临床应用中的争议、促进对研究证据的审慎解读，并为未来设计更严谨的临床试验提供了重要的启示和方向。

---

## 203. 45-50岁人群中不同结直肠癌筛查方式的检出率与完成率

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40054747](https://pubmed.ncbi.nlm.nih.gov/40054747)
**期刊：** Gastroenterology
**PMID：** 40054747
**DOI：** 10.1053/j.gastro.2025.02.022

### 第一部分 原文与翻译

**英文原标题：** Yields and Completion Rates of Colorectal Cancer Screening Modalities in Patients Aged 45-50.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该研究旨在评估和比较不同结直肠癌筛查方式在45-50岁年龄组人群中的检出效益与完成率。这项研究的临床价值显著，因为它直接回应了当前多个指南将结直肠癌筛查起始年龄下调至45岁的建议，对于优化该年龄段人群的筛查策略至关重要。通过分析各项筛查技术的实际检出成果和患者的依从性，其研究结果将为临床医生和公共卫生政策制定者提供重要依据。由于摘要缺失，无法获知具体的研究方法、比较的筛查方式及关键发现，这是解读本研究价值时的主要局限。

---

## 204. 确定肝移植前免疫检查点抑制剂的安全清洗期：一项国际性回顾性队列研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40042053](https://pubmed.ncbi.nlm.nih.gov/40042053)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 40042053
**DOI：** 10.1097/HEP.0000000000001289

### 第一部分 原文与翻译

**英文原标题：** Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study.

**英文摘要原文：**
BACKGROUND AND AIMS: Immune checkpoint inhibitors (ICIs) are increasingly used in patients with advanced HCC patients awaiting liver transplantation (LT). However, concerns about the risk of posttransplant rejection persist.

APPROACH AND RESULTS: We conducted an international retrospective cohort study including 119 HCC patients who received ICIs prior to LT. We analyzed the incidence of allograft rejection, graft loss, and posttransplant recurrence with a particular focus on the washout period between the last ICI dose and LT. In this study, 24 of the 119 (20.2%) patients experienced allograft rejection with a median time to rejection of 9 days (IQR 6-10) post-LT. A linear relationship was observed between shorter washout periods and higher rejection risk. Washout periods <30 days (OR: 21.3, 95% CI: 5.93-103, p< 0.001) and between 30 and 50 days (OR: 9.48, 95% CI 2.47-46.8, p =0.002) were significantly associated with higher rejection rates in the univariate analysis compared to the washout period above 50 days. Graft loss as a result of rejection occurred in 6 patients (25%) with rejection. No factors related to grafts were associated with rejection. A longer washout period was not associated with a lower recurrence-free survival posttransplantation at 36 months (71% vs. 67%, p =0.71).

CONCLUSIONS: Our findings suggest that a washout period longer than 50 days for ICIs before LT appears to be safe with respect to rejection risk. While these results may help guide clinical decision-making, future prospective studies are essential to establish definitive guidelines.

**中文摘要译文：**
背景与目的：免疫检查点抑制剂（ICIs）越来越多地用于等待肝移植（LT）的晚期肝细胞癌（HCC）患者。然而，关于移植后排斥反应风险的担忧持续存在。

方法与结果：我们进行了一项国际性回顾性队列研究，纳入了119名在肝移植前接受过ICIs治疗的HCC患者。我们分析了同种异体移植物排斥、移植物丢失和移植后复发的发生率，并特别关注了从最后一次ICI给药到LT之间的清洗期。在本研究中，119名患者中有24名（20.2%）经历了同种异体移植物排斥，发生排斥的中位时间为移植后9天（四分位距6-10天）。研究观察到，较短的清洗期与较高的排斥风险之间存在线性关系。与超过50天的清洗期相比，单变量分析显示，小于30天（OR: 21.3, 95% CI: 5.93-103, p< 0.001）和30至50天之间（OR: 9.48, 95% CI 2.47-46.8, p =0.002）的清洗期与更高的排斥率显著相关。在发生排斥的患者中，有6名（25%）因排斥导致了移植物丢失。没有任何与移植物相关的因素与排斥反应相关。较长的清洗期并未导致移植后36个月时更低的无复发生存率（71% vs. 67%, p =0.71）。

结论：我们的研究结果表明，就排斥风险而言，肝移植前ICIs的清洗期长于50天似乎是安全的。尽管这些结果可能有助于指导临床决策，但仍需未来的前瞻性研究来建立明确的指南。

### 第二部分 AI 大师评价

本研究旨在确定肝移植前使用免疫检查点抑制剂（ICIs）的安全“清洗期”，以降低术后排斥反应的风险。通过一项大规模的国际回顾性队列研究，该文明确揭示了清洗期与排斥风险的量化关系，其核心发现是超过50天的清洗期能显著降低排斥率，且不影响远期肿瘤复发风险。这项研究为肿瘤免疫治疗与肝移植交叉领域的关键临床难题提供了首个具体的、数据驱动的循证建议，具有重要的临床指导价值，并为未来制定权威指南奠定了基础。

---

## 205. 自身免疫性肝炎患者的健康相关生活质量受损：一项欧洲参考网络内的多中心横断面研究结果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/39970194](https://pubmed.ncbi.nlm.nih.gov/39970194)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 39970194
**DOI：** 10.1097/HEP.0000000000001271

### 第一部分 原文与翻译

**英文原标题：** Health-related quality of life is impaired in people with autoimmune hepatitis: Results of a multicentre cross-sectional study within the European Reference Network.

**英文摘要原文：**
BACKGROUND AND AIMS: Impaired health-related quality of life (HRQoL) contributes to the overall disease burden in autoimmune hepatitis (AIH). This study aimed to evaluate HRQoL in people with AIH and to identify potentially modifiable factors associated with impaired HRQoL using validated patient-reported outcome measures.

APPROACH AND RESULTS: Adult patients with AIH diagnosed at 12 European centers were enrolled in this prospective, cross-sectional study from July 2020 to June 2023. HRQoL was assessed using the Physical Component Score (PCS) and Mental Component Score (MCS) of the 12-item Short Form Health Survey (SF-12), and the European Quality-of-life 5-Dimension 5-Level (EQ-5D-5L) utility index score. Mixed-model regression analyses identified factors associated with HRQoL and somatic symptom severity. Controls were recruited from the general population in 5 European countries. A total of 882 patients with AIH (mean age: 51.0 y [SD: 17.0]; 76.4% female) and 178 controls were included. Physical but not mental HRQoL was impaired in the AIH group compared with the control group (PCS: 46.3 vs. 51.9, p <0.001; EQ-5D utility index score: 0.87 vs. 0.95, p <0.001). HRQoL was associated with severe somatic symptoms (PCS: β=-4.26, p <0.001), fatigue (PCS: β=-0.25, p <0.001; MCS: β=-0.25, p <0.001), and depression/anxiety (PCS: β=-3.37, p <0.001; MCS: β=-6.79, p <0.001). A complete biochemical response was associated with lower somatic symptom severity (OR: 0.69, p <0.05).

CONCLUSIONS: People with AIH had impaired HRQoL compared with controls, particularly in terms of physical well-being. HRQoL scores are associated with symptom burden, encompassing both somatic and psychosocial dimensions.

**中文摘要译文：**
背景与目的：受损的健康相关生活质量（HRQoL）是自身免疫性肝炎（AIH）总体疾病负担的一部分。本研究旨在评估AIH患者的HRQoL，并利用经过验证的患者报告结局指标，识别与HRQoL受损相关的潜在可干预因素。

方法与结果：本项前瞻性、横断面研究于2020年7月至2023年6月期间，纳入了在12个欧洲中心诊断的成年AIH患者。研究采用12项简明健康调查问卷（SF-12）的生理健康总评（PCS）和心理健康总评（MCS），以及欧洲五维五水平健康量表（EQ-5D-5L）的效用指数评分来评估HRQoL。通过混合模型回归分析，识别了与HRQoL和躯体症状严重程度相关的因素。对照组从5个欧洲国家的普通人群中招募。研究共纳入882名AIH患者（平均年龄：51.0岁 [标准差：17.0]；76.4%为女性）和178名对照者。与对照组相比，AIH组患者的生理HRQoL受损，但心理HRQoL无明显差异（PCS：46.3 vs. 51.9, p <0.001；EQ-5D效用指数评分：0.87 vs. 0.95, p <0.001）。HRQoL与严重的躯体症状（PCS：β=-4.26, p <0.001）、疲劳（PCS：β=-0.25, p <0.001；MCS：β=-0.25, p <0.001）以及抑郁/焦虑（PCS：β=-3.37, p <0.001；MCS：β=-6.79, p <0.001）相关。完全的生化应答与较低的躯体症状严重程度相关（OR：0.69, p <0.05）。

结论：与对照组相比，AIH患者的HRQoL受损，尤其是在生理健康方面。HRQoL评分与症状负担相关，涵盖了躯体和心理社会两个维度。

### 第二部分 AI 大师评价

本研究是一项大规模多中心横断面研究，旨在系统评估自身免疫性肝炎（AIH）患者的健康相关生活质量（HRQoL）并探寻相关影响因素。其核心发现是，AIH患者的生理健康水平显著低于普通人群，且这种损害与躯体症状、疲劳及心理困扰密切相关。该研究的价值在于，它利用标准化的患者报告结局工具，为AIH的疾病负担提供了强有力的量化证据，并强调了在临床实践中，除了追求生化指标的缓解，还应高度关注并管理患者的症状负担，从而全面改善患者的整体福祉。

---

## 206. 肝硬化和肝癌的趋势分化凸显了为消除肝炎所需付出的持续努力。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/39964290](https://pubmed.ncbi.nlm.nih.gov/39964290)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 39964290
**DOI：** 10.1097/HEP.0000000000001273

### 第一部分 原文与翻译

**英文原标题：** Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

本文献标题揭示了一项在肝炎消除背景下，关于肝硬化与肝癌发病趋势差异的研究。研究可能通过分析流行病学数据发现，尽管肝炎控制取得了进展，其两种主要并发症的演变路径却出现分化，这提示消除肝炎的道路依然复杂且充满挑战。该研究的核心价值在于警示公共卫生界和临床医生，即使病毒得到有效抑制，对高危人群的长期肝癌监测仍是不可或缺的一环。由于缺乏摘要，无法获知其具体方法和数据，但该标题已明确指出优化肝炎相关疾病长期管理策略的重要性。

---

## 207. 乙肝相关肝病的全球疾病负担：2000至2021年间，全球超过三分之一国家由慢性乙肝病毒感染所致的原发性肝癌呈上升趋势。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/39937958](https://pubmed.ncbi.nlm.nih.gov/39937958)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 39937958
**DOI：** 10.1097/HEP.0000000000001260

### 第一部分 原文与翻译

**英文原标题：** Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021.

**英文摘要原文：**
BACKGROUNDS AND AIMS: HBV-related liver disease ranks as the seventh leading cause of mortality. Despite advances in prevention and treatment, global disparities in the burden of primary liver cancer (PLC) persist. We evaluate global trends in the prevalence, incidence, and death of HBV-related liver disease.

APPROACH AND RESULTS: Data from the Global Burden of Disease Study 2021 evaluated acute HBV infection, HBV-related cirrhosis, and HBV-related liver cancer prevalence, incidence, and death. In 2021, there were 7.30 million cases of acute HBV, 283.64 million cases of HBV-related cirrhosis, and 288,110 cases of HBV-related PLC. HBV-related PLC accounted for 39% of the global incidence of PLC; Western Pacific had the highest rates for HBV-related PLC, with an incidence of 5.24 and a death rate of 4.38 per 100,000 population. Between 2000 and 2021, age-standardized incidence, prevalence, and death rates from HBV-related liver disease decreased; however, the incidence of HBV-related PLC rose in 65 countries from 2000 to 2021. In parallel, age-standardized prevalent rates from HBV-related PLC increased in Europe (annual percent change: 0.77%, 95% CI: 0.72%-0.81%) and the Americas (annual percent change: 1.05%, 95% CI: 1.00%-1.10%).

CONCLUSIONS: From 2000 to 2021, decreases in HBV-related liver disease incidence and prevalence were observed; however, more than one-third of countries showed an increase in the incidence of HBV-related PLC. These findings highlight the need for strengthened HBV treatment efforts to reduce the risk of liver cancer.

**中文摘要译文：**
背景与目的：乙肝病毒（HBV）相关肝病是全球第七大死亡原因。尽管在预防和治疗方面取得了进展，但原发性肝癌（PLC）的疾病负担在全球范围内仍然存在差异。本研究旨在评估HBV相关肝病的患病率、发病率和死亡率的全球趋势。

方法与结果：本研究采用2021年全球疾病负担研究（GBD 2021）的数据，对急性HBV感染、HBV相关肝硬化以及HBV相关肝癌的患病率、发病率和死亡率进行了评估。2021年，全球急性HBV感染病例为730万，HBV相关肝硬化病例为2.8364亿，HBV相关原发性肝癌（PLC）病例为288,110例。HBV相关PLC占全球PLC发病率的39%；西太平洋地区的HBV相关PLC发病率最高，其发病率为每10万人5.24例，死亡率为每10万人4.38例。在2000年至2021年间，年龄标准化的HBV相关肝病的发病率、患病率和死亡率均有所下降；然而，同期有65个国家的HBV相关PLC发病率出现上升。与此同时，欧洲（年度百分比变化：0.77%，95% CI: 0.72%-0.81%）和美洲（年度百分比变化：1.05%，95% CI: 1.00%-1.10%）的年龄标准化HBV相关PLC患病率也有所增加。

结论：2000年至2021年，尽管观察到HBV相关肝病的总体发病率和患病率有所下降，但超过三分之一的国家的HBV相关PLC发病率呈上升趋势。这些发现凸显了加强HBV治疗以降低肝癌风险的必要性。

### 第二部分 AI 大师评价

本研究利用2021年全球疾病负担（GBD）数据，旨在宏观评估2000年至2021年间乙肝相关肝病的全球趋势。其核心发现揭示了一个关键的悖论：尽管乙肝相关肝病的总体年龄标化发病率和患病率在下降，但全球超过三分之一的国家，特别是欧洲和美洲，其乙肝相关原发性肝癌的发病率却在上升。这一发现具有重要的公共卫生价值，它警示我们，即使在乙肝防控取得整体进展的背景下，仍需加强特定区域的乙肝治疗和肝癌监测策略，以有效遏制肝癌风险的增长。

---

## 208. 适配子引导的纳米囊泡介导策略在临床前胆管癌模型中靶向“不可成药”分子

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/39928593](https://pubmed.ncbi.nlm.nih.gov/39928593)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 39928593
**DOI：** 10.1097/HEP.0000000000001256

### 第一部分 原文与翻译

**英文原标题：** Aptamer-directed, nanovesicle-mediated targeting of undruggable molecules in preclinical cholangiocarcinoma models.

**英文摘要原文：**
BACKGROUND AND AIMS: Cholangiocarcinoma (CCA) is an aggressive malignancy arising from the biliary epithelium with limited therapeutic options and poor long-term survival rates. To address the limitations of CCA treatment, we investigated cell-targeted nanovesicles as a delivery platform for transcriptome-targeting therapeutics.

APPROACH AND RESULTS: Milk-derived nanovesicles were loaded with short interfering RNAs targeting Yes-associated protein (YAP), the downstream effector of the Hippo pathway; LCK, an upstream regulator of YAP; and tafazzin, a protein critical for the integrity of the inner mitochondrial membrane. These transcriptome-targeting nanovesicles were decorated with a lipid-coupled RNA aptamer to epithelial cell adhesion molecule, including a tracking fluorophore. In vitro studies were conducted using multiple CCA cell lines. In vivo studies were performed using C57BL/6 and non-obese diabetic/severe combined immunodeficient mice to evaluate delivery and efficacy in both an immunocompetent syngeneic murine and a patient-derived xenograft model. We demonstrated that transcriptome-targeting nanovesicles were selectively taken up by liver tumor cells, which was augmented by the incorporation of a targeting aptamer, and that milk-derived nanovesicles loaded with short interfering RNA effectively downregulated target gene expression, both in vitro and in vivo. Downstream effects of target gene inhibition were observed, including downregulation of YAP-TEAD target genes and an increase in reactive oxygen species production at the mitochondrial level. Administration of transcriptome-targeting nanovesicles targeting YAP, LCK, and tafazzin inhibited CCA growth and further synergized with chemotherapy in 2 preclinical CCA models.

CONCLUSIONS: Herein, we show that aptamer-directed, nanovesicle-mediated targeting of YAP, LCK, and tafazzin potentiates chemosensitivity in 2 CCA models when delivered using aptamer-guided milk-derived nanovesicles.

**中文摘要译文：**
背景与目的：胆管癌（CCA）是一种源于胆道上皮的侵袭性恶性肿瘤，治疗选择有限，长期生存率低。为解决胆管癌治疗的局限性，我们研究了细胞靶向性纳米囊泡作为转录组靶向治疗的递送平台。

方法与结果：我们利用牛奶源纳米囊泡装载靶向Yes相关蛋白（YAP，Hippo通路的下游效应器）、LCK（YAP的上游调节因子）以及对线粒体内膜完整性至关重要的tafazzin蛋白的短干扰RNA。这些转录组靶向纳米囊泡通过脂质偶联的RNA适配子进行修饰，该适配子靶向上皮细胞粘附分子，并包含一个用于追踪的荧光团。体外研究使用了多种胆管癌细胞系。体内研究则使用C57BL/6小鼠和非肥胖糖尿病/重度联合免疫缺陷小鼠，在一个免疫功能正常的同系小鼠模型和一个患者来源的异种移植模型中评估递送效果与疗效。我们证明了转录组靶向纳米囊泡能被肝肿瘤细胞选择性摄取，且靶向适配子的引入增强了这一过程；同时，装载了短干扰RNA的牛奶源纳米囊泡在体内外均能有效下调靶基因的表达。研究观察到了靶基因抑制的下游效应，包括YAP-TEAD靶基因的下调以及线粒体层面活性氧产量的增加。在两种临床前胆管癌模型中，施用靶向YAP、LCK和tafazzin的转录组靶向纳米囊泡抑制了胆管癌的生长，并与化疗产生协同增效作用。

结论：本研究表明，通过适配子引导的牛奶源纳米囊泡递送，适配子导向、纳米囊泡介导的针对YAP、LCK和tafazzin的靶向治疗，在两种胆管癌模型中增强了化疗敏感性。

### 第二部分 AI 大师评价

本研究巧妙地构建了一种新型药物递送系统，旨在攻克胆管癌（CCA）中难以成药的靶点。研究团队利用牛奶源纳米囊泡作为载体，装载针对YAP、LCK等关键分子的siRNA，并通过RNA适配子实现对肿瘤细胞的精准靶向。其关键发现是，该系统不仅能在临床前模型中有效抑制肿瘤生长，还能与传统化疗协同增效。这项工作将天然囊泡、基因干扰技术与精准靶向策略融为一体，为治疗侵袭性胆管癌提供了极具潜力的“特洛伊木马”式新思路，展现了重要的临床转化价值。

---

## 209. 根治性切除术后辅助性经动脉化疗栓塞术治疗肝细胞癌：一项随机、开放标签、3期临床试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/39808820](https://pubmed.ncbi.nlm.nih.gov/39808820)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 39808820
**DOI：** 10.1097/HEP.0000000000001233

### 第一部分 原文与翻译

**英文原标题：** Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial.

**英文摘要原文：**
BACKGROUND AND AIMS: The role of adjuvant transarterial chemoembolization (TACE) for HCC following curative resection remains controversial. We aimed to determine the effectiveness of postoperative adjuvant TACE in patients with HCC​​​​​.

APPROACH AND RESULTS: In this randomized phase 3 trial, histologically confirmed patients with HCC (American Joint Committee on Cancer TNM stage I and II) were randomly assigned (1:1) to adjuvant TACE or observation groups. The primary endpoint was recurrence-free survival (RFS) in the intention-to-treat (ITT) population. The secondary endpoints included overall survival and safety. A total of 332 patients (ITT population) were randomly assigned to the TACE group (n=166) or the observation group (n=166) between March 2014 and June 2021. The RFS was comparable between the 2 groups from the ITT population (median, both unreached; HR, 0.88; 95% CI: 0.62-1.24; p =0.468). The RFS rates at 1, 3, and 5 years were 87.3% (95% CI: 81.2-91.5), 70.7% (95% CI: 63.0-77.0), and 60.6% (95% CI: 51.9-68.3) in the adjuvant TACE group and 84.8% (95% CI: 78.3-89.5), 69.3% (95% CI: 61.6-75.8), and 58.1% (95% CI: 49.5-65.8) in the observation group, respectively. The overall survival was comparable between the TACE group and the observation group in the ITT population (median, both unreached, HR, 1.06; 95% CI: 0.63-1.76; p =0.838). There was no grade ≥ 3 adverse event or treatment-related death in either group.

CONCLUSIONS: Postoperative adjuvant TACE was not associated with prolonged RFS or overall survival in patients with American Joint Committee on Cancer TNM stage I or II HCC.

**中文摘要译文：**
背景与目的：根治性切除术后辅助性经动脉化疗栓塞术（TACE）在肝细胞癌（HCC）治疗中的作用仍存在争议。本研究旨在确定术后辅助TACE对此类患者的有效性。

方法与结果：在这项随机3期试验中，经组织学确诊的HCC患者（美国癌症联合会TNM分期I和II期）被以1:1的比例随机分配至辅助TACE组或观察组。主要终点是意向治疗（ITT）人群的无复发生存期（RFS）。次要终点包括总生存期和安全性。在2014年3月至2021年6月期间，共有332名患者（ITT人群）被随机分配到TACE组（n=166）或观察组（n=166）。在ITT人群中，两组的RFS相当（中位数均未达到；风险比HR, 0.88；95% CI: 0.62-1.24；p =0.468）。辅助TACE组的1年、3年和5年RFS率分别为87.3%（95% CI: 81.2-91.5）、70.7%（95% CI: 63.0-77.0）和60.6%（95% CI: 51.9-68.3），而观察组分别为84.8%（95% CI: 78.3-89.5）、69.3%（95% CI: 61.6-75.8）和58.1%（95% CI: 49.5-65.8）。ITT人群中，TACE组和观察组的总生存期也相当（中位数均未达到，HR, 1.06；95% CI: 0.63-1.76；p =0.838）。两组均未发生≥3级的不良事件或治疗相关死亡。

结论：对于美国癌症联合会TNM分期为I或II期的HCC患者，术后辅助TACE与延长无复发生存期或总生存期无关。

### 第二部分 AI 大师评价

本研究通过一项大规模、前瞻性的随机对照3期临床试验，旨在解决一个长期存在争议的临床问题：肝细胞癌（HCC）根治性切除术后，是否应常规给予辅助性经动脉化疗栓塞术（TACE）治疗。研究结果明确指出，对于TNM分期为I或II期的早期HCC患者，术后辅助TACE并未能显著延长其无复发生存期（RFS）或总生存期（OS）。这项研究以其严谨的设计和高级别的证据，为临床实践提供了重要参考，挑战了在该特定患者群体中常规使用辅助TACE的必要性，有助于避免过度治疗并可能影响未来的临床指南。

---

## 210. 对于肝硬化患者，择期TIPS术后即刻达到推荐的血流动力学目标并不能改善其临床结局。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/39774529](https://pubmed.ncbi.nlm.nih.gov/39774529)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 39774529
**DOI：** 10.1097/HEP.0000000000001224

### 第一部分 原文与翻译

**英文原标题：** End-procedural adherence to recommended hemodynamic targets does not improve the outcome of elective TIPS in patients with cirrhosis.

**英文摘要原文：**
BACKGROUND AND AIMS: In clinical practice, the reduction of portocaval pressure gradient (PCPG) following TIPS does not always meet the recommendation of current guidance. We evaluated the impact of different degrees of PCPG reduction, measured at the end of an elective TIPS, on ascites control, recurrence of portal hypertension-related bleeding (PHRB), and survival.

APPROACH AND RESULTS: Patients with cirrhosis receiving TIPS for refractory ascites (RA) or for the secondary prophylaxis of PHRB were consecutively enrolled. Reduction in PCPG was defined as inadequate hemodynamic response (IHR) in patients not achieving a PCPG <12 mm Hg for both secondary prophylaxis of PHRB and RA, or a reduction of at least 50% only for PHRB. Four hundred fifteen patients were analyzed. An adequate hemodynamic response (AHR) was achieved in 66%. Fifty percent of patients received an under-dilated (≤7 mm) endoprosthesis. No significant differences between patients with IHR and AHR were observed in rebleeding rate and ascites control, while overt HE was higher in AHR. Regardless of TIPS indication, survival was not significantly different between IHR and AHR, while advanced age and liver function before TIPS were significantly associated with a higher cumulative incidence of liver-related death. Notably, in patients with RA the cumulative incidence of liver-related mortality was higher when AHR was defined as a post-TIPS PCPG <12 mm Hg or a reduction ≥50%.

CONCLUSIONS: AHR measured at the end of an elective TIPS may not be essential to define the eventual outcome, while a marked drop in PCPG could negatively affect the prognosis of patients with RA.

**中文摘要译文：**
背景与目的：在临床实践中，TIPS术后门腔静脉压力梯度（PCPG）的降低值并非总能达到现行指南的推荐标准。我们旨在评估在择期TIPS术终时测量的不同程度PCPG降低对腹水控制、门静脉高压相关性出血（PHRB）复发以及生存率的影响。

方法与结果：本研究连续纳入了因顽固性腹水（RA）或为二级预防PHRB而接受TIPS治疗的肝硬化患者。对于PHRB二级预防和RA的患者，若其PCPG未能降至<12 mmHg，或（仅针对PHRB）降幅未能达到至少50%，则定义为血流动力学应答不佳（IHR）。共分析了415名患者。66%的患者达到了充分的血流动力学应答（AHR）。50%的患者接受了未充分扩张（≤7 mm）的内支架置入。在再出血率和腹水控制方面，IHR与AHR组患者之间未观察到显著差异，而AHR组的显性肝性脑病（HE）发生率更高。无论TIPS的适应症为何，IHR与AHR组之间的生存率无显著差异，而高龄和TIPS术前的肝功能状况与更高的肝脏相关死亡累积发生率显著相关。值得注意的是，在RA患者中，当AHR被定义为TIPS术后PCPG<12 mmHg或降幅≥50%时，其肝脏相关死亡率的累积发生率反而更高。

结论：在择期TIPS术终时测量的AHR可能对于决定最终结局并非至关重要，而PCPG的显著下降可能对RA患者的预后产生负面影响。

### 第二部分 AI 大师评价

本研究通过对415名接受择期TIPS的肝硬化患者进行分析，旨在挑战临床上普遍遵循的TIPS术后需达到特定门腔静脉压力梯度（PCPG）目标的标准。研究核心发现，术后即刻达到推荐的血流动力学目标（AHR）并未改善患者在腹水控制、再出血及生存率方面的结局，反而增加了肝性脑病的风险，甚至可能对顽固性腹水患者的生存产生不利影响。该研究的创新价值在于，它对现行的TIPS操作指南提出了质疑，提示对于部分患者，尤其是顽固性腹水患者，过度降低门脉压力可能有害无益，这为未来个体化、更为审慎的TIPS治疗策略提供了重要证据。

---

## 211. 儿童代谢功能障碍相关脂肪性肝病的标准治疗纵向应答：改善与恶化的比率及结局相关因素分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/39773889](https://pubmed.ncbi.nlm.nih.gov/39773889)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 39773889
**DOI：** 10.1097/HEP.0000000000001216

### 第一部分 原文与翻译

**英文原标题：** Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes.

**英文摘要原文：**
BACKGROUND AND AIMS: Longitudinal outcomes in children with metabolic dysfunction-associated steatotic liver disease (MASLD) remain unclear due to the absence of a standardized monitoring approach. This study aimed to (1) define improvement and worsening in children with MASLD, (2) estimate rates of improvement or deterioration with the standard of care (SOC) over 1 and 2 years, and (3) identify baseline and longitudinal factors associated with improvement or worsening.

APPROACH AND RESULTS: Using data from 2 large randomized controlled trials, we derived definitions for composite improvement and worsening of MASLD based on associations between changes in ALT, GGT, and liver histology after 1 and 2 years. Improvement was defined as ≥40% decrease in ALT and ≥20% decrease in GGT and worsening as ≥20% increase in both ALT and GGT. We applied definitions to a cohort of 440 children with MASLD. After 1 year of SOC, 22% of children with MASLD showed improvement, increasing to 31% after 2 years. However, 20% showed worsening after both 1 and 2 years despite receiving SOC. Logistic regression analysis, employing stepwise model selection, identified changes in body mass index z-score and cholesterol to be most associated with improvement or deterioration.

CONCLUSIONS: This study developed criteria for improvement and worsening in children with MASLD over 1 and 2 years of follow-up. With SOC, over one-quarter of children are likely to improve while one-fifth of children are likely to worsen. Targeting interventions that affect body mass index and lipid parameters may help improve MASLD over time.

**中文摘要译文：**
背景与目的：由于缺乏标准化的监测方法，儿童代谢功能障碍相关脂肪性肝病（MASLD）的纵向结局尚不明确。本研究旨在（1）定义儿童MASLD的改善和恶化标准，（2）评估在标准治疗（SOC）下1年和2年内的改善或恶化率，以及（3）识别与改善或恶化相关的基线及纵向因素。

方法与结果：我们利用来自两项大型随机对照试验的数据，基于1年和2年后ALT、GGT及肝脏组织学变化之间的关联，推导出了MASLD的复合改善和恶化定义。改善定义为ALT下降≥40%且GGT下降≥20%，恶化定义为ALT和GGT均升高≥20%。我们将这些定义应用于一个包含440名MASLD患儿的队列。在接受标准治疗1年后，22%的MASLD患儿出现改善，2年后该比例增至31%。然而，尽管接受了标准治疗，仍有20%的患儿在1年和2年后均表现出病情恶化。采用逐步模型选择的逻辑回归分析发现，体重指数z评分和胆固醇的变化与改善或恶化最为相关。

结论：本研究为儿童MASLD在1年和2年随访期内的改善和恶化制定了标准。在标准治疗下，超过四分之一的患儿可能改善，而五分之一的患儿可能恶化。针对影响体重指数和血脂参数的干预措施可能有助于随时间推移改善MASLD。

### 第二部分 AI 大师评价

本研究通过分析两项大型随机对照试验的数据，首次为儿童代谢功能障碍相关脂肪性肝病（MASLD）的临床随访建立了基于血清ALT和GGT变化的改善与恶化复合定义。研究关键发现，在标准治疗下，两年内约三分之一的患儿病情改善，但仍有五分之一出现恶化，且体重指数z评分和胆固醇变化是预测结局的关键因素。这项工作的创新性在于为评估治疗反应提供了量化、可操作的无创标准，对指导临床实践和未来新药研发具有重要价值，同时也揭示了当前标准治疗对部分患儿效果不佳的严峻现实。

---

## 212. LRP4突变促进复发性肝细胞癌的肿瘤进展及对PD-1抑制剂治疗的耐药

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/39723987](https://pubmed.ncbi.nlm.nih.gov/39723987)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 39723987
**DOI：** 10.1097/HEP.0000000000001212

### 第一部分 原文与翻译

**英文原标题：** LRP4 mutations promote tumor progression and resistance to anti-PD-1 therapy in recurrent hepatocellular carcinoma.

**英文摘要原文：**
BACKGROUND AND AIMS: HCC recurrence is a major factor limiting long-term survival and the cause of most deaths in patients with HCC. However, molecular characterization and potential therapeutic targets of recurrent HCC remain mostly unknown.

APPROACH AND RESULTS: We performed whole-exome sequencing in 63 matched primary and recurrent HCC tumors and combined the data with whole-genome sequencing results in 43 paired samples from our previous study. Sanger sequencing was used to identify all low-density lipoprotein receptor-related protein 4 ( LRP4 ) coding exons in 203 additional patients with recurrent HCC. We identified LRP4 somatic mutations in 7.8% (24/309) of recurrent tumors and only 0.97% (3/309) of primary tumors ( p <0.001). Prognosis after the second liver resection was poorer in patients with an LRP4 mutation. Biofunctional investigations demonstrated that inactivating LRP4 mutations promoted tumor progression and immunosuppression. Mechanistically, mutated LRP4 reduced intratumoral conventional type 1 dendritic cell and CD8 + T cell infiltration by repressing C-C motif chemokine ligand 4 expression and secretion through activation of β-catenin signaling, resulting in resistance to anti-programmed cell death protein-1 therapy. Patients with recurrent HCC carrying an LRP4 mutation did not benefit from anti-programmed cell death protein-1 treatment after their second resection surgery. A β-catenin inhibitor-reversed LRP4-induced resistance to anti-programmed cell death protein-1 therapy in humanized tumor-bearing mice.

CONCLUSIONS: Our results identified novel LRP4 mutations important in recurrent HCC. Inactivating LRP4 mutations were associated with resistance to anti-programmed cell death protein-1 therapy and could be useful biomarkers for precision therapy in patients with recurrent HCC.

**中文摘要译文：**
背景与目的：肝细胞癌（HCC）复发是限制患者长期生存的主要因素，也是导致大多数HCC患者死亡的原因。然而，复发性HCC的分子特征和潜在治疗靶点在很大程度上仍是未知的。

方法与结果：我们对63对匹配的原发性和复发性HCC肿瘤进行了全外显子组测序，并将这些数据与我们先前研究中43对样本的全基因组测序结果相结合。我们使用Sanger测序技术，在另外203名复发性HCC患者中鉴定了所有低密度脂蛋白受体相关蛋白4（LRP4）的编码外显子。我们在7.8%（24/309）的复发性肿瘤中鉴定出LRP4体细胞突变，而在原发性肿瘤中这一比例仅为0.97%（3/309）（p <0.001）。携带LRP4突变的患者在第二次肝切除术后预后更差。生物功能研究表明，失活型LRP4突变会促进肿瘤进展和免疫抑制。机制上，突变的LRP4通过激活β-catenin信号通路，抑制了C-C基序趋化因子配体4（CCL4）的表达和分泌，从而减少了肿瘤内常规1型树突状细胞和CD8+ T细胞的浸润，导致对PD-1抑制剂治疗产生耐药。携带LRP4突变的复发性HCC患者在第二次切除手术后未能从PD-1抑制剂治疗中获益。在人源化荷瘤小鼠模型中，β-catenin抑制剂逆转了由LRP4突变诱导的对PD-1抑制剂治疗的耐药性。

结论：我们的研究结果确定了在复发性HCC中起重要作用的新型LRP4突变。失活型LRP4突变与对PD-1抑制剂治疗的耐药相关，可作为复发性HCC患者精准治疗的潜在生物标志物。

### 第二部分 AI 大师评价

本研究聚焦于复发性肝细胞癌这一临床难题，通过对大规模队列进行多组学测序分析，创新性地揭示了LRP4失活突变是驱动肿瘤进展和免疫治疗耐药的关键分子事件。研究不仅阐明了LRP4突变通过激活β-catenin信号通路、抑制免疫细胞浸润从而导致PD-1抑制剂失效的详细机制，还通过动物实验验证了联合使用β-catenin抑制剂可有效逆转该耐药表型。该发现为复发性肝癌患者的精准分层和联合治疗策略开发提供了重要的生物标志物和理论依据，具有显著的临床转化潜力。

---

## 213. 既往化疗对尿路上皮癌二线帕博利珠单抗治疗应答的影响：3期KEYNOTE-045试验的探索性分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/39174409](https://pubmed.ncbi.nlm.nih.gov/39174409)
**期刊：** European urology
**PMID：** 39174409
**DOI：** 10.1016/j.eururo.2024.07.015

### 第一部分 原文与翻译

**英文原标题：** Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.

**英文摘要原文：**
BACKGROUND AND OBJECTIVE: Until recently, the standard first-line treatment for advanced urothelial carcinoma (UC) was platinum-based combination chemotherapy followed by avelumab maintenance therapy for patients without progressive disease (PD). For patients with advanced UC who experience PD or recurrence, standard-of-care treatment is pembrolizumab monotherapy based on the phase 3 KEYNOTE-045 study. This post hoc analysis of the KEYNOTE-045 study evaluated the efficacy of pembrolizumab compared with chemotherapy by the best response to prior platinum-based chemotherapy.

METHODS: Patients with advanced UC that progressed or recurred after first-line platinum-based chemotherapy were randomly assigned 1:1 to receive either pembrolizumab 200 mg every 3 wk (Q3W) for ≤2 yr or investigator's choice of chemotherapy (paclitaxel [175 mg/m], docetaxel [75 mg/m], or vinflunine [320 mg/m], each Q3W). Endpoints included overall survival (OS) from the initiation of the last treatment prior to death, objective response rate (ORR), and duration of response (DOR) as per Response Evaluation Criteria in Solid Tumors version 1.1 from the date of the first response.

KEY FINDINGS AND LIMITATIONS: An objective response to pembrolizumab was observed in all groups in terms of a prior response to first-line platinum-based chemotherapy. Median OS, ORR, and median DOR were numerically greater with pembrolizumab than with chemotherapy across subgroups. Patients with PD as the best response to prior platinum-based chemotherapy had the poorest OS outcomes. Limitations include a lack of formal hypothesis testing.

CONCLUSIONS AND CLINICAL IMPLICATIONS: When compared with chemotherapy, prolonged OS and durable responses to second-line pembrolizumab were observed independently of the response to or type of prior platinum-based chemotherapy. These findings further support pembrolizumab as second-line treatment for advanced UC.

**中文摘要译文：**
背景与目的：直到最近，晚期尿路上皮癌（UC）的标准一线治疗方案是铂类联合化疗，随后对无疾病进展（PD）的患者进行阿维鲁单抗维持治疗。对于出现PD或复发的晚期UC患者，基于3期KEYNOTE-045研究，其标准治疗是帕博利珠单抗单药治疗。这项对KEYNOTE-045研究的事后分析，根据既往铂类化疗的最佳应答，评估了帕博利珠单抗相较于化疗的疗效。

方法：将一线铂类化疗后出现进展或复发的晚期UC患者按1:1的比例随机分配，接受帕博利珠单抗（200毫克，每3周一次[Q3W]，最长2年）或研究者选择的化疗（紫杉醇[175 mg/m²]、多西他赛[75 mg/m²]或长春氟宁[320 mg/m²]，均为Q3W）。终点指标包括从死亡前最后一次治疗开始计算的总生存期（OS）、客观缓解率（ORR）以及根据实体瘤疗效评价标准1.1版从首次缓解日期计算的缓解持续时间（DOR）。

主要发现与局限性：在所有根据既往一线铂类化疗应答情况分组的患者中，均观察到了对帕博利珠单抗的客观缓解。在各亚组中，帕博利珠单抗组的中位OS、ORR和中位DOR在数值上均优于化疗组。既往铂类化疗最佳应答为PD的患者，其OS结局最差。研究的局限性包括缺乏正式的假设检验。

结论与临床意义：与化疗相比，无论患者对既往铂类化疗的应答情况或化疗类型如何，二线帕博利珠单抗治疗均能带来更长的OS和更持久的缓解。这些发现进一步支持帕博利珠单抗作为晚期UC的二线治疗方案。

### 第二部分 AI 大师评价

本研究是对关键性3期临床试验KEYNOTE-045进行的一项探索性事后分析，旨在探究既往铂类化疗的疗效是否会影响晚期尿路上皮癌患者接受二线帕博利珠单抗治疗的结局。研究发现，无论患者对一线化疗的应答如何（包括疾病进展者），帕博利珠单抗在总生存期和缓解持续时间上均优于标准化疗。该分析结果虽因其事后探索性质而存在局限性，但它强有力地证实了帕博利珠单抗作为二线标准疗法的普适性和稳健性，为临床决策提供了重要依据。

---

## 214. 肝细胞癌的诊断与管理

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/39018553](https://pubmed.ncbi.nlm.nih.gov/39018553)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 39018553
**DOI：** 10.1097/HEP.0000000000001010

### 第一部分 原文与翻译

**英文原标题：** Diagnosis and Management of Hepatocellular Carcinoma.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

根据文献标题判断，本文可能是一篇关于肝细胞癌（HCC）的临床实践指南或权威综述。其核心目的在于全面梳理并提供有关HCC诊断与管理的最新、最权威的循证医学建议。此类文献的临床价值极高，它通过整合最新的研究成果，为临床医生在筛查、诊断、分期、治疗选择及患者随访等关键环节提供了标准化指导，有助于规范临床行为并改善患者预后。由于暂无摘要，无法得知其具体的创新观点或推荐更新，但发表在肝病学顶级期刊《Hepatology》上，其权威性和重要性不言而喻。

---

## 215. MASH临床试验与药物研发管线：一场即将来临的浪潮

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/38502810](https://pubmed.ncbi.nlm.nih.gov/38502810)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 38502810
**DOI：** 10.1097/HEP.0000000000000860

### 第一部分 原文与翻译

**英文原标题：** MASH clinical trials and drugs pipeline: An impending tsunami.

**英文摘要原文：**
Metabolic dysfunction-associated steatotic liver disease, formerly known as NAFLD, has ascended to prominence as the predominant chronic liver disease in Western countries and now stands as a leading cause of liver transplantations. In the more advanced stage, metabolic dysfunction-associated steatohepatitis (MASH) may lead to fibrosis, a gateway to cirrhosis, liver cancer, and liver failure. Despite extensive research and exploration of various drug mechanisms, the anticipation for the inaugural approved drug to materialize by 2024 is palpable, marking a significant milestone. Numerous pathways have been investigated for MASH treatment, exploring thyroid hormone receptors, glucagon-like peptides 1, peroxisome proliferator-activated receptors, and agents influencing hepatic steatosis synthesis, inflammatory pathways, genetic components, fibrosis mechanisms, and an array of other avenues. Over time, key regulatory directions have crystallized, now manifesting in 2 primary endpoints under investigation: resolution of steatohepatitis without worsening fibrosis and/or improvement of fibrosis stage without worsening of steatohepatitis, especially used in phase 3 clinical trials, while alternative noninvasive endpoints are explored in phase 2 trials. The prospect of proving efficacy in clinical trials opens doors to combination therapies, evaluating the ideal combination of drugs to yield comprehensive benefits, extending beyond the liver to other organs. Certain combination drug trials are already underway. In this review, we discuss the forefront of MASH drug research as of 2023/2024, illuminating mechanisms, outcomes, and future trajectories. Furthermore, we tackle the challenges confronting MASH trials and propose potential strategies for surmounting them.

**中文摘要译文：**
代谢功能障碍相关脂肪性肝病（曾用名：非酒精性脂肪性肝病，NAFLD）已成为西方国家最主要的慢性肝病，并且是目前肝移植的一大主要原因。在其更晚期阶段，代谢功能障碍相关脂肪性肝炎（MASH）可导致肝纤维化，而肝纤维化是通往肝硬化、肝癌和肝功能衰竭的门户。尽管已对多种药物机制进行了广泛研究与探索，但首个获批药物有望于2024年问世的预期日益明朗，这标志着一个重要的里程碑。研究人员已探索了多种用于治疗MASH的通路，包括甲状腺激素受体、胰高血糖素样肽-1、过氧化物酶体增殖物激活受体，以及影响肝脏脂肪合成、炎症通路、遗传组分、纤维化机制的药物及其他多种途径。随着时间的推移，关键的监管方向已逐渐明晰，目前体现在正在研究的两个主要终点上：脂肪性肝炎消退且肝纤维化不恶化，和/或肝纤维化分期改善且脂肪性肝炎不恶化。这些终点尤其用于III期临床试验，而II期试验则在探索替代性的无创终点。在临床试验中证明疗效的前景为联合用药打开了大门，旨在评估理想的药物组合以产生超出肝脏、惠及其他器官的综合效益。某些联合用药试验已在进行中。在这篇综述中，我们探讨了截至2023/2024年MASH药物研究的最前沿，阐明了其作用机制、研究成果和未来发展轨迹。此外，我们还讨论了MASH试验面临的挑战，并提出了克服这些挑战的潜在策略。

### 第二部分 AI 大师评价

本篇综述精准把握了代谢功能障碍相关脂肪性肝炎（MASH）药物研发的脉搏，系统梳理了截至2024年初的药物管线、作用靶点及临床试验进展。文章清晰地指出了当前III期临床试验的核心终点，并前瞻性地探讨了联合用药作为未来治疗策略的必然趋势。作为一篇前沿总结，它为临床医生和研究人员提供了该领域最新动态的宝贵快照，深刻揭示了MASH治疗即将迎来的突破性变革及其面临的挑战。

---

## 216. MASLD/MASH相关性肝细胞癌的分子机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/38349726](https://pubmed.ncbi.nlm.nih.gov/38349726)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 38349726
**DOI：** 10.1097/HEP.0000000000000786

### 第一部分 原文与翻译

**英文原标题：** Molecular mechanisms in MASLD/MASH-related HCC.

**英文摘要原文：**
Liver cancer is the third leading cause of cancer-related deaths and ranks as the sixth most prevalent cancer type globally. NAFLD or metabolic dysfunction-associated steatotic liver disease, and its more severe manifestation, NASH or metabolic dysfunction-associated steatohepatitis (MASH), pose a significant global health concern, affecting approximately 20%-25% of the population. The increased prevalence of metabolic dysfunction-associated steatotic liver disease and MASH is parallel to the increasing rates of obesity-associated metabolic diseases, including type 2 diabetes, insulin resistance, and fatty liver diseases. MASH can progress to MASH-related HCC (MASH-HCC) in about 2% of cases each year, influenced by various factors such as genetic mutations, carcinogen exposure, immune microenvironment, and microbiome. MASH-HCC exhibits distinct molecular and immune characteristics compared to other causes of HCC and affects both men and women equally. The management of early to intermediate-stage MASH-HCC typically involves surgery and locoregional therapies, while advanced HCC is treated with systemic therapies, including anti-angiogenic therapies and immune checkpoint inhibitors. In this comprehensive review, we consolidate previous research findings while also providing the most current insights into the intricate molecular processes underlying MASH-HCC development. We delve into MASH-HCC-associated genetic variations and somatic mutations, disease progression and research models, multiomics analysis, immunological and microenvironmental impacts, and discuss targeted/combined therapies to overcome immune evasion and the biomarkers to recognize treatment responders. By furthering our comprehension of the molecular mechanisms underlying MASH-HCC, our goal is to catalyze the advancement of more potent treatment strategies, ultimately leading to enhanced patient outcomes.

**中文摘要译文：**
肝癌是全球第三大癌症相关死亡原因，也是第六大最常见的癌症类型。NAFLD或称代谢功能障碍相关脂肪性肝病（MASLD），及其更严重的形式NASH或称代谢功能障碍相关脂肪性肝炎（MASH），是一个影响全球约20%-25%人口的重大健康问题。代谢功能障碍相关脂肪性肝病和MASH患病率的增加与肥胖相关代谢性疾病（包括2型糖尿病、胰岛素抵抗和脂肪肝病）发病率的上升同步。受遗传突变、致癌物暴露、免疫微环境和微生物组等多种因素影响，每年约有2%的MASH病例会进展为MASH相关肝细胞癌（MASH-HCC）。与其他病因引起的肝细胞癌相比，MASH-HCC表现出独特的分子和免疫特征，且对男性和女性的影响均等。早至中期MASH-HCC的治疗通常包括手术和局部区域治疗，而晚期肝细胞癌则采用全身性治疗，包括抗血管生成疗法和免疫检查点抑制剂。在这篇综述中，我们整合了以往的研究发现，同时就MASH-HCC发生发展背后复杂的分子过程提供了最新的见解。我们深入探讨了与MASH-HCC相关的遗传变异和体细胞突变、疾病进展与研究模型、多组学分析、免疫学和微环境影响，并讨论了旨在克服免疫逃逸的靶向/联合疗法以及识别治疗应答者的生物标志物。通过加深我们对MASH-HCC潜在分子机制的理解，我们的目标是催化更有效治疗策略的进步，最终改善患者的预后。

### 第二部分 AI 大师评价

该文是一篇关于代谢功能障碍相关脂肪性肝炎（MASH）所致肝细胞癌（HCC）分子机制的全面综述。文章系统性地整合了MASH-HCC在遗传变异、多组学特征、免疫微环境等方面的最新研究进展，并探讨了靶向治疗、联合治疗策略及潜在生物标志物。其核心价值在于为理解这一日益重要的肝癌亚型提供了清晰的病理生理框架，并为开发克服免疫逃逸的新疗法指明了方向，对肝病与肿瘤学领域的科研及临床实践均有重要的参考价值。

---

## 217. 胆道癌的新辅助与辅助治疗：进展与局限

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/38266282](https://pubmed.ncbi.nlm.nih.gov/38266282)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 38266282
**DOI：** 10.1097/HEP.0000000000000760

### 第一部分 原文与翻译

**英文原标题：** Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations.

**英文摘要原文：**
Biliary tract cancers (BTC) are a rare and aggressive consortium of malignancies, consisting of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder carcinoma. While most patients present with metastatic disease, a minority of patients with BTC are eligible for curative surgical resection at the time of presentation. However, these patients have poor 5-year overall survival rates and high rates of recurrence, necessitating the improvement of the neoadjuvant and adjuvant treatment of BTC. In this review, we assess the neoadjuvant and adjuvant clinical trials for the treatment of BTC and discuss the challenges and limitations of clinical trials, as well as future directions for the treatment of BTC.

**中文摘要译文：**
胆道癌（BTC）是一组罕见且具有高度侵袭性的恶性肿瘤，包括肝内胆管癌、肝外胆管癌和胆囊癌。虽然大多数患者就诊时已发生转移，但仍有少数BTC患者在初诊时符合根治性手术切除的条件。然而，这些患者的5年总生存率较低且复发率高，因此亟需改进BTC的新辅助与辅助治疗。在这篇综述中，我们评估了用于治疗BTC的新辅助与辅助治疗的临床试验，并探讨了这些临床试验面临的挑战与局限，以及BTC治疗的未来方向。

### 第二部分 AI 大师评价

该综述精准聚焦于胆道癌（BTC）的围手术期治疗这一临床难题。文章通过系统评估相关新辅助与辅助治疗的临床试验，清晰地指出了当前根治性切除术后患者高复发率和低生存率的严峻现实。本文的价值在于全面梳理了该领域的现有证据、挑战与局限，并为未来的研究方向提供了重要参考，对指导临床实践和优化未来试验设计具有重要的指导意义。

---

速递结束，祝您工作愉快！